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Scope of this thesis

Over the past decades the incidence of cutaneous melanoma has been increasing 
worldwide. Adequate surgical resection remains the standard of care for patients 
with non-systemic disease. However, a small percentage of patients with cutaneous 
melanoma will develop distant metastases, resulting in an extremely poor prognosis. 
Melanoma is highly chemotherapy resistant but is considered one of the most 
immunogenic types of cancer. Therefore, different immunomodulatory approaches 
have been tested in melanoma, however, mostly without showing any therapeutic 
effect until recent trials with immune checkpoint inhibitors, anti-CTLA-4 and anti-PD-1 
antibodies. 
Specific stimulation of the immune system with the use of vaccines aims to induce 
melanoma-specific responses and avoids the toxicity associated with the enhanced 
activity across multiple subsets of effector cells, as seen with cytokines and immune 
checkpoint inhibitors. Dendritic cells (DC), the most effective antigen-presenting cells 
of the immune system, are exploited to induce melanoma-specific cytotoxic T cells 
in melanoma patients. Over the years, many parameters in DC vaccination have 
been optimized in clinical studies. In this thesis, we describe our contribution to the 
improvements made in DC-based immunotherapy.
Chapter 1 contains an introduction on DC biology and DC-based immunotherapy, 
including ways on how to improve the efficacy of DC vaccination. In part I of this thesis, 
we describe the clinical trials we performed based on preclinical data to improve the 
DC vaccine, testing new antigen loading techniques, maturation methods, and the 
application of naturally occurring myeloid DC. In chapter 2, we transfected DC with 
mRNA, an antigen loading technique with the advantage of presentation of epitopes in 
both MHC class I and II, and investigated the immunological responses. RNA technology 
can be exploited not only to improve antigen presentation but also to improve DC 
maturation and T cell stimulation. In chapter 3, we show the results of DC vaccination 
with DC electroporated with mRNA encoding CD40 ligand, CD70, and a constitutively 
active form of TLR4. A different maturation technique is described in chapter 4, using 
prophylactic vaccines containing GMP grade TLR ligands to mature DC. In chapter 5, 
we describe the immunologic and clinical responses in metastatic melanoma patients 
in the first clinical trial with myeloid DC, a subset of naturally occurring DC. 
Part II of this thesis focuses on immunologic monitoring in DC vaccination, as the 
ability to reliably measure the immune response induced after a given immunotherapy 
is of great importance. A major difficulty is the extremely low frequencies of tumor 
antigen-specific T cells in the peripheral blood, which are often not detected by the 
most frequently used techniques. In chapter 6, we analyzed the tumor antigen-
specific T cell responses in biopsies of delayed-type hypersensitivity reactions in DC 
vaccinated metastatic melanoma patients. Detectable T cells in the biopsies were able 
to extravasate and migrate into the tissues, similar to what is expected from effector 
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T cells at the tumor site, already representing some sort of functionality. Beside from 
immunomonitoring after DC-based immunotherapy, we searched for biomarkers 
predicting response to DC vaccination prior to start of treatment in chapter 7. 
A correlation between strong intratumoral versus peritumoral T cell infiltration in 
primary cutaneous melanomas and longer survival in patients who are treated with 
DC-based immunotherapy was found.
In part III of this thesis, the clinical outcome in both cutaneous and uveal melanoma 
patients are shown. The feasibility and safety of DC vaccination in metastatic uveal 
melanoma, a rare form of melanoma originating in the eye, is demonstrated in 
chapter 8. As immunotherapy is shown to be less effective in patients with a large 
tumor burden, due to presumed tumor-induced immune suppression, we might take 
better advantage of the unique capacity of DC to direct the immune response by 
exploiting DC-based immunotherapy earlier in the course of disease. In chapter 9, 
we vaccinated high risk uveal melanoma patients, based on monosomy 3 presence in 
the tumor, with DC in the adjuvant setting. In chapter 10, we present a large cohort 
of cutaneous melanoma patients, who were at high risk of disease recurrence and 
distant metastases after radical lymph node dissection for regional metastases, who 
were treated with DC vaccination in comparison to matched controls. 
Finally, in chapter 11 the findings in this thesis are summarized and a future 
prospective of developments in the field of DC-based immunotherapy, including 
combination treatment to counteract the immunosuppressive tumor microenvironment 
and in vivo DC targeting, is given. 
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1General introduction
Abstract
Dendritic cells (DC) are the most potent professional antigen-presenting cells of the 
immune system. They acquire and process antigen and migrate to the lymphoid 
organs where they present the antigen and control the activation of B and T cells, the 
mediators of specific immunity. DC-based immunotherapy is explored worldwide in 
clinical vaccination trials with cancer patients aiming to induce or augment an antitumor 
immune response. The majority of clinical trials up to the present have vaccinated 
patients with ex vivo-generated monocyte-derived DC, matured using cytokines and 
loaded with tumor antigen via peptides, protein, or lysates. 
Thus far, DC-based immunotherapy has proven to be feasible, safe, and potently 
able to induce immunological responses, particularly if the DC have been appropriately 
matured. Nevertheless, only a limited number of clinical responses have been observed. 
Although the evidence on clinical responses is still scarce, expectations are high because 
the clinical responses that are induced are often long lasting. To improve clinical 
responses of DC vaccination further, a number of variables are already being tested in 
clinical trials, including DC maturation via toll-like receptors, mRNA transfection to load 
antigen, and the use of naturally occurring DC subsets instead of monocyte-derived 
DC. Future aspects of DC vaccination that are being explored include combination 
treatment to counteract tumor escape mechanisms and in vivo targeting of DC. The 
full potential of DC-based immunotherapy has not yet been fully exploited, which in 
combination with data to date supports a promising role for DC-based immunotherapy.
18
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1 Introduction
As professional antigen-presenting cells, DC are the central players of the adaptive 
immune response. They acquire and process antigen and migrate to the lymphoid 
organs where they present the antigen to the specific arm of the immune system, 
resulting in the induction of primary T and B cell responses. Because of these unique 
qualities, they represent an interesting tool in cancer immunotherapy. 
It has been proposed that when a tumor reaches a certain size and causes damage 
to the surrounding tissues with release of products into the microenvironment, local 
DC become activated and subsequently the immune system is alerted.1 Depending on 
the size of the tumor and its immunomodulatory characteristics, the immune system 
might be able to eradicate the cancer. Often, however, malignant growth is a slow and 
silent process that fails to elicit a “danger signal” necessary for the activation of the 
immune system. The goal of DC vaccination is to mend this inattention of the immune 
system by providing it with ex vivo “educated” DC, that is, DC appropriately activated 
and loaded with tumor antigen.
The first clinical study of a dendritic cell vaccine was reported in Nature Medicine 
in 1996.2 At present, DC-based immunotherapy is explored worldwide in clinical 
vaccination trials with cancer patients aiming to induce or augment an anticancer 
immune response.
1.1 Dendritic cell immunobiology
Dendritic cells are the most potent professional antigen-presenting cells of the immune 
system. They instruct and control the activation of B and T cells, the mediators of 
specific immunity. DC are derived from hematopoietic bone marrow progenitor cells. 
From bone marrow, they migrate into the peripheral tissues where they reside as 
resting immature DC, mainly in parts of the body that are in close contact with the 
outside world, such as skin and mucosal tissue. They act as the sentinels of the immune 
system, continuously patrolling the environment in search of antigen. At this stage, 
they possess an immature phenotype that is mainly characterized by a low surface 
expression of major histocompatibility complex (MHC) class I and II molecules and co-
stimulatory molecules.3 These immature DC are very efficient at antigen uptake and 
processing, mediated by high endocytotic activity and expression of an array of cell 
surface receptors capable of capturing antigens that could harm the host.4,5
Exogenous antigens, derived from extracellular pathogens such as bacteria and 
yeasts, are internalized and processed by DC, and the antigenic peptides are presented 
in the MHC class II complexes on the cell surface. Endogenous antigens, either self-
proteins or viral proteins, are cleaved into peptides by proteasomes and assembled 
into stable MHC class I–peptide complexes in the endoplasmic reticulum, which are 
subsequently transported to the cell surface. Of importance for DC-based vaccines in 
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cancer immunotherapy is the finding that internalized antigens from exogenous sources, 
such as apoptotic or necrotic tumor cells, may also be present in MHC class I molecules. 
This process, called cross presentation, by which exogenous tumor antigens can be 
presented to CD8+ T cells, is a unique feature of DC.6 The immunological outcome of this 
entire process strongly depends on the activation state of DC. Resting DC or immature 
DC receiving inhibitory signals, such as interleukin-10 (IL-10) or corticosteroids, induce 
immune tolerance via T cell deletion or induction of regulatory T cells (Tregs), whereas 
mature DC induce active immunity.
To convert the DC into a cell that is exceptionally well equipped for antigen 
presentation and T cell activation, a maturation step, a tightly controlled series of 
events, is necessary. For maturation to begin, a “danger signal”, derived from tissue 
damage or microbial products, is required.7 The maturation process includes down-
modulation of endocytic and phagocytic receptors and upregulation of chemokine 
receptors CCR7 and CD62L, which leads to DC migration to secondary lymphoid organs. 
Furthermore, surface expression of MHC class I and II and co-stimulatory molecules 
such as CD40, CD58, CD80, CD83, and CD86 are upregulated, and changes in morphology 
of the DC lysosomal compartment occur.3 
In lymphoid tissues, DC present pathogen-derived peptides to resting T cells via MHC 
molecules. This interaction between the MHC–peptide complex and the T cell receptor 
(signal 1), stimulation via co-stimulatory molecules from the DC to the T cell (signal 
2) and cytokines in the microenvironment (signal 3) together lead to the activation 
of T cells. The activated T cells subsequently proliferate, leave the lymph nodes, and 
circulate through the body in search of cells that express antigen.
In addition, DC are also able to activate natural killer (NK) cells directly8 and can 
produce large amounts of interferon (IFN) upon encounter with viral pathogens9, 
thus providing a link between the adaptive and innate immune system. The unique 
capacity of DC to initiate and modulate immune responses is currently exploited by 
many investigative groups to fight infectious diseases and cancer.
1.2. Dendritic cell subsets
DC comprise a heterogeneous population of cells. In human peripheral blood, two 
main populations of DC can be distinguished: myeloid DC (mDC) and plasmacytoid 
DC (pDC).10 These DC subtypes differ in function, localization, and phenotype. mDC 
mainly migrate to or reside in the marginal zone of the lymph nodes (a primary entry 
point for blood-born antigens), whereas pDC mainly reside in the T cell areas of lymph 
nodes.3,11 Both subsets express distinct toll-like receptors (TLRs; Figure 1) and therefore 
respond differently to pathogenic stimuli, suggesting that each subset has a specialized 
function in directing immune responses.12 A large body of data suggest that mDC 
mainly recognize and respond to bacterial and fungal antigens, whereas pDC seem 
20
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Figure 1. Toll-like receptor (TLR)-activation of human DC subsets can enhance antitumor responses in 
vivo. (Reproduced with permission from G. Schreibelt et al.12). DC subsets express a wide repertoire of 
TLRs, which upon triggering induce DC activation. Where pDC predominantly express TLRs in endosomal 
compartments, mDC have a broader TLR expression pattern, both at endosomal and extracellular 
membranes. By cross talk between mDC and pDC, either by cell-cell contact or soluble factors such as 
type I interferons, TLR-induced activation of one subset can lead to the activation of the other subset. 
Type I interferons appear to yield more potent mDC in terms of IL-12 secretion, induction of tumor-specific 
cytotoxic T cells, and T helper 1 responses in vitro. Upon direct TLR activation, mDC gain the ability to 
secrete large quantities of IL-12, which is beneficial for the polarization of a T helper 1 response. Both mDC 
and pDC have the capacity to evoke T helper cell responses. Moreover, pDC can promote the ability of mDC 
to cross-prime CD8+ T cells. Consequently, TLR activation of mDC and pDC and the cross talk between those 
two subsets can strongly enhance antitumor responses in vivo.
specialized for viral recognition. More recent observations suggest that both pDC and 
mDC might be of importance for the induction of antitumor responses with and without 
DC-based immunotherapy. 
Since natural DC constitute only about 0.2% of peripheral blood leukocytes, several 
ways to generate DC from precursors have been investigated for DC vaccination 
purposes. In 1994 this resulted in the discovery that DC can be generated from 
monocytes or CD34+ progenitors by culture in the presence of IL-4 and granulocyte-
macrophage colony-stimulating factor (GM-CSF), allowing the procurement of these 
otherwise scarce cells in considerable numbers essential to conduct clinical trials.13 
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1.2.1 Plasmacytoid dendritic cells
Human pDC are a rare subpopulation of cells. pDC are devoid of lineage markers and 
myeloid antigens and do not express CD11c. They express BDCA2 and BDCA4.10 In 
the steady state, they are round, nondendritic, and relatively long-lived cells. After 
receiving inflammatory stimuli, pDC develop a dendritic cell morphology and function. 
They express TLR7, which recognizes single stranded RNA, and TLR9, which recognizes 
unmethylated CpG DNA. Both are intracellular TLRs that are located in the endosomal 
compartments (Figure 1). Most notably, pDC produce large amounts of type I IFNs in 
response to viruses and are therefore thought to be crucial to antiviral immunity.14
Initially, pDC were thought to be of lymphoid origin.15 However, several human 
and mouse studies pointed out that the cytokine FMS-like tyrosine kinase 3 ligand 
(Flt3L) is of importance for pDC development and that pDC can develop from myeloid 
precursors under the influence of Flt3L.14,16,17 pDC reside in blood as well as in several 
lymphoid organs and some recent studies suggest functional differentiation between 
different tissue-residing pDC.18 
1.2.2 Myeloid dendritic cells
mDC found in peripheral blood are defined by the expression of myeloid markers, such 
as CD13 and CD33. They lack lineage-specific markers (CD3, CD14, CD19, and CD56), 
but express MHC class II and CD11c. The mDC population can be further subdivided 
into three classes based on differential surface expression of BDCA1/CD1c, BDCA3/
CD141, and CD16.12 The mDC subsets differ in their expression of cell surface markers 
and potency to stimulate T cells.19-21 For instance, the recently identified C-type lectin 
receptor (CLR) CLEC9a is expressed only by BDCA3-expressing mDC.22 mDC express 
two extracellular TLRs on the cell surface that recognize exterior components of 
bacteria and fungi, for example, cell wall components such as lipopolysaccharide 
(TLR4) and peptidoglycan (TLR2; Figure 1). TLR 3 and 8 are expressed intracellularly 
to respond to viral RNA. Upon activation, mDC mainly produce IL-12 to regulate the 
differentiation of naive T cells into T helper 1 cells to augment a cellular immune 
response. One interesting possibility is to combine mDC together with pDC as it has 
been suggested that pDC and mDC cooperate and act synergistically.23,24 Future studies 
will address whether mDC-pDC cross talk can indeed improve antitumor responses 
in cancer patients.
1.2.3 Ex vivo-generated dendritic cells
As discussed above, most clinical studies carried out to date have been used ex vivo-
generated monocyte-derived dendritic cells.5 Monocytes are pre-DC that originate 
from myeloid progenitor cells and are easily obtained by leukapheresis. In vivo, 
monocytes are capable of transforming into DC after sensing inflammatory signals and 
are important for the replenishment of DC in the host. Ex vivo, a cocktail of GM-CSF 
22
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and IL-4 differentiates monocytes into immature monocyte-derived DC over a period 
of 3-5 days.5,13 Subsequent maturation can be achieved by addition of cytokines such 
as tumor necrosis factor-α (TNF-α), prostaglandin E2, IL-1β, and IL-6 or monocyte-
conditioned medium, the supernatant of activated autologous monocytes.25,26 This 
allows the generation of large quantities (> 500 x 106) of clinical grade DC from a 
single leukapheresis.5,13 Although ex vivo-generated monocyte-derived DC share many 
phenotypic and functional characteristics with circulating mDC, it remains unclear to 
what extent they resemble natural blood DC. 
In addition to monocytes, CD34+ progenitors in blood are also used to generate 
DC for vaccination of cancer patients. CD34+ progenitors are cultured in the presence 
of GM-CSF, Flt3L, and TNF-α for about a week.27 They consist of two populations: one 
with Langerhans cell-like properties and another called interstitial/dermal DC with 
properties resembling monocyte-derived DC. Yields from leukapheresis after in vivo 
Flt3L expansion and negative selection ex vivo are much lower than from monocytes.28 
To date most clinical DC vaccination studies use monocytes to generate DC ex 
vivo. However, immunological and clinical responses have been observed in cancer 
patients vaccinated with monocyte-derived DC as well as with CD34+ progenitor-
derived DC.27,29,30
2 Dendritic cell maturation
The term “mature” DC has generally been used to describe T cell-stimulatory DC. 
Immature DC are considered to be primarily involved in the recognition and uptake 
of antigen. Upon receiving maturation signals, these immature DC then change their 
chemokine receptor repertoire, down-modulate endocytic and phagocytic receptors, 
and upregulate their co-stimulatory molecules, thus acquiring the phenotype and 
functionality of mature DC that are capable of migration to the lymph nodes and 
activation of T cells. In the absence of maturation signals, DC would not upregulate 
their co-stimulatory molecules and thus remain anergy- or tolerance-inducing antigen-
presenting cells. 
Besides taking up, processing, and presenting antigens, DC need proper activation 
by adjuvants to elicit a productive immune response. DC maturation is highly complex 
and should be regarded as a flexible process of which the outcome depends on the type 
of signals the DC receives in the periphery. While these maturation signals primarily 
come from contact with pathogens or tissue injury in vivo31,32, ex vivo maturation can 
be achieved by coculturing DC with several stimuli such as cytokines33, pathogen-
associated triggers7, or endogenous danger signals such as heat shock proteins.34
In the majority of clinical studies, immature or semimature monocyte-
derived DC have been used.30 Studies that have compared the immunogenicity of 
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immature versus mature DC show that maturation is essential for the induction of 
immunological responses in cancer patients.35,36 Moreover, the use of mature DC 
appears to be associated with a better clinical outcome compared to immature 
DC.36,37 This difference may partly be explained by the better migratory capacity to the 
draining lymph nodes of mature DC compared to immature DC after intradermal or 
subcutaneous injection. Also within the lymph node, mature DC show a pronounced 
migration into the T cell areas where antigen presentation takes place, whereas 
immature DC remain at the periphery.38 Besides their enhanced migratory capacity, 
mature DC also have a higher expression of MHC and co-stimulatory molecules. 
Together this leads to superiority of mature DC in antigen presentation and therefore 
in inducing T cell responses.
2.1 Tolerogenic dendritic dells
While clinical DC vaccination studies in the field of cancer immunotherapy are aimed 
at stimulating immune responses, the finding that immature DC play a critical role 
in the continuous induction of peripheral tolerance and thereby preventing both 
autoimmunity and hyperreactivity39 suggests a potential role for clinical DC applications 
in management of transplantation, allergy, autoimmunity, and chronic inflammatory 
diseases. Several factors such as IL-10, vitamin-D3, and corticosteroids can skew the DC 
into a more suppressive T cell type of inducer.40 Indeed, a number of trials have been 
initiated aimed at silencing the immune system in diseases like rheumatoid arthritis 
and Crohn disease.
2.2 Cytokine maturation docktails
Maturation of DC can be induced by proinflammatory cytokines such as IL-1β or IL-6. 
Several maturation methods have been applied with maturation being defined by a 
high expression of mature DC-specific surface markers such as CD80, CD83, CD86, and 
MHC molecules. Since the maturation stage of DC cannot be fully characterized by the 
expression of co-stimulatory molecules and surface MHC, it is therefore critical that 
the phenotypic and functional characteristics of the used DC be carefully described 
when reporting clinical DC vaccination trials.30 For example, functionality of DC can 
be measured by the production of IL-12, a proinflammatory cytokine that plays an 
essential role in the differentiation of T cells in T helper 1 cells. The most widely used 
method to mature immature DC is a cytokine cocktail that includes TNF-α, with any of 
the following cytokines in any combination: IL-1β, IL-6, prostaglandin E2, or monocyte-
conditioned medium that was used in early clinical studies.25,26,33,41,42 There is some 
evidence that culturing DC with IL-15 may lead to a type of mature DC that induces 
stronger T helper 1 type of immune responses.43 However, no comparative studies have 
yet been reported. Lastly, CD40 ligation has also been used as a method of activation 
of DC in a clinical setting.44,45 
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In addition, another level of complexity is added by the timing and duration of the 
maturation signal. Different cytokine cocktails require different lengths of maturation 
periods and can induce some differences in expression of co-stimulatory molecules 
and cytokine production of the DC.46,47 None of these different maturation methods 
has shown to be clearly superior, which is mainly due to the fact that there are no 
direct comparative studies, although the use of prostaglandin E2 for maturation may 
negatively affect DC function because of reduced IL-12 production.48,49
2.3 Maturation via toll-like receptors
More recently, TLR ligands that trigger TLRs on DC are being explored to mature DC. 
TLRs are part of the pattern recognition receptors by which DC can detect pathogens.50 
Triggering of these TLRs might be a more natural route to induce DC maturation. 
During evolution, the immune system has acquired various receptor families that 
recognize several crucial molecular components of pathogens. This set of pathogen-
associated molecular patterns (PAMPs) recognized by the immune system is limited and 
constituted mostly of general molecular patterns that are absent on host cells and are 
essential for survival of the microbe. On DC membranes, two main pattern recognition 
receptor families are present, C-type lectins and TLRs, of which the TLR family is best 
characterized and recognizes the most diverse group of PAMPs. Fifteen mammalian 
TLRs are now known (TLR1-15), of which ten are found in humans.51,52 
The better-described TLR1-9 can be divided in two main groups: extracellular 
TLRs that are found on the cell surface (TLR1, TLR2, TLR4, TLR5, and TLR6) and the 
intracellular TLRs that are located in endosomal compartments (TLR3, TLR7, TLR8, and 
TLR9). In general, intracellular TLRs recognize nucleotide-containing structures. For 
example, RNA molecules are recognized by TLR3, TLR7, and TLR8, and unmethylated 
CpG DNA originating from viruses and bacteria is recognized by TLR9. Extracellular 
TLRs recognize exterior components of bacteria and fungi, for example, cell wall 
components. Besides PAMPs derived from pathogens, TLRs have been proposed to 
recognize endogenous ligands such as heat shock proteins or necrotic cells.53,54 The 
signaling pathways associated with ligation of the different TLRs are not identical, and 
therefore, distinct biological responses are initiated. Ligand binding of TLRs recruits 
one or more adaptor molecules. The difference in signaling outcome (e.g., variation 
in cytokine production) can be explained in part by the use of different adaptor 
molecules by the TLRs. The binding partners of the recently discovered TLR10-15 are 
less well-known.
Recently it became apparent that subsets of DC naturally circulating in the blood 
express different TLRs and respond distinctly to TLR ligands. Human monocyte-
derived DC and mDC show very similar TLR expression profiles. These DC subsets 
express the extracellular TLRs TLR1, TLR2, TLR4, TLR5, and TLR6 and the endosomal 
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TLRs TLR3 and TLR8. In addition, both monocyte-derived DC and mDC respond to 
specific ligands of these TLRs, leading to a mature phenotype and production of 
proinflammatory cytokines.55-63 However, some significant differences between 
monocyte-derived DC and mDC in TLR expression and ligand reactivity were found. 
Most notably, monocyte-derived DC show negligible TLR10 expression, whereas 
blood mDC do express TLR10. Unfortunately, the ligand and functionality of TLR10 
are still unknown. 
Through the formation of heterodimers with TLR1 or TLR6, TLR2 gains the capacity 
to bind a wide variety of bacterial and yeast-derived ligands. Consequently, this plays 
a central function in pathogen recognition by DC. TLR1/2/6 activation leads to DC 
maturation and secretion of several cytokines important in immune system activation, 
especially IL-6, IL-8, IL-10, IL-12, and TNF-α. Human monocyte-derived DC and mDC do 
not express TLR9 and do not respond to TLR9 ligands.55,58 TLR9 is only expressed by 
pDC in the human setting and is responsible for a very high type I IFN response.64 In 
summary, data suggest that both monocyte-derived DC and mDC express TLR1-8 and 
not TLR9, and only mDC express TLR10. The mRNA expression of these receptors was 
confirmed by DC reactivity studies using TLR ligands.
pDC show a more distinct pattern of TLRs compared to monocyte-derived DC and 
mDC. They abundantly express TLR7 and TLR9 in their endosomal compartments. In 
addition, triggering of TLR7 and TLR9 on pDC leads to high type I IFN secretion and a 
typical mature DC phenotype. Interestingly, it has been suggested that in human pDC, 
TLR9 exhibits a unique feature not shared by the other described TLRs: depending on 
the stimulus, activation of TLR9 on human pDC can have different outcomes. The dual 
function of TLR9 is attributed to the distinct intracellular locations where TLR9 can be 
triggered. They can either activate an innate immune response via IFN-α secretion 
after encountering nucleic acids via early endosomes or activate an adaptive immune 
response through IL-6 and TNF-α secretion in late endosomes.65 
Both the timing of the activation signal and the exposure to antigen are of crucial 
importance for optimal antigen presentation; only the simultaneous presence of 
apoptotic cells and TLR ligands to DC results in efficient antigen presentation and 
subsequent T cell activation.66 With respect to the type of TLR ligands, it has been 
shown that combinations of different TLR ligands can have a synergistic effect on the 
immunogenic potential of DC ex vivo67 and in vivo.68 
The combination of clinical grade TLR ligands and prostaglandin E2 resulted in the 
generation of mature DC that secrete high levels of IL-12, IFN-γ, and TNF-α.69 With the 
discovery of those promising ex vivo data, the potency of these TLR ligand-activated 
monocyte-derived and naturally occurring blood DC is being explored in clinical trials. 
Despite the low number of naturally occurring blood DC, preliminary data indicate that 
these cells are extremely potent in initiating immune responses in cancer patients.12
26
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3 Dendritic cell antigen loading
To induce an immune response in cancer patients, the MHC molecules of a mature DC 
must be loaded with relevant tumor antigens. Preferably, tumor antigens are presented 
by DC to both CD4+ T helper cells (via MHC class II) and CD8+ cytotoxic T cells (via MHC 
class I), since there is convincing preclinical evidence that targeting both cytotoxic 
T cells and T helper cells is of crucial importance for the induction of a strong and 
sustained antitumor T cell response . Several methods of loading of DC with relevant 
tumor epitopes have been examined, of which the most widely used will be discussed 
in the following paragraphs. 
3.1 Peptide- or protein-pulsed dendritic cells
Several techniques have been developed to load human DC with tumor-associated antigens, 
the most widely used being incubation of DC with human leukocyte antigen (HLA) class 
I–binding peptides that can bind directly to MHC molecules on the cell surface.27,33,36,70-83 
In some clinical vaccination studies, HLA class I-binding peptides are combined with class 
II-binding peptides to also allow the activation of CD4+ T helper cells.41,84 
Tumor antigen-derived peptides have the advantage that many peptides are 
commercially available, but the antigens have to be known for each specific tumor and 
the peptides are restricted to a given HLA type. Unfortunately, the half-life of MHC–
peptide complexes is relatively short due to low affinity and MHC turnover. Further 
immune response, if any, is restricted to the epitope(s) used. On the other hand, a 
phenomenon known as antigen spreading can occur. In antigen (or epitope) spreading, 
killing of tumor cells after vaccination against a single epitope results in release of 
tumor antigens from killed tumor cells. These antigens can subsequently be taken up 
by DC and presented to T cells, resulting in T cell responses against antigens that were 
not included in the vaccine.76
Aside from HLA-binding peptides, peptides can be endogenously loaded onto MHC 
molecules after proteolytic processing of recombinant protein or endocytosed tumor 
lysates. The DC processes the protein into peptides, which has the advantage that 
multiple epitopes are presented in both MHC class I and II and that it is not limited 
to the HLA restriction of smaller peptides. Unfortunately, only few clinically grade 
recombinant proteins are available.85
Autologous72,86-91 or allogeneic44,92-94 tumor cell lysates have also been applied as a 
source of antigens. This has several advantages: the antigen expression by the tumor 
does not need to be defined, and a wide array of both MHC classes I and II epitopes 
are presented including tumor-specific antigens. Possible drawbacks of this approach 
are the presentation of autoantigens, the requirement of a sufficient volume of tumor 
tissue for preparation of the lysate and difficulties in monitoring tumor-specific T cell 
responses since the antigens relevant to T cell responses are not known. 
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Very novel thoughts also include sequencing of the tumor and to focus on those 
mutated proteins that contain MHC-binding peptides, thus increasing the number of 
potentially immunogenic tumor-specific antigens.95
3.2 mRNA-transfected dendritic cells
Transfection of DC with RNA comprises an alternative antigen loading technique96, 
with either tumor-derived RNA97,98 or synthetic RNA encoding full-length tumor 
antigens being used.99 The most widely used technique to transfect DC with RNA is 
RNA electroporation, the transient permeabilization of the plasma membrane during 
application of an electric field at which point the RNA can enter the cell. A benefit of 
this technique lies in the presentation of several MHC class I epitopes and sometimes 
also MHC class II epitopes, depending on the presence of an endosomal targeting 
sequence.100 It could also lead to a more prolonged presentation of the antigen as 
compared to peptide loading, which appears to be short lived.101 Disadvantages of 
RNA transfection include a variable expression and a low yield of viable cells after 
transfection, although without loss of phenotype and maturation potential of the viable 
cells. mRNA electroporation is more efficient compared to plasmid DNA electroporation, 
and since it is a nonviral method of transfection, the RNA lacks the potential to integrate 
into the host genome, thereby obviating the safety concerns associated with clinical 
gene therapy trials. 
Although tumor-derived RNA potentially harbors tumor-specific epitopes of mutated 
genes, it has the additional disadvantage that an unknown number of autoantigens 
will also be presented. However, several studies have shown that this technique is 
feasible and results in highly efficient DC transfection.99,102-105 Furthermore, antitumor 
T cell responses and some evidence for clinical activity have been reported in patients 
vaccinated with DC electroporated with tumor-derived RNA.106,107
Another technique consist of using DC-tumor cell fusion hybrids. Inactivated tumor 
cells are fused with mature DC. Ex vivo, this method has shown to be feasible and 
results in effective antigen presentation.108 As with tumor lysates, the advantages of 
this technique are that the antigens expressed by the tumor do not need to be defined 
and a wide array of epitopes are presented. On the other hand, cultured tumor cells 
are needed and the inactivated tumor cells might still exhibit tumorgenicity in vivo.109
Furthermore, RNA technology can be exploited not only to improve antigen 
presentation but also to improve DC maturation and T cell stimulation. For example, 
it has been shown that the T cell-stimulatory capacity of peptide-pulsed DC can be 
greatly enhanced by providing them with three different molecular adjuvants through 
electroporation with mRNA encoding a so-called TriMix of CD40 ligand (CD40L), 
CD70, and a constitutively active form of TLR4. The combination of CD40L and TLR4 
electroporation would mimic CD40 ligation and TLR4 signaling of the DC and generates 
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phenotypically mature, cytokine-secreting DC. Further, the introduction of CD70 into 
the DC provides a co-stimulatory signal to CD27+ naive T cells by inhibiting activated 
T cell apoptosis and by supporting T cell proliferation.110 
At present, all of the above DC-loading methods have been tested in preclinical 
models or already used in DC vaccination trials. All have their own advantages and 
disadvantages, but the optimal method for antigen loading with any strategy remains 
unknown. 
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Figure 2. The induction of tumor antigen-specific T cells via ex vivo or in vivo dendritic cell vaccination. 
DC cultured from monocytes or CD34+ progenitor cells can be loaded with tumor antigen ex vivo and 
administered to cancer patients via different routes, after culture in the presence of maturation stimuli 
such as proinflammatory cytokines. Within the lymph node, DC present antigens to T cells, in combination 
with a co-stimulatory signal to initiate an immune response. The activated tumor antigen-specific T cells 
proliferate and migrate out of the lymph node toward the site of the antigen, the tumor site. At the tumor 
site, MDSCs and Tregs are able to create an immunosuppressive microenvironment, inducing peripheral 
tolerance and complicating tumor clearance by T cells. Exploiting natural DC subsets can be performed 
either by isolating pDC or mDC and stimulating them ex vivo with adjuvant and antigen (not shown) or 
by targeting them in vivo exploiting nanoparticles that carry antigen and adjuvant and are coated with 
antibodies against DC-specific surface receptors. Both pDC and mDC can stimulate T cells. Cross talk 
between both DC subsets can also stimulate other immune cells such as NK cells. Im-moDC, immature 
monocyte-derived dendritic cell; mo-DC, mature monocyte-derived dendritic cell; i.d., intradermal; s.c., 
subcutaneous; i.v., intravenous; i.n., intranodal; mDC, myeloid dendritic cell; pDC, plasmacytoid dendritic 
cell; CD4, CD4+ T helper cell; CD8, CD8+ cytotoxic T cell; NK, natural killer cell; MDSC, myeloid-derived 
suppressor cell; Treg, regulatory T cell.
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4 Dendritic cell vaccination trials
During the past decade, DC-based immunotherapy is explored worldwide in 
clinical vaccination trials, predominantly in cancer patients.111 Most clinical studies 
use autologous ex vivo-cultured, antigen-loaded monocyte-derived DC or CD34+ 
progenitor-derived DC that are administered to patients with the aim of inducing 
tumor-specific effector T cells that can reduce the tumor mass specifically and that 
can induce immunological memory to control tumor relapse (Figure 2).
In recent years, over 100 clinical studies have been or are being carried out in 
cancer patients. Most studies carried out were small exploratory studies aimed at 
optimizing vaccines and measuring immune responses. In short, we can conclude that 
DC immunotherapy has been introduced into the clinic and has proven to be feasible 
and safe and potently induces immunological responses, particularly if the DC have 
been appropriately matured. Nevertheless thus far, only a very limited number of 
long-term clinical responses have been observed.
4.1 DC maturation status and antigen loading
The majority of the initial vaccines used immature or semimature rather than 
mature DC, which might have affected the immunological and clinical outcomes.30 
Studies that compared the immunogenicity of immature versus mature DC showed 
that maturation is essential for the induction of immunological responses in cancer 
patients.35,36 Moreover, the use of mature DC appeared to be associated with a better 
clinical outcome compared to immature DC.36,37 Vaccination with immature DC might 
even promote antigen-specific tolerance.112
This superiority of mature DC in inducing T cell responses is probably not only 
related to their high expression of MHC and co-stimulatory molecules but also to their 
enhanced migratory capacity. Compared with immature DC, mature DC migrate much 
better to draining lymph nodes after intradermal or subcutaneous injection, although 
this migration process is still rather inefficient. Within the lymph node, mature DC show 
a pronounced migration into the T cell areas where antigen presentation takes place, 
whereas immature DC remain at the periphery.38
To date, the optimal mode of DC maturation for clinical use has still not been 
established completely. Although a wide range of cytokine maturation cocktails have 
been tested in clinical studies, DC maturation via triggering of TLRs has been explored 
in great detail only recently. This not only holds for monocyte-derived DC and CD34+ 
progenitor-derived DC but also for naturally circulating DC subsets, which are now also 
being considered for therapy.
Besides the optimal maturation method, mature DC have not been used in clinical 
studies comparing different antigen loading techniques. Most of the early vaccine 
studies focused on MHC class I-restricted antigens as targets for cancer-specific CD8+ 
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T cells. Identification of MHC class II-restricted antigens as targets for CD4+ T cell 
responses allowed concurrent immunization with class I and class II epitopes to generate 
more potent immune responses. In addition, exploitation of mRNA transfection even 
led to presentation of multiple MHC class I and II epitopes on the cell surface and 
prevented the need for HLA selection of patients. There is consensus that mRNA is 
preferred over peptide loading because of the multiple epitopes presented, although 
mRNA application is not always possible. For instance, because of the rather fragile 
nature of natural DC, mRNA transfection is not possible tem, and peptide loading is 
preferred. Also the number of RNAs that can be applied is limited.
4.2 Clinical trial overview
Clinical trials with DC vaccines are being carried out in a wide variety of human cancers. 
In theory, DC-based immunotherapy should be applicable to all cancer types, although 
several practical limitations mean that it is mostly investigated in certain types of 
tumors. Limitations include the lack of appropriate tumor-associated antigens or the 
absence of sufficient tumor material when tumor lysates are used for loading of DC. 
In general, two types of antigens have been used: (1) tumor cell-associated antigens, 
which are also expressed by their nonmalignant counterpart, and (2) tumor-specific 
antigens including the MAGE antigens, which are only expressed at immune privileged 
sites or only during embryogenesis. Nowadays, genomic and proteomic approaches 
are also used to identify tumor-specific antigens that are derived from mutated genes.
Of all cancer types, melanoma is by far the most studied cancer type in DC 
immunotherapy. This is mainly because in melanoma a large variety of tumor-associated 
antigens have been characterized, consisting of tumor differentiation antigens such as 
gp100 and tyrosinase and tumor-specific antigens such as MAGE-3.113 Other reasons 
are that melanoma is considered of one of the most immunogenic tumors and that no 
first-line treatment is available which improves overall survival in the case of metastatic 
disease.114-116
Hematological malignancies form another group of cancer types that are studied 
more extensively, mainly the lymphomas and myelomas. For example, malignancies 
of B cell origin express monoclonal immunoglobulins carrying unique tumor-specific 
antigenic determinants in the variable regions, called idiotypes.117 These idiotypes can 
be isolated from B cell malignancies and subsequently be used as DC-loading antigens 
for the induction of specific CD4+ and CD8+ T cells. In contrast to the antigens used in 
solid tumors, these antigens are thus not only tumor specific but also patient specific.
Other tumor types that have been investigated using DC vaccines include colon 
cancer, renal cell carcinoma, breast cancer, ovarian cancer, nasopharyngeal carcinoma, 
hepatocellular carcinoma, pancreatic tumors, adrenal carcinoma, cholangiocarcinoma, 
parathyroid carcinoma, non-small cell lung cancer, head and neck cancer, sarcoma, 
bladder cancer, glioma, and pediatric malignancies.118-125 In most of these studies, 
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DC were cultured without maturation stimuli. In colorectal cancer, the most widely 
used antigen for loading on DC is carcinoembryonic antigen (CEA).126 Patients with 
CEA-expressing malignancies have also been treated with Flt3L expanded DC pulsed 
with a modified CEA peptide or with monocyte-derived DC transfected with RNA 
encoding CEA.
Because a new vaccine has to be prepared for each patient, this has hampered the 
development of DC vaccines by the pharmaceutical industry. The first dendritic cell-
based vaccine that has been brought to the market by a private company is sipuleucel-T 
(Provenge; Dendreon), a vaccine used in men with metastatic castration-resistant 
prostate cancer. Despite the discussion about the DC characteristics of this vaccine, 
the impact of this first FDA-approved cancer vaccine has been significant and certainly 
boosted the field. Furthermore, because of the highly individual DC vaccines, there is 
a large interest in developing strategies to target DC in vivo instead.
4.3 Immunological monitoring methods and results
The ability to measure the expected immune response of a given immunotherapy 
reliably, including in DC vaccination, is of major importance. Further, correlation with 
clinical outcome remains notoriously difficult and laborious. Although there is an 
abundance of different assays that are being used to measure tumor antigen-specific 
T cell responses27,41,127, many of these assays have not shown consistent results, and 
none has been validated in prospective clinical trials. A major reason is the extremely 
low frequencies of high-affinity tumor antigen-specific T cells in the peripheral 
blood. These frequencies can be as low as 1 in 40,000 T cell. 128 These low responses 
are often not detected by the most frequently used techniques such as enzyme-
linked immunosorbent spot analysis or direct MHC tetramer staining of peripheral 
blood lymphocytes. 
Further, the general immune status of a patient is not necessarily indicative of the 
clinical outcome. For example, control antigens such as the foreign protein keyhole 
limpet hemocyanin are frequently used to assist monitoring for immune monitoring 
purposes. While reactivity against keyhole limpet hemocyanin is often seen after 
vaccination, no correlation between the reactivity against keyhole limpet hemocyanin 
and the clinical outcome has been observed. Also, cloning of the antigen-specific T cells 
and subsequent T cell receptor sequence analysis of the clones has only been limited 
successful.128 A correlation between clinical outcome and circulating antigen-specific 
T cell response is found in only a minority of studies.
Another approach is analyzing T cell responses from biopsies of delayed-type 
hypersensitivity reactions in vaccinated patients with antigen-loaded DC.127,129 The 
rationale for biopsying the skin comes from the observation that measuring induration 
upon delayed-type hypersensitivity challenge is not predictive of vaccine-related 
32
1Dendritic cell-based cancer immunotherapy
T cell responses.26 By contrast, the presence of antigen-specific and functional T cells 
present in biopsies from delayed-type hypersensitivity was significantly correlated with 
a prolonged progression-free survival in metastatic cancer patients.127 One argument 
why this assay correlates better with survival is the fact that in this case, antigen-
specific T cells have been identified that were able to extravasate and migrate into 
the tissues, similar to what is expected from effector T cells infiltration into the tumor. 
Perhaps only a fraction of the antigen-specific T cells is capable of that function.
Although correlations between tumor regression and T cell responses are sometimes 
observed79, the use of immune responses as a surrogate end point in clinical trials 
still remains limited. Furthermore, the immunological studies performed so far are 
unfortunately too diverse in their setup to allow for a meta-analysis.130 Nevertheless, 
some lessons can be drawn from these studies. For example, an intact and proper 
functioning immune system seems to have a higher potential to react to immune 
therapy, and tumor antigen-specific T cells are less frequently induced in patients with 
distant metastatic disease compared to patients with solely local (non-metastatic) 
disease.131 In addition, more emphasis should be put on monitoring immune responses 
at the effector site, or at surrogate effector sites as discussed above, given that T cell 
responses in peripheral blood and the tumor microenvironment can show markedly 
different patterns.132
4.4 Clinical results
The first proof of principle studies exploring DC vaccination were performed in the late 
1990s, showing the feasibility and the potential efficacy of DC vaccination in cancer 
patients.2,33,72 DC vaccines have proven to be safe with only minimal side effects in 
multiple phase I and/or II trials in adults27,35,36,41,71,133-135 as well as in children.136 Side 
effects seen with the majority of DC vaccination protocols were mostly limited to 
transient chills, fever, fatigue, nausea, and headache. Although immunological responses 
are often reported using several immune monitoring methods and different culture 
protocols, objective clinical responses remain anecdotal with objective response rates 
not exceeding 5–15%, with disease stabilization and mixed responses being observed 
more often.29 Interestingly, however, in cases where clinical responses were induced, 
these were often long lasting.137
Several of the early studies published were inadequate in their design and 
interpretation. Indeed, quality control of the DC vaccines and information on phenotypic 
differences between DC of individual patients have been largely lacking in many studies. 
Rather, the miraculous cure of a single patient is highlighted without proper discussion 
of the potential reasons for treatment failure in other patients. 
To date, only very few phase III trials have been performed with DC-based 
immunotherapy, mainly because it is thought that the current vaccines have not yet 
33
1General introduction
reached their full potential and also because financial support is hard to obtain as 
most companies are not interested in producing laborious patient-specific vaccines. 
However, less than 2 years after one of the first publications on dendritic cell therapy 
was published72, a prospective phase III trial was initiated in 2000 that compared 
standard dacarbazine chemotherapy with a dendritic cell vaccine as first-line treatment 
of patients with metastatic melanoma.84 The trial was prematurely discontinued at the 
first interim analysis after the inclusion of 103 patients owing to lack of efficacy. The 
authors identified several possible negative contributing factors, including a variable 
quality of the dendritic cell vaccine among participating centers and a suboptimal 
maturation state, dose, and route of administration of the DC. In retrospect, this trial 
was carried out too soon and was performed at a time when DC vaccination was too 
early in its development. Although this trial could be interpreted as a negative trial 
for DC vaccination in melanoma patients, equality with the standard therapy for the 
last 30 years is perhaps not a bad starting point, given the fact that there are many 
parameters regarding DC vaccination that have been optimized over the last decade 
and still can be optimized in the following years. 
More recently sipuleucel-T, a DC-based vaccine used in men with metastatic 
castration-resistant prostate cancer, a patient population without any other available 
effective treatment options, has been brought to the market by a private company. 
This cell-based vaccine consists of autologous peripheral blood mononuclear cells 
obtained by leukapheresis, which include professional antigen-presenting cells that 
have been activated with a fusion protein (PA2024) of the prostate antigen pro static 
acid phosphatase and the immunostimulant GM-CSF. Sipuleucel-T was approved based 
on results from two placebo-controlled phase III randomized trials. No significant 
difference in time to biochemical failure, defined as serum prostate-specific antigen 
≥ 3.0 ng/ml138, or improvement in progression-free survival could be shown.139,140 
However, median overall survival was prolonged by approximately 4 months compared 
with the placebo group, from 21.4 to 25.9 months139 and 21.7 to 25.8 months.140 A 
relative reduction of 22% in the risk of death was also shown.140
The finding of a discrepancy between lack of benefit in progression-free survival 
and an advantage in overall survival could possibly be explained by the measuring 
technique. The classic World Health Organization (WHO)141 and Response Evaluation 
Criteria In Solid Tumors (RECIST)142,143 criteria that are applied to measure the efficacy 
of cytotoxic chemotherapy depend on tumor shrinkage, and any increase in tumor 
size beyond a certain level as well as the appearance of new lesions is considered 
as a treatment failure. However, there is now ample evidence that these criteria 
do not apply to immunotherapy. Immunotherapy-induced tumor regressions have 
been well documented after initial progression and even after the appearance 
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of new lesions, which are presumably caused by the infiltration of lymphocytes 
into tumors.144
These observations have led to the proposal of novel immune-related response 
criteria, as response evaluation according to conventional response criteria (such as 
WHO and RECIST) can lead to unwanted early cessation of treatment owing to initial 
tumor growth.145 These observations reflect the different dynamics of the immune 
response compared with the direct effects of cytotoxic drugs on cancer cells.146 
At present, the majority of studies have investigated the therapeutic effects of DC 
vaccines in late-stage cancer patients with metastases, despite the finding that more 
potent immune responses are induced in patients without end-stage disease.131 Part 
of the use of late-stage patients can be attributed to the notion that immunotherapy is 
less effective in patients with a large tumor burden, owing to the presumed correlation 
of immune suppression and tumor burden, and the delay in time taken to translate 
immune responses into a survival benefit, which is not possible in most patients with 
advanced disease. We thus might take better advantage of the unique capacity of DC 
to direct the immune response by exploiting DC-based cellular therapy earlier in the 
disease course. 
It has been demonstrated that melanoma-specific T cells are present together 
with antigen-presenting cells in sentinel nodes at initial evaluations of melanoma 
patients without known metastases. In this window between primary tumor and 
metastasis, immunological processes can be crucial. It might be at this turning point 
in the development of metastatic disease that ex vivo-generated DC can best assist 
the immune system, such as in prophylactic studies in patients suffering from ocular 
melanoma where the primary tumor is removed have been initiated, as well as studies 
in high-risk patients for developing cancer because of familial genetic predisposition. A 
further interesting observation was made in advanced melanoma patients vaccinated 
with monocyte-derived DC that were pulsed with a single melanoma peptide. The only 
clinically responding patient showed evidence of spreading of T cell reactivity against 
other antigens as well, suggesting that determinant spreading is of importance for the 
induction of clinical responses.76
5 Novel concepts and future perspectives
5.1 General considerations
The immunological and clinical responses in clinical trials thus far support the concept 
of using DC-based immunotherapy successfully to treat cancer. Nevertheless, a number 
of variables need to be evaluated and controlled to improve clinical outcomes further 
in DC vaccination in more patients. Among these are optimization of the ex vivo 
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generation of DC; the use of different, naturally circulating DC subsets; route of DC 
administration; maturation stimuli for DC69; and antigen loading of DC.30 These variables 
still provoke an ongoing debate, but one can clearly conclude that the full potential of 
DC-based immunotherapy has not yet been fully realized exploited. 
Second, upon induction of tumor antigen-specific T cells, the next hurdle to 
overcome is the local immune suppressive environment created by the tumor. No 
matter how effective a DC vaccine is, an immunosuppressive tumor microenvironment 
can inhibit its efficacy. In particular in end-stage cancer patients, this misbalance is 
already in favor of the metastasizing tumor. It is reported that in some patients, tumor 
antigen-specific T cells are present after DC vaccination, but they still experience 
disease progression. It became clear that these tumor antigen-specific T cells did not 
produce relevant cytokines nor exhibit cytotoxic activity upon tumor challenge.131 
Apparently, these effector cells were not capable of overcoming the local suppressive 
tumor environment. To circumvent or tackle these hurdles, novel concepts are under 
development to further improve DC-based immunotherapy.
5.2 Natural dendritic cell subsets
Whether DC differentiated ex vivo from precursor cells are the optimal source of DC 
for the induction of potent immune responses remains unclear. The extensive culture 
period (7-9 days) of ex vivo-generated DC and compounds required to differentiate them 
into DC might negatively affect DC function, especially their capacity to migrate toward 
the site of T cell interaction by exhaustion of the cells.147,148 Therefore, it is attractive to 
consider alternative DC sources, such as natural blood DC: mDC and pDC. While natural 
blood DC might not require extensive culture, to be effective, they must be activated 
through molecularly defined triggers of DC activation, such as TLRs or CD40 ligand, prior 
to reinfusion.58 This is of particular importance as nonactivated or improperly activated 
DC might result in T cell tolerance rather than productive T cell immunity.39 Also, since 
the frequency of naturally occurring circulating blood DC is very low, it was thought that 
multiple leukapheresis would be needed to obtain sufficient numbers of DC. However, it 
has proven feasible to obtain more than 10 million pDC and even higher numbers of mDC 
after a single leukapheresis. Furthermore, to collect even more DC, Flt3L is a potential 
candidate for expanding human DC in vivo without activating them.149,150
Recently, a first clinical trial with tumor antigen-loaded, TLR ligand-matured pDC in 
stage IV melanoma patients was completed, which appeared feasible and safe. In the 
majority of patients vaccinated with pDC, responses against the monitoring protein 
were found, demonstrating that even small numbers of naturally occurring DC can 
induce immunological responses. Although this phase I study was primarily aimed 
at determining potential toxicity, the clinical results were extremely promising with 
significantly extended survival in the majority of the patients.
Several ex vivo and preclinical studies suggest that pDC and mDC might cooperate 
and act synergistically. Human mDC and pDC activate each other after specific 
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stimulation of only one of the DC subsets with appropriate TLR ligands ex vivo.24 
Importantly, when mDC and pDC are used in combination, both DC subsets will need 
stimulation with carefully selected TLR ligands, due the fact that they express different 
repertoires of TLRs (Figure 1). Since TLRs act in synergy151, the combination of different 
TLR ligands might even be more potent. Therefore, it is of crucial importance to find 
TLR ligand combinations that either induce optimal maturation of both mDC and pDC 
or at least do not interfere with maturation of either DC subtype. Ex vivo findings 
with human cells suggest that in a clinical setting, vaccination with both pDC and mDC 
might also generate stronger antitumor responses than vaccination with monocyte-
derived DC alone. 
5.3 Targeting dendritic cells in vivo
Another recent approach to exploit natural DC for cancer immunotherapy is to target 
DC subsets in vivo. To this end, instead of isolating the various subsets, laborious 
culturing, and antigen loading ex vivo, antibodies are used to target DC with activating 
agents and antigens directly in vivo.152 Early studies have shown that when antigen 
is bound to antibodies directed against surface receptors of DC that are implicated 
in endocytosis, that this leads to uptake of antigen. Antigens loaded through these 
receptors are efficiently channeled into endocytic compartments for loading of MHC 
class I and II molecules and the subsequent induction of immune responses.153 However, 
if the antibody-antigen conjugates are not accompanied by adjuvant to stimulate the 
immune system, tolerance rather than immunity might occur.152,153 
Therefore, several investigators have embarked on the development of 
nanoparticles154 that are coated with antibodies to target natural DC subsets and 
that are loaded with both antigen and adjuvant (Figure 2).155,156 The advantage of this 
approach is that adjuvants only activate those DC that are targeted by the antibodies, 
thereby preventing systemic activation and toxicity. Co-targeting of TLR ligands in 
nanoparticles as an adjuvant has shown substantially enhanced DC maturation and 
production of immune-stimulatory cytokines. In addition, corresponding antigen-
specific activation of CD8+ T cells in mice was observed, without a so-called cytokine 
storm and related toxicity that may be associated with the administration of soluble 
TLR ligands.156
Another major advantage of in vivo targeting strategies is that they can be produced 
in bulk quantities, whereas vaccines based on DC loaded with antigens ex vivo require 
extensive tailor-made procedures for each individual. However, ex vivo culture 
conditions allow careful control of maturation and activation, while due to lack of 
direct control in in vivo targeting strategies, the duration and stability of the vaccine 
following administration will be difficult to determine.152
Many of the receptors that are studied in targeting strategies belong to the CLR 
family. These CLRs comprise a family of calcium-dependent lectins that share primary 
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structural homology in their carbohydrate domain. Through this domain, CLRs bind 
to specific self or nonself sugar residues and are implicated in antigen capture and 
endocytosis. For example, the CLR DC-SIGN is predominantly expressed on immature 
DC and at lower levels on mature DC and macrophage.157-160 Anti-DC-SIGN antibodies 
efficiently target mDC in vivo and reach saturation with one single dose. The binding 
of a humanized antibody to DC-SIGN showed high-affinity and facilitated endocytosis. 
Furthermore, targeted human monocyte-derived DC with delivery of antigen 
conjugated to the humanized DC-SIGN-specific antibody leads to presentation of 
the antigen by both MHC class I and II molecules and elicits both naive and memory 
T cell responses ex vivo.160 DEC205 (CD205) is another CLR that is widely explored as a 
potential targeting antibody in mice. DEC205 expression levels in human are highest 
in mature DC, but it is also expressed by B cells, T cells, monocytes, macrophages, 
and natural killer cells.161 In mice, DEC205 seems to be more potent in mediating cross 
presentation ex vivo compared to the other CLRs. Several studies are ongoing to 
compare and determine the efficacy of different targeting receptors.
To conclude, although it will probably still take several years before direct targeting 
of antigens via nanoparticles to DC surface receptors in vivo will be applied in clinical 
trials in cancer patients, it might replace laborious and expensive ex vivo culturing in 
time and facilitate large-scale application of DC-based vaccination therapies.
5.4 Combating tumor escape mechanisms
The immune system has several ways to tune down immune responses in order to prevent 
autoimmunity or excessively long or vigorous inflammatory reactions. In addition, 
tumors have evolved various mechanisms to evade immunological surveillance or to 
counterattack the immune response to facilitate their own progression, so-called tumor 
escape mechanisms.162 The immunosuppressive strategies used by tumors interfere 
with multiple steps and pathways in the generation of an effective immune response. 
They include the evasion of immune recognition, the secretion of immunosuppressive 
cytokines, the expansion and recruitment of Tregs, and the activation of negative 
regulatory pathways. The degree to which the immune system is compromised by the 
tumor presence is variable, the most aggressive tumors appear to be more successful 
in creating an optimal microenvironment suppressing antitumor immune responses to 
favor tumor progression. It is evident that when developing novel vaccines, we must 
deal with and revert local immune suppression.
5.4.1 Overcoming Reduced Tumor Immunogenicity 
To evade immune recognition, tumor cells frequently modify, downregulate, or even 
lose expression of tumor antigens on their cell surface. Modification of tumor antigens 
can result in peptides that do not fit into the MHC class I groove or form a MHC 
class I – peptide complex that cannot be recognized by T cells. Besides altered antigen 
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expression, downregulation or loss of MHC class I expression can occur independently 
and is frequently seen in various cancer types, particularly in metastatic lesions.133,163-165 
Both processes allow tumor cells to avoid recognition by CD8+ cytotoxic T cells.166 For 
example, in melanoma it has been shown that downregulation of both antigen and 
MHC class I has a negative effect on prognosis.167,168 
Besides alterations in MHC class I and antigen expression, another aberration 
frequently seen in tumor cells involves downregulation of the expression of co-
stimulatory molecules on the tumor cell surface.169 This leads to an insufficient co-
stimulatory signal (signal 2) that is necessary for the induction of an effective T cell 
response in combination with MHC class I antigen presentation. In its absence, T 
cells are rendered anergic.170 Evidently, novel vaccines cannot compensate for this 
deficiency, but one could attempt to design vaccines that also boosts natural killer cell 
activity besides stimulating T cell-mediated immunity.
5.4.2 Soluble factors influencing the immune system
Tumor cells produce a variety of cytokines and small molecules to promote tumor 
progression, mainly by increasing tumor invasiveness and angiogenesis. Some of these 
cytokines also possess immunosuppressive properties that, together with the lack of 
immunostimulating cytokines, create a cytokine imbalance responsible for immune deviation 
seen at the tumor site and distantly. The best characterized immunosuppressive factors 
to date involved in the tumor microenvironment and/or systemic immunosuppression 
are transforming growth factor β (TGF-β), vascular endothelial growth factor (VEGF), 
IL-10, and prostaglandin E2.171-177 It has been shown that TGF-β induces IL-10 secretion 
that negatively affects the maturation and activation of DC and causes a shifts toward 
T helper 2 responses.178 The immunosuppressive function of VEGF is mainly dependent 
on the alteration of the function of DC by blocking DC maturation.179 The expression of 
the small molecule prostaglandin E2 is correlated with impaired DC and T cell function.180
5.4.3 Regulatory T cells and myeloid suppressor cells
The accumulation of immunosuppressive cells at the tumor site is another mechanism 
contributing to tumor escape (Figure 2). The most well-known type of cell that can 
suppress the immune system and plays a key factor in peripheral tolerance is the 
Treg. Tregs are not only capable of infiltrating a site of infection; it is also a well-known 
phenomenon that they can infiltrate tumors.181-188 Besides Tregs, myeloid-derived 
suppressor cells also have a suppressive effect on the host immunity and consist of a 
group of cells including macrophages, granulocytes, and DC.189,190 It is evident that new 
vaccines should also be aimed at reverting the T regulatory/T effector cell balance, for 
instance by inducing strong T helper 1 type of cytokines. 
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5.4.4 Therapeutic options to counteract the tumor escape mechanisms
It is clear that the most fantastic vaccines can be developed, but if we are not able 
to manipulate immunosuppression at the site of the tumor at the same time, DC 
vaccinations will have little or no long-term effect. Approaches to tilt the balance 
toward more effective DC-based immunotherapy involve ways to counteract the 
tumor escape mechanisms discussed above, either by optimizing the DC vaccine or by 
combining treatment modalities.
To counteract the evasion of immune recognition, one can think of several 
strategies. Vaccines containing multiple tumor antigens can partly bypass the 
emergence of antigen loss; however, this solution will probably not be effective 
enough since multiple tumor antigens can be downregulated simultaneously. Instead 
of using standardized tumor peptides, proteins, or RNA to load DC with tumor-specific 
antigen for vaccination purposes, the development of RNA sequencing technologies 
allows the determination of the complete range of mutated antigens from the 
primary tumor and metastases of a patient, thereby possibly enabling tailor-made 
therapeutic vaccines to the patient’s tumor in the near future.191 Furthermore, novel 
vaccines might also be directed at activating innate cells such as natural killer cells 
that can recognize tumor cells that have downregulated MHC expression, in addition 
to stimulating the adaptive immune response. Finally, it is suggested that histone 
deacetylase inhibitors are able to upregulate MHC class I expression on tumor 
cells by increasing the expression of many components of the antigen-processing 
machinery192 and thus enhance their susceptibility to killing by cytotoxic T cells. 
However, there are also studies showing an immunosuppressive effect of histone 
deacetylase inhibitors that necessitates further research before clinical application 
in combination with DC vaccination.
Soluble factors secreted by the tumor create a suppressive environment, including 
preventing differentiation and maturation of natural infiltrating DC.193,194 Several studies 
have now demonstrated that a topical TLR7 agonist (imiquimod) led to enhanced 
pDC recruitment and type I IFN production by resident pDC at the tumor site, which 
then generated an inflammatory environment resulting in tumor regression.195,196 
Furthermore, activation of tumor-resident pDC can also be achieved by intratumoral 
injection of CpG motifs inducing TLR9 triggering. This strategy has therapeutic potential 
in patients with basal cell carcinoma and melanoma skin metastases.197 Since TLR9 is 
thought to be expressed only by pDC, CpG injection will not directly activate mDC. 
TGF-β inhibitors, anti-VEGF antibodies, and selective inhibitors of cyclooxygenase 2, an 
enzyme involved in the prostaglandin E2 synthesis, also have potential to counteract 
tumor escape by blocking the suppressive effects of secreted soluble factors.198-201
Reducing the negative effects of the cytokines produced by tumor cells or creating 
an immunostimulatory microenvironment by adding cytokines that stimulate the 
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immune system to DC vaccination is being applied in the clinic but has shown little 
clinical benefit thus far.
Breaking peripheral tolerance mediated by Tregs theoretically potentiates the 
natural occurring antitumor immune response or the induced effects of immunotherapy. 
In line with this concept, depletion of Tregs by anti-CD25 antibodies, targeting the 
α-chain of the IL-2 receptor, in murine models demonstrated an improved immune-
mediated tumor rejection.202-205 Furthermore, it resulted in enhanced therapeutic 
efficacy of immune-based therapy206,207, including DC vaccination.208-211 Also other 
treatments to counteract tumor escape, such as anti-PD-L1 antibodies or indoleamine-
2,3-dioxygenase inhibitors, might enhance the efficacy of various immunotherapies, 
including DC-based immunotherapy.212,213 Further research is needed, also to combine 
these approaches with DC vaccination.
5.5 Toward combination treatment
5.5.1 Tumor-debulking therapies
Given that immunotherapy is considered to be less effective in patients with a 
large tumor burden, owing to the presumed correlation of immune suppression 
and tumor burden, it is tempting to speculate on the possibility of tumor debulking 
as one treatment modality, combined with immune surveillance and immune 
memory induction by DC-based immunotherapy to clear small residues and to 
prevent relapses.
Tumor debulking, depending on the tumor type, could, for example, be accomplished 
with chemotherapy, targeted therapy, radiotherapy, or surgery.214 Beside a positive 
effect on the immune system when tumor burden decreases, local tumor-destructing 
therapies induce tumor cells to undergo apoptosis, with release of tumor antigens, 
which might elicit additional tumor-specific immune responses via in vivo loading of 
DC.215 However, since these modalities in themselves rarely induce a potent antitumor 
immune response, the immunogenicity of these methods need further enhancement 
by the local delivery of DC-activating signals.216,217 
5.5.2 Adoptive T cell transfer
Adoptive T cell therapies are based on the infusion of large numbers of tumor-specific 
T cells. It is currently under investigation whether DC vaccination can enhance the 
graft-versus-tumor effect of stem cell transplantation and donor lymphocyte infusions 
in hematological malignancies.218 Adoptive T cell transfer generates a high but short 
peak of antigen-specific T cells, whereas DC vaccination induces T cell responses more 
gradually that endure longer219, providing a rationale to combine the two treatment 
modalities. In preclinical models, DC vaccination indeed boosted and sustained 
antitumor T cell responses after adoptive T cell transfer.219,220 
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5.5.3 Concomitant cytokine therapy
In contrast to the above-discussed immunosuppressive cytokines involved in the tumor 
escape mechanisms, immunostimulatory cytokines play a key role in regulation of 
lymphocyte survival.221 It is thought that DC vaccination, among other immunotherapies, 
is likely to favor concomitant cytokine therapy with the goals of protecting effector 
CD8+ T cells from tumor-mediated dysfunction or death and of restoration of normal 
lymphocyte homeostasis. Most experience with combined cytokine treatments is 
obtained with IL-2, which not only prolongs survival of transferred CD8+ T cells but 
also enhances their antitumor activity.222 Along with IL-2, GM-CSF and IL-12 are also 
being explored in preclinical models and in the clinical setting as well, either alone or in 
combination with other treatment modalities.223 Thus far, clinical successes are limited, 
partly due to the restricted systemic administration because of toxic effects or due to 
unwanted immunosuppressive side effects. Type I IFNs have been well documented 
to suppress growth of tumor cells through inducing apoptosis and cell cycle arrest and 
have been clinically applied for treatment of certain tumor types, although various 
adverse effects impede optimal clinical application. Results of the combination of IFN-α 
with DC vaccination shows that it is safe, but it only elicits limited immune responses.70 
5.5.4 Chemotherapy 
For a long time, the dogma has been that the myelosuppressive effects of 
chemotherapy would prevent its combined use with immunotherapy. However, in 
recent years more evidence is accumulating that some forms of chemotherapy 
may not harm T cell responses224 and may in fact have a synergistic effect together 
with immunotherapeutic approaches.225-228 More recently, this notion of a possible 
synergistic effect of chemo- and immunotherapy has been supported through studies 
showing that treatment of tumor-bearing mice with gemcitabine results in enhanced 
cross presentation and T cell activation.227 Subsequent studies have demonstrated 
that chemotherapy-induced cell death can indeed invoke an immune response, 
depending on the biochemical cell death cascade that is induced by the drug.228 These 
data clearly show that chemotherapeutic agents can have a beneficial effect on the 
antitumor immune response and may even imply that at least part of the clinical effect 
of chemotherapy depends on its immunological effects. In addition, recent data from 
clinical studies in patients with cancer have shown that T cell induction is not hampered 
by chemotherapy treatment.229,230 
The optimal sequence of immunotherapy–chemotherapy combination treatments 
remain to be established. As different cytotoxic drugs have different immunological 
effects, it is conceivable that optimal treatment strategies will differ depending on 
both the cytotoxic compound chosen and the immunotherapeutic approach. Clinical 
data are lacking; however, trials combining chemotherapy and DC vaccination are 
in progress.
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5.5.5 Anti-CTLA-4 antibodies
Considering that CTLA-4 is constitutively expressed on Tregs, blockade of CTLA-4 was 
thought to deplete Tregs. However, data indicate that CTLA-4-blocking antibodies did 
not result in depletion or decreased suppressive activity of Tregs, but execute their 
immune-stimulatory effect by preventing normal downregulation of activated T cells 
by blocking CTLA-4/B7 interaction.231-233 
Since treatment with anti-CTLA-4 is antigen nonspecific, the combination with a 
vaccine could potentially direct the T cell response in a more specific manner, thereby 
diminishing autoimmune side effects. There is anecdotal information that anti-CTLA-
4 treatment after DC vaccination may indeed enhance DC vaccine-induced T cell 
responses.234 Further, the combination of anti-CTLA-4 plus DC vaccination could be 
synergistic rather than additive. However, clinical trials that are specifically designed 
to answer this question have not yet been published. 
To conclude, one can speculate of countless currently available and combined 
treatment modalities which may have a positive effect on the immune system. Trials 
in the near future will have to answer the question whether DC vaccination can elicit 
sustainable clinical responses in a substantial percentage of treated patients or can add 
to the clinical efficacy of other anti-cancer treatment modalities. With the wealth of 
information currently available on the molecular mechanisms that control the immune 
system, there is no doubt that these are exciting times for immunotherapy.
6 Summary and conclusions
In conclusion, DC vaccination has proven to be safe in multiple phase I(/II) trials. In 
the early days, trials were mainly performed with immature or semimature DC which 
is now known to have a negative effect on immunological and clinical responses. 
The first phase III trial in melanoma patients showed no survival advantages of DC 
vaccination over first-line chemotherapy, but also suffered from the early stage of the 
DC vaccination field. Thus far, sipuleucel-T is the only DC vaccine tested in phase III trials 
and proven to induce a survival benefit. To date many different mature DC vaccination 
studies in patients with various types of cancer are in progress, continuing to optimize 
the vaccines before starting a meaningful phase III trial. Naturally circulating DC subsets 
are now also being clinically explored as are the first studies on in vivo targeting of DC. 
Although observations of meaningful clinical responses are still scarce, expectations 
remain high, because when clinical responses have beend induced, they are often long 
lasting. Thus, DC vaccination research has now entered a stage somewhere between 
“proof of principle” and “proof of efficacy” trials. Crucial questions to answer at this 
moment are: why the clinical responses generally remain limited and what can be 
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done to improve the efficacy of vaccination. The answers to these questions probably 
lie in the preparation and administration of the DC vaccines. While DC vaccines have 
made significant advances over the last decade, multiple hurdles still remain. Within 
the next decade, the field will have to demonstrate maturity and not only yield a 
higher percentage of clinically responding patients but preferentially also develop 
means to predict at an early stage which patients will likely benefit and which not. The 
implementation of DC vaccination as the preferred form of standard therapy for cancer 
cannot become a reality until all these issues are fully addressed. We will not only have 
to improve our vaccines but also our clinical and monitoring tools. The latter will not 
only be beneficial for DC vaccination but also for other forms of immunotherapy such 
as antibody therapies against immune checkpoint molecules such as CTLA-4 and PD-1.
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2Part I: Modulation of DC vaccines
Abstract 
Electroporation of dendritic cells (DC) with mRNA encoding tumor-associated antigens 
(TAA) has multiple advantages compared to peptide loading. We investigated the 
immunologic and clinical responses to vaccination with mRNA-electroporated DC 
in 26 stage III HLA-A*02:01 melanoma patients scheduled for radical lymph node 
dissection (stage III disease) and 19 melanoma patients with irresectable locoregional 
or distant metastatic disease (referred to as stage IV disease). Monocyte-derived DC, 
electroporated with mRNA encoding gp100 and tyrosinase, were pulsed with keyhole 
limpet hemocyanin and administered intranodally. TAA-specific T cell responses were 
monitored in blood and skin-test infiltrating lymphocyte (SKIL) cultures. Comparable 
numbers of vaccine-induced CD8+ and/or CD4+ TAA-specific T cell responses were 
detected in SKIL cultures; 17/26 stage III patients and 11/19 stage IV patients. Strikingly, 
in this population, TAA-specific CD8+ T cells that recognize multiple epitopes and produce 
elevated levels of IFNγ upon antigenic challenge in vitro, were significantly more often 
observed in stage III patients; 15/17 versus 3/11 stage IV patients, p=0.0033. In stage 
IV patients, one mixed and one partial response were documented. The presence or 
absence of IFNγ-producing TAA-specific CD8+ T cells in stage IV patients was associated 
with marked difference in median OS of 24.1 months versus 11.0 months, respectively. 
In conclusion, vaccination with mRNA-electroporated DC induces a broad repertoire 
of IFNg-producing TAA-specific CD8+ and CD4+ T cell responses, particularly in stage III 
melanoma patients.
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Translational relevance 
Electroporation of dendritic cells (DC) with mRNA encoding tumor-associated 
antigens has multiple advantages compared to the conventional peptide loading. 
The presentation of multiple naturally processed epitopes in both MHC Class I 
and II should broaden the repertoire of responding lymphocytes. 
We studied in detail the immunologic response to vaccination with mRNA-
electroporated DC in 2 cohorts of melanoma patients: as palliative treatment 
for distant or irresectable locoregional metastatic disease and as adjuvant 
treatment following radical dissection of regional lymph nodes. A wide spectrum 
of tumor-specific IFNg-producing CD8+ T cells was detected, in particular in 
patients vaccinated in the adjuvant setting. Furthermore, vaccine-induced CD4+ 
T cells were shown to be FoxP3 negative.  
In conclusion, vaccination with mRNA-electroporated DC successfully 
enhances antitumor cytotoxic T cell responses and appears to be a promising 
adjuvant treatment of stage III melanoma patients. 
Introduction
DC are the most effective antigen-presenting cells (APC) of the immune system, highly 
capable of stimulating naive T cells. Immunotherapy with ex vivo-generated autologous 
DC pulsed with tumor peptides has provided proof of concept in clinical trials.1 We, 
and others, have showed that tumor-specific immune responses can be induced in 
both stage III and IV melanoma patients.1-5 Because objective clinical responses are 
observed in a minority of patients, further optimization of DC-based immunotherapy 
is warranted. 
To date, the majority of clinical studies on DC-based vaccinations have been 
conducted with MHC class I restricted peptide-pulsed monocyte-derived DC in 
patients with measurable distant metastatic disease. However, there are at least 
several theoretical disadvantages against these protocols, which might be improved 
to induce more effective and sustained immunologic responses. First, the exploitation 
of MHC class I restricted peptide epitopes target CD8+ CTL only, without involving 
CD4+ T helper cells to enhance and sustain antitumor CTL responses. Second, pulsing 
DC with peptide epitopes implicates the use of a given HLA type, with defined tumor-
associated antigens (TAA). Moreover, peptide-loaded DC expose the antigen only for 
a short period of time 6, because the peptides may readily dissociate from the MHC 
molecules.7 Importantly, peptide loading does not account for posttranscriptional 
modifications of peptide epitopes.8,9 
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One strategy to circumvent most of these disadvantages of peptide pulsing is 
electroporation with synthetic mRNA encoding TAA, resulting in endogenous synthesis 
of the complete TAA. It has been shown previously that electroporation of DC with mRNA 
is effective and safe.7,10,11 DC retain their phenotype and maturation potential upon 
electroporation, as well as their migratory capacities.10,12 Electroporated DC express TAA 
antigens, encoded by the electroporated mRNA and induce specific CD8+ T cell responses 
in melanoma patients.10 Importantly, because mRNA lacks the potential to integrate into 
the host genome, it obviates safety concerns associated with gene therapy trials.
It is now widely recognized that high tumorload in patients with end-stage cancer 
often induces local, or even systemic, immune suppression by the secretion of 
suppressive cytokines and attraction of regulatory T cells.13-15 This suppressive tumor 
microenvironment will hamper the effective antitumor responses. Melanoma patients 
with locoregional lymph node metastases are at high risk of relapse and currently no 
standard adjuvant treatment is available which results in overall survival benefit.16 
Given the minimal burden of tumor; we hypothesized that vaccination of patients 
adjuvant to therapeutic radical lymph node dissection might enhance vaccine efficacy.
In this study we investigated in detail the immunologic responses to intranodal 
vaccination with monocyte-derived DC electroporated with mRNA encoding gp100 and 
tyrosinase in 2 cohorts of melanoma patients; with distant metastatic or irresectable 
locoregional disease following  radical regional lymph node dissection. 
Patients and Methods
Patient population
Melanoma patients with locoregional resectable disease (further referred to as stage III), 
before or within 2 months after radical dissection of regional lymph node metastases, and 
patients with irresectable locoregional or distant metastatic disease (further referred to 
as stage IV) were included. Additional inclusion criteria were HLA-A*02:01 phenotype, 
melanoma expressing the melanoma-associated antigens gp100 and tyrosinase, and 
World Health Organization performance status 0 or 1. Patients with brain metastases, 
serious concomitant disease, or a history of a second malignancy were excluded. The 
study was approved by our Institutional Review Board, and written informed consent 
was obtained from all patients. Clinical trial registration number is NCT00243529. 
Study protocol
Patients received a DC vaccine intranodally, injected into a clinically tumor-free lymph 
node under ultrasound guidance. The DC vaccine consisted of autologous mature 
monocyte-derived DC electroporated with mRNA encoding for gp100 and tyrosinase 
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protein, and pulsed with keyhole limped hemocyan (KLH) protein. Patients received 
3 vaccinations with a biweekly interval. Ten patients received an extra vaccination 
1 or 2 days before the radical lymph node dissection for additional imaging studies. 
One to 2 weeks after the last vaccination a skin test was conducted. In absence of 
disease progression or recurrence, patients received a maximum of 2 maintenance 
series at 6-month intervals, each consisting of 3 biweekly intranodal vaccinations 
(Supplementary Figure 1). All vaccinations were administered between May 2006 
and May 2010. Patients were considered evaluable when they had completed the 
first vaccination cycle. Vaccine-specific immune response was the primary endpoint, 
clinical response was a secondary endpoint in stage IV patients. Progression-free and 
overall survival were calculated from the time from apheresis to recurrence (for stage 
III patients) or progression (for stage IV patients), or death.
DC preparation and characterization
DC were generated from peripheral blood mononuclear cells (PBMC) prepared 
from leukapheresis products as described previously.17 After leukapheresis, part of 
the PBMC was used for the generation of monocyte-conditioned medium (MCM).18 
Supplementary figure 1. CONSORT flow chart.
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Plastic-adherent monocytes or monocytes isolated by centrifugal elutriation were 
cultured for 5 to 7 days in X-VIVO 15 medium (BioWhittaker) supplemented with 2% 
pooled human serum (HS) (Bloodbank Rivierenland), interleukin 4 (IL-4; 500 U/mL), and 
granulocyte macrophage colony-stimulating factor (800 U/mL; both from Cellgenix). 
Immature DC were pulsed at day 3 with KLH (10 µg/mL; Calbiochem). Two days before 
the harvesting, cells were matured with autologous MCM, prostaglandin E2 (10 µg/mL; 
Pharmacia & Upjohn) and recombinant tumor necrosis factor alpha (10 ng/mL; provided 
by Dr. G Adolf, Bender Wien).19 This protocol gave rise to a mature phenotype meeting 
the release criteria described previously20: low expression of CD14, high expression of 
MHC class I, MHC class II, CD83, CD80, CD86, and CCR7, and expression of gp100 and 
tyrosinase after electroporation with mRNA (Supplementary Figure 2). Harvested DC 
were tested by fluorescence-activated cell sorting (FACS) analysis as described below. 
Plasmids and in vitro mRNA transcription
Plasmids have been sent to CureVac GmbH for the production of documented GMP grade 
gp100 and tyrosinase RNA for ex vivo use in clinical DC vaccination. The documented 
gp100 and tyrosinase mRNA was produced from the plasmids pGEM4Z/hgp100/A64 
and pGEM4Z/tyrosinase/A64 (provided by Kris Thielemans, Free University Brussels, 
Belgium) according to GMP guidelines. CureVac mRNA contains a 5’ cap and 3’ poly A-tail 
that leads to high RNA stability and increased protein expression in transfected cells. 
The mRNA is purified by PUREmessenger technology. This chromatography method 
efficiently eradicates traces of DNA and proteins. The mRNA production process is 
carried out in clean room facilities and is documented by in-process controls. RNA 
quality was verified by agarose gel electrophoresis, RNA concentration was measured 
spectrophotometrically, and RNA was stored at -80ºC in small aliquots. 
Supplementary figure 2. Vaccine characteristics of first cycle of all patients. (A) Expression of HLA-ABC, 
HLA-DR/DP, HLA-DQ, CD80, CD86, CD83, and CCR7 was analyzed by flow cytometry. (B) Tumor antigen 
expression by DC 2-4 hrs after electroporation with mRNA encoding gp100 and tyrosinase. Data are shown 
as percentage of positive DC used for the first vaccination. The graphs represent mean ± SD of all patients.
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Electroporation of DC
Mature DC were electroporated as described previously.10 Briefly, DC were washed 
twice in PBS and once in OptiMEM without phenol red (Invitrogen). Twenty micrograms 
of RNA encoding either gp100 or tyrosinase were transferred to a 4 mm cuvette 
(Bio-Rad) and 8×106 cells were added in 200 µL OptiMEM and incubated for 3’ before 
being pulsed in a Genepulser Xcell (Bio-Rad) by an exponential decay pulse of 300 V, 
150 µF, as described before.10 Immediately after electroporation, cells were washed 
and were transferred to warm (37ºC) X-VIVO 15 without phenol red (Cambrex Bio 
Science) supplemented with 5% HS and left for at least 2 hours at 37ºC, before further 
manipulation. The first vaccination was given with fresh DC 4 hours after electroporation. 
DC for subsequent vaccinations were frozen 2 hours after electroporation, thawed 
at the day of vaccination, and incubated for 2 more hours at 37ºC before injection. 
Electroporation efficiency was analyzed by intracellular staining and flow cytometric 
analysis for each separate TAA, electroporated DC were mixed before vaccination. 
Flow cytometric analysis
The following fluorescein isothiocyanate-conjugated mAbs were used: anti-HLA 
class I (W6/32), and anti-HLA DR/DP (Q5/13); and PE-conjugated mAbs: anti-CD80 
(BD Biosciences), anti-CD14, anti-CD83 (both Beckman Coulter), and anti-CD83 (BD 
Pharmingen). For intracellular staining of the TAA the following mAb were used: 
NKI/beteb (IgG2b; purified antibody) against gp100, T311 (IgG2a; Cell Marque Corp.) 
against tyrosinase. For intracellular staining cells were fixed for 4’ on ice in 4% (w/v) 
paraformaldehyde (Merck) in PBS, permeabilized in PBS/2%BSA/0.02% azide/0.5% 
saponin (Sigma-Aldrich; PBA/saponin), and stained with mAb diluted in PBA/
saponin/2%HS, followed by staining with allophycocyanin-labeled goat-anti-mouse 
(BD PharMingen). Flow cytometry was performed with FACSCalibur flow cytometer 
equipped with CellQuest software (BD Biosciences).
Flow cytometric analysis of T cells was conducted using directly labelled mAbs against 
CD4, CD8, CD25, CD127, CTLA-4 (BD Pharmingen), and FoxP3 (eBiosciece), all according 
to the manufacturer’s protocol. Tregs were defined as CD4+FoxP3+CD25highCD127low 
cells; percentage of Tregs was defined as the number of CD4+FoxP3+CD25highCD127low 
cells divided by the total number of CD4+ cells x100.
KLH-specific proliferation
KLH-specific cellular responses were measured before and after vaccination by 
proliferation assay. PBMC were isolated from heparinized blood by Ficoll-Paque density 
centrifugation. PBMC were stimulated with KLH (4 µg/2×105 PBMC) in medium with 
10% human AB serum. After 3 days, cells were pulsed with 3H-thymidine for 8 hours, 
and incorporation was measured with a betacounter. Experiments were conducted 
in triplicate. 
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KLH-specific antibody production
KLH-specific antibodies were measured in the sera of patients before and after 
vaccination. Microtiter plates (96 wells) were coated overnight at 4ºC with KLH (25 µg/mL 
in PBS). Different concentrations of patient serum (range 1:100 to 1:50,000) were added 
for 60’ at room temperature. After extensive washing, patient antibodies were detected 
with mouse anti-human IgG, IgA, or IgM antibodies labelled with horseradish peroxidase 
(Invitrogen).  3,3’ 5,5-tetramethyl-benzidine was used as a substrate and plates were 
measured with a microtiter plate reader at 450 nm. For quantification, an isotype-
specific calibration curve for the KLH response was included in each microtiter plate.
Skin-test infiltrating lymphocyte cultures
Note that 0.2 - 1 x 106 DC pulsed with the gp100 and/or tyrosinase peptides and DC 
electroporated with gp100 and/or tyrosinase mRNA each were injected intradermally in 
the skin of the back of the patient at 4 or 6 different sites.21 The maximum diameter of 
induration was measured after 48 hours (A detailed description of the DTH procedure 
can be found at http://www.labtube.tv/playvideo.aspx?vid=131825). From each site 
induration was measured and punch biopsies (6 mm) were obtained. Half of the biopsy 
was cryopreserved and the other part was manually cut and cultured in RPMI 1640 
containing 7% HS and IL-2 (100 U/mL). Every 7 days, half of the medium was replaced 
by fresh medium containing HS and IL-2. After 2 to 4 weeks of culturing, SKILs were 
tested. In general, similar results were obtained per patient, regardless of the method 
of antigen-presentation (for example, Supplementary Figure 3). 
Tetramer staining
SKILs and freshly isolated PBMC were stained with tetrameric-MHC complexes containing 
the HLA-A2-binding epitopes gp100:154-162, gp100:280-288, or tyrosinase:369-377 
(Sanquin) or HLA-DR4-binding epitopes gp100:44-59 and tyrosinase:448-462 (provided 
by William Kwok, Benaroya Research Institute, Seattle, WA) as described previously.19 
In addition, PBMC of patients with tetramer positive CD4+ T cells were restimulated for 
8 days with DR4-binding gp100 or tyrosinase peptides and stained with tetrameric-MHC 
complexes containing class II epitopes gp100:44-59 and tyrosinase:448-462. Tetrameric-
MHC complexes recognizing HIV were used as controls; at least a 2-fold increase of the 
double-positive population compared to control was regarded to be positive.
Antigen and tumor recognition
Antigen recognition was determined by the production of cytokines and cytotoxic 
activity of SKILs in response to T2 pulsed with the indicated peptides or BLM 
(a melanoma cell line expressing HLA-A*02:01 but no endogenous expression of gp100 
and tyrosinase), transfected with control antigen G250, with gp100 or tyrosinase, or 
an allogenic HLA-A*02:01-positive, gp100-positive, and tyrosinase-positive tumor cell 
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line (MEL624) were measured. Cytokine production was measured in supernatants 
after 16 hours of coculture by a cytometric bead array (Th1/Th2 Cytokine CBA 1; BD 
PharMingen). Positive and specific cytokine production was defined as a 2-fold increase 
compared with stimulation with the cell lines pulsed with an irrelevant peptide.
Statistical analysis
Differences between the groups were evaluated using the Fisher exact test or one-way 
ANOVA. Statistical significance was defined as p<0.05.  GraphPad Prism 5.0 was used 
for all analyses.
Results
Patient characteristics
A total of 48 HLA-A*02:01 positive melanoma patients were enrolled (Supplementary 
Figure 1), of which 3 patients (IV-D-13, IV-D-12, IV-D-07) were regarded as nonevaluable, 
because they did not complete the first cycle because of rapid progressive disease. Two 
stage IV patients were only evaluable for immunologic response; patient IV-C-05 had 
no measurable disease at baseline and patient IV-D-15 had proven brain metastasis 
after the second vaccination but completed the first cycle. Twenty-six stage III and 19 
stage IV patients were included. Twenty-three stage III patients received 1 cycle of 
Supplementary figure 3. Detection of tumor-specific T cells in SKIL cultures does not require challenge 
with defined epitopes. Tetramer analysis of SKILs cultured from biopsies of DTH reactions to DC pulsed 
with tumor peptides (upper plots) or DC electroporated with mRNA encoding tumor proteins (lower plots) 
of patients II-E-09 (A), II-E-03 (B), and II-E-10 (C). This figure shows that sampling DTH biopsy cultures with 
tetramers yields similar results when the patient is challenged with intradermal injections with DC pulsed 
with defined epitopes or DC electroporated with mRNA encoding the full tumor antigen.
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maintenance vaccinations and 20 patients completed the full 3 cycles. Three stage IV 
patients received 1 cycle of maintenance vaccinations; 1 patient completed the full 3 
vaccination cycles. No unexpected or severe adverse events were observed. Patient 
characteristics are summarized in Table 1. 
Vaccine characteristics
Phenotypic and functional release criteria were defined for DC vaccines to ensure 
minimal quality criteria and the usage of mature DC in clinical vaccination protocols.22 
The phenotype of the ex vivo-generated DC was determined by flow cytometry and all 
produced vaccines met the standard release criteria, with respect to expression of MHC 
class I and II, and co-stimulatory molecules, CD83 and CCR7 (Supplementary Figure 2A). 
Furthermore, we confirmed the intracellular expression of TAA gp100 and tyrosinase 
after electroporation by flow cytometry (Supplementary Figure 2B). Patients received 
on average 12×106 DC per vaccination with a maximum of 15×106 DC per vaccination.
Immunologic response to KLH
For immunomonitoring purposes all DC have been loaded with the control antigen KLH. 
PBMC, isolated after each vaccination, showed increased proliferation upon stimulation 
with KLH after vaccination in almost all patients in the first cycle (Figure 1A). One 
patient first developed a proliferative response to KLH in the second cycle. Anti-KLH 
antibodies were detected in 9 out of 17 stage IV patients tested, and 15 out of 26 stage 
III patients tested (Figure 1B). These data demonstrate that the vaccine effectively 
induced de novo immune responses.
Figure 1. KLH-specific immune responses before and after DC vaccination. (A) KLH-specific T cell 
proliferation was analyzed before the first vaccination and after each DC vaccination during the first 
vaccination cycle in PBMC of stage III (filled circles) and stage IV (open circles) melanoma patients. Per 
time point each dot represents 1 patient. Proliferative response to KLH is given as proliferation index 
(proliferation with KLH/proliferation w/o KLH). * p<0.05; NS, not significant. (B) KLH-specific IgG, IgA, and 
IgM antibodies were quantitatively measured after the first vaccination cycle in sera of vaccinated patients. 
Numbers indicate the number of patients without proliferative (A) or humoral (B) KLH-response.
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2Part I: Modulation of DC vaccines
TAA-specific responses in blood
To investigate TAA-specific immune responses, PBMC were screened with tetrameric-
MHC complexes before and after each cycle of 3 vaccinations at the time point of 
SKIL test. TAA-specific CD8+ T cells were only found in freshly isolated PBMC from 3 
stage III and 3 stage IV patients after vaccination (Figure 2; Table 2). Because it has 
been described that melanoma patients can already have a substantial number of 
TAA-specific T cells circulating in their blood, we analyzed the presence of TAA-specific 
T cells in PBMC isolated before vaccination. Three out of these 6 patients had no 
detectable TAA-specific CD8+ T cells circulating before vaccination, suggesting that TAA-
specific CD8+ T cells were newly induced, or at least enhanced, by the DC vaccinations 
in these patients, in concordance with previous reports.23 
Evidence is emerging that CD4+ T cells needs to be antigen-specific in order to 
potentiate the CD8+ immune response. Therefore we analyzed the presence of TAA-
specific CD4+ T cells in PBMC of all 15 DR4+ patients. Four patients were positive 
after vaccination (patients IV-C-01, IV-C-02, IV-C-03, IV-C-08; Figure 3A; Table 2). 
Tetramer analysis of PBMC restimulated in vitro with DR4-binding peptides confirmed 
the presence of TAA-specific CD4+ T cells (Figure 3B). TAA-specific CD4+ T cells were 
detectable before vaccination in only 1 patient (IV-C-03), but only after in vitro 
restimulation of PBMC with DR4-binding peptides, suggesting that tumor-specific CD4+ 
T cells were induced, or at least enhanced, by DC vaccinations in these patients. We 
identified concurrent TAA-specific CD8+ T cells in SKIL cultures in 3 of the 4 patients with 
tumor-specific CD4+ T cells in their blood (patients IV-C-01, IV-C-02, IV-C-03; Table 2). 
To exclude that the TAA-specific CD4+ T cells have a suppressor phenotype, we tested 
their FoxP3 expression, all were negative (Figure 3C).
TAA-specific responses in SKIL cultures
Figure 2. Tumor antigen-specific CD8+ T cell responses in peripheral blood. An example of tetramer 
analysis of PBMC from patient II-E-08 is shown. Cells were stained with tetramers encompassing the 
HLA*02-specific gp100:154-162, gp100:280-288, tyrosinase:369-377 peptide or an irrelevant peptide and 
with anti-CD8 mAb. The irrelevant control peptide stained 0.01% of the PBMC.
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Figure 3. Tumor antigen-specific CD4+ T cell responses in peripheral blood. An example of tetramer 
analysis of PBMC of patient IV-C-02 after the first cycle of DC vaccination is shown. (A) Freshy isolated 
PBMC were stained directly after isolation with tetramers encompassing the HLA-DR4-specific gp100:44-
59 peptide, tyrosinase:448-462 peptide, or an irrelevant peptide and with anti-CD4 mAb. (B) Tetramer 
analysis of PBMC after 8 days of in vitro restimulation with DR4-binding gp100 or tyrosinase peptides. Note 
that before restimulation (A), only gp100-specific CD4+ T cells are found, whereas after restimulation (B) 
both gp100- and tyrosinase-specific CD4+ T cells are detectable. (C), the in vitro stimulated population of 
gp100- or tyrosinase-specific CD4+ PBMC of patient IV-C-02 was further characterized for FoxP3 expression. 
TAA-specific CD4+ T cells did not express FoxP3. 
Previously we showed that the presence of TAA-specific T cells in SKIL cultures positively 
correlates with clinical outcome in stage IV melanoma patients.22 Skin tests were 
carried out after each cycle of vaccinations. Because conducting skin tests and taking 
biopsies puts a great burden to the patient, and previously we observed in a series of 
patients who underwent prevaccination skin test analysis that none of the patients had 
detectable levels of TAA-specific T cells before vaccination, we choose not to conduct 
prevaccination skin tests, but rather conduct in-depth analysis on the postvaccination 
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samples. Tetramer positive CD8+ SKILs were detected in 17 stage III patients and in 11 
stage IV patients (p=0.7574 Fischer exact test). In 8 stage III patients and in 2 stage 
IV patients, CD8+ SKILs were specific for all 3 tested epitopes (Table 2; Figure 4A). Six 
stage III and 3 stage IV patients had TAA-specific CD8+ T cells against 2 of the 3 epitopes 
tested, although CD8+ T cells of the other patients recognized 1 epitope. 
Merely the presence of TAA-specific CD8+ T cells is not necessary sufficient for 
effective antitumor responses. Therefore, we tested whether the vaccine-induced 
TAA-specific CD8+ T cells were “functional” in terms of selective IFNg production 
Figure 4. Tumor antigen-specific CD8+ T cell responses in posttreatment SKIL cultures. The presence and 
functionality of TAA-specific T cells were tested in lymphocytes cultured form skin-test biopsies (SKILs). 
(A) An example is shown of tetramer analysis of SKILs from patient II-E-07, cultured from a delayed-type 
hypersensitivity (DTH) reaction to DC pulsed with tumor peptides. Cells were stained with tetramers 
encompassing the gp100:154 peptide, gp100:280, tyrosinase or an irrelevant peptide (control), and with 
anti-CD8 mAb. The irrelevant control peptide stained 0.07% of the T cells. The biopsy contains gp100- 
and tyrosinase-specific CD8+ T cells. (B) IFNg production by the same T cells after stimulation with T2 
cells loaded with gp100:154-162 peptide and gp100:280-288 or tyrosinase:369-377 peptide (peptide 
stimulation), BLM cells expressing gp100 or tyrosinase protein (protein stimulation), or Mel624 cells 
expressing both gp100 and tyrosinase (tumor stimulation). (C) Example of functional responses of SKILs 
of patient IV-C-14, cultured from a biopsy of a DTH reaction to DC electroporated with tyrosinase mRNA, 
showing recognition of tyrosinase epitopes when presented by HLA-A2.1 positive tyrosinase-transfected 
BLM cells or endogenously tyrosinase expressing Mel624 cells, by the specific and elevated production of 
IFNγ, although it does not recognize the specific epitopes used in previous vaccination studies. This indicates 
that a broad repertoire of TAA-specific T cells can be stimulated by vaccination with mRNA-transfected DC. 
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upon coculture with peptide-, or protein-loaded target cells or tumor cells (Table 2; 
Figure 4B). Strikingly, although we detected tetramer-specific CD8+ T cells in both stage 
III and IV melanoma patients to similar extend, we found increased IFNg production 
only in 3 out of 11 stage IV melanoma patients. In contrast, in stage III patients with no 
measurable disease, we found IFNg production in 15 out of 17 patients with tetramer-
positive CD8+ SKIL cultures, (p=0.0033 Fisher exact test). 
Interestingly, SKILs of 3 patients (IV-C-02, IV-C-10, IV-C-14) that did not produce 
cytokines upon coculture with the HLA-A*02:01 binding peptides, produced IFNγ upon 
coculture with the respective tumor protein, indicating that T cells recognized different 
epitopes. SKILs derived from three additional patients (II-E-04, II-E-05, IV-C-12) that 
produced IFNγ upon stimulation with only one of the HLA-A*02:01 binding peptides, 
produced IFNγ upon coculture with gp100-expressing cell lines or tyrosinase-expressing 
cell lines (Table 2; Figure 4C), suggesting that TAA-specific T cells with another specificity 
than the epitopes used for peptide stimulation and tetramer staining were induced 
by the DC vaccine. 
Clinical outcome in stage III patients
One patient had progressive disease within 4 months after start of vaccinations. As 
of June 2011, 15 out of 26 patients progressed at 3 to 37 months after the start of 
vaccination. Twelve of 26 patients are in ongoing remission for up to 45 months. The 
median progression-free survival (PFS) is 34.3 months, and the median overall survival 
has not yet been reached. Extended follow-up is necessary to draw conclusions on 
the potency of vaccination with mRNA electroporated DC as an adjuvant therapy in 
melanoma patients. 
Clinical outcome in stage IV patients
All stage IV patients were evaluated for clinical response at 3-month intervals with 
CT scan. Five patients had stable disease up to 15 months and 1 patient (IV-C-02) 
showed a mixed response. One patient (IV-D-11) with irresectable primary melanoma 
of the nasal mucosa with bilateral lymph node metastases in the neck region and 
metastases in the maxillary sinus, showed a partial response of the primary tumor after 
3 vaccinations, allowing resection of the primary tumor. The lymph node metastases 
and sinus metastases completely regressed upon further vaccination and this patient 
is in ongoing complete remission for 52+ months (Figure 5). DR4 expression was not 
correlated with survival (data not shown) in the vaccinated patients. 
We observed a trend towards improved PFS in patients with TAA-specific T cells 
in their blood or SKIL cultures compared to patients without TAA-specific responses, 
with 8.1 month versus 2.8 months, respectively (p=0.062). Similarly, patients with 
TAA-specific T cells showed improved overall survival compared to patients without 
TAA-specific T cells, 24.1 months versus 11.0, respectively (p=0.101).
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Figure 5. Partial response after 3 intranodal vaccinations with mRNA-transfected DC.  (A) Patient IV-D-11 
presented with a irresectable primary melanoma from nasal mucosa with extension into the nasal septum, 
maxillary and ethmoid sinus, and bilateral lymphadenopathy of level 1, 2, and 5. (B) Three intranodal 
vaccinations with mRNA-transfected DC induce a partial response, allowing resection of the primary tumor. 
(C) Patient is in ongoing remission.
A
B
C
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Discussion
Early clinical trials have shown that vaccination with DC loaded with tumor peptides 
is feasible, safe, and can induce tumor-specific immune responses in advanced 
cancer patients.1,5,24 Although these results are promising, further improvement is 
warranted before its use can be accepted in clinical practice. In the present study, 
we show that DC presenting multiple naturally processed epitopes following mRNA 
electroporation, enhance tumor-specific CD8+ and CD4+ T cell responses in melanoma 
patients. Importantly, both the presence of TAA-specific CD8+ T cells and their capacity 
to produce IFNg upon encounter of their cognate antigen was significantly increased 
in stage III patients treated in the adjuvant setting.
Long-lasting T cell receptor stimulation of several hours by fully matured DC is 
necessary to activate naive T cells to proliferate and differentiate into effector cells.25,26 
The generated DC highly and sustainably expressed gp100 and tyrosinase after 
electroporation with mRNA. In vitro, DC were able to activate gp100-specific CTL up 
to 48 hours after electroporation. Previously, we showed that gp100 and tyrosinase 
protein can be detected inside lymph nodes up to 24 hours after intranodal injection 
of mRNA electroporated DC.10 In this study, TAA-specific T cells were induced in the 
majority of patients, which clearly shows that electroporated DC are indeed potent 
inducers of tumor-specific T cells. 
We detected TAA-specific CD8+ T cells in peripheral blood of only 6 of the 45 patients. 
This is an underestimation, likely because of the low frequencies of these cells in the 
circulation and the observation that substantially more TAA-specific CD8+ T cells were 
detected in SKIL cultures. Still, the number of TAA-specific T cells measured in this study 
might be underestimated because we screened with HLA-A*02:01 binding tetramers 
only. Indeed, in 6 patients SKILs produced IFNγ upon coculture with the protein gp100 
and/or tyrosinase, although no IFNγ production was detected upon coculture with the 
corresponding HLA-A*02-binding peptide(s), supporting the notion that T cells with a 
broader specificity than the HLA-A*02:01 epitopes were induced. Recently, Bonehill 
and colleagues reported on the use of monocyte-derived DC electroporated with 
mRNA encoding multiple tumor antigens, CD40 ligand, active TLR4 and CD70 (TriMix-
DC).27 Although they monitored tumor-specific T cells by using autologous Epstein-Barr 
virus-transformed B cells transfected with tumor antigens as target cells, comparable 
frequencies of gp100 and tyrosinase-specific CD8+ T cells were found. 
In 4 out of 10 patients tested, mRNA-electroporated DC induced concomitant TAA-
specific CD4+ T cells. The observation that these cells did not express FoxP3, suggest 
that these cells were T helper cells and not regulatory T cells. Initially, the main function 
of CD4+ T helper 1 cells was thought to be the production of cytokines providing growth 
and differentiation signals to precursor CTLs to become effector CTLs.28 However, 
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CD4+ T cells have also been shown to participate in the elimination of tumor and the 
maintenance of long-term protective immunity.29-31 In addition, activated T helper cells 
can stimulate precursor CTLs by reciprocal activation of APCs, for instance via CD40-
CD40L interactions.32 Recently it was shown that CD4+ T cells enhance the recruitment 
of CD8+ T cells to the lymph nodes 33 and tumor.34-36 Moreover, a direct antitumor 
effect of T helper cells has been shown.37-39 This may be of particular relevance for the 
antitumor response against melanoma because this tumor type frequently expresses 
class II molecules constitutively.40,41 Indeed, CD4+ T cell responses have been identified in 
peripheral blood from melanoma patients who remained disease-free after treatment 
for multiple relapses.39
Our data suggests a trend toward improved overall survival, when compared 
with recently reported survival data in comparative arms from large randomized 
prospective studies on immunotherapy with anti-CTLA4 antibodies in irresectable 
metastatic melanoma patients.42,43 It is tempting to speculate that the observed clinical 
responses result from vaccine-induced immune responses. Indeed, stage IV melanoma 
patients with TAA-specific T cell responses showed increased clinical outcome after 
vaccination with mRNA-loaded DC when compared with patients with no vaccine-
enhanced TAA-specific T cell responses. These data confirm and extend our previous 
findings that the presence of tumor-specific T cells in SKIL cultures identifies a subgroup 
of patients that might benefit from immunotherapy.21 Moreover, these studies show 
that sustained disease control can be achieved in increasing numbers of patients, but 
objective antitumor responses might take several months to years to develop.44,45 The, 
in general, delayed response patterns in immunotherapy and the high response rates to 
novel targeted therapies in melanoma, obviously warrants future studies that combine 
both modalities to achieve durable tumor control. Such studies should implement SKIL 
culture analyses pre- and postintervention in both active and comparative arms in 
order to elucidate the dynamics and nature of the induced immune responses. 
The higher tumor burden in stage IV as compared to stage III melanoma patients may 
hamper the induction of effective immune responses but instead favor local immune 
suppression. The present study shows that robust immunologic responses are more 
frequently induced in patients with no evidence of disease compared with patients with 
macroscopic tumor burden. On the basis of the association of tumor-specific T cells 
and improved clinical outcome, this suggests that DC-based vaccination is a promising 
adjuvant treatment of stage III melanoma patients. However, extended follow-up is 
warranted to draw conclusions on the clinical efficacy of DC-based vaccination in this 
stage of disease. 
In summary, the advantages of vaccination with DC electroporated with mRNA 
encoding TAA include lack of HLA-restriction, presentation of multiple TAA epitopes 
to both CD8+ and CD4+ T cells, and the subsequent induction of a large repertoire 
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of TAA-specific T cells. We show that vaccination of melanoma patients with mRNA-
electroporated DC induces robust tumor-specific CD4+ and CD8+ T cell responses, 
in particular in stage III melanoma patients treated adjuvant to radical lymph node 
dissection.
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3Abstract
Autologous dendritic cell (DC) therapy is an experimental cellular immunotherapy 
that is safe and immunogenic in patients with advanced melanoma. In an attempt to 
further improve the therapeutic responses, we treated 15 patients with melanoma, 
with autologous monocyte-derived immature DC electroporated with mRNA encoding 
CD40 ligand (CD40L), CD70 and a constitutively active TLR4 (caTLR4) together with 
mRNA encoding a tumor-associated antigen (TAA; respectively gp100 or tyrosinase). In 
addition, DC were pulsed with keyhole limpet hemocyanin (KLH) that served as a control 
antigen. Production of this DC vaccine with high cellular viability, high expression of co-
stimulatory molecules and MHC class I and II and production of IL-12p70, was feasible in 
all patients. A vaccination cycle consisting of three vaccinations with up to 15x106 DC per 
vaccination at a biweekly interval, was repeated after 6 and 12 months in the absence 
of disease progression. mRNA-optimized DC were injected intranodally, because of low 
CCR7 expression on the DC, and induced de novo immune responses against control 
antigen. T cell responses against tyrosinase were detected in the skin-test infiltrating 
lymphocytes (SKILs) of two patients. One mixed tumor response and two durable tumor 
stabilizations were observed amongst 8 patients with evaluable disease at baseline.  In 
conclusion, autologous mRNA-optimized DC can be safely administered intranodally 
to patients with metastatic melanoma but showed limited immunological responses 
against tyrosinase and gp100.
90
Part I. Modulation of DC vaccines
3Introduction
DC are the most potent professional antigen-presenting cells of the immune system. 
At present, DC-based immunotherapy is explored at different centers in therapeutic 
vaccination trials in cancer patients aiming to induce and augment the anticancer 
immune response.1,2 Immature DC are considered to be primarily involved in the 
recognition and uptake of antigens. When stimulated by appropriate “danger signals” 
they mature and migrate from peripheral tissues to lymphoid organs.  Maturation 
is characterized by the upregulation of cell surface molecules involved in antigen 
presentation and co-stimulation (e.g., CD80, CD86, CD40, and MHC class II) as well as 
the release of pro-inflammatory cytokines (e.g., interleukin (IL)-12 p70). Within the 
lymph node, matured DC are able to activate naive T cells which recognize the antigenic 
epitopes presented on the surface of the DC.3-5 Immunotherapy with ex vivo-generated 
autologous DC pulsed with tumor peptides has provided proof of concept in clinical 
trials.6 We and others have demonstrated that tumor-specific immune responses can 
be induced in regional and distant metastatic melanoma patients and clinical responses 
have been reported in a small percentage of patients.7-10
One important aspect in DC-based immunotherapy is the ex vivo maturation of 
DC.11 Studies that have compared the immunogenicity of immature vs. mature DC 
show that maturation is essential for the induction of immunological responses in 
cancer patients.11,12 Moreover, the use of mature DC appears to be associated with a 
better clinical outcome as compared to immature DC.11,13 IL-12p70, a pro-inflammatory 
cytokine, plays an essential role in the type of immune response that is induced as 
IL-12p70 promotes Th1 responses necessary for obtaining an effective cytotoxic T cell 
response. The cytokine cocktails commonly used for obtaining DC maturation however 
fail to induce such production of IL-12p70 by the DC in vitro.14 The IL-12p70 production 
and the T cell-stimulatory capacity of DC can be greatly enhanced by providing them 
with three different molecular adjuvants through electroporation with mRNA encoding 
CD40L, CD70, and a constitutively active form of TLR4 (caTLR4).15,16 The combination of 
CD40L and TLR4 mimics CD40 ligation17 and TLR4 signaling of the DC18 and generates 
phenotypically mature, cytokine-secreting DC. The introduction of CD70 into the DC 
provides a co-stimulatory signal to naive T cells by inhibiting activated T cell apoptosis 
and by supporting T cell proliferation.19 In early clinical trials, mRNA-optimized DC were 
shown to prime CD4+ and CD8+ T cells in melanoma patients.20,21
Another crucial aspect in DC-based immunotherapy is the efficacy of antigen-
loading of DC. To date, one of the most widely used techniques to load human DC with 
TAA for the induction of an antitumor immune response is the incubation of DC with 
HLA class I-binding peptides. Tumor antigen-derived peptides have the advantage that 
many peptides are commercially available. On the downside, antigenic peptides are 
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3restricted to a given HLA type, restricting the number of patients that can be treated. 
Furthermore, MHC-peptide complexes have a relative short half-life due to low affinity 
and MHC turnover,22,23 and peptide loading does not account for posttranscriptional 
modifications of peptide epitopes.24,25 In addition, the exploitation of MHC class 
I-restricted peptides targeting cytotoxic CD8+ T cells only, do not activate CD4+ T helper 
cells which are able to enhance and sustain antitumor responses by cytotoxic T cells.26 
For all of these reasons various methods have been designed to enhance tumor 
antigen presentation by DC, including electroporation with synthetic mRNA encoding 
full length TAA, or fusion proteins of TAA and an HLA-class II processing signal. Proteolytic 
processing of the endogenously produced antigen within the DC will result in loading of 
multiple suitable peptides onto the patient’s own MHC molecules expressed by the DC. 
mRNA-loading obviates the need of specified epitopes and there is no need for restriction 
of patients based on HLA type.27 Another benefit of this technique is the presentation of 
multiple epitopes in both MHC class I for the induction of CD8+ T cells and in MHC class 
II for interaction with CD4+ T helper cells. Although DC loading with tumor cell lysate has 
overlapping advantages with TAA mRNA electroporation, it not only leads to presentation 
of all relevant TAA but also of self-antigens, which may lead to immune suppression 
or auto-immunity. Furthermore, the method is dependent on the availability of tumor 
tissue. Previously, it has been shown that electroporation of DC with mRNA is effective 
and safe.23,28,29 DC retain their phenotype and maturation potential upon electroporation, 
as well as their migratory capacities.28,30 The loading of tumor antigen by mRNA encoding 
TAA can be simultaneously performed with mRNA electroporation with CD40L, CD70 and 
caTLR4 to improve the DC maturation and T cell stimulation.16
Previously, so-called TriMix DC vaccination was found to be feasible, safe and 
immunogenic after intradermal, intravenous or combined intradermal/intravenous 
administration in metastatic melanoma patients in single center studies.10,21 In addition, 
intradermally/intravenously injected TriMix DC co-electroporated with MAGE.A3, 
MAGE.C2, tyrosinase, and gp100 resulted in durable objective clinical tumor responses 
in 4 out of 15 patients treated in a phase IB clinical trial.21 In this phase I/II study 
we investigated the feasibility, safety, and immunological responses in metastatic 
melanoma patients to intranodal vaccination with monocyte-derived mRNA-optimized 
DC loaded with tyrosinase and gp100 mRNA. Intranodal vaccination was chosen 
because of low CCR7 expression on mRNA-optimized DC. CCR7 is a chemokine receptor, 
with CCL19 and CCL21 as its ligands, known to facilitate directed migration of DC from 
the peripheral tissue to the T cell rich areas in draining lymph nodes.31 A potential 
advantage of injecting DC directly into a lymph node is that the cells are immediately 
located inside the network of target lymphoid organs, minimizing the requirements for 
migration in order to reach the anatomical location where stimulation of T cells occurs 
and resulting in a more efficient distribution of the vaccine over multiple lymph nodes. 
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3Patients and Methods
Patient population
In this phase I/II study, melanoma patients with locoregional resectable disease 
(referred to as stage III) within 2 months after radical dissection of regional lymph 
node metastases and patients with irresectable locoregional or distant metastatic 
disease were included. Additional inclusion criteria were melanoma expressing 
the melanoma-associated antigens gp100 (compulsory) and tyrosinase (non-
compulsory), and WHO performance status 0 or 1. Patients with brain metastases, 
serious concomitant disease or a history of a second malignancy were not eligible. 
The study was approved by the appropriate Medical Ethical Review Board, and 
written informed consent was obtained from all patients. Clinical trial registration 
number is NCT01530698. 
Study protocol
Patients received a DC vaccine via intranodal injection. Intranodal vaccination was 
conducted in a clinically tumor-free lymph node under ultrasound guidance. The 
mRNA-optimized DC vaccine consisted of autologous immature monocyte-derived DC 
electroporated with mRNA encoding CD40L, CD70 and caTLR4 combined with mRNA 
encoding gp100 or tyrosinase protein, and pulsed with KLH protein for an immune 
control. Patients received a cycle consisting of three vaccinations at a biweekly 
interval. Prior to each vaccination 80 mL of blood was collected for immunological 
monitoring. One to two weeks after the last vaccination a skin test was performed. 
All patients who remained free of recurrence (stage III) or disease progression (distant 
metastases) after the first vaccination cycle received a maximum of two maintenance 
cycles at 6-month intervals, each consisting of three biweekly intranodal vaccinations 
followed by a skin test. All vaccinations were administered between May 2010 and 
February 2012. 
Study endpoints
The main study endpoints were the toxicity of mRNA-optimized DC and immunological 
responses upon DC vaccination. Clinical efficacy was a secondary endpoint, defined as 
disease-free survival in stage III melanoma patients and as progression-free survival in 
stage IV melanoma patients. All distant metastatic patients were evaluated for clinical 
response at 3-month intervals with CT scan or at extra time points when progressive 
disease was clinically suspected. A clinical response was defined as stable disease for 
more than 4 months or any partial or complete response, according to the Response 
Evaluation Criteria in Solid Tumors (RESIST version 1.1). Toxicity was assessed according 
to NCI common toxicity criteria version 3.0. 
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3DC preparation and characterization
Monocyte-derived DC were generated from peripheral blood mononuclear cells 
(PBMC) prepared from leukapheresis products as described previously.11 Briefly, plastic-
adherent monocytes or monocytes isolated by counterflow elutriation using Elutra-cell 
separator (Gambro BCT, Inc.) were cultured for 5-7 days in X-VIVO 15TM medium (Lonza) 
supplemented with 2% pooled human serum (HS; Sanquin) in the presence of IL-4 (500 
units/mL) and granulocyte macrophage colony-stimulating factor (800 units/mL; both 
from Cellgenix). DC were pulsed with KLH (10 µg/mL; Immucothel, Biosyn Arzneimittel 
GmbH) and matured via electroporation with mRNA encoding CD40L, CD70, and caTLR4. 
For the delayed type hypersensitivity (DTH) skin test, DC were matured with a 
cytokine cocktail consisting of recombinant tumor necrosis factor α (10 ng/mL), IL-1β 
(5 ng/mL), IL-6 (15 ng/mL) (all CellGenix), and prostaglandin E2 (10 µg/mL,
 Pharmacia & 
Upjohn) for 48 h (cytokine-matured DC).7 Harvested DC were analyzed by FACS analysis 
as described below. 
Plasmids and in vitro mRNA transcription
Plasmid pGEM4Z-5’ÚT-hgp100-3’UT-A64, pGEM4Z-5’ÚT-CD40L-3’UT-A64, pGEM4Z-5’ÚT-
CD70-3’UT-A64 and pGEM4Z-5’ÚT-caTLR4-3’UT-A64 were provided by Vrije Universiteit 
Brussel. PGEM4Z-5’ÚT-tyrosinase-3’UT-A64 was constructed by digestion of pGEM4Z-5’UT-
tNGFR-3’UT-A64 with BglII and XbaI and digestion of pcDNA1.amp/tyrosinase with BamHI 
and XbaI and insertion of the tyrosinase into the cut pGEM4Z. Plasmids were linearized 
with SpeI (pGEM4Z-5′UT-CEA-3′UT-A64) or NotI enzyme (pGEM4Z-5′UT-tNGFR-3′UT-A64, 
pGEM4Z-5′UT-hgp100-3′UT-A64, and pGEM4Z-5′UT-tyrosinase-3′UT-A64), purified with 
phenol/chloroform extraction and ethanol precipitation, and used as DNA templates.15 
Good manufacturing practice (GMP) grade gp100 and tyrosinase mRNA was produced by 
CureVac GmbH as described previously.32 Despite the absence of an MHC class II trafficking 
signal, we showed antigen-specific CD4+ T cell responses in our previous trial with mRNA-
electroporated DC, proving the MHC class II expression of the used antigens, gp100 and 
tyrosinase.32 CD40L-, CD70- and caTLR4-mRNA was manufactured according to GMP by 
University Hospital Erlangen. The generated mRNAs contain a 5’ cap and 3’ poly A-tail 
that leads to high RNA stability and increased protein expression in transfected cells. RNA 
quality was verified by agarose gel electrophoresis; RNA concentration was measured 
spectrophotometrically; and RNA was stored at −40°C in small aliquots.
mRNA electroporation of DC
DC were washed twice in PBS and once in OptiMEM without phenol red (Invitrogen). 
mRNA-optimized DC were electroporated in immature state. Twenty micrograms of 
mRNA encoding gp100 or tyrosinase and 6.6 µg of each mRNA encoding CD40L, CD70 
and caTLR4 were transferred to a 4 mm cuvette (Bio-Rad) and 10-12 x 106 cells were 
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3added in 200 µL OptiMEM and incubated for 3’ before being pulsed in a Genepulser 
Xcell (Bio-Rad) by an exponential decay pulse of 300 V, 150 µF, as described before. 28 
Immediately after electroporation, cells were transferred to warm (37°C) X-VIVO 
15TM without phenol red supplemented with 5% HS and left for at least 2 h at 37°C, 
before further manipulation. Electroporation efficiency was analyzed after 4 h by flow 
cytometric analysis. After overnight culture, DC were harvested, the phenotype was 
analyzed by flow cytometry and viability was assessed by Trypan Blue (Invitrogen Life 
Technologies) exclusion. The first vaccination was given with fresh DC the day after 
electroporation. DC for subsequent vaccinations were frozen, thawed at the day of 
vaccination, and incubated for an additional hour at 37°C before injection. Protein 
expression of the tumor antigens was not affected by freezing and thawing of the DC.
Flow cytometric analysis
Flow cytometry was done using the following monoclonal antibodies (mAb) and 
appropriate isotype controls: anti–HLA class I (W6/32), anti–HLA DR/DP (Q5/13), 
anti–HLA DR, anti-CD70, anti-CD80 (all BD Biosciences), anti-CD14, anti-CD83 (both 
Beckman Coulter), anti-CD86 (BD Pharmingen), and anti-CCR7 (R&D systems). For 
intracellular staining of the TAA NKI/beteb (IgG2b; purified antibody) against gp100, 
and T311 (IgG2a; Cell Marque Corp.) against tyrosinase were used. Cells were also 
stained intracellular with anti-CD40L (Beckman Coulter). For intracellular staining, cells 
were fixed for 4’ on ice in 4% (w/v) paraformaldehyde (Merck) in PBS, permeabilized 
in PBS/2%BSA/0.02% azide/0.5% saponin (Sigma-Aldrich) (PBA/saponin), and stained 
with mAb diluted in PBA/saponin/2%HS, followed by staining with Alexa488-labeled 
goat-anti-mouse (BD Pharmingen). Flow cytometry was performed with FACSCaliburTM 
flow cytometer equipped with CellQuest software (BD Biosciences). 
IL-12p70 production
Immediately after electroporation, 10-12 x 106 cells were transferred to 5 ml warm 
(37°C) X-VIVO 15TM. The production of IL-12p70 was measured in the supernatants 
approximately 16 h after electroporation with mRNA using a standard sandwich ELISA 
(Pierce Biotechnology).
KLH-specific antibody production
KLH-specific antibodies were measured in the sera of patients before and after 
vaccination by ELISA (www.klhanalysis.com). Briefly, microtiter plates (96 wells) were 
coated overnight at 4°C with KLH (25 μg/mL in PBS per well). After washing the plates, 
patient serum was added in duplicate for 1 h at room temperature. After extensive 
washing, patient KLH-specific antibodies were detected with mouse anti-human 
IgG, IgA or IgM antibodies labeled with horseradish peroxidase (Invitrogen). 3,3’ 
5,5-tetramethyl-benzidine was used as a substrate and plates were measured in a 
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3microtiter plate reader at 450 nm. For quantification an isotype-specific calibration 
curve for the KLH response was included in each microtiter plate.33
Proliferative response to KLH
Cellular responses against KLH were measured before and after vaccination by 
proliferation assay. PBMC were isolated from heparinized blood by Ficoll-Paque density 
centrifugation. PBMC were stimulated with KLH (4 μg/2x105 PBMC) in medium with 2% 
human AB serum. After 3 days, cells were pulsed with 1 µCi/well 3H-thymidine for 8 h, 
and incorporation was measured with a betacounter. Experiments were performed in 
sextuplicate. A proliferation index >2 was considered positive. 
Skin-test infiltrating lymphocytes cultures
One to two weeks after the last DC vaccination a DTH skin test was performed, as 
described before7,8 and at www.labtube.tvplayvideo.aspx?vid=131825. Briefly, 
cytokine-matured DC electroporated with gp100-encoding mRNA or tyrosinase-
encoding mRNA or mRNA-optimized DC electroporated with gp100-encoding mRNA 
or tyrosinase-encoding mRNA were injected intradermally in the skin of the back of the 
patients at four different sites (1x106 DC each). The maximum diameter (in millimeters) 
of induration was measured after 48 h and punch biopsies (6 mm) were obtained under 
local anesthesia. Half of the biopsy was cryopreserved for immunohistochemistry 
and the other half was manually cut and cultured in RPMI1640 containing 7% HS 
supplemented with IL-2 (100 U/mL; Proleukin®, Chiron). Every 7 d, half of the medium 
was replaced by fresh medium containing HS and IL-2. After 2 to 4 weeks of culturing, 
SKILs were tested for antigen recognition and tetramer binding. 
Tetramer staining
SKILs and PBMC from HLA-A*02:01 positive patients were stained with tetrameric-
MHC complexes containing the HLA-A*02:01 epitopes gp100:154-162, gp100:280-288 
or tyrosinase:369-377 (Sanquin) combined with CD8 staining as described previously.7 
Tetrameric-MHC complexes recognizing HIV were used as a negative control. 
Antigen and tumor recognition
Antigen recognition by SKILs was determined using autologous EBV- B cells as 
described previously. 34 Autologous EBV-B cells were generated from PBMC and 
either loaded with HLA-A2-binding gp100 (gp100:154-162 or gp100:280-288) or 
tyrosinase (tyrosinase:369-377) peptides (for HLA-A*02:01-positive patients only) or 
electroporated with mRNA encoding full-length gp100 or tyrosinase (CureVac GmbH). 
For mRNA electroporation, EBV-B cells were washed twice in PBS and once in OptiMEM 
without phenol red. Twenty micrograms of mRNA were transferred to a 4 mm cuvette 
(Bio-Rad) and 10-20×106 cells were added in 200 µL OptiMEM and incubated for 3’ 
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3before being pulsed in a Genepulser Xcell (Bio-Rad) by an exponential decay pulse of 
450 V, 150 µF. Immediately after electroporation, cells were transferred to warm (37ºC) 
X-VIVO 15 without phenol red supplemented with 6% HS and left for at least 2 h at 
37ºC, before further manipulation. EBV-B cells electroporated with CEA-mRNA were 
used as a negative control. mRNA- or peptide-loaded EBV-B cells were co-cultured 1:1 
with SKILs for 24 h and after 24 h antigen specificity was analyzed by flow cytometry 
by expression of the early activation markers CD69 and CD137 on CD8+ T cells. PMA-
stimulated (5 µg/mL; Sigma-Aldrich) SKILs were used as a positive control. Cytokine 
production was measured in supernatants after 24 h of co-culture with a FlowCytomix 
Multiplex kit (Bender MedSystems GmbH). Cytotoxicity was evaluated through addition 
of PeCy5-conjugated CD107a (BD Pharmingen) and GolgiStopTM (1:2000; monensin, BD 
Biosciences Pharmingen) during co-culture and subsequent analysis of surface binding 
of CD107a antibodies to CD8+ T cells by flow cytometry. A DTH test response was 
considered positive when the percentage of CD8+CD137+, CD8+CD69+ or CD8+CD107a+ 
cells was more than twice that obtained with the negative control.
For HLA-A*02:01-positive patients, antigen recognition was also determined by 
the production of cytokines of SKILs after co-culture with T2 cells pulsed with HLA-
A*02:01-binding peptides gp100:154-162, gp100:280-288 or tyrosinase:369-377 or BLM 
(a melanoma cell line expressing HLA-A*02:01 but no endogenous expression of gp100 
and tyrosinase), transfected with control antigen G250, with gp100 or tyrosinase, or 
an allogeneic HLA-A*02:01-positive, gp100-positive, and tyrosinase-positive tumor 
cell line (MEL624). Cytokine production was measured in supernatants after 16 h of 
co-culture with a FlowCytomix Multiplex kit (Bender MedSystems GmbH). 
Statistical analysis
Data were analyzed statistically by means of analysis of variance and Student-Newman-
Keuls test. Statistical significance was defined as p < 0.05. Progression-free and overall 
survival were calculated from the time from apheresis to recurrence (stage III) or 
progression (distant metastases) or death, respectively. 
Results
Patient characteristics
A total of 15 melanoma patients, 5 patients with regional metastases (AJCC stage 
III disease) and 10 patients with distant metastases (AJCC stage IV disease), were 
included in this study. Ten patients had primary melanoma of the skin, three patients 
presented with a primary uveal melanoma and one patient had an unknown primary. 
One patient with distant metastatic disease was non-evaluable for safety and 
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3immunogenicity, since he did not receive any vaccinations due to rapid progressive 
disease (A-07). One additional patient was only evaluable for safety and immunologic 
response. He had not been documented with progressive disease on prior treatment 
with dacarbazine at revision of the pre-study CT scan, but completed the first cycle 
of vaccinations (DE-04). Fourteen patients completed the first cycle of three DC 
vaccine administrations.  Five patients (3 out of 5 stage III patients and 2 out of 9 
distant metastatic patients) completed the full three cycles. Patient characteristics 
are summarized in Table 1.
Vaccine characteristics 
Phenotypic and functional release criteria were predefined for the mature DC used in 
our clinical vaccination protocol to ensure the DC vaccines comply with the minimal 
Table 1. Patient characteristics.
Patient Sex
Age 
(yrs) Stage Site of disease
LDH 
(U/l) Gp100d Tyrosinased
No of 
vac.
Patients with distant metastatic melanoma
DE-01 f 40 M1c lung, LN, spleen, pancreas, adrenal 340 +++ ++ 3
DE-02 f 71 M1ca lung, LN, adrenal 447 +++ +++ 9
DE-03 m 44 M1c liver, lung, LN, skin, spleen 365 +++ ++ 3
DE-04 m 68 M1c liver, lung, skin, bone 441 +++ + 3
DE-05 f 46 M1a LN 334 +++ +++ 3
A-01 f 49 M1ca liver 424 + + 3
A-03 f 44 M1c liver, lung, LN, kidney, subcutaneous 504b +++ + 3
A-04 f 47 M1ca cardia, muscle, sigmoid 440 +++ + 9
A-08 m 71 M1a LN 395 +++ ++ 3
Patients with resected regional metastatic melanoma (stage III)
A-02 f 37 N1b LN 268 +++ +++ 8e
A-05 m 62 N3 LN, in transits 652c +++ +++ 3
A-06 m 70 N2b LN 342 ++ ++ 3
A-09 f 59 N1b LN 297 +++ ++ 9
A-10 m 64 N2b LN 297 +++ +++ 9
Abbreviations: LN, lymph node.
a  Primary uveal melanoma.
b LDH normalized before first vaccination (upper limit of normal 450 U/L).
c LDH normal at screening (441), increase due to rapid progressive disease.
d gp100 and tyrosinase expression on the primary tumor or metastasis was analyzed by 
immunohistochemistry. Intensity of positive cells were scored centrally and semi-quantitatively by a 
pathologist. Intensity was scored as low (+), intermediate (++), or high (+++).
e Too little viable cells to complete last cycle of vaccinations.
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3quality criteria.2 The phenotype of the ex vivo-generated DC was determined by 
flow cytometry prior to injection. Viability of the DC after electroporation was >50% 
in all DC productions, and >70% in 19 out 21 productions (90%). Electroporation of 
immature DC with mRNA encoding CD40L, CD70 and caTLR4 induced expression of 
the co-stimulatory molecules CD80 and CD86 (Figure 1A). The phenotype of cytokine-
matured DC (used for DTH testing only) showed a different expression pattern than 
the mRNA-optimized DC of the same patients. For example, cytokine-matured DC 
show a higher median CCR7 expression compared mRNA-optimized DC (median 
35% and 1%, respectively; Supplementary Figure 1A). In general, MHC class I and 
class II were highly expressed on mRNA-optimized DC. Intracellular expression of 
tumor-associated antigens gp100 and tyrosinase 4 h after electroporation was highly 
variable, with in general low expression of tyrosinase (Figure 1B), and decreased 
within 24 h after electroporation (Supplementary Figure 1B).  IL-12p70 production 
by activated DC is desired as it stimulates IFNγ production in naive T cells, thereby 
promoting Th1 responses. The median IL-12p70 concentration in culture medium after 
overnight incubation of DC was 41 pg/mL (range; 8–201 pg/mL) (Figure 1C). IL-12p70 
production is rarely seen in cytokine-matured DC (median 0 pg/mL: range 0-17 pg/
mL; unpublished data). These data demonstrate the feasibility of the production of 
mRNA-optimized DC and are in line with the previously published results on TriMix 
DC production.15,16
Figure 1. mRNA-optimized dendritic cell 
(DC) vaccine characteristics. Expression of 
HLA-ABC, HLA-DR/DP, HLA-DQ, CD80, CD86, 
CD70 and CD40L was measured by flow 
cytometry on DC of all patients (A). Tumor 
antigen expression of gp100 and tyrosinase 
by DC 4 h after electroporation with mRNA 
encoding gp100 and tyrosinase (B). Data 
are shown as percentage of positive DC of 
the first DC vaccine of each patient. The 
production of IL-12p70 by DC was measured 
in the supernatants 16 h after induction of 
maturation (C). Each dot represents the first 
DC vaccine of a patient.
A
B
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3Supplementary Figure 1. Characteristics of mRNA-optimized dendritic cells (DC) used for vaccination and 
cytokine-matured DC from the same patients generated and used for DTH testing. Expression of HLA-ABC, 
HLA-DR/DP, HLA-DQ, CD80, CD86 and CCR7 was measured by flow cytometry on both mRNA-optimized 
DC (used for DC vaccination; filled dots) and cytokine-matured DC (used only for DTH testing; open dots) 
of patients. Expression of all markers is higher on cytokine-matured DC compared to mRNA-optimized DC 
(A). Antigen expression of CD40 ligand (CD40L) and the tumor antigens gp100 and tyrosinase by mRNA-
optimized DC are shown at 4 h (filled squares) and 24 h after electroporation (open squares; B). Data are 
shown as percentage of positive DC of the first DC vaccine of each patient. 
DC-related adverse events
Based on the experience with our cytokine-matured DC and the studies performed at 
the Vrije Universiteit Brussel exploiting TriMix DC, we expected that the DC vaccines 
would be well tolerated.10,21,32 Mild flu-like symptoms and local reaction at the injection 
site, not exceeding CTCAE grade 1 severity, were each seen in four patients (29%; 
Table 2). Flu-like symptoms were usually of short duration, around 2 days, and did not 
require any intervention. The injection site reactions consisted of minimal swelling of 
the lymph node region and redness of the overlying skin.
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3Proliferation of PBMC upon stimulation with KLH
To test the capacity of the patients in this study to generate an immune response 
upon DC vaccination, we loaded the DC with the control antigen KLH. All patients 
showed increased T cell proliferation upon stimulation with KLH in PBMC isolated after 
vaccination, even patients who received a limited amount of DC (Figure 2A). Anti-KLH 
IgG antibodies were detected in 5 out of 5 stage III patients and 3 out of 9 distant 
metastatic patients after one cycle of vaccinations. Anti-KLH IgA and IgM antibodies 
were detected in 7 and 5 patients, respectively (Figure 2B,C,D). These data demonstrate 
that the vaccine induced de novo immune responses. 
Tumor-associated antigen-specific T cell responses in blood and skin
DTH skin tests were performed after each series of vaccinations to monitor TAA-specific 
T cell responses. Cytokine-matured DC or mRNA-optimized DC electroporated with 
gp100-encoding or tyrosinase-encoding mRNA were injected intradermally in the 
skin of the back of the patients at four different sites. Previously we showed that the 
presence of TAA-specific T cells in SKILs cultures positively correlates with survival in 
Table 2. Immunological and clinical responses.
Patient HLA-A2 TAA-specific T cells Toxicity Flu/Inj (grade)
PFS 
(months)
OS 
(months)
Best clinical 
response
Patients with distant metastatic melanoma
DE-01 - - 0/0 1 3 PD
DE-02 + - 1/1 22 26 SD
DE-03 - - 0/0 2 17 PD
DE-04 + - 0/0 6 10 NE
DE-05 + + 1/0 2 18 PD
A-01 + - 0/1 2 10 PD
A-03 + - 0/0 6 14 MR
A-04 - - 0/1 28 53 SD
A-08 - - 0/0 2 21 PD
Patients with resected regional metastatic melanoma (stage III)
A-02 + - 0/1 56+ 56+ NED
A-05 + + 1/0 2 6 PD
A-06 + - 0/0 3 4 PD
A-09 - - 0/0 52+ 52+ NED
A-10 - - 1/0 28 51+ NED
Abbreviations: Flu/Inj, flu-like symptoms/injection site reaction; MR, mixed response; NE, not evaluable; 
NED, no evidence of disease; OS, overall survival; PD, progressive disease; PFS, progression-free survival; 
SD, stable disease; TAA, tumor-associated antigen.
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3Figure 2. KLH-specific immune responses before and after dendritic cell (DC) vaccination. KLH-specific T cell 
proliferation was analyzed after each DC vaccination during the first vaccination cycle in peripheral blood 
mononuclear cells of melanoma patients. The proliferative response to KLH is given as a proliferation index 
(proliferation with KLH/proliferation without KLH) (A). KLH-specific IgG (B), IgA (C) and IgM antibodies (D) 
were quantitatively measured before and after each vaccination cycle in sera of vaccinated patients. The best 
Ig response was shown for each patient. Each dot represents 1 patient or the number of patients as indicated.
distant metastatic melanoma patients.8 The maximum diameter of induration was 
measured after 48 h and was on average 3 mm (range 0-20 mm), with no differences in 
induration between stimulation with mRNA-optimized DC or cytokine-matured DC after 
the first cycle of vaccination (p=0.24; Figure 3). To investigate if TAA-specific immune 
responses were induced by vaccination, PBMC and SKILs, cultured from punch biopsies 
of the DTH sites, of HLA-A*02:01-positive patients were screened with tetrameric-
MHC complexes. Additionally, in both HLA-A*02:01-postive and -negative patients we 
determined the presence of TAA-specific immune responses in SKILs using autologous 
EBV-transformed B (EBV-B) cells, as described previously.34 Tetramer positive CD8+ 
T cells in SKILs were detected in 1 out of 8 HLA-A*02:01-positive patients, recognizing 
tyrosinase (DE-05; Supplementary Figure 2A). No tetramer positive CD8+ T cells were 
detected in PBMC after vaccination. We did not find any positive responses in the six 
HLA-A*02:01-negative patients with the EBV-assay.  In one of the HLA-A*02:01-positive 
patients CD137 was evidently upregulated, but without concomitant upregulation of 
CD69 or CD107a (A-05; Supplementary Figure 2B). Whereas, the combination of CD137 
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3upregulation together with IFNγ or TNF-α secretion, without CD69 or CD107a, can be 
considered as a functional tumor-specific immune response.34
Supplementary Figure 2. Tumor-associated antigen (TAA)-specific T cell responses. Skin-test infiltrating 
lymphocytes of HLA-A*02:01-positive patients were screened with tetrameric-MHC complexes. In patient 
DE-05 tetramer positive CD8+ T cells were detected, recognizing tyrosinase (A). The presence of TAA-specific 
immune responses was also determined using autologous EBV-transformed B cells. In patient A-05 CD137 
was upregulated on CD8+ T cells after co-culture with EBV-transformed B cells loaded with tyrosinase mRNA 
and peptide (B), but without concomitant upregulation of CD69 or CD107a (data not shown).
Figure 3. Induration at the delayed type hypersensitivity 
(DTH) skin tests after cycle 1. DTH skin tests were 
performed after each series of vaccinations. Cytokine-
matured dendritic cells (cDC) or mRNA-optimized DC 
(mRNA DC) electroporated with gp100-encoding mRNA 
or tyrosinase-encoding were injected intradermally in 
the skin of the back of the patients at four different sites. 
The maximum diameter of induration was measured 
after 48 h. Induration after the first vaccination cycle 
is shown. Dots representing the same patient are 
connected with a line. 
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3Clinical outcome 
Two stage III patients had progressive disease within 3 months after start of vaccinations 
and died shortly thereafter. In both patients the absence of distant metastasis had 
been confirmed by a PET scan before radical lymph node dissection. Another patient 
developed two in transit metastases after the second cycle of vaccinations which 
were resected and vaccinations were continued; eventually, the patient progressed 
16 months later. The other two stage III patients still have no evidence of disease with 
follow-up of 52 and 56 months. 
One patient with distant metastatic disease (A-03) showed a mixed response with 
progression of pulmonary, renal and subcutaneous metastases, while metastases in 
liver and lymph nodes decreased in size. The patient developed symptomatic brain 
metastases 6 months after inclusion. Two patients with advanced melanoma (DE-02 and 
A-04) had stable disease for approximately 2 years, one of those patients (A-04) lived 
over 4 years after the start of DC vaccination for metastatic melanoma. The other 6 
patients with distant metastases had progressive disease at the first clinical evaluation.
Discussion
In this study we show the feasibility and safety of the intranodal administration of 
autologous mRNA-optimized DC presenting the tyrosinase and gp100 melanoma 
associated antigens. Viable DC could be produced in all patients and only grade 1 local 
injection site reactions and flu-like symptoms occurred after intranodal vaccination. 
Previously, it was reported that intradermal and intravenous administration of TriMix 
DC showed similar side effects with slightly higher severity (up to CTCAE grade 2); in 
addition, intravenous administration produced CTCAE grade 2 acute post- infusion chills. 
In this study, intranodal administration of mRNA-optimized DC showed good 
feasibility and safety but limited TAA-specific immunological responses were observed. 
In previous TriMix DC vaccination trials, were the vaccine was administered intradermal 
or intradermal/intravenous, TAA-specific T cells were found in about 50% of patients.10,21 
In our trial, TAA-specific T cell responses were detected in only two patients (14%). 
One response was detected by tetramer analysis (DE-05) and one by the EBV-based 
antigen presentation assay (A-05). We did not find any positive responses in the six 
HLA-A*02:01-negative patients. Various factors may be underlying the absence of TAA-
specific T cell responses in HLA-A*02:01-negative patients. Previously we have shown 
that the prevalence of a positive SKILs test following DC vaccination in patients with 
distant metastatic melanoma is approximately 30%8 and about 70% of the stage III 
melanoma patients. Given the small number of HLA-A*02:01-negative patients and 
most patients had distant metastatic disease; the odds of detecting a positive SKILs 
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3test in this study were anticipated to be low beforehand. However, one HLA-A*02:01-
negative distant metastatic patients showed an interestingly long progression-free 
survival (A-04) of 28 months. As immunological responses are less frequently detected 
in more advanced disease stages, less frequent immunological responses could be 
expected in our trial compared to the previous TriMix DC vaccination trial, as we 
had relatively more patients with distant metastatic melanoma and less stage III 
melanoma patients. Secondly, in contrast to previous studies where TriMix DC were 
injected intradermally or intradermally/intravenously, mRNA-optimized DC injected 
intranodally could be less potent in the activation of the immune system compared to 
cytokine-matured monocyte-derived DC. In this study anti-KLH IgG antibodies were 
detected only in 3 out of 9 distant metastatic patients after one cycle of vaccinations. 
Previously, we could detect anti-KLH IgG antibodies in about 60% of patients receiving 
mature DC, while we could detect no KLH IgG antibodies in any of the patients receiving 
immature DC.11,32,35 Furthermore, although KLH-specific T cell responses were induced 
in the majority of patients in this trial, proliferation indices were generally lower after 
mRNA-optimized DC vaccination (on average 9; range 2-26) vs. on average 32 (range 
2-116) in cytokine-matured DC-vaccinated metastatic melanoma patients in previous 
trials.32,35
The seemingly lower potency of DC in this study, compared to cytokine-matured 
DC and intradermal/ intravenous administered TriMix DC, could be explained by lower 
peptide expression on the DC, usage of different tumor antigens (e.g., MAGE), the 
intranodal route of administration or the minor differences in DC manufacturing protocol 
(e.g., different culture medium, time of DC administration after electroporation) which 
might have resulted in lower IL-12p70 secretion. Intranodal vaccination was chosen 
because of low CCR7 expression on mRNA-optimized DC.  Previously, intradermal 
vaccination of cytokine-matured DC showed superior TAA-specific T cell induction 
compared to intranodal vaccination.36 This might in part be explained by the partial 
destruction of the lymph node architecture by injection of DC directly into a lymph 
node. Additionally, naturally, DC mature on their way towards the lymph node and 
arrive in a mature state in the lymph node. After intradermal injection, all DC that 
enter the lymph nodes are viable and have migrated. They may represent the most 
mature and hence most potent DC. In contrast, as a result of intranodal injection, all DC, 
including less mature or nonviable DC, are directly delivered into the lymph node and 
might even activate nonspecific or nonfunctional T cells or regulatory T cells. This may 
be even more unfavorable for mRNA-optimized DC than for cytokine-matured DC, since 
mRNA-optimized DC were injected into the lymph node in a semi-immature state and 
expected to mature further after injection. Upregulation of co-stimulatory molecules 
was seen after electroporation of immature DC with mRNA encoding CD40L, CD70 and 
caTLR4, although in a lesser extent compared to cytokine-matured DC, but with higher 
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3IL-12p70 production.26,32 On the contrary, the difference in the degree of upregulation 
of co-stimulatory molecules might be explained by the time of measurement. mRNA-
optimized DC are administered to the patient within a few hours after electroporation, 
while maturation is still ongoing and thus further upregulation will take place in vivo. 
In vivo maturation of DC, and the subsequent release of immunostimulatory cytokines 
in vivo, resembles the natural process of DC activation more closely and thus might 
lead to enhanced T cell activation rather than decreased T cell activation. 37 Another 
factor underlying the absence of TAA-specific T cell responses may be low tyrosinase 
expression and antigen presentation by the mRNA-optimized DC. This could be caused 
by the concomitant electroporation with four different types of mRNA, resulting in 
competition between the types of mRNA to enter the DC and to be translated into 
protein. However, protein expression might not be an appropriate measure, as the assay 
measures the endogenously produced full protein within the DC, and not the peptide 
presented in the MHC molecule on the cell surface. Fast processing of the protein 
might have led to the low expression levels. Indeed, despite low expression levels, 
specific T cells against the tyrosinase peptide were detected in both immunological 
responding patients. 
One of the major advantages of the usage of DC loaded with mRNA encoding the 
whole TAA, compared to peptide loaded DC, is that it obviates HLA restriction and 
immune responses will not be restricted to a specific HLA-type. The endogenous 
processing of TAA will result in the presentation of multiple peptides in both MHC 
class I and II molecules and could lead to the induction of a considerable larger 
repertoire of TAA-specific T cells. As a consequence, the monitoring of TAA-specific 
immunological responses will become far more complicated. Of the broad array of 
possible epitopes, only a few will be recognized by the tetramers available and used in 
this study. Therefore, the induction of CD8+ T cell responses after mRNA-optimized DC 
vaccination were analyzed by a recently developed alternative approach. 34 The assay 
combines the use of autologous EBV-immortalized B cells as antigen presenting cells 
and CD137 upregulation to detect antigen-specific T cells in blood or SKILs. Previously, 
the combination of CD137 upregulation together with IFNγ or TNF-α secretion was 
considered as a functional tumor-specific immune response.34 Unfortunately, the 
cytokine secretion was not measured in the patient with CD137 positive cells (A-05) 
and did not show a functional profile in the patient with tetramer positive TAA-specific 
T cells (DE-05). 
Finally, high background activation of SKILs by EBV-transfected B cells may have 
masked TAA-specific T cell activation in our EBV assays. Most people are exposed 
to EBV early in life and have consequently developed EBV-specific T cells. Since only 
relative small numbers of TAA-specific T cells are usually induced by DC vaccination, 
these might be lost in the background scatter caused by EBV-specific T cells. This could 
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3explain why we could detect TAA-specific T cells by this method in only one patient, and 
not in the patient with tetramer positive TAA-specific T cells. To bypass this problem, 
peripheral blood lymphocytes electroporated with TAA mRNA could be used instead or 
immortalized  autologous B cells generated by retroviral introduction of the oncogene 
BCL-6 and the anti-apoptotic gene BCL-XL.38
DC-based immunotherapy has proven to be feasible, safe and able to induce or 
augment tumor-specific immune responses. Nevertheless, only a limited number 
of clinical responses have been observed. Besides the electroporation of DC with 
CD40L, CD70, and caTLR4 mRNA to improve immunological and clinical responses 
of DC vaccination strategies, a number of other variables, e.g., the use of naturally 
occurring DC subsets, are being tested in clinical trials.39,40 Furthermore, combination 
treatments to counteract tumor escape mechanisms are being explored. Recently, 
the treatment of TriMix DC combined with ipilimumab, a monoclonal anti-CTLA4 
antibody, showed an encouraging rate of durable tumor responses.41 Further studies 
should determine the optimal treatment modality that may enhance the efficacy of 
DC-based immunotherapy.
In conclusion, this study demonstrates that therapeutic vaccination with an 
autologous mRNA-optimized DC vaccine can be safely administered intranodally to 
patients with metastatic melanoma. However, few TAA-specific immunological and 
clinical responses were detected suggesting that for mRNA-optimized DC the intranodal 
route of administration probably is not preferred over technically less demanding 
intradermal or intravenous administration.
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Abstract
Dendritic cell (DC)-based immunotherapy is explored worldwide in cancer patients, 
predominantly with DC matured with pro-inflammatory cytokines and prostaglandin 
E2. We studied the safety and efficacy of vaccination with monocyte-derived DC 
matured with a cocktail of prophylactic vaccines that contain clinical-grade Toll-like 
receptor ligands (BCG, Typhim, Act-HIB) and prostaglandin E2 (VAC-DC). Stage III and IV 
melanoma patients were vaccinated via intranodal injection (12 patients) or combined 
intradermal/intravenous injection (16 patients) with VAC-DC loaded with keyhole limpet 
hemocyanin (KLH) and mRNA encoding tumor antigens gp100 and tyrosinase. Tumor 
antigen-specific T cell responses were monitored in blood and skin-test infiltrating 
lymphocyte (SKIL) cultures. Almost all patients mounted prophylactic vaccine- or KLH-
specific immune responses. Both after intranodal injection and after intradermal/
intravenous injection, tumor antigen-specific immune responses were detected, which 
coincide with longer overall survival in stage IV melanoma patients. VAC-DC induce 
local and systemic CTC grade 2 and 3 toxicity, which is most likely caused by BCG in 
the maturation cocktail. The side effects were self-limiting or resolved upon a short 
period of systemic steroid therapy. We conclude that VAC-DC can induce functional 
tumor-specific responses. Unfortunately, toxicity observed after vaccination precludes 
the general application of VAC-DC, since in DC maturated with prophylactic vaccines 
BCG appears to be essential in the maturation cocktail.
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Introduction
DC have the unique capacity to activate naive tumor-specific T cells.1 They play a 
critical role in determining the magnitude and quality of the immune response to an 
antigen. Immunotherapy applying ex vivo-generated and tumor antigen-loaded DC 
has now been introduced in the clinic.2, 3 A limited, but consistent, number of objective 
immunological and clinical responses have been observed.3 Thus far, it remains unclear 
why some patients respond while others do not, but there is a general consensus 
that the current protocols applied to generate DC may not result in the induction of 
optimal T helper 1 (Th1) responses and hence cytotoxic T cell responses. We and others 
have demonstrated that DC maturation is one of the crucial factors to induce effective 
anti-tumor immune responses in cancer patients.4-7 Currently, DC are mostly matured 
with a cocktail of pro-inflammatory cytokines, including IL-1b, IL-6, tumor necrosis 
factor alpha (TNFa) and prostaglandin E2
 (PGE2). However, DC matured in the presence 
of Toll-like receptor (TLR) ligands may unleash more potent immune responses, as 
mouse studies have shown that TLR-matured DC are able to promote T helper 1 cell 
differentiation and induce full effector T cell differentiation.8 TLR-mediated maturation 
of ex vivo-generated human monocyte-derived DC (moDC) may thus be used to improve 
immunological and clinical responses in DC vaccination of cancer patients.
TLR are pattern recognition receptors that sense microbial and viral products, like 
bacterial cell wall components or double-stranded RNA. TLR engagement on DC induces 
maturation and cytokine secretion. In humans, 11 TLR have been described for which 
many specific ligands have been identified.9, 10 Whereas several TLR ligands have been 
shown to yield mature Th1-directing DC, limited availability of Good Manufacturing 
Practice (GMP)-compliant produced ligands impede the use of these TLR ligands for the 
generation of DC for immunotherapy in patients. However, prophylactic vaccines against 
infectious diseases frequently contain molecules derived from bacteria or viruses, which 
are natural TLR ligands. We identified a cocktail of the clinical-grade prophylactic vaccines 
BCG, Influvac and Typhim that contains a multitude of natural TLR ligands and is capable 
of optimally maturing DC.11 These so-called prophylactic vaccine-matured DC showed 
high expression of CD80, CD83, and CD86 and secreted high levels of IL-12. Although 
these DC exhibited an impaired migratory capacity, this could be restored by addition 
of PGE2. DC matured with prophylactic vaccines and PGE2 are potent inducers of T cell 
proliferation, Th1 polarization, and tumor antigen-specific CD8+ effector T cells ex vivo. 
Prophylactic vaccine-induced DC maturation is compatible with mRNA electroporation 
as an antigen loading strategy of DC.11 Here, we studied the safety, immunoreactivity, 
migratory capacity, and efficacy of intravenous/intradermal (i.v./i.d.) or intranodal 
(i.n.) vaccination with DC matured with a prophylactic vaccine cocktail, consisting of 
the clinical-grade prophylactic vaccines BCG, Typhim and Act-HIB, together with PGE2 
(VAC-DC) in a dose escalation study in stage III and IV melanoma patients.
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Patients and methods
Patient population
Melanoma patients with regional lymph node-positive resectable disease (further 
referred to as stage III), before or within 2 months after radical lymph node dissection, 
and patients with locally irresectable or distant metastatic disease (further referred 
to as stage IV) were included. Additional inclusion criteria were melanoma expressing 
gp100 (compulsory) and tyrosinase (non-compulsory), and WHO performance status 0 
or 1. In protocol A HLA-A*02:01 phenotype was an additional inclusion criteria. Patients 
with brain metastases, serious concomitant disease, use of immunosuppressive drugs, 
or a history of a second malignancy were excluded. The studies were approved by the 
Dutch Central Committee on Research involving Human Subjects, written informed 
consent was obtained from all patients, and all procedures were performed in 
accordance with the Declaration of Helsinki. ClinicalTrials.gov registration numbers 
are NCT00940004 (protocol A) and NCT01530698 (protocol B). 
Clinical protocol and immunization schedule
A leukapheresis was performed from which DC were generated. Patients received a 
VAC-DC vaccine i.v./i.d. (protocol A; 2/3 i.v. and 1/3 i.d.) or i.n. (protocol B; Supplementary 
Figure 1). Intranodal vaccination was conducted in a clinically tumor-free lymph node 
under ultrasound guidance. The VAC-DC vaccine consisted of autologous mature moDC 
electroporated with mRNA coding for gp100 and tyrosinase protein, and pulsed with 
keyhole limpet hemocyanin (KLH) protein. Patients received three biweekly vaccinations 
per cycle. Eight patients received an extra vaccination before radical lymph node dissection 
for additional imaging studies. One to two weeks after the last vaccination, a skin test was 
performed. In absence of disease recurrence or progression, patients received a maximum 
of two maintenance cycles at 6-month intervals. All vaccinations were administered 
between June 2009 and May 2012. Endpoints of this trial were safety, the induction of 
tumor antigen-specific immune responses, and the clinical response of stage IV patients 
according to the RECIST1.1 criteria. Toxicity was assessed according to NCI CTC version 3.0. 
DC preparation and characterization
Monocytes were enriched from leukapheresis products by counterflow elutriation 
using Elutra cell separator (Gambro BCT) and cultured as described.5, 12 In our preclinical 
study, we developed a TLR maturation cocktail consisting of BCG, Typhim and Influvac as 
clinical-grade alternative for synthetically produced TLR ligands for moDC maturation.11 
Since Influvac is only available during the flu season and has a different composition 
each year, we replaced Influvac by Act-HIB in our maturation cocktail. Both maturation 
cocktails gave rise to highly mature, IL-12 producing DC (Supplementary Figure 2). 
Therefore, in the present study, DC were matured with a cocktail of prophylactic vaccines 
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including BCG vaccine SSI (4% v/v, Nederlands Vaccin Instituut), Typhim Vi (4% v/v, Sanofi 
Pasteur MSD), and Act-HIB (4% v/v, Aventis Pasteur), supplemented with PGE2 (10 µg/
mL, Pharmacia & Upjohn) for 48 h (VAC-DC).11 For the delayed-type hypersensitivity 
(DTH) skin test, DC were matured either with the prophylactic vaccine cocktail or with 
a cytokine cocktail consisting of TNFa (10 ng/mL), IL-1β (5 ng/mL), IL-6 (15 ng/mL; all 
CellGenix) and PGE2 (10 µg/mL) for 48 h (cDC).
5 Mature DC were electroporated with 
GMP-grade gp100 and tyrosinase-encoding mRNA and characterized by flow cytometry 
as described.13 The release criteria were: ≥ 70% viability, ≥ 50% expression of CD83,  and 
expression of MHC class I, MHC class II, CD80, CD86, and CCR7.
Supplementary Figure 1. Schematic treatment schedule and CONSORT flow chart. (A) Schematic 
treatment schedule. (B) CONSORT flow chart.
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[111Indium] Labeling and Scintigraphy 
DC migration was measured after the first vaccination by scintigraphic imaging as 
described.14 DC were incubated with 111In-oxine (GE Healthcare) in 0.1 mL/L Tris-HCl 
(pH 7.0) for 15 min at room temperature. Cells were washed three times with PBS, 
1% HSA. In vivo planar scintigraphic images were acquired with a gamma-camera 
equipped with medium energy collimators, 10 min and 48-72 h after the first 
vaccination. Migration was quantified by region-of-interest analysis of the individual 
nodes visualized on the images and expressed as the relative fraction of 111In-labeled 
DC in the injection depot. 
Immunological responses to KLH and prophylactic vaccines
Antibodies against KLH were measured in serum from vaccinated patients by ELISA 
(www.klhanalysis.com).15 Cellular responses against KLH and prophylactic vaccines 
were measured in a proliferation assay. Peripheral blood mononuclear cells (PBMC) 
(4 μg/2 × 105) were stimulated with KLH, Act-HIB (4% v/v), BCG-SSI (4% v/v), or Typhim 
Vi (4% v/v) in medium with 2% human serum. After 3 days, cells were pulsed with 1 μCi/
Supplementary Figure 2. Prophylactic vaccine maturation cocktail with Influvac compared to with 
Act-HIB . Monocyte-derived DC were matured for 48h with the conventional cytokine cocktail (cDC; Il-1b, 
IL-6, TNFa, PGE2), or with either prophylactic vaccine cocktail BTI (BCG, Typhim, Influvac) or cocktail BTA 
(BCG, Typhim, Act-HIB) with PGE2. (A) The expression of maturation markers CD80, CD83, CD86, and CCR7 
was measured by flow cytometry. Results are shown as percentage of positive cells. The figures show mean 
± SEM of three experiments with different donors. (B) IL-12p70 production was measured by ELISA in the 
supernatant of DC cultures 48h after maturation. Per condition each symbol represents one donor. Means 
are shown for each maturation cocktail. (c) The allostimulatory capacity of the DC was tested in a mixed 
lymphocyte reaction. Allogeneic peripheral blood leukocytes were co-cultured with differently matured 
DC and T cell proliferation was measured by incorporation of tritiated thymidine. The graph represents 
mean ± SEM counts per minute relative to cDC of three experiments with different donors, performed in 
triplicate. (d) DC were electroporated with mRNA encoding gp100. After 3h, gp100 protein expression was 
determined by FACS analysis. Filled curves show staining with specific antibody; thin-lined curves show the 
isotype control. Numbers indicate mean fluorescence intensity. 
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well tritiated thymidine for 8 h, and incorporation of tritiated thymidine was measured 
with a beta-counter. A proliferation index >2 was considered positive.
Proliferative and cytokine response of bronchoalveolar lavage (BAL) cells
Autologous DC of patients V-A-01 and V-A-08 were matured for 48 h with the 
conventional cytokine cocktail (cDC), the complete prophylactic vaccine cocktail 
(VAC-DC), or the separate prophylactic vaccines BCG, Typhim, or Act-HIB. cDC were 
loaded with KLH, gp100 peptides (10 µM gp100:280-288 + 10 µM gp100:154-162), or 
tyrosinase peptide (10 µM tyrosinase:369-377). 1 x 104 DC were co-cultured with 5 x 104 
autologous cells obtained from a bronchoalveolar lavage in RPMI + 7% human serum. 
Cytokine production was measured in the supernatant after 24 h by cytometric bead 
array (human Th1/Th2 11 plex kit, eBioscience) or standard sandwich ELISA (human 
IL-17 DuoSet ELISA, R&D Systems). To study T cell proliferation, cells were pulsed after 4 
days with 1 µCi/well tritiated thymidine for 8 h, and incorporation of tritiated thymidine 
was measured with a beta-counter.
MHC tetramer staining
SKILs and PBMC were stained with tetrameric-MHC complexes containing HLA-A*02:01 
epitopes gp100:154-162, gp100:280-288 or tyrosinase:369-377 (Sanquin). HIV tetramers 
were used as a negative control. 
Skin-test infiltrating lymphocytes cultures
One to two weeks after the last DC vaccination, a DTH skin test was performed, as 
described (http://www.labtube.tvplayvideo.aspx?vid=131825).16, 17 For HLA-A*02:01-
positive patients, antigen recognition was determined by the production of cytokines 
of SKILs after co-culture with T2 cells pulsed with the indicated peptides or BLM 
(a melanoma cell line expressing HLA-A*02:01 but no endogenous expression of gp100 
and tyrosinase), transfected with control antigen G250, gp100 or tyrosinase, or an 
allogeneic HLA-A*02:01-, gp100-, and tyrosinase-positive tumor cell line (MEL624). 
Cytokine production was measured in supernatants after 24 h of co-culture with a 
FlowCytomix Multiplex kit (Bender MedSystems GmbH). For HLA-A*02:01-negative 
patients, antigen recognition by SKILs was determined using autologous EBV-
transformed B (EBV-B) cells electroporated with gp100 mRNA or tyrosinase mRNA 
as described.18, 19 
Statistical analysis
Planned patient accrual was 25 in protocol A and 17 in protocol B. Data were analyzed 
statistically by means of analysis of variance and Student-Newman-Keuls test, or by 
means of Mann Whitney U nonparametric statistics. Statistical significance was defined 
as p<0.05. Progression-free and overall survival were calculated from the time from 
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apheresis to disease recurrence (for stage III patients) or progression (for stage IV 
patients) or death. Differences between Kaplan-Meier estimates of survival times were 
assessed using the log-rank test.
Results
Patient characteristics and vaccination cycles
A total of 29 melanoma patients, 11 stage III patients and 18 stage IV patients, were 
included. One stage IV melanoma patient showed rapid progressive disease with signs 
of spinal cord compression before vaccination started and went off study to receive 
local treatment. Sixteen patients were vaccinated i.v./i.d (protocol A); 12 patients 
were vaccinated i.n. (protocol B; Supplementary Figure 1). Patient characteristics are 
summarized in Table 1.
In the i.v./i.d. group, the first five patients received increasing doses of VAC-DC 
(7.5 to 30 x 106 DC). Eight additional patients received the full dose of maximally 30 x 
106 VAC-DC. Due to serious side effects (see below), the maximum dose was reduced 
to 15 x 106 DC. As toxicity did not diminish after dose reduction, the inclusion of 
patients in protocol A was terminated. In the i.n. group, the first five patients received 
increasing doses of VAC-DC (1.5 to 15 x 106 DC). An additional seven patients received 
the maximum dose of 15 x 106 VAC-DC. Due to serious side effects (see below), none 
of the patients in the i.n. group received maintenance cycles, and further inclusion of 
patients was stopped. 
Characteristics of injected DC
After maturation, VAC-DC of all patients had a mature phenotype based on expression 
of MHC class I and II, co-stimulatory molecules, CD83, and CCR7 (Supplementary 
Figure 3A). Intracellular expression of tumor-associated antigens gp100 and tyrosinase 
after electroporation was variable, but for each patient expression of either gp100 or 
tyrosinase was at least 30% (Supplementary Figure 3B). 
Migratory capacity of VAC-DC
In four patients the distribution of 111Indium-labeled VAC-DC was determined by 
scintigraphic imaging 10 min and 2-3 days after the first i.d. vaccination. In all four 
patients, VAC-DC migrated from the injection depot to multiple nearby lymph nodes 
(Figure 1A). The median overall redistribution of injected DC was 1.8% (range 1.1-
3.6%), and median 3 lymph nodes were reached (range 2-4; Figure 1B). These results 
demonstrate that VAC-DC have the capacity to migrate towards lymph nodes after 
i.d. injection.
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Supplementary Figure 3. Vaccine characteristics of first cycle of all patients. (A) Expression of HLA-ABC, 
HLA-DR/DP, HLA-DQ, CD80, CD83, CD86, and CCR7 was analyzed by flow cytometry. (B) Tumor antigen 
expression by VAC-DC 2-4h after electroporation with mRNA encoding gp100 and tyrosinase. Data are shown 
as percentage of positive VAC-DC used for the first vaccination. The graphs represent mean ± SD of all patients. 
Data is shown separately for each administration route; intravenous/intradermal (i.v./i.d.) and intranodal 
(i.n.) injection of VAC-DC. 
Figure 1. VAC-DC migration after intradermal injection. In four patients VAC-DC migration to nearby lymph 
nodes (LN) was analyzed by scintigraphy of the lymph node region 48h to 72h after intradermal injection of 
111Indium-labeled VAC-DC. (A) Example of a scintigraphic image showing the redistribution to multiple lymph 
nodes of 111Indium-labeled DC from the injection depot (arrow) to four nearby LN (arrow heads) in patient A-13. (B) 
Percentage of cells migrated to nearby LN (left) and number of reached LN (right). One symbol represents a single 
patient who received maximally 10 x 106 cells by intradermal injection; horizontal lines represent the median.
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Table 1. Patient characteristics. (Continued)
Patient Sex Age Stage
LDH
U/L 
Site of 
disease
No of 
mets Gp100b
Tyrosi-
naseb
HLA-
A*02:01
Mutation 
status
Post-DC 
treatment
i.v./i.d.
stage
IV
A-1 F 50 M1c 663 Liver, lung, 
skin
>10 + - + wt S
A-2 F 66 M1a 383 Distant LN >5 +++ +++ + wt -
A-3 M 60 M1b 396 Distant LN, 
lung
>5 pos - + wt S, C, I
A-4 M 65 M1b 368 Lung 4 +++ - + wt C
A-5 M 32 M1c 329 Liver, distant 
LN, soft 
tissue
>5 pos n.t. + n.t. S
A-6 M 37 M1c 389 Liver, lung, 
bone, skin, 
cardiac
>10 +++ +++ + n.t. -
A-7 M 53 M1c 517 Liver, bone >5 + - + n.t. I
A-8 M 55 N3irr 445 Inguinal + 
paraaortic LN
>5 +++ + + n.t. -
A-9 F 35 M1a 269 Skin 2 +++ +++ + BRAF S
stage
III
A-10 M 46 N2b 340 Cervical LN 2 +++ +++ + BRAF S, T1, I
A-11 F 51 N1b 431 Inguinal LN 1 +++ ++ + n.t. n.a.
A-12 M 60 N1b 372 Axillair LN 1 +++ + - n.t. n.a.
A-13 M 64 N3 287 Cervical LN 5 ++ ++ - NRAS T2
A-14 F 43 N3 385 Cervical LN >5 +++ +++ + BRAF -
A-15 M 51 N3 421 Inguinal LN >10 ++ ++ + n.t. S
A-16 M 53 N2b 337 Inguinal LN 2 +++ +++ + NRAS -
i.n.
stage
IV
B-1 M 60 M1b 427 Distant LN, 
lung, skin
>5 +++ +++ + BRAF S, I, T1
B-2 M 48 M1b 321 Lung, skin 5 ++ - - n.t. I
B-3 M 42 M1a 450 Distant LN, 
skin
>10 +++ +++ + wt I, S
B-4 M 69 M1b 381 Distant LN, 
lung
>5 ++ ++ + BRAF C, T1
B-5 M 57 M1c 251 Bone 1 +++ ++ - n.t. C
B-6 M 29 N3 irr 341 Axillair LN 
+ in transit 
mets
>10 +++ + - NRAS C, I, T2
B-7 M 63 M1b 340 Lung 2 ++ ++ - wt S, I
B-8 F 56 M1a 267 Distant LN, 
skin
5 +++ +++ - BRAF -
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Table 1. Patient characteristics. (Continued)
Patient Sex Age Stage
LDH
U/L 
Site of 
disease
No of 
mets Gp100b
Tyrosi-
naseb
HLA-
A*02:01
Mutation 
status
Post-DC 
treatment
stage
III
B-9 F 57 N3 312 Inguinal LN >5 +++ ++ + wt -
B-10 M 72 N3 353 Cervical LN >5 +++ ++ - n.t. n.a.
B-11 M 37 N3 296 Inguinal LN 4 +++ +++ - BRAF T1
B-12 M 26 N2a 353 Axillair LN 2 +++ +++ - n.t. n.a.
Abbreviations: BRAF, BRAF mutation present; C, chemotherapy; I, immunotherapy (anti-CTLA-4); LDH, 
lactate dehydrogenase (ULN<450 U/L); mets, metastases; n.a., not applicable; NRAS, NRAS mutation 
present; n.t., not tested; S, surgery; T1, targeted therapy (BRAF inhibitor); T2, targeted therapy (MEK 
inhibitor); wt, wild type (no BRAF or NRAS mutation present).
a as per pathology report of the radical lymph node dissection in stage III melanoma patients and per CT 
scan in stage IV melanoma patients.
b gp100 and tyrosinase expression on the primary tumor was analyzed by immunohistochemistry. 
Intensity of positive cells were scored centrally and semi-quantitatively by a pathologist. Intensity was 
scored as low (+), intermediate (++), or high (+++), or not scored (pos).
Flu-like symptoms and injection site reactions
Almost all patients vaccinated with VAC-DC experienced CTC grade 2 toxicity with higher 
fever and stronger injection site reaction as compared to patients vaccinated with cytokine-
matured DC (cDC) in previous studies (Table 2; Supplementary Figure 4A). Interestingly, 
two patients in the i.v./i.d. group (A-2 and A-3) showed re-appearance of induration of 
the injection site of recent i.d. VAC-DC vaccination after regular seasonal flu vaccination 
(Supplementary Figure 4B), whereas the flu vaccine was not part of the maturation cocktail. 
In the i.n. group, the injection site reactions induced substantial lymphadenopathy and 
erythema of the overlying skin. In some cases it was accompanied by purulent discharge, 
resembling suppurative lymphadenitis (Supplementary Figure 4C+D). 
Remarkably, patient A-3 showed vitiligo on the chest and back after the second cycle 
of i.v./i.d. VAC-DC vaccinations. The occurrence of vitiligo in patients with melanoma is 
reported for patients undergoing immunotherapy and can be an indication of an immune 
response directed against melanoma/pigmented cells and correlate with survival.20, 21 
Hepatotoxicity and pneumonitis
In all but four patients hepatotoxicity was observed. A rise in liver enzymes was most 
pronounced after i.v./i.d. injection and occurred in five patients up to CTC grade 3 
severity (Table 2). Although in some patients progressive liver metastases could not 
be excluded as a causative factor, the transient increase of liver tests during the 
vaccination cycle in most patients clearly support a toxic effect of VAC-DC vaccination. 
The increases in liver tests returned to baseline within one month after vaccination and 
were not accompanied by alterations in bilirubin.
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Six patients in the i.v./i.d. group presented with acute onset of dyspnea and 
dry cough. In the first two patients a CT-angiography scan was made of which the 
results excluded a pulmonary embolism. High-resolution CT scans of these patients 
and two others showed diffuse increased density of the lung parenchyma, classified 
as interstitial pneumonitis (Figure 2A). All four patients were treated with a short 
course of systemic steroids, resulting in improvement of dyspnea within 2 days. The 
CT abnormalities resolved in one to three months (Figure 2B). Two other patients 
presented with similar symptoms but did not show signs of pneumonitis on a planned 
CT scan for response evaluation. A high-resolution CT scan was not performed in these 
patients. A planned CT scan showed a segmental pulmonary embolism in one patient, 
which was considered to be a coincidental finding as this patient had no pulmonary 
complaints at that time. 
Immune cells obtained from a BAL of patients A-9 and A-10 proliferated and 
produced interferon gamma (IFNγ) and TNFa when co-cultured with autologous 
VAC-DC or BCG alone. BAL-derived immune cells of patient A-9 also responded to KLH, 
but did not proliferate upon stimulation with gp100 or tyrosinase peptides. In addition, 
staining with tetrameric MHC complexes could not demonstrate the presence of tumor 
antigen-specific T cells in the BAL fluid. These data suggest that at least part of the 
infiltrated cells were BCG-specific (Figure 2C-F). 
KLH- and BCG-specific immune responses
To test the capacity of the patients in this study to generate an immune response, we 
loaded the VAC-DC with the control antigen KLH. All 16 evaluable patients in the i.v./i.d. 
group and 11 out of 12 patients in the i.n. group showed increased T cell proliferation 
upon stimulation with KLH, irrespective of the dose of DC administered (Figure 3A). 
The only patient who did not show an increased T cell response after i.n. vaccination 
with VAC-DC already had a T cell response and KLH-specific antibodies in serum before 
vaccination. Overall, these data demonstrate that both i.v./i.d. injected VAC-DC and i.n. 
injected VAC-DC effectively induced de novo immune responses in melanoma patients.
For some patients, we also analyzed the induction of T cells specific for the 
prophylactic vaccines that were used for VAC-DC maturation. As expected, prophylactic 
vaccine-specific T cell responses were already present before VAC-DC vaccination in 
some patients (Figure 3B). However, for all three prophylactic vaccines, increased T cell 
responses were found in a part of the patients, indicating that the prophylactic vaccines 
that are used for VAC-DC maturation are processed by the DC and presented to specific 
T cells after injection.
Tumor antigen-specific T cell responses 
To study tumor antigen-specific T cell responses, DTH skin tests were performed. 
Induration of sites injected with VAC-DC was significantly stronger than at sites injected 
with cDC (Figure 4A). 
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Figure 2. VAC-DC induced lung toxicity. Example of high-resolution CT scan (patient A-10) showing diffuse 
infiltration in the lungs suggestive of pneumonitis (A), which resolved after short treatment with systemic 
steroids (B). Cells obtained from bronchoalveolar lavage of patients A-9 (C,D) and A-10 (E,F) were co-
cultured with autologous DC loaded with KLH, gp100, tyrosinase, the prophylactic vaccine cocktail, or 
with BCG, Typhim or Act-HIB. (C,E) T cell proliferation was measured in triplicate by incorporation of 
tritiated thymidine after 4 days. (D,F) Cytokine production was measured in the supernatant after 24h by 
cytometric bead array and ELISA. In F, cytokine production is normalized to the highest value, due to large 
differences in concentration between the different cytokines. Maximum cytokine concentrations (100%) 
were: IFNg 9.7 ng/ml; TNFa 328 ng/ml; IL-10 161 ng/ml; IL-17 181 pg/ml. In conclusion, cells obtained from 
the bronchoalveolar lavage of both patients showed that infiltrated cells were BCG-specific; this might 
have caused the development of pneumonitis.
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Figure 3. KLH- and prophylactic vaccine-specific T cell responses before and after VAC-DC vaccination. 
(A) KLH-specific T cell proliferation was analyzed before the first vaccination and after each VAC-DC 
vaccination during the first vaccination cycle in PBMC. Per time point each dots represents one patient; 
black dots represent patients that received i.v./i.d. VAC-DC vaccination, open dots represent patients that 
received i.n. VAC-DC vaccination. Horizontal lines represent group averages per time point. In all patients 
except one, a KLH-specific T cell response was induced. (B) BCG-, Act-HIB-, and Typhim-specific T cell 
proliferation was analyzed before and after VAC-DC vaccination in PBMC. Proliferative responses to KLH 
or prophylactic vaccines are given as proliferation index (proliferation with KLH or vaccines/proliferation 
without KLH or vaccines). ** p<0.01, paired t-test. 
To investigate if tumor-associated antigen (TAA)-specific immune responses where 
induced by vaccination with VAC-DC, PBMC and SKILs of HLA-A*02:01 positive patients 
were screened with tetrameric MHC complexes. After i.v./i.d. vaccination, tetramer-
positive PBMC were detected in peripheral blood of three out of nine stage IV patients 
and two out of five stage III patients tested. Tetramer-positive SKILs were detected 
in two out of eight stage IV patients tested and four out of five stage III patients 
tested (Table 2). In none of the i.v./i.d. vaccinated stage IV patients, SKILs produced 
cytokines upon co-culture with peptide- or protein-loaded target cells, whereas in 
three stage III patients SKILs recognized endogenously processed tumor proteins. After 
i.n. vaccination, tetramer-positive CD8+ T cells were detected in peripheral blood of 
two out of three stage IV patients, whereas tetramer-positive SKILs were detected in 
two out of four HLA-A*02:01-positive patients, one stage IV and one stage III patient. 
Interestingly, SKILs of patient B-9 produced IFNγ upon co-culture with tumor protein 
and not with HLA-A*02:01-binding peptides (Figure 4B+C), indicating that T cells 
recognized different epitopes. 
In one HLA-A*02:01-negative stage III patient (patient B-11), SKILs produced IFNγ 
upon co-culture with EBV-B cells, but without concomitant upregulation of CD69 or 
CD107a. Nevertheless, our analysis for HLA-A*02:01 presented epitopes demonstrate 
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that VAC-DC can induce or enhance tumor-specific immune responses in melanoma 
patients both after i.v./i.d. and i.n. injection. 
Clinical outcome in stage III patients
The median follow-up was 46 months (range 7-64). In the i.v./i.d. group, five patients 
had recurrence of disease, of whom three patients died and two patients are alive with 
disease. In the i.n. group, two patients had recurrence of disease and died. In both 
groups, two patients have no evidence of disease (Table 2). 
Supplementary Figure 4. Injection site reactions. (A) Example of injection site reaction (patient A-11) after 
intradermal injection with VAC-DC. (B) Induration of the injection site after regular flu vaccination (patient A-3). 
Showing redness over an area with a diameter of 3 to 4 cm. (C) Example of injection site reaction (patient B-12) 
after intranodal injection with VAC-DC, showing substantial swelling of the lymph node (region), redness of the 
overlying skin and discharge of pus. (D) [18F]FLT-PET/CT scan of patient B-12 showing profound lymphadenopathy 
of the right inguinal lymph nodes after intradermal injection with VAC-DC, with moderately increased [18F]FLT 
accumulation in the rim and absent tracer accumulation in the centre, suggestive of necrosis (arrow). 
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Figure 4. Tumor antigen-specific T cell responses in skin-test infiltrating lymphocyte cultures. (A) 
Induration of delayed-type hypersensitivity (DTH) sites measured 48h after intradermal injection of VAC-DC 
or cytokine-matured DC (cDC) loaded with gp100 mRNA or tyrosinase mRNA. Data are shown in mm 
induration. Each dot represents one DTH site. The line indicates the mean of DTH sites. *** p<0.001, ns: 
not significant, paired t-test. (B) Example of tetramer staining of T cells cultured from a DTH site of patient 
B-9. Cells were stained with allophycocyanin-labeled tetramers encompassing the gp100:154 peptide, 
gp100:280 peptide, tyrosinase peptide, or control peptide and with CD8-FITC. Numbers indicate the 
percentage of tetramer-positive cells CD8+ T cells of total CD8+ T cells. (C) IFNγ production by the same T cells 
of patient B-9 after stimulation with T2 cells loaded with tumor peptides or BLM cells expressing tumor 
proteins. (D) Kaplan–Meier analyses of overall survival according to the presence of tetramer-positive 
populations in skin-test infiltrating lymphocyte cultures from DTH skin test biopsies or in peripheral blood 
in HLA-A*02:01-positive stage IV patients. The presence of tumor antigen-specific T cells (Tc+) correlates 
with longer overall survival after VAC-DC vaccination in metastatic melanoma patients compared to patients 
without detectable tumor antigen-specific T cells (Tc-).
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Clinical outcome in stage IV patients
The median follow-up was 12 months (range 3-54). All stage IV patients were evaluated 
for clinical response at 3-month intervals with CT scans or at earlier time points when 
progressive disease was clinically suspected. In the i.v./i.d. group, one patient had 
stable disease and received a second vaccination cycle. The remaining eight patients 
showed progressive disease prior to or at first evaluation. Patient A-9 is still alive with 
follow-up of nearly 4 years (April 2015), the other eight patients died between 3 and 
21 months. Mutation status and subsequent treatments after progressive disease are 
shown in Table 1. 
In the i.n. group, three patients had stable disease (8–14 months), of which one had 
a mixed response, showing a reduction in size of mediastinal lymph node metastases 
and a increase in size of abdominal lymph node metastases. The other five patients 
showed progressive disease at the first clinical evaluation. All patients died between 
8 and 36 months (Table 2). 
Despite the small sample size, our data suggest a correlation between the 
immunological responses and survival of HLA-A*02:01-postive patients, with an overall 
survival ranging from 14 months to 28 months in patients with TAA-specific T cells 
(n=4), whereas in the absence of these cells (n=7) the overall survival ranges from 3 to 
11 months (p=0.003; Figure 4D).
Discussion
Based on our in vitro data, showing the potential of DC matured by a cocktail of 
three prophylactic vaccines (BCG, Typhim and Influvac or Act-HIB) and PGE
2,
11 we 
initiated a study on the safety and the capacity to induce immune responses against 
tumor antigens of VAC-DC in vivo. Our major conclusions are (1) VAC-DC can induce 
tumor antigen-specific T cell responses, both after i.v./i.d. and i.n. injection; (2) VAC-DC 
induce more severe side effects as compared to cDC matured with a conventional 
cytokine cocktail.
Side effects of cDC vaccines are usually mild and if present include low-grade flu-like 
symptoms and local reaction at the injection site. Compared with our experience with 
cDC vaccination4, 13, 22, 23 and the experience of other groups with Trimix-matured or 
α type 1-polarized moDC,7, 24, 25 in the present study with VAC-DC vaccination side 
effects were of higher grade and occurred more often as well as earlier after the first 
vaccination. Injection site reactions are uncommon upon i.n. injection with cDC26; 
however, upon VAC-DC vaccination substantial lymphadenopathy and erythema of 
the overlying skin was observed with purulent discharge occurring in some patients. 
In addition, flu-like symptoms were more severe after VAC-DC vaccination compared 
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to cDC vaccination and were more often accompanied by the presence of fever. Both 
the injection site reactions and flu-like symptoms were self-limiting but dissolved 
less rapidly. The foreign KLH antigen in cDC vaccines is regarded a major cause of 
fever and flu-like symptoms after vaccination with cDC. However, in VAC-DC the 
BCG vaccine may be responsible for both the side effects, since prophylactic BCG 
vaccination, intravesicular BCG treatment in bladder cancer patients, and active 
specific immunotherapy with BCG in colon carcinoma patients are known to induce 
flu-like symptoms, fever and suppurative lymphadenitis, resembling the clinical picture 
we observed, as well as pulmonary infiltrates and increased liver function tests.27-29 
The relation of the pneumonitis and the usage of the BCG vaccine in the maturation 
cocktail of the VAC-DC was substantiated by the observed proliferation and cytokine 
production in immune cells obtained from BAL in response to stimulation with BCG 
antigens. We hypothesize that VAC-DC trapped in the lungs after i.v. injection attract 
BCG-specific immune cells, thereby causing pneumonitis. Symptoms started in the 
second cycle of vaccinations in three patients and in the first cycle (after the second 
vaccination) in one patient with a proven pneumonitis. This suggests that the BCG-
specific cells were induced by the first round of VAC-DC vaccinations. The patient who 
developed pneumonitis after the second vaccination had a very high BCG-specific T cell 
proliferation index before vaccination, suggesting that these cells were already present 
prior to VAC-DC vaccination. Attempts to replace or remove BCG from the maturation 
cocktail consisting of prophylactic vaccines have so far been unsuccessful, as BCG 
appears to be essential to obtain IL-12 producing DC with a mature phenotype.11 Both 
protocols were prematurely terminated; this was mainly due to the pulmonary toxicity 
(protocol A) that occurred and the extensive injection site reactions (protocol B).
For DC to induce an effective immune response, it is crucial to migrate to the T cell 
areas of the lymph node after injection. VAC-DC express CCR7, and our in vivo data 
show that after i.d. injection VAC-DC migrate towards regional lymph nodes. Compared 
to our previous migration studies with i.d. injected cDC,30 i.d. injected VAC-DC migrate 
in a comparable percentage to nearby lymph nodes but to a somewhat larger number 
of nodes. Our in vitro studies showed that addition of PGE2 to the vaccine cocktail 
is needed to obtain DC that are responsive to lymph node chemokines.11 However, 
PGE2 also has suppressive activities, including suppression of IL-12 production by DC.
31 
Indeed, in our in vitro studies, addition of PGE2 to the maturation cocktail reduced 
IL-12 production. However, secreted IL-12 levels were still 100-fold higher than levels 
secreted by cytokine-matured DC and sufficient to induce IFNγ-producing Th1 cells.11 
Vaccination with VAC-DC induced tumor antigen-specific CD8+ T cell responses, both 
after i.v./i.d. injection and after i.n. injection. Previously, we showed that the presence of 
tumor antigen-specific T cells in DTH skin tests positively correlates with clinical outcome 
in metastatic melanoma patients after cDC vaccination.16,17 Although groups are too small 
to draw firm conclusions, we found a similar correlation between the immunological 
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responses and overall survival in stage IV HLA-A*02:01-positive melanoma patients. In 
line with our previous studies,13, 16, 32 robust immunologic responses were more frequently 
detected in patients with no evidence of disease (stage III melanoma) than in patients 
with macroscopic tumor burden (stage IV). This is in line with the hypothesis that high 
tumor burden may hamper the induction of effective immune responses by the secretion 
of suppressive cytokines and attraction of regulatory T cells.33 
In the i.v./i.d. group the percentage of patients with immunological responses was 
comparable to that after vaccination with cDC.16 By contrast, in the i.n. group very few 
tumor antigen-specific immune responses were detected. The majority of patients 
in this group was HLA-A*02:01 negative, which is, however, not a prognostic factor 
in melanoma but might be predictive for response to DC vaccination.34 In theory, as 
DC were loaded with mRNA encoding the whole TAA, this obviates HLA restriction 
and allows immune responses against a broad array of epitopes. Unfortunately, 
the monitoring of tumor antigen-specific immunological responses in HLA-A*02:01-
negative patients is far more complicated, and the alternative approach using EBV-B 
cells might not allow the detection of all tumor antigen-specific immune responses.18 
Furthermore, the low frequency of tumor antigen-specific immune responses may 
be due to the i.n. injection route,35 which may cause partial destruction of the lymph 
node architecture. Additionally, after i.d. injection, the DC that reach the lymph nodes 
may represent the most mature and hence most potent DC. Lastly, patients in the i.n. 
group received lower number of vaccinations, due to treatment discontinuation for 
reasons of toxicity. 
We conclude that vaccination of melanoma patients with VAC-DC results in 
functional tumor antigen-specific T cell responses, however, at the cost of substantial 
toxicity. This impedes the general application of VAC-DC, as DC-based immunotherapy 
nowadays competes with the immune checkpoint inhibitors, and its main advantages 
are the limited toxicity and maintenance of good quality of life. To avoid this toxicity 
but still allow the benefit from VAC-DC-induced immunological responses, GMP-grade 
purified TLR-ligands may be an alternative.
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5Part I. Modulation of DC vaccines
Abstract
Thus far, dendritic cell (DC)-based immunotherapy of cancer was primarily based on in 
vitro-generated monocyte-derived DC, which require extensive in vitro manipulation. 
Here, we report on a clinical study exploiting primary CD1c+ myeloid DC, naturally 
circulating in the blood. Fourteen stage IV melanoma patients, without previous 
systemic treatment for metastatic disease, received autologous CD1c+ myeloid DC, 
activated by only brief (16 hours) ex vivo culture and loaded with tumor-associated 
antigens of tyrosinase and gp100. Our results show that therapeutic vaccination against 
melanoma with small amounts (3-10 x 106) of myeloid DC is feasible and without 
substantial toxicity. Four out of 14 patients showed long-term progression-free survival 
(12-35 months), which directly correlated with the development of multifunctional 
CD8+ T cell responses in three of these patients. In particular, high CD107a expression, 
indicative for cytolytic activity, and IFNγ as well as TNFα and CCL4 production was 
observed. Apparently, these T cell responses are essential to induce tumor regression 
and promote long-term survival by stalling tumor growth. In conclusion, we show that 
vaccination of metastatic melanoma patients with primary myeloid DC is feasible and 
safe and results in induction of effective antitumor immune responses that coincide 
with improved progression-free survival. 
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Introduction
DC are central players in immune responses. As professional antigen-presenting cells, 
DC sample the tissue microenvironment and phagocytose both pathogen-derived 
products and dying host cells, including tumor cells.1 DC have the unique capacity to 
attract and activate naive (tumor) antigen-specific CD4+ and CD8+ T cells. DC-based 
immunotherapy exploits this property of DC: tumor antigen-loaded DC are injected 
into cancer patients to stimulate T cells and initiate tumor eradication.2, 3 In clinical 
trials, this approach resulted in effective immunologic responses that coincided with 
favorable clinical outcomes.4, 5 However, the number of objective clinical responses is 
limited, hampering its implementation as standard treatment. 
In the majority of clinical DC vaccination studies performed so far, DC differentiated 
in vitro from monocytes or CD34+ progenitors have been used, which may not be the 
optimal DC source for immunotherapy.6 The extensive culture period (8-9 days) and 
compounds required to differentiate these cells into DC may negatively affect their 
immunologic potential and their capacity to migrate to the T cell areas of the lymph 
nodes.7, 8 Therefore, naturally circulating primary DC may be a potent alternative for 
monocyte-derived DC (moDC), irrespective of the fact that they are relatively scarce 
(ranging from 1 x 107 to 1 x 108 DC in a single apheresis). A major advantage of exploiting 
primary DC instead of moDC is the brief ex vivo exposure to activate the cells and load 
them with tumor antigens, usually less than 24 hours. This might better preserve their 
functional capacities and prevent exhaustion.
Translational relevance
Vaccination with DC loaded with tumor peptides is feasible, safe, and can 
induce tumor-specific immune responses in advanced cancer patients. Thus far, 
DC-based immunotherapy of cancer was primarily based on in vitro-generated 
monocyte-derived DC that require extensive in vitro manipulation, which may 
affect the survival of these cells in vivo, their capacity to migrate to the lymph 
nodes, as well as their immunogenic potential. Here, we vaccinated metastatic 
melanoma patients with primary myeloid DC, directly isolated from patient’s 
blood and activated by only brief ex vivo culture. We found that vaccination is 
well tolerated and can induce de novo immune responses and objective clinical 
responses, which were associated with the presence of multifunctional tumor 
antigen-specific T cells in both blood and tissues. The rapid vaccine production 
procedure is highly standardized and will therefore expedite larger randomized 
multicenter trials.
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Two main populations of naturally circulating primary DC can be distinguished 
in human peripheral blood: myeloid (m)DC and plasmacytoid (p)DC. These subsets 
differ in function, localization, and phenotype. mDC mainly migrate to, or reside in, 
the marginal zone of the lymph nodes (a primary entry point for blood-borne antigens) 
and are specialized in immunity against bacteria and fungi.9-11 pDC on the other hand, 
mainly localize to the T cell areas of lymph nodes and seem specialized for viral antigen 
recognition.9 Depending on the pathogens they encounter, both DC subsets have the 
capacity to initiate suitable T cell responses. Antitumor responses induced by both 
mDC and pDC have been reported in animal models.12, 13
Recently, we completed the first vaccination trial exploiting ex vivo-activated and 
tumor antigen-loaded autologous primary pDC in metastatic melanoma patients. Although 
the trial was designed as a safety and feasibility study, we obtained promising clinical 
results; 7 of 15 metastatic melanoma patients were still alive two years after the initiation 
of treatment.14 Both activated pDC, which produce high amounts of IFNα, and activated 
mDC have the capacity to induce T helper 1 cells, cytotoxic T cells, natural killer cells, and 
natural killer T cells, leading to a potent cellular immune response.15-17 Moreover, primary 
mDC isolated from healthy donors and cancer patients are able to prime tumor-specific 
CD8+ T cells in vitro.18 Human mDC can be further subdivided into two populations, based 
on their differential surface expression of CD1c (BDCA1) and CD141 (BDCA3).10, 19 Here, 
we studied the feasibility and safety of vaccination of metastatic melanoma patients with 
ex vivo-activated and tumor antigen-loaded autologous CD1c+ mDC and investigated 
whether primary mDC are capable of inducing antitumor responses. In peripheral blood 
and cultures of skin test biopsies of vaccinated patients, we monitored the presence 
and functionality of tumor antigen-specific T cells. The results show that mDC vaccines 
induce cytotoxic T cells in vivo that express multiple functional markers simultaneously. 
The presence of these multifunctional T cells coincided with improved progression-free 
survival, demonstrating the potential of primary mDC for anticancer immunotherapy.
Patients and Methods
Patient characteristics and clinical protocol
The study, CMO2004/093, was approved by the local Institutional Review Board 
(Committee on Research involving Human Subjects Arnhem-Nijmegen) and in 
concordance with the Declaration of Helsinki. Clinical trial registration number is 
NCT01690377. Written informed consent was obtained from all patients. Fifteen 
metastatic melanoma patients (stage IV or irresectable stage IIIc according to the 
2009 American Joint Committee on Cancer staging system20) were enrolled in this 
phase I/II feasibility study (Table 1). One patient was excluded from analysis due to a 
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protocol violation, the patient did not meet an inclusion criterion (VI-B-15; HLA-A*02:01 
negative). Therefore, fourteen patients were considered evaluable for immunologic and 
clinical response. However, one patient did not complete the scheduled vaccinations 
due to rapid progression of disease (VI-B-04) so a delayed-type hypersensitivity 
(DTH) skin test was not available for immunomonitoring. Eligibility criteria included 
a measurable target lesion, HLA-A*02:01 phenotype, histologically documented 
melanoma expressing gp100 (compulsory) and tyrosinase (non-compulsory), no serious 
active infection or immune suppressive conditions, serum LDH concentration within 
normal limits, and WHO performance status 0 or 1. All vaccinations were administered 
between November 2010 and October 2013. The primary objective of this study was 
to generate clinical grade mature mDC preparations and to determine a safe and 
immunologically effective dosage of the vaccine. When the appropriate dosage of the 
vaccine was determined, we evaluated the efficacy of the mDC to initiate antitumor T 
cell responses in patients with metastatic melanoma. 
CliniMACS mDC isolation and immunization schedule
Patients were vaccinated with autologous mDC loaded with HLA-A*02:01-binding 
tumor peptides derived from the melanoma-associated antigens gp100 and tyrosinase. 
The first patient received a maximum of 3 x 106 mDC per vaccination, patients 2 and 
3 received maximally 5 x 106 mDC per vaccination, and patients 4 and 5 received 
maximally 10 x 106 mDC per injection. Considering the yield from mDC isolation, this is 
the maximum feasible dose, which was also given to patients 6 to 15. Three subsequent 
intranodal injections were given once every two weeks followed by a DTH challenge. 
In the absence of disease progression, patients were eligible for a maximum of two 
maintenance cycles consisting of three biweekly vaccinations and a DTH challenge, 
each with a 6-month interval. 
mDC were directly isolated from apheresis products using the fully closed 
immunomagnetic CliniMACS isolation system (Miltenyi Biotec; Supplementary 
Figure 1). GMP-grade magnetic bead-coupled antibodies were used, following the 
manufacturer’s guidelines. First, B cells were depleted using magnetic bead-coupled 
CD19 antibodies, followed by positive selection of CD1c+ mDC with biotin-coated 
CD1c antibodies and magnetic bead-coupled anti-biotin antibodies. This procedure 
resulted in clinically applicable purified mDC, which had an average purity of 93% 
and a yield between 27 x 106 and 96 x 106 cells (Figure 1A, B). After apheresis and 
CliniMACS isolation, mDC were cultured overnight (16 hours) at a concentration of 
106 cells/mL in X-VIVO-15 (Lonza) containing 2% pooled human serum (HS; Sanquin), 
supplemented with 800 U/mL recombinant human GM-CSF (Cellgenix) and 1 mg/
mL keyhole limpet hemocyanin (KLH; Immucothel, Biosyn Arzneimittel GmbH) for 
immunomonitoring. This procedure gave rise to mature mDC meeting the following 
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Supplementary Figure 1. Schematic overview of the 44 h mDC vaccine preparation cycle and vaccination 
strategy.
release criteria: more than 50% viability, high expression of MHC class I, MHC class 
II, CD83, and CD86.2 Part of these mDC were directly loaded with the melanoma-
associated HLA-A*02:01-restricted peptides gp100
154-162 
(KTWGQYWQV), gp100
280-288
 
(YLEPGPVTA), and tyrosinase
369-377
 (YMNGTMSQV) for the first vaccination, which was 
given directly after the peptide loading.21 The remainder of the mDC was frozen with 
10% DMSO for subsequent vaccinations or DTH. Upon subsequent vaccinations/DTH, 
frozen mDC were thawed and loaded with the melanoma-associated peptides. The 
peptide-loaded mDC were administered intranodally in a clinically tumor-free lymph 
node under ultrasound guidance. 
Flow cytometry
The purity of mDC after CliniMACS isolation and the phenotype of the mDC were 
determined by flow cytometry. The following primary monoclonal antibodies (mAbs) 
and the appropriate isotype controls were used: anti-CD1b/c-FITC (Diaclone), anti-CD20-
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PE, anti-CD45-PerCP, anti-CD14-APC, anti-HLA-DQ-PE (all BioLegend), anti-HLA-ABC-PE, 
anti-HLA-DR-PE, anti-CD80-PE, anti-CD83-PE, and CD86-PE (all BD Pharmingen). Flow 
cytometry was performed with a FACS Calibur (BD Biosciences). 
Immunomonitoring
Peripheral blood mononuclear cells (PBMC) and serum samples were obtained before 
the start of the vaccination regimen and after each individual vaccination. Samples 
were tested for the presence of KLH-specific T cells by proliferation and 3H-thymidine 
incorporation, and the presence of KLH-specific antibodies in serum using ELISA.22 
Within one to two weeks after the third vaccination, a DTH skin test was performed 
as described previously.4, 5 Briefly, moDC (1 x 106; cultured as previously described21) and 
mDC (0.5 x 106), pulsed with gp100 or tyrosinase peptides, were injected intradermally 
in the skin of the back of the patient at four different sites. The maximum diameter of 
induration was measured after 48 hours. Punch biopsies (6 mm) were obtained from 
all DTH sites and cultured as previously described.4, 5 After a culture period of 2 to 5 
weeks, skin-infiltrating lymphocytes (SKILs) were tested for specificity against gp100 
and tyrosinase. 
PBMC and SKILs were stained with tetrameric-MHC complexes containing the 
gp100
154-162
, gp100
280-288
 or tyrosinase
369-377
 peptide (Sanquin) combined with CD8 
staining as described previously.5 All samples were tested with HIV77–85-HLA-A*02:01-
tetramers recognizing the irrelevant HIV-peptide (SLYNTVATL) for background staining. 
Antigen recognition was determined by the production of cytokines by SKILs in 
response to T2 cells pulsed with the indicated peptides or BLM cells transfected with 
control antigen G250, with gp100, or with tyrosinase, or the allogeneic HLA-A*02:01-
positive, gp100-positive, and tyrosinase-positive Mel624 tumor cell line. Cytokine 
production was measured in the supernatants after 16 hours of coculture by a 
cytometric bead array (eBioscience). 
Analysis of multifunctional T cells in peripheral blood
Analysis was performed as previously described.23 Cryopreserved PBMC or peripheral 
blood lymphocytes (PBL) were thawed and suspended in Iscove Modified Dulbecco’s 
Medium (IMDM; Gibco) supplemented with 10% HS (Sigma Aldrich) and antibiotic-
antimycotic (Gibco). T cells were stimulated using CD28/49c-coated beads (BD 
Bioscience), either alone or in combination with 10 μg/mL peptide gp100154–162, gp100280–
288 or tyrosinase369–376. Brefeldin A (10 μg/mL; Sigma Aldrich) and Monensine (2 μmol/L; 
eBioscience) were added and cells were incubated for 5 to 6 hours at 37°C and 10% CO2. 
After incubation, T cells were stained with Fixable Viability Dye eFluor780 (eBioscience) 
and surface markers APC-Cy7- or PE-Cy7-labeled anti-CD4 (BD Pharmingen; eBioscience) 
and PE-CF594- or BV510-conjugated anti-CD8 (BD Horizon). Subsequently, the cells 
were fixed using 4% paraformaldehyde (Merck), permeabilized using 0.5% Saponin 
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(Riedel-de Haën), and stained with PerCP-Cy5.5- or BV421-conjugated anti-IFNγ (BD 
Pharmingen), PE-labeled anti-IL-2 (eBioscience), Alexa700- or APC-labeled anti-CD107a 
(BD Pharmingen), FITC-labeled anti-CCL4 (R&D systems), and PE-Cy7- or PerCP-Cy5.5-
labled anti-TNFα (eBioscience). Fluorescence was acquired using a CyAn ADP Analyzer 
(Beckman Coulter), a FACSAria or a FACSVerse (both Becton Dickinson) and analyzed 
with FlowJo software (Tree Star). For SEB- and peptide-stimulated samples, at least 
10,000 and 25,000 viable CD8+ T cells were recorded. For each patient and time point, 
1 to 4 samples treated only with costimulatory beads were analyzed and at least 
18,000 viable CD8+ T cells were recorded for each replicate sample. To analyze the 
functional diversity of CD8+ T cells, combination gates were created using the built-in 
Boolean gating algorithm of FlowJo. To account for unspecific activation, samples were 
background subtracted using the average values of 1 to 3 corresponding replicate 
samples stimulated only with costimulatory beads. To account for the different 
magnitude of total antigen-specific CD8+ T cell responses, the frequencies of cytokine 
combinations were normalized and given as the percentage of total tumor antigen-
specific response. To reduce noise in the dataset, only samples with a minimum of 
0.2% responding CD8+ T cells after background subtraction were considered positive 
based on an escalating variance model. Analysis and presentation of distributions was 
performed using SPICE version 5.3, downloaded from http://exon.niaid.nih.gov and 
PRISM for windows version 5.03 (GraphPad Software Inc.).24
Analysis of surgically resected tumors
Resected tumors were partially embedded in paraffin for immunohistochemistry and 
part of the resected tumors was used to make cell suspensions as described previously.25 
Briefly, tumor tissue was cut into small fragments in Hanks balanced salt solution 
medium (Gibco) with 50 μg/mL collagenase type 1A, 10 μg/mL DNase, and 1 μg/mL 
trypsin inhibitor (Sigma Chemical Co.). The fragments were incubated for 30 minutes 
at 37°C. The resulting cell suspension was put on a modified Ficoll gradient and tumor-
infiltrating lymphocytes were harvested from the interphase. Flow cytometric analysis 
was performed with a FACS Calibur (BD Biosciences) using directly labeled mAbs against 
CD4, CD8, CD25, CD127 (all BD Pharmingen), FoxP3 (eBioscience), and tetrameric-MHC 
complexes containing the gp100
154-162
, gp100
280-288
, or tyrosinase
369-377
 peptide.
Immunohistochemical staining of tumor tissue was done on paraffin-embedded 
tissue sections using mAbs against gp100, CD8 (both Dako), tyrosinase (Monosan), CD4 
(Thermo Scientific), and FoxP3 (eBioscience). Antigen retrieval was done by microwave 
boiling in 10 mmol/L sodium citrate buffer (pH 6.0) for 10 minutes. After rinsing with 
PBS, slides were pretreated with 20% normal horse serum for 10 minutes to reduce 
nonspecific staining. All sera and antibodies were dissolved in PBS with 1% bovine 
serum albumin. Subsequently, slides were incubated with the primary antibody at 4°C 
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for 16 to 20 hours. The avidin-biotin complex (Vector Laboratories) method was used 
for visualization with 3-amino-9-ethyl-carbazole or 3,3′-diaminobenzide hydrochloride 
solution. Slides were counterstained with hematoxylin solution or nuclear fast red, 
dehydrated, and mounted in Permount (Fisher Chemicals).
Statistical analysis
Kaplan-Meier probability estimates of progression-free survival and overall survival 
were calculated, statistical differences between the survival of the groups were 
determined with a log-rank test. Progression-free survival and overall survival were 
defined as time from apheresis to the onset of progression of disease or to death 
of any cause, respectively. Patients without progression of disease or still alive at 
analysis, respectively, were censored at the time of last follow-up. The hazard ratio 
was calculated by the Cox proportional hazards model. Statistical significance was 
defined as p<0.05. SPSS20.0 was used for survival analyses.
Results
Patient and vaccine characteristics
In this study, we vaccinated metastatic melanoma patients with autologous, tumor 
peptide-loaded primary CD1c+ mDC that were freshly isolated from peripheral blood 
and cultured overnight in the presence of GM-CSF (Supplementary Figure 1). Freshly 
isolated mDC had an average purity of 93% (Figure 1A, B). The phenotype of the ex 
vivo-activated DC was determined by flow cytometry; all produced vaccines expressed 
high levels of MHC class I and II, CD83, and CD86 and met the predefined release 
criteria (Figure 1C, D). Expression of CD80 and CCR7 was lower and highly variable. The 
mean viability of injected DC was 86% (range 53-100%) of the first (fresh) vaccination 
and 87% (range 55-98%) of thawed mDC vaccines (vaccinations 2 and 3; Figure 1E). 
Patients received on average, 6 × 106 DC per vaccination, depending on the yield of 
mDC after harvesting, with a maximum of 10 × 106 DC per vaccination. The yield, 
combined with lower CCR7 expression, provided the rationale to administer mDC 
vaccines intranodally. 
A total of 14 HLA-A*02:01-positive melanoma patients were vaccinated with three 
vaccinations at bi-weekly intervals. Patient characteristics are summarized in Table 1. 
One patient (VI-B-04) did not complete the scheduled vaccinations and immune 
monitoring due to rapid progression of disease and was excluded from further 
analysis of immunologic responses (Supplementary Figure 2). Thirteen patients were 
considered evaluable for immunologic response. Five patients received a second 
cycle of three vaccinations and 3 of these patients completed the full three cycles. 
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The vaccines were very well tolerated and no signs of severe toxicity were observed. 
The most common side effects associated with DC vaccination consist of transient 
flu-like symptoms, including fever, and erythema at the site of injection. However, 
none of the vaccinated patients experienced injection site reactions, and only 4 
patients developed grade 1, and one patient grade 2 flu-like symptoms (Table 2). 
Besides one patient with grade 1 pain at the injection site and 4 patients with grade 1 
fatigue, no other vaccine-related side effects were observed. From this, we conclude 
that it is feasible and safe to administer activated and tumor peptide-loaded mDC 
to melanoma patients.
Figure 1. mDC vaccine characteristics. (A) Purity (%) and yield (number of cells) in 22 CliniMACS-based 
CD1c+ mDC isolations on patients’ apheresis material. Each dot represents the result of one mDC isolation. 
Lines represent the mean of all isolations. *mDC of patient VI-B-06 had lower purity with unknown cause. 
(B) Representative example of flow cytometric analysis of mDC purity after CliniMACS isolation. (C) 
Expression of HLA-ABC, HLA-DQ, HLA-DR, CD80, CD83, CD86 and CCR7 on mDC after overnight culture in 
the presence of GM-CSF was analyzed by flow cytometry. Data are shown as percentage of positive DC 
used for the first vaccination cycle. (D) Representative flow cytometry plots of phenotype analysis. Filled 
histograms indicates marker expression, black line is the isotype control. (E) Viability of freshly administered 
mDC (vaccination 1) and thawed mDC (vaccination 2 and 3) of the first vaccination cycle of each patient. 
Each dot represents an mDC vaccine. The line represents the mean of all vaccines.
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mDC vaccination induces anti-KLH responses in metastatic melanoma 
patients
For immunomonitoring purposes and to provide CD4+ T cell help, all DC have been 
loaded with the control antigen KLH. PBMC, isolated after each vaccination, showed 
increased proliferation upon stimulation with KLH after the first cycle of vaccinations 
in 11 of 13 patients (Supplementary Figure 3A; Table 2), indicating that the vaccine 
effectively induced de novo immune responses in these patients. We also followed 
the levels of serum anti-KLH antibody after each cycle of vaccinations. In 4 of 13 
patients, anti-KLH IgG could be detected, albeit just above detection limits in two 
of these patients (Supplementary Figure 3B; Table 2). In 2 patients anti-KLH IgG was 
already detectable before vaccination, but these patients showed increased levels 
after subsequent vaccinations. Patient VI-B-01 showed a clear IgG response after the 
second cycle of mDC vaccinations, which coincided with the presence of anti-KLH IgA. 
Anti-KLH IgM was not detected. 
Supplementary Figure 2. Flow chart.
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Table 2. Immunological and clinical responses.
Patient
Flu-like 
symptoms 
(grade)
Anti-KLH 
responsea
Tumor antigen-specific CD8+ T cells
PFS 
(mo)
OS 
(mo)
Best 
response
Salvage 
treatment
Bloodb
DTHc
No of 
epitopes 
recognizeddT cell Antibody Pre-vac Post-vac
VI-B-01 0 + + - +(+) +++ 3 18 22 SD S, T
VI-B-02 1 + - n.t. - - <4 7 PD C, RT
VI-B-03 1 + - -(-) -(-) - 7 40 SD T, I
VI-B-04 0 n.a. n.a. n.t. n.a. n.a. <4 3 PD RT, C
VI-B-05 0 + + n.t. - + <4 9 PD I
VI-B-06 0 + - n.t. - - 4 13 SD RT
VI-B-07 0 + + n.t. - - <4 11 PD T
VI-B-08 1 + - +(+) +(+) +++ 2 15 29 MR I, RT, T, S
VI-B-09 0 + - n.t. - - 12 15 SD T, RT
VI-B-10 0 - + -(-) -(-) - <4 38 PD T, I
VI-B-11 2 - - +(-) +(-) - <4 6 PD -
VI-B-12 0 + - n.t. n.t. - <4 11 PD RT, T
VI-B-13 0 + - - +(+) +++ 2 35+ 35+ CR -
VI-B-14 1 + - n.t. - - <4 13 PD C, RT
Abbreviations: C, chemotherapy; CR, complete remission; DTH, delayed-type hypersensitivity skin test; 
I, immunotherapy (anti-CTLA4 antibody); MR, mixed response; n.a., not applicable; n.t., not tested; 
OS, overall survival; PD, progressive disease; PFS, progression-free survival; S, surgery; SD, stable disease; 
T, targeted therapy (BRAF inhibitor); RT, radiotherapy.
a KLH-specific cellular proliferation and antibodies after vaccination with myeloid dendritic cells. 
Responses were scored as the best response after all cycles of DC vaccinations.
b Presence of tetramer-positive CD8+ T cells in peripheral blood is marked as +. In brackets, the presence 
of functional CD8+ T cells is marked as +. Functionality was defined as CD8+ T cells expressing at least 
one of the functionality markers CD107a, IFNγ, CCL4, TNFα or IL-2 above threshold level (0.2% after 
background subtraction) after in vitro peptide stimulation.
c Presence of tetramer-positive T cells in DTH is marked as +, presence of functional tetramer-positive 
T cells in DTH is marked as +++. Functionality was defined as the production of IFNγ after stimulation 
with T2 cells loaded with HLA-A*02:01-binding gp100 or tyrosinase peptides (peptide recognition), 
BLM transfected with gp100 or tyrosinase protein (protein recognition) or the gp100- and tyrosinase-
expressing tumor cell line Mel624 (tumor recognition). Responses were scored as the best immunologic 
response after all cycles of DC vaccinations.
d Total number of tumor antigen epitopes (gp100
154-162
, gp100
280-288
, tyrosinase
369-377
) recognized by 
functional T cells from peripheral blood or DTH skin test in all cycles of DC vaccinations.
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Supplementary Figure 3. KLH-specific immune responses before and after DC vaccination. (A) KLH-specific 
T cell proliferation was analyzed before the first vaccination and after each DC vaccination during the first 
vaccination cycle in peripheral blood of vaccinated metastatic melanoma patients. Per time point each 
dot represents 1 patient. Proliferative response to KLH is given as proliferation index (proliferation with 
KLH/proliferation without KLH). The two patients not showing a KLH-specific T cell response are shown in 
grey. (B) KLH-specific IgG, IgA, and IgM antibodies were quantitatively measured after each vaccination 
cycle in sera of vaccinated patients. Per isotype each dot represents one patient. Best KLH responses per 
patient are shown.
mDC induce multifunctional tumor antigen-specific T cell responses in vivo
Cytotoxic T cells are crucial for immune-mediated tumor eradication. Previously, we 
showed that the presence of tumor antigen-specific T cells in DTH skin tests positively 
correlates with clinical outcome in metastatic melanoma patients after moDC 
vaccination.4, 5 We analyzed the presence of tumor antigen-specific SKILs in biopsies 
taken from DTH skin tests after each cycle of vaccinations. In 4 of 13 patients tested, 
tetramer-positive CD8+ T cells were detected in SKIL cultures (Table 2; Figure 2A, 2D). 
In 3 of these patients (VI-B-01, -08, and -13), the antigen-specific CD8+ T cells were 
fully functional and produced high levels of IFNγ upon antigen-specific stimulation 
with HLA-A*02:01-binding gp100 or tyrosinase peptides (peptide recognition). SKILs of 
patient VI-B-01 recognized gp100
154-162
, gp100
280-288
, and tyrosinase
369-277
, whereas SKILs 
of patient VI-B-08 recognized gp100
154-162
 and SKILs of patient VI-B-13 recognized both 
gp100 epitopes (Table 2; Figure 2B, 2E). SKILs of all three patients also produced high 
levels of IFNγ upon coculture with tumor cells expressing gp100 or tyrosinase protein 
(protein recognition). Interestingly, all 3 patients showed progression-free survival of 
more than 15 months and two of them showed objective clinical responses (see below). 
Tetramer analysis of PBMC after each cycle of 3 mDC vaccinations revealed tumor 
peptide-specific CD8+ T cells in peripheral blood of 4 out of 12 patients tested (VI-B-01, 
-08, -11, and -13) (Table 2; Figure 3A). Recent studies showed that T cell functionality is 
an important indicator for an effective immune response. In HIV patients, the presence 
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of T cells that simultaneously express more than three effector functions correlates 
with long-term disease control26, 27 and also in DC-vaccinated melanoma patients, these 
cells preferentially appear in patients with extended overall survival.23 We assessed the 
functionality of tumor-specific CD8+ T cells by measuring the simultaneous expression 
of CD107a (as a surrogate marker for cytolytic activity; expressed on the cell surface 
upon release of perforin and granzymes), the proinflammatory cytokines IFNγ, TNFα, and 
IL-2, and the chemokine CCL4 by tumor antigen-specific T cells after in vitro stimulation 
(Figure 3B). Functional T cells, that is, cells expressing at least one of the functional markers 
upon antigen stimulation, could be identified in PBMC of 3 of the 4 patients that exhibited 
tetramer-positive CD8+ T cells in the blood, completely overlapping the three patients with 
IFNγ-producing SKILs (VI-B-01, -08, -13; Table 2; Figure 3C). We could not detect functional 
tumor antigen-specific T cells in blood of patients VI-B-03, VI-B-10, or VI-B-11, despite these 
patients were long survivors (VI-B-03, VI-B-10) or showed tetramer-positive CD8+ T cells in 
PBMC (VI-B-11). Patient VI-B-08 already harboured high frequencies of tyrosinase-specific 
CD8+ T cells in the peripheral blood even before vaccination, which further increased after 
DC vaccination. However, tyrosinase-specific T cells were not detected in the SKILs of this 
same patient, indicative of the possible incapacity of these cells to home into the skin. 
Functional T cell responses were dominated by CD107a expression, followed by 
secretion of IFNγ, CCL4, and TNFα (Figure 3D). Production of IL-2 was not observed. 
The functionality of tumor antigen-specific CD8+ T cells differed markedly between and 
within tested individuals and reached from high fractions of T cells with 3 or 4 functions 
(VI-B-01, -08) to mainly monofunctional responses (VI-B-01, -13). Patient VI-B-08 
displayed high fractions of T cells with three functions already before vaccination, 
which increased after one cycle of DC vaccinations (Figure 3E). Furthermore, patient 
VI-B-01 displayed considerable fractions of tumor antigen-specific T cells with three 
functions after vaccination. T cells exhibiting four or more functions were only found 
in less than 4% of tumor antigen-specific T cells. From these data, we conclude that 
vaccination with small numbers of primary CD1c+ mDC can induce multifunctional 
tumor-specific CD8+ T cell responses in metastatic melanoma patients. 
Clinical responses
Five patients showed at least stable disease upon the first vaccination cycle (7, 12, 15, 
18, and 35+ months duration, respectively) and were therefore eligible for an additional 
vaccination cycle consisting of another three mDC vaccinations (Tables 1 and 2). In two 
of these patients, disease progression occurred after the second vaccination cycle. 
The three remaining patients also received a third cycle of three mDC vaccinations, 
of which one M1a, one M1b, and one M1c patient. All patients were evaluated for 
clinical response at 3-month intervals with CT scans. Two patients showed objective 
tumor responses, which coincided with the presence of functional T cells in peripheral 
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Figure 2. Immunological and clinical responses of patients VI-B-13 and VI-B-08. (A-C) The presence and 
functionality of tumor antigen-specific T cells were tested in lymphocytes cultured from skin test biopsies 
(SKILs) of patient VI-B-13. (A) Example of tetramer analysis by flow cytometry of SKILs cultured from a biopsy of 
a positive post-treatment DTH reactions of patient VI-B-13 after the first cycle of three DC vaccinations. SKILs 
were stained with tetramers encompassing the HLA-A*02:01-specific gp100
154-162
, gp100
280-288
, tyrosinase
369-377
 
peptide or an irrelevant peptide (HIV) and with anti-CD8. The percentage in the upper right quadrant represents 
the percentage of CD8+ tetramer+ cells. (B) IFNγ production by the same T cells after stimulation with T2 cells 
loaded with gp100
154-162
, gp100
280-288
 or tyrosinase
369-377
 peptide (peptide recognition), BLM cells expressing 
gp100 or tyrosinase protein (protein recognition), or Mel624 cells expressing both gp100 and tyrosinase (tumor 
recognition). (C) CT scans of the chest of patient VI-B-13 showed clear reduction in size of a pulmonary metastasis 
after one cycle of mDC vaccinations (middle) and complete remission after three cycles of mDC vaccinations 
(right). (D-H) The presence and functionality of tumor antigen-specific T cells were tested in lymphocytes 
cultured from skin test biopsies of (SKILs) patient VI-B-08. (D) Example of tetramer analysis by flow cytometry 
of SKILs cultured from a biopsy of a positive post-treatment DTH reaction of patient VI-B-08 after the first cycle 
of three DC vaccinations. SKILs were stained with tetramers as in Figure 2A. (E) IFNγ production by the same T 
cells after stimulation with target cells as in Figure 2B. (F) CT scan of patient VI-B-08 before (left), after 1 cycle 
of mDC vaccinations (middle) and after 2 cycles of mDC vaccinations (right), showing an evident subcutaneous 
lesion dorsally of the left os ilium, which clearly reduces after the first cycle of DC vaccinations and further 
reduces after the second cycle of DC vaccinations. (G) Immunohistochemistry of progressive tumor showing that 
the melanoma-associated antigen gp100 is still expressed (left, gp100 in red). Both CD8+ T cells (middle, CD8 in 
brown) as well as FoxP3+ cells (right, FoxP3 in brown) are present in the tumor. (H) Flow cytometric analysis of 
tumor infiltrating lymphocytes isolated from a progressive tumor showing CD4+FoxP3+ lymphocytes. 
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Figure 3. Tumor antigen-specific T cell responses in peripheral blood. (A) Examples of tetramer analysis 
of peripheral blood mononuclear cells (PBMCs) of patients VI-B-01, -03, -08, -10, -11 and -13. PBMCs 
were stained with tetramers encompassing the HLA-A*02:01 specific peptides gp100
154-162
, gp100
280-288
, 
tyrosinase
369-377 
or an irrelevant peptide (HIV) and with anti-CD8. The percentage in the upper right quadrant 
represents the percentage of CD8+ tetramer+ cells. Best results of all vaccination cycles per patient are 
shown. (B) To analyze the functionality of tumor antigen-specific CD8+ T cell responses, PBMCs or peripheral 
blood lymphocytess were stimulated with tumor peptides (gp100
154-162
, gp100
280-288
, tyrosinase
369-377
) for 5-6 
h and subsequently analyzed for expression of CD107a, IFNγ, CCL4, TNFα and IL-2 using flow cytometry. (C) 
Shown is the frequency of total tumor antigen-specific CD8+ T cells. Horizontal red line indicates cut-off 
value of 0.2% responding CD8+ T cells. (D+E) Displayed for each patient is the CD8+ T cell response with the 
highest fraction of T cells expressing 3 or more functions (indicated by ò in C). (D) The relative contribution 
of each functional marker was measured. (E) Fractions of tumor antigen-specific CD8+ T cells with 1, 2, 3, 
4, or 5 functions. 
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blood and DTH skin tests (Figure 2, 3). CT scans of patient VI-B-13 showed evident 
regression of pulmonary and mediastinal nodal metastases already after one cycle of 
DC vaccinations, which converted into a complete response after the second cycle of 
DC vaccinations (Figure 2C). The patient is in ongoing complete remission and good 
clinical condition 35 months after initiation of vaccinations with mDC. 
Patient VI-B-08 showed a mixed response; a subcutaneous lesion was strongly 
reduced in size after the first cycle of DC vaccinations and reduced even further after 
the second cycle (Figure 2F), while two other lesions remained stable. However, a 
subcutaneous metastasis on the scalp increased in size during the same time period. 
This lesion was resected during the second cycle of vaccinations and analyzed by flow 
cytometry and immunohistochemistry. Tumor antigens gp100 (90% of the tumor cells 
strongly positive) and tyrosinase (70% of the tumor cells weakly positive; not shown), 
and MHC class I (not shown) were still expressed by the tumor cells and CD8+ T cells 
were present both peritumorally and intratumorally (Figure 2G). Intriguingly, a massive 
infiltration of FoxP3+ T cells was observed (34% of CD4+ T cells; Figure 2G, 2H), indicative 
of regulatory T cells that might have locally inhibited an effective antitumor response. 
As no other lesions showed progression at this stage, the patient received a third 
cycle of vaccinations. Unfortunately, shortly after completion of the third cycle the 
patient progressed. Two further lesions were resected, which also expressed gp100, 
tyrosinase, and MHC class I and were infiltrated by both CD8+ T cells and, to a lesser 
extent, CD4+ and FoxP3+ cells (data not shown). Subsequent treatments with both 
ipilimumab 3mg/kg (3 cycles) and vemurafenib (3 months) did not improve the clinical 
status and the patient died of disease 29 months after initiation of mDC vaccinations. 
Figure 4. Correlation between the presence of functional specific T cells and clinical outcome. Kaplan–
Meier analyses of progression-free survival (A) and overall survival (B) according to the presence of 
functional tumor antigen-specific T cells in peripheral blood or skin-infiltrating lymphocytes. Statistical 
significance between mDC-vaccinated patients with functional T cell responses compared to patients 
without functional T cell responses was determined by a log rank test. 
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Despite the small sample size, our data strongly suggest a correlation between 
the immunologic responses and progression-free survival (Figure 4A). The median 
progression-free survival was 17.6 months for patients with functional T cells in blood 
and IFNγ-producing SKILs (n=3), compared to 2.3 months for patients with no functional 
T cells (p=0.019; HR 0.15; 95%CI, 0.04-0.57). The median overall survival of patients 
with functional T cells was 29.0 months, whereas in the absence of functional T cells, 
the median overall survival was 10.9 months (Figure 4B; p=0.103; HR 0.43; 95%CI, 0.12-
1.54). The median overall survival of all patients was 13.3 months. 
Discussion
Three conclusions can be drawn from this study: (i) vaccination with naturally 
circulating primary CD1c+ mDC can induce de novo immune responses and objective 
clinical responses, even in advanced metastatic melanoma patients. The treatment is 
well tolerated and warrants follow-up by a prospective randomized trial. (ii) Prolonged 
progression-free survival was associated with the presence of multifunctional tumor 
antigen-specific T cells in the blood and the DTH (SKILs). (iii) Primary mDC vaccines can, 
even at numbers as low as 3-10 x 106 mDC per vaccination, induce de novo immune 
responses. This highly standardized and rapid vaccine production procedure (within a 
period of 48 hours) will certainly expedite larger randomized multicenter trials.
By overnight culture in the presence of GM-CSF, we obtained mDC that highly 
expressed MHC class I, MHC class II, CD83, and CD86. CD80 and CCR7 were expressed 
at lower and highly variable levels, which may be suboptimal. DC activation with 
appropriate adjuvants, such as TLR ligands, will induce increased levels of costimulatory 
molecules and production of proinflammatory cytokines, which is favorable for potent 
antitumor responses. Unfortunately, limited availability of GMP-compliant produced 
products impeded the use of TLR ligands for mDC maturation in this study. We 
recently optimized DC maturation with clinical-grade protamine-mRNA complexes 
that induce TLR7/8-mediated upregulation of maturation markers and production of 
proinflammatory cytokines in mDC as well as pDC,28 which will be used in our future 
studies. 
Five of 14 vaccinated patients, including patients with widespread disease, showed 
long-term overall survival (22-40 months). In three of these patients, this coincided with 
the presence of tumor antigen-specific T cells and prolonged progression-free survival, 
while in the two patients without tumor antigen-specific T cells progression-free 
survival was short. Recent studies in HIV-infected patients showed that the functional 
quality, rather than the magnitude of the T cell response, is an important indicator 
for effective immune responses. In those HIV patients, the presence of T cells that 
simultaneously express more than three effector functions correlated with long-term 
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disease control.26, 27 Similarly, to obtain more insight in the functional capabilities of 
T cells from mDC-vaccinated melanoma patients, we examined their capacity to exert 
multiple functions at the same time. Besides cytotoxicity, necessary for induction of 
tumor cell apoptosis (analyzed by the expression of degranulation marker CD107a), also 
secretion of proinflammatory cytokines and chemokines such as IFNγ, TNFα, IL-2, and 
CCL4 proved important for long-term tumor control by increasing immune recognition 
and inducing permanent senescence in cancer cells and by activation and recruitment of 
other immune cells, such as DC and NK cells.23, 29-31 Although the phenotype of induced 
peripheral blood CD8+ T cells was dominated by CD107a expression, also IFNγ, CCL4, 
and TNFα were secreted. Various levels of T cell functionality could be observed; two 
patients displayed high fractions of T cells expressing three or more functions (VI-B-01 
and VI-B-08). Regression of the tumor was seen in two patients harboring functional 
T cells in their peripheral blood and DTH skin test (VI-B-08 and VI-B-13). Apparently, 
robust T cell responses are essential for tumor cell killing. These results highlight the 
ability of primary mDC to induce comprehensive T cell responses in vivo. 
Interestingly, patient VI-B-08 already displayed high frequencies of multifunctional 
tyrosinase-specific CD8+ T cells in the peripheral blood even before vaccination. mDC 
vaccination increased the frequency as well as the functionality of these T cells. 
However, as tyrosinase-specific T cells were not detected in the SKILs of this same 
patient, these cells may not have the capacity to home into the skin and tumor. By 
contrast, IFNγ-secreting gp100-specific cytotoxic T lymphocytes were detected in SKILs 
of this patient. Possibly, these gp100-specific T cells were responsible for regression 
of the responding lesion. Unfortunately, we could not obtain tumor material of this 
regressing lesion to confirm this hypothesis. 
Five of 14 patients (36%) had tetramer-positive T cells in peripheral blood or SKILs. 
In 3 of these 5 patients (21%) functional T cells were detected. This response rate is 
similar to that of moDC-vaccinated stage IV melanoma patients in our previous studies.4 
The high tumor burden in stage IV melanoma patients may hamper the induction of 
effective immune responses and cause the lack of response in the remaining patients, 
which is underscored by our observation that response rates in stage III melanoma 
patients are higher.32, 33 Therefore, we hypothesize that DC vaccination may be more 
potent in the adjuvant setting.
Until 2013, the recommended standard therapy for metastatic melanoma 
patients was DTIC, which did not considerably affect overall survival.34 Recently, 
anti-CTLA4 antibodies (ipilimumab)35, 36 and anti-PD-1 antibodies (nivolumab and 
pembrolizumab)37, 38 proved to be effective forms of immunotherapy for patients with 
metastatic melanoma and replaced DTIC as standard treatment. Although the number 
of patients studied here is too small for direct comparison and to allow any conclusions 
regarding significant clinical efficacy, it is notable that the overall survival of mDC-
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vaccinated patients appeared to be comparable with that of similar patients treated 
with ipilimumab reported in literature.35, 36 However, four patients included in our study 
received ipilimumab upon disease progression, of which three patients were among 
the five patients with long-term overall survival. Nevertheless, none of these patients 
showed an objective response or long-term stable disease upon ipilimumab treatment; 
progression occurred between 5 and 8 months. Only one patient (VI-B-08) with a 
functional tumor-specific T cell response after mDC vaccination received ipilimumab; 
she showed progressive disease 7 months after start of ipilimumab treatment. Still, 
subsequent treatment has confounded the overall survival data. However, as the 
correlation of a functional T cell response with progression-free survival, where no such 
confounding has taken place, is significant, we believe this is due to mDC vaccination. 
We did not obtain sufficient data to speculate on the combination of mDC vaccination 
and checkpoint inhibitors, but as mDC vaccines specifically activate tumor antigen-
specific T cells and immune-checkpoint inhibition activates T cells in a non-antigen-
specific manner, one can hypothesize that a combination of the two could be beneficial, 
as CTLA4- or PD-1 blockade could improve the functionality and limit exhaustion of 
mDC-induced tumor antigen-specific T cells. This is supported by data suggesting a 
correlation between prior DC vaccination and objective responses upon subsequent 
treatment with ipilimumab.39 These results urge for a randomized phase II trial to 
explore the clinical efficacy of mDC as an anticancer vaccine, possibly in combination 
with immune checkpoint inhibitors.
In our previous study, using naturally circulating pDC, vaccinated melanoma 
patients showed a beneficial effect on overall survival, irrespective of the observation 
that the induction of tumor antigen-specific T cells was not as prominent as in previous 
moDC-vaccination trials or in the current study.14 This might suggest that either the 
antigen-specific T cells that were induced by pDC are very potent or more functional 
in terms of migration, cytokine secretion, or survival, or that other mechanisms, such 
as activation of NK cells or other innate immune cells by the massive pDC-derived 
type I IFN secretion, are involved in pDC-related clinical outcome. mDC and pDC may 
utilize different mechanisms and could synergize in the induction of clinical responses 
in metastatic melanoma patients. We therefore hypothesize that coadministration 
of naturally circulating mDC and pDC, and thus activation of multiple, possibly 
complementary, antitumor mechanisms, may generate more potent and longer-lasting 
antitumor responses in cancer patients compared to administration of individual 
naturally circulating DC subsets.17, 40 Indeed, in a murine tumor model, simultaneous 
injection of mDC and pDC proved superior in generating antitumor responses when 
compared to immunization with either DC subset alone.41 Future DC vaccination studies 
in cancer patients should elucidate whether this also holds true for human DC subsets. 
In vitro studies have already demonstrated that human mDC and pDC synergize via 
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bidirectional cross-talk.11, 42 Addition of CD141+ myeloid DC may even further improve the 
potency of DC vaccines, as CD141+ DC are highly efficient in antigen cross-presentation 
to CD8+ T cells and are able to secrete IFNγ and IL-12 upon activation, which allows the 
effective induction of T helper 1 and cytotoxic T lymphocyte responses.43-48. However, 
the limited presence of DC in blood and lack of GMP-grade isolation reagents currently 
impedes the use of CD141+ DC for DC-based immunotherapy.
In conclusion, we showed that vaccination of metastatic melanoma patients with 
primary mDC is feasible and safe and results in the induction of effective antitumor 
immune responses that coincide with improved progression-free survival. The virtual 
lack of side effects of primary mDC vaccines, their swift and highly controlled production, 
and their potency in inducing multifunctional antigen-specific T cell responses, warrants 
further exploration of these natural circulating DC subsets in larger randomized trials.
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Abstract
The identification of responding patients early during treatment would improve the 
capability to develop effective new immunotherapies more rapidly. Here, we describe a 
bioassay that may link early T cell-mediated immune responses to later clinical benefits. 
This bioassay rests upon the tenet of immunotherapy that tumor-specific effector T 
cells capable of invading peripheral tissue can recognize tumor antigens and exert 
cytotoxic functions there. To demonstrate its utility, we conducted a retrospective 
study of a large cohort of metastatic melanoma patients (n=91) enrolled in dendritic 
cell (DC)-based vaccination protocols to examine a hypothesized correlation of 
posttreatment skin-infiltrating lymphocytes (SKILs) with overall survival (OS). Stringent 
immunologic criteria were defined to identify long-term survivors. The presence of 
tumor-associated antigen (TAA)-specific CD8+ T cell populations within SKILs (criterion 
I) was highly predictive for long-term survival. Further restriction by selecting for the 
presence of TAA-specific CD8+ T cells specifically recognizing tumor peptide (criterion 
II) was also associated with improved OS. Recognition of naturally processed antigen 
(criterion III) maximized the accuracy of the test, with a median OS of 24.1 versus 
9.9 months (p=0.001). Our results show that detailed characterization of SKILs can 
permit an accurate selection of metastatic melanoma patients who benefit most from 
DC-based vaccination. This simple and robust bioassay integrates multiple aspects 
of cellular functions that mediate effective immune responses, thereby offering an 
effective tool to rapidly identify patients who are responding to immunotherapy at an 
early stage of treatment. 
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Introduction 
The focus of treatment for metastatic cancer patients is shifting from a generalized 
approach based on population markers, to a personalized approach based on 
individual tumor and host characteristics.1 Immunotherapy is intrinsically a 
personalized treatment modality, as it acts via the patients’ own immune system 
to induce anticancer immunity. Recent trials have underscored the potential of 
immunotherapy in metastatic cancers, especially in melanoma.2 Owing to their 
unique immune stimulatory properties, DC are an essential target for anticancer 
immunotherapy. We and others have explored DC-based therapy to induce TAA-
specific immune responses in this population.3,4 Interestingly, the reported rates of 
long-lasting responses in immunotherapy trials are generally low, but remarkably 
constant, regardless of the chosen regimen.5 This long-standing observation hints 
at a subgroup of ‘immune reactive’ patients. Identification of responding patients 
early during treatment would, therefore, greatly improve clinical efficacy of these 
novel and costly therapies. Thus, bioassays that accurately link immune responses 
to clinical outcome are warranted.1 
The mainstay of immunotherapy is to induce, enhance, or sustain TAA-specific 
effector T cell immunity. Consequently, currently used bioassays focus on cellular 
immune responses at different time points after immunotherapeutic intervention. 
For example, most vaccination studies include a control antigen like keyhole limpet 
hemocyanin (KLH) or tetanus toxoid as a surrogate marker for immune competence.6 
However, the high immunogenicity of these control antigens often induces profound 
cellular and humoral responses, which do not accurately model the less abundant, and 
often self-antigens, TAA-specific cellular responses. Another widely used approach 
is ELIspot, which determines the production of a single cytokine upon antigenic 
stimulation, for example, IFN-γ ELIspots. Typically, ELIspots are conducted on cell 
samples obtained from peripheral blood, whereas antitumor effects can only be 
expected from immune cells capable of leaving the circulation and invading peripheral 
tissues. Although ELIspots are rather sensitive, they need careful standardization.7,8 
Moreover, they evaluate a single cytokine, whereas cytokine profiles better reveal 
the functional programming of effector cells. Imaging results from previous trials 
using adoptive cell transfer show that the migratory capacity of effector cells is 
positively correlated to clinical outcome9, suggesting that this functionality should be 
incorporated in bioassays as well.10 Novel techniques have recently been developed 
that allow high throughput assessment of individual variations in many functional 
processes, for example, differences in signalling pathways in immune cells.11 However, 
as of now these techniques lack validation and are not yet applicable in the evaluation 
for therapy-induced immune responses. 
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Previously, we reported that screening cultures from delayed-type hypersensitivity 
(DTH) skin-test biopsies, by using tetrameric MHC-peptide complexes, provides a 
valuable tool to link immune responses to clinical outcome in metastatic melanoma 
patients who underwent DC-based vaccinations.12 In this study, we extend these 
findings in a large cohort and show that detailed analysis of SKIL cultures is a solid 
bioassay to predict survival in metastatic melanoma patients. This bioassay is simple, 
feasible, and integrates multiple aspects of effector cell functions needed for effective 
immune responses.
Patients and Methods
Patient characteristics
We retrospectively analyzed a cohort of 91 patients with irresectable locoregional or 
distant metastatic melanoma, who were enrolled in our vaccination studies between 
June 1999 and June 2008 (Table 1). Eligibility criteria included melanoma patients with 
irresectable locoregional or distant metastatic disease, according to the 2001 American 
Joint Committee on Cancer Staging criteria.13 Other inclusion criteria include HLA-A*02:01 
phenotype, known HLA-DRB*01*04 status, melanoma expressing the melanoma-
associated antigens gp100 and tyrosinase and World Health Organization performance 
status 0 or 1. Patients with symptomatic brain metastases, serious concomitant disease, 
or a history of second malignancy were excluded. The studies were approved by our 
Institutional Review Board and written informed consent was obtained from all patients.
Treatment schedule
All patients were vaccinated with cytokine-matured monocyte-derived autologous 
DC loaded with TAA of gp100 and tyrosinase according to a schedule of 3 biweekly 
vaccinations followed in week 7 to 8 by a DTH skin test (Supplementary Figure 1). 
Differences in protocols included the route of administration (intranodal, intradermal, 
or combined intradermal/intravenously), method of antigen loading (detailed 
information below) and pretreatment with anti-CD25 antibody; described in Table 1. 
Unless progressive disease was documented, patients received a maximum of 3 
vaccination cycles, each with a 6-month interval. For the exact details about the 
vaccination protocols, we refer to these individual studies.14-18
Dendritic cell vaccine
Monocytes were enriched from leukapheresis products by counterflow centrifugation 
using Elutra-cell separator (Gambro BCT, Inc.) and single-use, functionally sealed 
disposable Elutra sets, as described before19 and according to the manufacturer. 
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Monocytes were cultured in the presence of interleukin (IL)-4 (500 U/mL), GM-CSF 
(800 U/mL) (both Cellgenix) and KLH (10 μg/mL, Calbiochem). DC were matured with 
autologous monocyte-conditioned medium (30%, v/v) supplemented with prostaglandin 
E2 (10 μg/mL, Pharmacia & Upjohn) and 10 ng/mL tumor necrosis factor-α (Cellgenix) 
for 48 hours as described previously.20 This procedure gave rise to mature DC meeting 
the release criteria described previously.3 DC were pulsed with the HLA class I gp100-
derived peptides gp100:154-162, gp100:280-288, and the tyrosinase-derived peptide 
tyrosinase:369-377. DC from HLA-DRB*01*04–positive patients were also pulsed with 
HLA-DRB*01*04–binding peptides of both gp100 and tyrosinase (gp100:44-59 and 
tyro:448-462 analog).21,22 Peptide pulsing was conducted as described previously.16 In 
the other protocols, mature DC were electroporated with mRNA encoding gp100 or 
tyrosinase as described previously23 and cells were resuspended in 0.1 mL for injection.
KLH-specific proliferation and IFN-γ production
Peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood 
by Ficoll-Paque density centrifugation, stimulated with KLH (4 µg/2×105 PBMC) in 
X-VIVO with 2% HS. After 3 days, cells were incubated with 3H-thymidine for 8 hours; 
incorporation was measured with a β-counter. Experiments were conducted in 
Table 1. Vaccination protocols and characteristics of SKIL cultures.
Protocol 
No of 
evaluable 
patients (total) 
Method 
of antigen 
loading 
Route of 
adminis-
tration 
Anti-CD25 
mAba 
No of cultures 
with outgrowth, 
pos/total (%)
Mean, 
x106 Range, x106 
1 1 (1) Class I wtb id No 4/4 (100) 0.15 0.09–0.2 
2 13 (17) Class I wt in No 48/48 (100) 0.50 0.03–5.6 
3 17 (22) mRNAc in No 115/126 (86) 0.53 0.01–7.0 
4 13 (15) Class I wt iv/id No 44/63 (70) 0.59 0.01–1.8 
5 9 (10) Class I modd iv/id No 21/48 (44) 0.16 0.01–1.3 
6 11 (11) Class I/II wte in No 65/73 (89) 0.53 0.01–3.1 
7 13 (15) Class I wt iv/id Yes 42/54 (78) 0.44 0.01–3.3 
Total 77 (91) 339/416 (82) 
Abbreviations: id, intradermal; in, intranodal; iv, intravenous; mAb, monoclonal antibody; mod, 
modified; wt, wild-type.
a Four or 8 days before the first vaccination, anti-CD25 antibody 0.5 mg/kg was administered intravenously.
b Class I wt, HLA class I-restricted wild-type gp100-derived peptides 154 to 162 and 280 to 288 and HLA 
class I-restricted tyrosinase-derived peptide 369 to 377.
c mRNA, messenger RNA encoding full-length gp100 and tyrosinase.
d Class I mod, HLA class I-restricted modified gp100-derived peptides 154 to 162 Q→A and 280 to 288 
A→V and HLA class I-restricted tyrosinase-derived peptide 369 to 377.
e Class II, HLA class II-restricted gp100-derived peptide 44 to 59 and tyrosinase-derived peptide 448 to 
462 analog.
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triplicate, nonspecific proliferation upon stimulation with ovalbumin (OVA) was used 
as control. IFN-γ production was measured in the supernatants after 24 hours by ELISA. 
Human IFN-γ monoclonal antibody 2G1 was used for coating (0.75 µg/mL), human 
IFN-γ biotin-labeled mAb M701B (0.05 mg/mL) was used for detection (all Thermo 
Scientific Inc). Recombinant human IFN-γ RIFNG100 was used as standard. At least a 
2-fold increase compared with OVA was considered positive. 
Skin-test infiltrating lymphocyte analyses
Skin tests were conducted within 1 to 2 weeks after each vaccination cycle 
(Supplementary Figure 1).12  Briefly, 2 to 10×105 DC pulsed with either gp100, tyrosinase 
or both epitopes or transfected with mRNA encoding either gp100 or tyrosinase or both 
(specifically indicated in the relevant text and figures) were injected intradermally in 
the skin of the back of the patient at different sites, 4 cm apart from each other. After 
48 hours, the maximum diameter of induration was measured by palpation and punch 
biopsies (6 mm) were taken. Half of the biopsy was cryopreserved by snap freezing and 
the other part was manually cut and cultured for 2 to 4 weeks in RPMI-1640 containing 
7% HS and IL-2 (100 U/mL), every 7 days half of the medium was replaced by fresh IL-2 
containing RPMI-1640 7%HS. 
Tetramer staining of SKILs
SKIL cultures were stained with tetrameric-MHC complexes containing the MHC-I 
epitopes gp100:154-162, gp100:280-288, or tyrosinase:369-377 (Sanquin) as described 
Supplementary Figure 1. Schedule of treatment and monitoring. Patients received 3 vaccinations at a 
biweekly interval, followed by a delayed-type hypersensitivity (DTH) skin test. After completing one cycle 
and if no progression of disease was confirmed on CT-scan, patients were eligible to receive a maximum 
of two more cycles and were followed up to 5 years. Abbreviations: Vx = visit x; M = month; D = day; 
W = week; Y = year; vacx = vaccination x; FU = follow-up; * follow-up visits were planned every 3 months; 
# CT-scans were planned every 6 months. 
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previously.12 Tetrameric-MHC complexes recognizing HIV were used as correction for 
background binding. Tetramer positivity was defined as at least 2-fold increase in the 
double positive population. 
Cytotoxic activity of SKILs
Cytotoxic activity by SKILs in response to T2 cells pulsed with the indicated peptides 
or BLM (a melanoma cell line expressing HLA-A*02:01 and no endogenous expression 
of gp100 and tyrosinase), transfected with control antigen G250, or with gp100 or 
with tyrosinase, or an allogenic HLA-A*02:01-positive, gp100-positive, and tyrosinase-
positive tumor cell line (Mel624) were measured. Target cells were incubated with 
100 µCi Na2[
51Cr]O4 (Amersham) and, after washing, added to SKILs (1×10
5 cells) and 
unlabeled K562 cells (1×104 cells) in triplicate wells of a round bottom microtiter plate 
(E/T ratio 10/1). After 4 hours, supernatants were harvested and radioactivity was 
measured. The specific percentage of cytotoxicity was defined by the following formula:
 
4 
 
tyrosinase-positive tumor cell line (Mel624) were measured. Target cells were incubated with 100 µCi 
Na2[51Cr]O4 (Amersham) and, after washing, added to SKILs (1×105 cells) and unlabeled K562 cells (1×104 cells) 
in triplicate wells of a round bottom microtiter plate (E/T ratio 10/1). After 4 hours, supernatants were 
harvested and radioactivity was measured. The specific percentage of cytotoxicity was defined by the following 
formula:  
 
specific cytotoxicity= (experimental release [cpm] - spontaneous release [cpm])(maximum release [cpm] - spontaneous release [cpm])  ×100% 
 
Positive and specific cytotoxic activity was defined as a 2-fold increase compared with stimulation with the 
same cell-lines pulsed with an irrelevant peptide.  
 
Cytokine production profiles by SKILs 
The production of IFN-γ, TNF-α, IL-10, IL-5, IL-4, and IL-2 by SKILs was measured in supernatants after 16 hours 
of coculture with different target cells to obtain a cytokine profile of postvaccination SKILs. Target cells include 
T2 cells pulsed with the indicated peptides or BLM (a melanoma cell line expressing HLA-A*02:01 and no 
endogenous expression of gp100 and tyrosinase), transfected with control antigen G250, or with gp100 or with 
tyrosinase, or an allogenic HLA-A*02:01-positive, gp100-positive, and tyrosinase-positive tumor cell line 
(Mel624) with SKILs, using the cytometric bead array [Thelper 1/Thelper 2  (Th1/Th2) Cytokine CBA 1; BD 
Pharmingen], according to the manufacturer instructions. Positive and specific cytotoxic activity was defined as 
a 2-fold increase compared to stimulation with the same cell lines pulsed with an irrelevant peptide.  
 
Skin-test infiltrating lymphocyte culture evaluation 
SKILs were evaluated according to increasingly stringent criteria; the presence of TAA-specific CD8+ T cells by 
tetrameric MHC-peptide complexes (criterion I); peptide-recognition by specific production of Th1 cytokines 
(e.g. IFN-γ and/or IL-2) or cytotoxicity and no Th2 cytokines (criterion II); or tumor recognition of naturally 
processed TAA by specific production of Th1 cytokines or cytotoxicity and no Th2 cytokines (criterion III), an 
example is provided in Supplementary Figure 2. The best overall TAA-specific responses was used for analyses, 
regardless of the time point at which the SKILs were obtained within the study, as this reflects the individual 
competence to generate a specific immune response.  
 
Statistical analysis 
OS was calculated from the date of apheresis to date of death and analyzed by Kaplan-Meier estimation using 
SPSS19.0 (SPSS Inc). Statistical significance was evaluated using the log-rank test. Cox proportional hazard 
model was used to calculate hazard ratio (HR) for survival. 
 
Results  
Vaccination protocols and SKIL cultures 
Seventy-seven patients completed at least 1 scheduled cycle and were thus evaluable for immunologic 
response (Table 1). Fourteen patients did not complete 1 scheduled cycle because of rapid progressive disease. 
The patients were vaccinated according to the various vaccination protocols, including intranodal, intradermal, 
intravenous/intradermal vaccinations; mode of antigen loading of DC was either pulsing with MHC Class I or 
MHC Class I and II defined epitopes derived from gp100 and tyrosinase (submitted), or electroporation with 
mRNA encoding these tumor associated antigens. In 1 protocol, patients received a single infusion of anti-CD25 
antibody therapy before to the first vaccination.14 
To show that this procedure is feasible for large-scale clinical studies, we determined the rate of successful SKIL 
cultures and their yield (Table 1). 329 out of 410 (80%) cultures yielded sufficient numbers of cells to allow 
further analysis, which results appear to be independent of the vaccination protocol (Table 1). On average, 4 
successful cultures with different specificities were obtained per patient during complete course of 3 
vaccination cycles. 
Positive and specific cytotoxic activity was defined as a 2-fold increase compared with 
stimulation with the same cell-lines pulsed with an irrelevant peptide. 
Cytokine production profiles by SKILs
The production of IFN-γ, TNF-α, IL-10, IL-5, IL-4, and IL-2 by SKILs was measured in 
supernatants after 16 hours of coculture with different target cells to obtain a cytokine 
profile of postvaccination SKILs. Target cells include T2 cells pulsed with the indicated 
peptides or BLM (a melanoma cell line expressing HLA-A*02:01 and no endogenous 
expression of gp100 and tyrosin se), transfected with control antigen G250, or with 
gp100 or with tyrosin se, or an allogenic HLA-A*02:01-positive, gp100-positive, and 
ty osinase- ositive umor cell line (Mel624) w th SKILs, us ng the cytometric bead 
array [Thelper 1/Thelper 2  (Th1/Th2) Cytokine CBA 1; BD Pharmingen], according 
to the manufacturer instructions. Positive and specific cytotoxic activity was defined 
as a 2-fold increase compared to stimulation with the same cell lines pulsed with an 
irrelevant peptide. 
Skin-test infiltrating lymphocyte culture evaluation
SKILs were evaluated according to increasingly stringent criteria (Supplementary 
Figure 2); the presence of TAA-specific CD8+ T cells by tetrameric MHC-peptide complexes 
(criterion I); peptide-recognition by specific production of Th1 cytokines (e.g. IFN-γ 
and/or IL-2) or cytotoxicity and no Th2 cytokines (criterion II); or tumor recognition of 
naturally processed TAA by specific production of Th1 cytokines or cytotoxicity and 
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no Th2 cytokines (criterion III), an example is provided in Supplementary Figure 3. 
The best overall TAA-specific responses was used for analyses, regardless of the time 
point at which the SKILs were obtained within the study, as this reflects the individual 
competence to generate a specific immune response. 
Supplementary Figure 2. Patient selection based on SKIL criteria. SKIL criteria are applied to select patients 
with immune responses meeting increasingly stringent criteria.
Statistical analysis
OS was calculated from the date of apheresis to date of death and analyzed by Kaplan-
Meier estimation using SPSS19.0 (SPSS Inc). Statistical significance was evaluated using 
the log-rank test. Cox proportional hazard model was used to calculate hazard ratio 
(HR) for survival.
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Results 
Vaccination protocols and SKIL cultures
Seventy-seven patients completed at least 1 scheduled cycle and were thus evaluable 
for immunologic response (Table 1). Fourteen patients did not complete 1 scheduled 
cycle because of rapid progressive disease. The patients were vaccinated according 
to the various vaccination protocols, including intranodal, intradermal, intravenous/
intradermal vaccinations; mode of antigen loading of DC was either pulsing with MHC 
Class I or MHC Class I and II defined epitopes derived from gp100 and tyrosinase 
Supplementary Figure 3. Definition of criteria for SKIL culture evaluation. Three examples are shown 
to illustrate the definition of SKIL culture criteria. (A) Criterion III, one patient (IV-B-16) with a clear 
population of TAA-specific CD8+ T cells in SKIL cultures, which produce high levels of IFN-γ upon encounter 
of both the defined gp100 peptides and naturally processed gp100 presented by a HLA-A*02:01 positive 
melanoma cell line (Mel624). Moderate amounts of IL-2 are produced and minimal production of IL-5, 
representing a clear IFN-γ dominant cytokine profile.  (B) Criterion II, a patient (IV-B-11) with TAA-
specific CD8+ T cells in SKIL cultures which produce high levels of IFN-γ and IL-2 upon encounter of the 
gp100 peptide, but fail to recognize the naturally processed gp100. (C) Criterion I, a patient (IV-A-07) 
with a population of TAA-specific CD8+ T cells in SKIL cultures, recognizing the g100-154 peptide, but 
not the naturally processed gp100. Furthermore, those TAA-specific CD8+ T cells do not produce IFN-γ 
but produce elevated levels of IL-5 instead, indicating that the immune system is skewed towards 
tumor tolerance. 
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(submitted), or electroporation with mRNA encoding these tumor associated antigens. 
In 1 protocol, patients received a single infusion of anti-CD25 antibody therapy before 
to the first vaccination.14
To show that this procedure is feasible for large-scale clinical studies, we determined 
the rate of successful SKIL cultures and their yield (Table 1). 329 out of 410 (80%) cultures 
yielded sufficient numbers of cells to allow further analysis, which results appear to be 
independent of the vaccination protocol (Table 1). On average, 4 successful cultures 
with different specificities were obtained per patient during complete course of 3 
vaccination cycles.
Figure 1. KLH-specific T cell responses do 
not predict clinical outcome. Kaplan-Meier 
analyses of OS according to KLH-specific T 
cell responses during DC-based vaccination 
in melanoma patients. (A) the levels of 
KLH-specific proliferation, expressed as SI 
compared with proliferative responses to 
the irrelevant protein, were not predictive 
for OS. (B) The production of significant 
levels of IFN-γ upon KLH stimulation was not 
associated with improved OS. (C) The maximum 
diameter of induration of the skin test was not 
associated with OS. 
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Table 2. Hazard ratios associated with criteria for response.
NOTE: A graphical representation of the hazard ratios (HR) associated with different response criteria were 
estimated using Cox proportional-hazard models. HR  less than 1 defines a positive correlation with OS if 
the criterion is met. Horizontal lines represent 95%CIs. Abbreviation: KLH, keyhole limpet hemocyanin.
KLH-specific T cell responses do not predict overall survival
Peripheral blood samples during and after completion of each vaccination cycle were 
available for 70 patients for testing of KLH-specific CD4+ T cell proliferation. The 
maximum standard index (SI) compared with OVA was recorded and designated strong 
if more than 40. No significant difference in median OS was observed for patients 
with or without strong KLH-specific CD4+ T cell response; being 6.9 and 9.0 months 
respectively (p=0.95; Figure 1A, Table 2). We analyzed the cytokines produced upon 
KLH encounter and 9 out of 40 tested patients showed a clear IFN-γ dominant response. 
However, this parameter did not significantly discriminate between patients with good 
and poor prognosis; median OS 16.7 and 11.0 months respectively, p=0.40 (Figure 1B; 
Table 2). 
Induration at the injection site is not predictive for clinical outcome 
After completing the first cycle of 3 vaccinations, the induration in 70 evaluable patients 
upon intradermal challenge with DC expressing gp100 or tyrosinase was median 13mm 
(range 0–36mm) and 13mm (0–34mm) respectively. The degree of induration was 
not predictive for clinical outcome with a maximum induration more than 15mm 
corresponding with a median OS of 9.8 months and a maximum induration 15mm or 
less corresponding with 13.0 months, p=0.675 (Figure 1C).
2 
 
Table 2.  ratios a sociated with criteria for response. 
 
NOTE: A graphical representation of the hazard ratios (HR) associated with different response criteria were estimated using Cox proportional-hazard models. HR  less than 1 defines a positive correlation with OS if 
the criterion is met. Horizontal lines represent 95%CIs. Abbreviation: KLH, keyhole limpet hemocyanin.  
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Figure 2. Analyses of SKIL cultures predict clinical outcome of DC-based therapy in metastatic melanoma 
patients. Kaplan-Meier analyses of OS according to different criteria for immune response in SKIL cultures 
obtained during DC-based vaccination in melanoma patients. (A) The breadth of the vaccine-specific 
immune responses, measured as the number of vaccine-specific tetramer-positive populations in SKIL 
cultures, correlates with OS. (B) SKIL cultures were sampled with tetrameric MHC-peptide complexes for 
the presence of TAA-specific CD8+ T cells (criterion I). (C) Next, SKIL cultures were evaluated for recognition 
of tumor peptides by the production of IFN-γ or cytotoxicity, but no IL-5 production (criterion II), improving 
the accuracy of this bioassay to select patients with a favorable clinical outcome. (D) lastly, SKIL cultures 
were evaluated according to the most stringent criterion III, specific IFN-γ production or cytotoxicity,  but 
no IL-5 production upon recognition of naturally processed tumor antigen, which was highly associated 
with improved OS.
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SKIL procedure does not require the presence of defined epitopes 
In some protocols, we exploited DC transfected with mRNA encoding gp100 and 
tyrosinase, thus expressing multiple undefined epitopes. To investigate whether the 
results of tetramer screening of SKIL cultures depend on the presence of defined TAA 
epitopes, we conducted parallel skin-test challenges within individual patients. In 
1 cohort (n=17), we conducted the DTH procedure with intradermal injections of DC 
pulsed with defined epitopes (gp100:154-162, gp100:280-288, and tyrosinase:369-377) 
and DC transfected with mRNA encoding the same tumor antigens (full-length 
gp100 and tyrosinase) within individual patients, who were vaccinated with mRNA-
transfected DC. Cultures from SKILs obtained from DTH sites containing DC loaded 
with defined epitopes or mRNA-transfected DC, yielded equal numbers of cells and 
successful cultures. In total, 126 DTH challenges were conducted in parallel, of these, 
59 of 63 mRNA-DC-challenged and 54 of 63 peptide-DC-challenged skin-test biopsies 
yielded successful cultures. Comparable average yields per culture were obtained, 0.53 
(range 0.01–7.0) x106 cells with mRNA-transfected DC and 0.40 (range 0.01–2.8) x106 
cells for peptide pulsed DC. Furthermore, tetramer screening for TAA-specific T cells 
showed that challenge with DC pulsed with defined epitopes or DC transfected with 
mRNA have similar sensitivity and specificity (data not shown). TAA-specific CD8+ T cells 
directed against all 3 defined epitopes were detected in single SKIL cultures obtained 
from intradermal challenge with DC transfected with mRNA encoding both gp100 and 
tyrosinase (data not shown). 
SKIL culture evaluation accurately predicts clinical outcome
To investigate the role of the breadth of response, we analyzed the clinical outcome in 
relation to the number of epitopes that were recognized. The presence of 1 TAA-specific 
CD8+ T cell population in SKIL cultures was shown in 14 patients, who had a median 
OS of 9.8 months [95% confidence interval (CI), 7.3–12.3] compared with 10.9 months 
(95%CI, 5.7–16.0) in 52 patients in whom no TAA-specific CD8+ T cell populations were 
detected (Figure 2A). Two or 3 TAA-specific CD8+ T cell populations were detected in 
8 and 3 patients, respectively, corresponding with a median OS of 14.2 months (95%CI, 
0.4–30.7) and median not reached, respectively (Figure 2A). Overall, the presence 
of TAA-specific CD8+ T cells in SKIL cultures (criterion I) was shown in 25 patients 
and was associated with improved survival; median OS 14.1 months compared with 
10.9 months in patients without TAA-specific CD8+ T cells (Figure 2B) and HR 0.60 
(95%CI, 0.42–0.86; p=0.005; Table 2). As patients were vaccinated with DC loaded 
with either multiple melanoma peptides or mRNA-transfected DC presenting multiple 
undefined antigens, T cell populations with different specificities could have been 
induced. In 18 patients with TAA-specific CD8+ T cells we also showed vaccine-specific 
peptide-recognition (criterion II), which was strongly associated with improved survival; 
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Figure 3. Immunologic response closely relates to the individual clinical course of disease. Two patients 
are shown in whom the immunologic evaluation predicted the course of their disease. (A) Data of IV-A-01 
is depicted in whom TAA-specific CD8+ T cells with specific cytotoxic capacity were detected after the first 
cycle of vaccinations. (B) After completing the third cycle of vaccinations, IFN-γ-producing TAA-specific 
CD8+ T cells were detected in SKIL cultures and no IL-5 was produced. As of May 2012, this patient survived 
120+ months from start of vaccinations. (C) Data of IV-A-05 is shown in whom no TAA-specific CD8+ T cells 
were detected after the first cycle of vaccinations.  (D) However, SKIL culture evaluation upon the third 
cycle of vaccinations revealed TAA-specific CD8+ T that produced high levels of IL-5 upon antigen encounter. 
Planned evaluation showed rapid progression of disease; the patient died shortly after the third vaccination 
series, 20 months after start of vaccination. 
median OS 14.2 months versus 10.2 months in patients without vaccine-specific 
peptide-recognition, Figure 2C and HR 0.42 (95%CI, 0.23–0.77; p=0.005; Table 2). To 
even better identify immune responsive patients, we selected for SKILs responding to 
naturally processed antigen by producing Th1 cytokines, predominantly IFN-γ. This was 
observed in 12 of these 18 patients who had a median OS of 24.1 versus 9.9 months in 
patients without SKILs responding to naturally processed antigen (Figure 2D) and HR 
0.30 (95%CI, 0.14–0.65, p=0.002, Table 2). As multiple cytokines were measured in SKIL 
cultures, we were able to identify functionally different cytokine profiles. As mentioned 
above and Supplementary Figure 3, in the majority of cases, we detected IFN-γ 
dominated cytokine production. However, in 2 patients, we detected predominantly 
IL-5 production by SKILs responding to peptide-pulsed target cells, indicative of Th2 
skewing of the immune response. The detection of this response coincided with rapid 
progressive disease in both patients (Figure 3). 
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Discussion
Although the presence of tumor-specific cytotoxic T cells (CTL) in cancer patients 
has been reported to associate with favourable clinical outcome24, bioassays that 
accurately link vaccine-specific immune responses to survival are lacking. Although 
tetramer analysis or ELIspot assays of TAA-specific responses in peripheral blood are 
available, the low prevalence of TAA-specific T cells in peripheral blood makes this 
procedure less suitable for routine monitoring. Moreover, besides antigen specificity 
and effector activity, antitumor CD8+ T cells must be able to extravasate and migrate 
into peripheral target tissues. We addressed this issue by evaluating SKIL cultures. This 
bioassay integrates multiple facets of an effective immune response. First, it serves 
as a fitness test; the in vivo intradermal challenge selects TAA-specific T cells that 
possess the migratory capacities to leave the circulation and penetrate peripheral 
tissue. Secondly, tetrameric MHC-peptide complexes allow sampling of different 
specificities (criterion I) within the SKIL population. As SKILs are expanded in vitro in 
the absence of antigen, the composition of different specificities closely parallels the in 
vivo situation. Thirdly, more stringent recognition can be assessed by challenging SKILs 
either with target cells loaded with defined antigenic peptides (criterion II) or by target 
cells that express naturally processed TAA (criterion III). Finally, measuring cytokine 
profiles upon antigenic challenge reflects the in vivo programming of TAA-specific 
T cells either towards Th1 or Th2 immune responses. The latter is of crucial importance 
to interpret antitumor responses and eventual clinical outcome. 
In most clinical studies a highly immunogenic nontumor antigen is included in the 
vaccine, such as KLH or tetanus toxoid. The rationale for this approach is 2-fold; it is 
used as a surrogate marker to which excessive humoral and proliferative responses will 
be induced, in that respect is serves to evaluate immune competence per individual. 
Secondly, these immunogenic proteins contain a multitude of predominantly T helper 
cell epitopes; ergo, it functions as a nontumor specific adjuvant. We have previously 
investigated the magnitude and dynamics of humoral responses in this cohort of 
metastatic melanoma patients who underwent DC-based therapy.25 Our findings show 
that humoral anti-KLH responses are dictated by different vaccination parameters, such 
as route of administration and anti-CD25 mAb pretreatment. CD8+ CTLs, as the endpoint 
effectors, represent a critical population for anticancer immunity. However, cellular 
responses to KLH are invariantly induced in the vast majority of patients, regardless 
of the vaccination protocol.14-18,26 In this study, we show that neither the magnitude of 
KLH-specific T cell responses, nor the quality of the KLH-specific responses in terms 
of IFN-γ production is predictive for clinical outcome. This shows that loading ex vivo 
generated DC with KLH does not provide adequate means to assess antitumor cellular 
immune competence. This notion is further supported by the lack of correlation 
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Supplementary Figure 4. KLH-specific T cell responses according to SKIL classification. Regardless of the 
number of epitopes or the increasingly stringent criteria for TAA-specific immune responses; the levels of 
KLH-specific T cell responses were similar and highly variable between individuals. One-way ANOVA was 
used for comparison of KLH-specific T cell responses in groups of patients with increasing breadth of TAA-
specific CD8+ T cell responses. Student t-test was used for comparison of KLH-specific T cell responses in 
groups of patients as defined by different SKIL criteria. 
between the quality of vaccine-specific immune responses, as determined by the 
above-mentioned SKIL criteria, and the magnitude of KLH-specific cellular responses 
(Supplementary Figure 4). 
It has been reported in some studies that the degree of induration at the injection 
site would reflect the individual capacity to mount a vaccine-specific immune response, 
and therefore, correlate to therapy response. If so, the degree of induration would 
provide an easy and accessible measure for therapy evaluation. In general, induration 
is regarded as a typical CD4+ T cell reaction. On the contrary, others have shown that 
intradermal injection site can be briskly infiltrated by CD8+ T cells, suggesting that the 
level of induration would in fact show Th1-type immune induction. Our data clearly 
illustrate that induration is not associated with OS or with TAA-specific CD8+ T cell 
responses (Supplementary Figure 5). Furthermore, the measurement of induration is 
subject to high inter-test variability that complicates standardization. 
Our increasing understanding of the complex interaction of an individuals’ immune 
system and cancer and the development of immunotherapeutic interventions with 
clinical benefit, have drastically influenced the way we design and conduct clinical 
studies on immunotherapy.27 From small proof-of-principal studies focussing on a 
single parameter3, we now focus on large randomized prospective studies with adjusted 
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Supplementary Figure 5. Levels of induration according to SKIL classification. Regardless of the number of 
epitopes or the increasingly stringent criteria for TAA-specific immune responses; the maximum induration 
at the injection site was similar in all groups. One-way ANOVA was used for comparison of induration in 
groups of patients with increasing breadth of TAA-specific CD8+ T cell responses. Student t-test was used 
for comparison of induration in groups of patients as defined by different SKIL criteria. 
endpoints, designed to evaluate potential biomarkers and specific clinical response 
patterns.1,28 In this respect, we evaluated SKIL culture analyses for its feasibility in large 
studies. With notion of its invasive nature, this procedure is relatively easy to conduct, 
does not need specialized personnel and is not labor intensive and is acceptable 
to the large majority of patients. Importantly, this procedure consistently yields 
sufficient numbers of SKILs to address the vaccine-specific immune response, which 
is independent of the vaccination protocol or intradermal challenge conditions. Even 
in patients vaccinated with DC loaded with modified tumor peptides to enhance MHC-
binding efficacy, we detected CD8+ SKILs directed against the tumor to similar extend as 
in other vaccination protocols. This is in line with our previous observation that modified 
peptides efficiently elicit responses to wild-type peptides, resulting in comparable 
immunologic responses in vivo as vaccination with wild-type peptide loaded DC.15
The development of tools to monitor immune responses during immunotherapy 
is complicated by the evaluation of different effector T cell populations over time in 
response to vaccination and tumor changes. So far, it is not clear which time window 
after start of treatment reflects the vaccine-induced responses best and might be 
predictive of clinical outcome. Furthermore, the relevant effector populations are 
distributed over several body compartments, such as draining lymph nodes, tumor 
tissue, bone marrow, and peripheral blood; and it is debatable what compartment is 
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best suitable to monitor vaccine-specific immune responses. The patients displayed 
in Figure 3 illustrate that the evaluation of both the kinetics and functional status of 
vaccine-specific responses is critical for correct correlation with clinical outcome. In 
the first patient, if only the percentage of vaccine-specific SKILs would have been 
assessed, it would have been a decline in vaccine-specific SKILs, however, the specific 
Th1 type responses after 1 and 3 cycles classifies this response as favorable. In the 
second patient, the appearance of vaccine-specific SKILs could have been interpreted 
as a favorable response. However, as we measured a typical Th2 skewed functional 
status, this response was correctly classified as nonfavorable. We acknowledge that 
further studies, incorporating multiple facets of tumor-specific immune responses 
at multiple time points after treatment, are warranted to elucidate the optimal time 
window to conduct immune monitoring. 
In conclusion, by evaluating the migratory, antigen recognition, as well as the 
effector function of SKILs, we are able to select for multifunctional CD8+ T cells with 
high tumor recognition efficacy. We showed that analyzing SKILs is a simple and robust 
bioassay to predict OS in metastatic melanoma patients. Therefore, it represents an 
ideal candidate for immune monitoring in upcoming immunotherapy trials. 
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Abstract
Tumor-infiltrating lymphocytes appear to be a predictor of survival in many cancers, 
including cutaneous melanoma. We applied automated multispectral imaging to 
determine whether density and distribution of T cells within primary cutaneous 
melanoma tissue correlate with survival of metastatic melanoma patients after dendritic 
cell (DC) vaccination. CD3+ T cell infiltration in primary tumors from 77 metastatic 
melanoma patients was quantified using the ratio of intratumoral versus peritumoral T 
cell densities (I/P ratio). Patients with longer survival after DC vaccination had stronger 
T cell infiltration than patients with shorter survival in a discovery cohort of 19 patients 
(p=0.000026) and a validation cohort of 39 patients (p=0.000016). I/P ratio was the 
strongest predictor of survival in a multivariate analysis including M substage and serum 
lactate dehydrogenase (LDH) level. To evaluate I/P ratio as a predictive biomarker, we 
analyzed 19 chemotherapy-treated patients. Longer survival times of DC-vaccinated 
compared with chemotherapy-treated patients was observed for high (p=0.000566), 
but not low (p=0.154) I/P ratios. In conclusion, T cell infiltration into primary melanoma 
is a strong predictor of survival after DC vaccination in metastatic melanoma patients 
who, on average, started this therapy several years after primary tumor resection. 
The infiltration remains predictive even after adjustment for late-stage prognostic 
markers. Our findings suggest that the I/P ratio is a potential predictive biomarker for 
treatment selection.
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Introduction
The incidence and, to a lesser extent, the mortality of cutaneous melanoma have 
rapidly increased over the past decades in many countries.1 Until recently, metastatic 
melanoma patients have had a 5-year survival rate of less than 20%2 and systemic 
therapy showed only minimal effect.3 With the currently approved immune checkpoint 
inhibitors against CTLA-4 and PD-1, 10 to 40% of all metastatic melanoma patients 
have long-term benefit and survival rates seem to improve.4 As checkpoint inhibitors 
are expensive, often induce toxicity, and the majority of patients have no long-term 
benefit, there is a strong need for biomarkers that can predict, ideally at an early stage 
of disease, whether a patient will or will not benefit from therapy.
Currently, in melanoma, only a few biomarkers that accurately predict response to 
treatment have been found, for example, BRAF mutation status for vemurafenib. In 
contrast, multiple prognostic factors of patient outcome at initial diagnosis are well 
established, including histological characteristics such as Breslow thickness, mitotic 
rate, and ulceration status. In the advanced metastatic setting, tumor substage 
(M1a/b/c) and serum LDH levels have significant prognostic value.2 These prognostic 
markers only lead to a rough estimation of survival and do not predict response to 
treatment. However, more recently, it has been suggested that LDH might also have a 
predictive value; elevated serum LDH levels correlate with dramatically lower response 
rates to anti-CTLA-4 antibodies,5 but the response rate in patients with normal serum 
LDH levels remains limited.
With the lack of simple and early biomarkers to be found in the blood, the focus 
has shifted toward the tumor microenvironment. 6 As many primary tumors are heavily 
infiltrated by a complex repertoire of immune cells, which is considered to be indicative 
of a spontaneous host immune response to tumor antigens,7 it is hypothesized that the 
T cell landscape in primary tumors has prognostic value and might also be of predictive 
significance. Most studies so far have been performed in colorectal cancer8 and other 
solid tumors,9,10 and have mainly focused on distant metastatic lesions. These studies 
have shown that infiltration of the tumor by T cells, especially CD3+ and CD8+ T cells, is 
associated with good prognosis.8 In primary cutaneous melanoma Clark and colleagues 
were amongst the first to show the importance of tumor-infiltrating lymphocytes (TIL) 
as an independent predictor of patient survival.11 In recent years, several studies have 
confirmed this finding,12-14 while others found no significant correlation between TILs 
and clinical outcome.15-17 Adverse effects of TILs are also documented, for example, the 
presence of large numbers of regulatory T cells or myeloid-derived suppressor cells 
clearly correlated with poor survival after immunotherapy.18 
Two factors could contribute to these partly conflicting results. First, in most 
cases, immune cell infiltration was assessed manually and qualitatively using various 
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scoring systems. To assess T cell infiltration in an objective and reproducible manner, 
we exploited a new quantitative digital imaging technique to analyze the density and 
distribution of T cells within primary tumors of metastasized melanoma patients. 
Second, the T cell infiltration could only be relevant for a subset of patients or certain 
treatments. This might explain that for DC vaccination, and other immunotherapies, 
only a subset of patients appears to benefit.19-23 We previously demonstrated that 
skin-infiltrating T cells isolated from delayed-type hypersensitivity (DTH) biopsies 
strongly correlate with increased survival after DC vaccination.24-26 Therefore, we 
expected that if strong T cell infiltration in the primary tumor does indeed have 
a positive effect on survival, this should be augmented with immunotherapy 
and therefore more easily detectable in these patients. To test this hypothesis, 
we analyzed T cell infiltration in two cohorts of patients that were treated with 
DC-based immunotherapy and compared the results with those in patients treated 
with standard chemotherapy.
Materials and Methods
Patients and samples
We retrospectively analyzed the primary cutaneous tumors of 77 metastatic melanoma 
patients. An initial discovery cohort consisted of 19 patients who were enrolled in 
prospective DC vaccination studies at our center. Subjects were selected on the basis 
of the availability of the primary tumor at our center, and known BRAF/NRAS mutation 
status. Furthermore, we selected patients with an overall survival of less than 1 year 
(n=11, short survivors) or more than 1.5 years (n=8, long survivors).
The validation cohort included 39 additional patients who received DC vaccination 
of which the primary tumor was available at our center, independent of survival time 
and mutation status. From one patient of whom 2 primary melanomas were available, 
we included the primary tumor with the highest Breslow thickness in our analysis (both 
non-ulcerated). Three patients had an initial incision biopsy of their primary melanoma, 
followed by a complete excision of the same tumor; for these patients, we included 
both specimens in our analysis.
In addition, we analyzed 19 patients receiving standard treatment, at that time 
comprising of chemotherapy (dacarbazine 850 to 1,000 mg/m2 i.v. at 3 weekly 
intervals), between April 2000 and April 2009. Subjects were selected on the basis 
of the availability of the primary tumor at our center. Patients that received prior or 
subsequent immunotherapy were excluded. Ethical approval was obtained from the 
appropriate Medical Ethical Review Board.
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Dendritic cell vaccination
All DC-vaccinated patients were enrolled in our DC vaccination studies between June 
1999 and January 2011 and had metastatic disease upon inclusion. All studies were 
approved by the appropriate Medical Ethical Review Board and written informed 
consent was obtained from all patients. All patients were vaccinated with autologous 
DC, obtained from leukapheresis, loaded with tumor-associated antigens of gp100 
and tyrosinase according to a schedule of 3 biweekly vaccinations with a maximum of 
3 cycles. Variations in protocols included the type of DC, route of administration, and 
method of antigen loading. For the exact details regarding the vaccination protocols, 
we refer to the individual studies.20,21,27-31
Immunohistochemistry
Slides of 4-µm thickness were cut from formalin-fixed, paraffin-embedded (FFPE) 
primary melanoma tissue blocks. The slides were deparaffinized, after which antigen 
retrieval using 10 mmol/L citrate buffer (pH 6.0; Skytek) for 10 minutes at 96ᵒC was 
performed. After this pretreatment, the slides were placed in an Autostainer 480 (Thermo 
Scientific). In the stainer, the endogenous peroxidase was blocked using 3% hydrogen 
peroxidase in methanol (EMD Millipore) followed by primary antibody incubation (anti-
CD3; Thermo Scientific; dilution: 1/40) for 60 minutes at room temperature. Next, 
incubation with Brightvision poly-HRP-anti Ms/Rb/Rt IgG (Immunologic BV; dilution: 
1/2) was performed for 30 minutes at room temperature followed by a visualization 
step with the Vector Nova Red Substrate Kit (Vector laboratories) for 7 minutes at room 
temperature. Between each step, samples were rinsed using PBS (Klinipath; dilution: 
1/10). After visualization, the slides were manually counterstained with haematoxylin 
and enclosed with Quick-D mounting medium (Klinipath).
Tissue imaging and quantitative digital analysis
Whole tissue slides were imaged using Vectra Intelligent Slide Analysis System 
(Version 2.0.8, PerkinElmer Inc.). This imaging technology combines imaging and 
spectroscopy to collect entire spectra at every location of the image plane. Images 
of single stained tissues for each reagent and unstained tissue were used to build 
spectral libraries of the single dyes and of the melanin pigmentation, respectively, 
by using the Nuance Multispectral Imaging System (Version 3.0.2, PerkinElmer Inc.). 
The reagents used were haematoxylin for nuclear staining and nova red (Vector 
laboratories) for CD3+ T cells. These spectral libraries were used to unmix the original 
multispectral images obtained with the Vectra imaging system, in particular, to 
separate the spectrum of melanin, which can interfere with the nova red chromogen 
signal, to obtain an accurate and specific quantification of the nova red positive 
signal. A selection of 10 to 15 representative original multispectral images was used 
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to train the inForm Advanced Image Analysis Software (Version 2.0.2, PerkinElmer 
Inc.) for quantitative image analysis (tissue segmentation, cell segmentation, and 
positivity score) as described previously (Supplementary Figure 1).32,33 All the settings 
applied to the training images were saved within an algorithm allowing batch analysis 
of multiple original multispectral images of the same tumor. A separate algorithm 
was generated per single patient applying the same settings for cell segmentation 
and positivity score but with different training for tissue segmentation due to the 
numerous morphological differences between and within tumors, which is very 
common in melanoma. Vectra Review (Version 2.0.8, PerkinElmer Inc.) was used to 
select the areas for analysis; this consisted of the entire tumor parenchyma and the 
tumor margin (stroma surrounding the tumor with a thickness of 500-700 µm and 
stromal areas within the tumor not containing tumor cells). Thus, intratumoral CD3+ 
T cells were quantified in the tumor parenchyma and the peritumoral CD3+ T cells 
were quantified in the stroma, at the margin of the tumor.
To visualize the spatial distribution of stroma cells, melanoma cells, and T cells, 
each pixel representing a location less than 50 µm apart from the nearest cell nucleus 
according to the type of that cell was attributed with a certain color (dark, tumor; 
light, tumor margin). To appreciate the T cell distribution patterns at low resolution, 
we clustered the T cell positions using hierarchical mean linkage clustering, with a 
distance threshold of 150 µm (i.e., clusters whose centers were more than 150 µm 
apart were not joined).
Statistical analyses
Pairwise comparisons between groups were made using the Mann-Whitney U test. 
Correlations between intra/peritumoral CD3+ T cell density ratios (I/P ratios) and 
survival times were measured using the linear (Pearson) correlation coefficient on 
log-transformed data. When dichotomizing I/P ratios, we used a cutoff of 1, that is, 
an I/P ratio was considered “high” if T cell density was higher intratumorally than 
peritumorally and “low” otherwise. Overall survival was calculated from the date of 
first chemotherapy (chemotherapy cohort) or the date of leukapheresis (DC vaccination 
cohorts) to death of any cause. Time to M stage was calculated from the time of initial 
diagnosis to the time of reaching M stage. LDH levels were dichotomized in the analysis 
(≤/> the upper limit of normal) and gender was dummy-coded as male=0, female=1. 
Differences between Kaplan-Meier estimates of survival times were assessed using the 
log-rank test. AUC analyses used above-median survival time as the outcome variable, 
and multivariate AUC analysis was performed by fitting a logistic regression model and 
ranking the patients by their fitted score. 
To compare survival times of chemotherapy-treated and DC-vaccinated patients, 
we matched each patient of the chemotherapy cohort to two patients from the DC 
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Supplementary Figure 1. Multispectral imaging and melanin unmixing using fully automated quantitative 
analysis of tumor infiltrating lymphocytes by Vectra/InForm platform. (A) Original multispectral image. 
(B) Pseudo-fluorescent unmixed image. (C) Tissue segmentation of tumor (=red) and stroma (=green). (D) 
Individual cell segmentation based on nuclear heamatoxylin counterstain and individual cell scoring based 
on nova red staining (red=positive, blue=negative) in the stroma compartment. One representative (20x) 
image is shown.
vaccination cohorts who had the same LDH status (high/low) and the same status with 
respect to M substage 1c. These matching criteria were chosen based on the results of 
our multivariate analysis, which indicated that those were the most relevant prognostic 
criteria in our cohorts, whereas other common matching factors like gender and age 
appeared to play no role. Matching was performed using the R package “optmatch”.34 
All statistical analyses were performed using the R platform for statistical computing 
(R Core Team, 2015; https://www.R-project.org). 
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Results
Quantifying CD3+ T cell infiltration in the primary tumor
To measure T cell infiltration within primary tumors in a quantitative, automatic, and 
objective manner, whole slide imaging covering the entire tumor cross-section was 
performed on three cohorts of patients (tt in total). Depending on the size of the 
primary tumor, 20 to 750 fields per patient were analyzed. Figure 1A shows typical 
examples of T cell localization within the primary tumor of a patient where most T cells 
appear confined to the peritumoral area (margin; left), and a patient where T cells 
strongly infiltrate into the intratumoral area (tumor; right). A computer-generated 
overview (“landscape”) of this contrast can be seen for the entire tissue area analyzed 
in Figure 1B, with a pronounced difference in T cell density and location. As a simple 
metric to quantify the strength of T cell infiltration, we computed the ratio of 
intratumoral over peritumoral CD3+ T cell densities (I/P ratio), which is low in weakly 
infiltrated tumors and high in strongly infiltrated tumors. Landscapes of all primary 
tumors studied are shown in Supplementary Table 1 (online only). In the majority of 
tumors (45 out of 77), we found either high (above-median; n=21) or low (n=24) T cell 
densities in both the tumor and the margin, whereas 32 tumors showed contrasting 
T cell densities, that is, low in the tumor and high in the margin (n=16) or the other 
way round (n=16). We studied the I/P ratio in primary melanoma tumors of metastatic 
melanoma patients with this new computational imaging system to evaluate a potential 
relationship with overall survival.
Long survival after DC vaccination correlates with strong T cell 
infiltration of the primary tumor
At first, we were interested to investigate patients that survived long upon therapy, 
and therefore selected a discovery cohort of 11 patients who survived <1 year (“short 
survivors”) and 8 patients who survived >1.5 years (“long survivors”) after DC-based 
immunotherapy. Baseline patient characteristics are shown in Table 1. On the basis 
of this discovery cohort, we aimed to determine whether strong T cell infiltration is 
associated with long survival, and whether the I/P ratio is an appropriate measure on 
which to base this prognosis.
Indeed, we found clear differences between short and long survivors when 
analyzing the T cell distributions (Figure 2A). The median I/P ratio was 0.16 in short 
survivors versus 4.48 in long survivors (p=0.000026; Figure 2B); there was a near-
perfect concordance between high ratios (>1) and long survival. Importantly, there 
were no clear differences in tumor area and in margin area between short versus long 
survivors (Figure 2C), which could have biased this analysis. Analyzing intratumoral and 
peritumoral T cell densities separately (Figure 2D) shows that high intratumoral T cell 
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densities appear beneficial, whereas high peritumoral densities appear detrimental. 
However, these individual differences  are smaller than the differences in I/P ratio. 
Taken together, these data clearly show that the I/P ratio is a diagnostically more 
relevant measure of T cell infiltration than the individual T cell counts and has a strong 
association with survival in this discovery cohort. Thus, we focused on I/P ratio as a 
measure of T cell infiltration in our further analysis.
Validation of T cell infiltration as a survival predictor for metastatic 
melanoma patients who received DC vaccination
To validate our findings of the discovery cohort, we analyzed the primary tumors of a 
second and larger cohort of 39 metastatic melanoma patients that received DC-based 
immunotherapy (Table 1; Figure 3A). Importantly, this cohort was not selected based 
on patient survival. In line with the discovery cohort, there were no clear differences 
between the size of the tumor or the margin of short versus long survivors (data not 
shown). The differences in intratumoral and peritumoral T cell densities between short 
and long survivors (Figure 3B) are similar to those in the discovery cohort. Figure 3C 
shows a clear correlation (r=0.58, p=0.00012) between the I/P ratio and survival in 
Table 1. Baseline characteristics in all cohorts.
Discovery cohort Validation cohort Chemotherapy
Number of patients 19 39 19
Gender
Male
Female
12 (63.2%)
7 (36.8%)
25 (64.1%)
14 (35.9%)
11 (57.9%)
8 (42.1%)
Age, years
Median (range) 57 (20-76) 51 (19-73) 57 (30-77)
Breslow thickness, mm
Median (range) 3.3 (0.8-13.0) 2.1 (0.7-12.0) 2.4 (0.4-10.0)
M stage at inclusion 
M1a
M1b
M1c
5 (26.3%)
4 (21.1%)
10 (52.6%)
8 (20.5%)*
10 (25.6%)
21 (53.9%)
2 (10.5%)
3 (15.8%)
14 (73.7%)
LDH at inclusion
Normal
Elevated
13 (68.4%)
6 (31.6%)
24 (60.5%)
15 (39.5%)
11 (57.9%)
8 (42.1%)
Time to M stage, months
Mean (range) 31.0 (1.1-74.7) 39.5 (0.0-137.0) 48.6 (7.4-179.9)
Overall survival, months
Mean (range) 22.4 (2.9-130.0) 12.5 (1.1-63.9) 6.6 (1.2-27.4)
*Includes 1 irresectable stage III melanoma patient. 
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the validation cohort. Stratification of this cohort by M substage at start of therapy 
(Figure 3D, E) shows that T cell infiltration is more strongly predictive for patients 
in substage M1a/M1b (r=0.78, p=0.00015) than for substage M1c (r=0.31, p=0.17). 
Figure 1. Mapping out T cell landscapes near primary tumors. (A) Typical example (20x) of CD3+ T cell 
distribution in the primary tumor with weak (left) and strong intratumoral T cell infiltration (right). (B) Tissue 
classification and T cell localization in two of the analyzed slides. The I/P ratio is the result of (intratumoral 
T cells/mm2)/(peritumoral T cells/mm2) and therefore is a ratio of T cell densities rather than T cell counts. 
For illustrative purposes, individual T cell positions less than 150 μm apart were clustered. 
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Survival was furthermore evaluated with Kaplan-Meier estimates comparing patients 
with low (<1, n=33) and high (>1, n=6) I/P ratios (Figure 3F). The survival curves for these 
two groups were distinct, with strong T cell infiltration (high I/P ratio) being linked to 
longer survival than weak T cell infiltration (low I/P ratio; p=0.0011). A ROC analysis 
(Figure 3G) discriminating short survivors (bottom 50% of survival) and long survivors 
(top 50%) resulted in an AUC of 0.88. Thus, using three different statistical methods 
we consistently found an association between strong T cell infiltration, as determined 
by the I/P ratio, and long survival after DC vaccination.
Figure 2. Strong CD3+ T cell infiltration of primary tumors tissue correlates with long survival after DC 
vaccination. (A) Relative tumor size, size of peritumoral area, and CD3+ count for short and long survivors 
in the discovery cohort. Overall survival is shown above each tumor in months. Each large bullet point 
represents 1,000 T cells within the tumor (white) or in the peritumoral area (black). (B) Differences in intra/
peritumoral CD3+ T cell density ratio (I/P ratio) between long survivors (n=8) and short survivors (n=11). 
(C) Size of the tumor area (tumor) and tumor margin (margin) in the analyzed tissue samples for short and 
long survivors. (D) Peritumoral (margin) and intratumoral (tumor) CD3+ T cell densities (CD3+ T cells/mm2) 
shown separately for short and long survivors.
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Figure 3. Validation of the I/P ratio as a predictor of survival after DC vaccination. (A) Relative tumor size, 
size of peritumoral area, and CD3+ count of all patients in the validation cohort. Overall survival is shown 
above each tumor in months. Each large bullet point represents 1,000 T cells within the tumor (white) or in 
the peritumoral area (black). (B) Peritumoral (margin) and intratumoral (tumor) CD3+ T cell densities (CD3+ 
T cells/mm2) shown separately for short and long survivors. (C-E) Correlation between I/P ratio and overall 
survival, shown on a log-log scale for all patients (C), patients with substage up to M1b (D) and patients with 
substage M1c (E). (F) Survival of patients with low (<1, n=33) and high (>1, n=6) I/P ratios (p=0.0011, log-rank 
test). (G) AUC analysis for discriminating short survivors (bottom 50% survival times) and long survivors 
(top 50%) using the I/P ratio (AUC of 0.88). (H) Comparison to two other relevant prognostic markers. A 
combined logistic regression model incorporating the ratio and LDH achieves an AUC of 0.95 (M substage 
alone: 0.68; LDH alone: 0.72), which is no longer improved by also taking the M substage into account. 
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T cell infiltration remains predictive after combination with established 
late-stage prognostic markers
Given the long interval between excision of the primary melanoma and the 
development of distant metastasis and onset of treatment (mean time to M stage >3 
years; Table 1), it was important to establish whether the I/P ratio would still provide 
added value compared with the known prognostic markers in the metastatic setting. 
ROC analyses for predicting above-median survival (Figure 3H) showed superior results 
of the I/P ratio (AUC=0.88) compared with LDH (AUC=0.72) and M substage (AUC=0.68). 
Combining the I/P ratio with LDH in a logistic regression model, we even obtained 
an AUC value of 0.95. In a larger multivariate analysis (Table 2), the I/P ratio was the 
strongest predictor (p=0.001; log odds ratio 0.4, 95% CI 0.19 to 0.61) for survival in the 
validation cohort. LDH level remained an independent, but weaker predictor (p=0.013; 
log odds ratio -0.37, 95% CI -0.64 to -0.1), whereas M substage at start of DC-based 
immunotherapy, gender, Breslow thickness, age, and time to M stage did not show 
significant prognostic value. These multivariate analyses provide compelling evidence 
that strong T cell infiltration in the primary melanoma is an independent predictor of 
survival in metastatic melanoma patients receiving DC-based immunotherapy, despite 
the fact that several years typically pass between resection of the primary tumor and 
the onset of treatment.
T cell infiltration is a potential predictive biomarker for DC vaccination 
The I/P ratio in primary tumors would be tremendously useful as a predictive biomarker 
for (adjuvant) treatment selection due to its availability at an early stage of disease. 
Establishing a biomarker requires analysis of data from a randomized controlled trial, 
which is not available yet for DC vaccinations worldwide; so far, most DC studies are 
small stage I/II studies varying from 10 to 40 patients. Therefore, as an approximation, 
Table 2. Multivariate analysis. Logistic regression model showing that the difference in ratio in the validation 
cohort is not explained by including M substage, LDH and other possible confounders as covariates.
Log odds ratio (95% CI) p
Intercept 0.82 (0.05,1.6) 0.044
I/P ratio (log10) 0.4 (0.19,0.61) 0.001
M stage at inclusion 0 (-0.18,0.19) 0.97
LDH -0.37 (-0.64,-0.1) 0.013
Gender 0 (-0.3,0.31) 0.98
Months to M stage 0 (0,0.01) 0.54
Breslow thickness 0 (-0.06,0.06) 0.96
Age at inclusion 0 (-0.01,0.01) 0.83
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we compared our DC-vaccinated cohorts to a cohort of patients receiving standard 
treatment (chemotherapy) in the same time-frame, matched on known prognostic 
factors to minimize confounding. While this approach cannot provide definitive proof 
of biomarker status, it did allow us to probe our hypothesis that patients require strong 
intratumoral T cell infiltration to benefit from immunotherapy.
We analyzed 19 primary melanomas of patients that had received chemotherapy 
(Table 1; Figure 4A). Survival was evaluated with Kaplan-Meier estimates comparing 
patients with low (<1, n=6) and high (>1, n=13) I/P ratios (Figure 4B). Although the 
survival curves suggest that strong T cell infiltration may correspond to longer survival 
in chemotherapy-treated patients, the difference is not significant (p=0.089). There was 
also no appreciable direct correlation between survival and I/P ratio (r=0.12, p=0.62; 
Figure 4C), thus, the I/P ratio is not a strong predictor of survival in chemotherapy-
treated patients. This is in line with our hypothesis that the effect of T cell infiltration 
in the primary tumor needs to be augmented by immunotherapy to improve survival. 
To further support this hypothesis, we matched each chemotherapy patient to 
two DC vaccination patients based on LDH level and M substage (Figure 4D). DC-
vaccinated patients with low I/P ratios showed no significant difference in survival 
after the different treatments (Figure 4E), indicating no survival benefit of DC-based 
immunotherapy when T cell infiltration is weak. On the other hand, patients with high 
I/P ratios clearly survived longer after DC-based immunotherapy than patients with 
high I/P ratios treated with chemotherapy (Figure 4F), and therefore seem to benefit 
from DC-based immunotherapy.
In summary, our matched analyses indicates that the I/P ratio could indeed be a 
predictive marker for DC-based immunotherapy: patients with high I/P ratios appear 
to benefit from receiving DC-based immunotherapy, whereas patients with low I/P 
ratios do not. It will be important to test this result in future randomized trials with 
DC vaccination and other immunotherapies.
Discussion
The rapidly evolving field of melanoma management and novel treatments mandates 
development of new biomarkers, especially given the high costs associated with current 
treatments and their substantial toxicity. While for targeted therapies, effective genetic 
tools are available to select patients who are most likely to benefit from treatment, 
that is, BRAF mutation status for vemurafenib, this is much less so for immunotherapy. 
Established factors that are known to correlate with survival after immunotherapy are 
mostly derived from metastases. When looking at immunotherapy in general, several 
studies have shown specific gene expression profiles, identified on pretreatment 
biopsies of melanoma metastases that correlate with outcome after immunotherapy.35 
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Figure 4. Strong intratumoral T cell infiltration is associated with a larger difference between DC 
vaccination and chemotherapy in a matched cohort. (A) Relative tumor size, size of peritumoral area, 
and CD3+ count of all patients in the chemotherapy cohort. Overall survival is shown above each tumor 
in months. Each large bullet point represents 1,000 T cells within the tumor (white) or in the peritumoral 
area (black). (B) Survival of patients treated with chemotherapy with low (<1, n=6) and high (>1, n=13) I/P 
ratios (p=0.089). (C) Correlation between I/P ratio and survival in months, shown on a log-log scale for all 
patients. (D) Analysis of a combined cohort in which each of the 19 chemotherapy patients was matched to 
two patients from the DC vaccination cohorts (giving n=57) that were matched on LDH and M1c substage. 
(E) Longer survival upon immunotherapy is not apparent in patients with low I/P ratio (<1; n=36). (F) Yet, 
there is a significant difference for patients with high I/P ratio (>1; n=21). 
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Besides gene profiling, multiple studies have focused on finding a predictive biomarker 
in the tumor microenvironment. For instance, the expression of FoxP3 and indoleamine 
2,3-dioxygenase (IDO) in pretreatment biopsies of melanoma metastases have been 
linked to a positive association with clinical activity of anti-CTLA-4 antibody.36 Also, 
several studies investigated biomarkers for PD-1 pathway-blocking agents, in particular, 
the expression of the PD-1 ligand (PD-L1). Unfortunately, the many different PD-L1 
clones and differences in assessment of the PD-L1 immunohistochemical staining 
complicate interpretation of the different studies.37 Nonetheless, in melanoma, there 
seems to be an association between PD-L1 expression on tumor cells and response 
to an anti-PD-1-antibody.38 A recent study has focused both on the role of PD-L1 
expression as well as CD8+ T cells in melanoma metastases and has shown that the 
density of pre-existing CD8+ T cells in both the tumoral area and the invasive tumor 
margin has a predictive value for the treatment outcome of patients receiving anti-PD-1 
therapy.39 This study highlights the importance of pretreatment T cell infiltration in the 
tumor area as it correlates with clinical outcome. 
A disadvantage of most of these potential biomarkers is that tumor material from 
metastases can be difficult to access and only becomes available when patients reach 
systemic disease, and are therefore not suitable for decision-making at earlier stages 
of disease in which adjuvant immunotherapy might be beneficial. Furthermore, 
biomarkers observed in metastases might not be suitable for analysis of the primary 
tumor, for instance, the positive association between PD-L1 expression in metastases 
and melanoma-specific survival could not be confirmed in primary melanoma.40 
Finally, markers like skin-infiltrating T cells isolated from DTH biopsies, although 
useful for monitoring response to therapy, cannot be used for pretherapeutic 
decision-making.
In this study, we investigated whether the T cell landscape within the primary 
tumor is relevant for survival of 77 patients with metastatic melanoma. Given partly 
contradicting results in the literature, our approach aimed to exploit a novel observer-
independent methodology, and focused on patients who received immunotherapy 
as we expected the relevance of immune infiltration to be higher in this setting. Our 
results show that strong CD3+ T cell infiltration into the primary tumor is an excellent 
early predictor of longer survival in metastatic melanoma patients receiving DC-based 
immunotherapy. This was revealed in a discovery cohort and confirmed in a validation 
cohort, which showed a clear correlation between intratumoral CD3+ T cell infiltration 
and survival. Multivariate analyses showed that the I/P ratio improves upon and 
can be combined with LDH levels, measured at the time treatment decisions must 
be made. This led to the most accurate survival prediction in our validation cohort 
(AUC=0.95), which also outperformed the conventional classification based on the 
TNM staging system. 
202
7T cell landscape within primary melanoma
T cell recognition of tumor cells relies upon presentation of tumor-specific antigens 
on MHC molecules. Therefore, a potential mechanism explaining the relevance of T 
cell infiltration might be that weak T cell infiltration into the primary tumor reflects 
poor immunogenicity of the tumor and thus also of potential future metastases. 
Weak immunogenic tumors might also be more difficult to treat with immunotherapy. 
If so, then intratumoral T cell infiltration should also be an appropriate marker for 
selecting patients for treatment with immunotherapy. Our analysis of the matched 
cohort provides support for this hypothesis. When data from randomized trials 
with DC vaccination become available, it will be possible to confirm this predictive 
biomarker status.
Consistently, with earlier studies, we found high intratumoral T cell densities to be 
beneficial. However, in the cohorts studied here, a high T cell density in the margin 
appears to be detrimental. In theory, a high marginal T cell density could reflect  an 
efficient homing rate of T cells from the circulation towards the tumor site. But it 
could also reflect a poor infiltration rate of T cells from the margin into the tumor. By 
measuring the I/P ratio, we focus on the infiltration rate, which predicts survival better 
than either of the individual densities. This might indicate that the infiltration rate is 
of particular importance in primary tumors, which may not be the case in metastases. 
A major advantage of analyses of T cell infiltration in primary tumors is that it can 
be assessed at initial diagnosis, which could select patients at high risk for metastatic 
disease and a high I/P ratio for adjuvant immunotherapy. This is indeed of interest, as 
we have recently shown that DC vaccination more frequently induced functional tumor-
specific immune responses in stage III melanoma patients, compared with patients with 
metastatic disease, in which their presence correlated with clinical outcome.25,41 Also, 
other studies have shown a benefit in terms of recurrence-free survival of treatment 
with the anti-CTLA-4 antibody in the adjuvant setting.42 Anti-CTLA-4 has recently been 
approved by the FDA for stage III melanoma patients; yet, it is still questionable whether 
anti-CTLA-4 is to be recommended as an adjuvant treatment because of its high toxicity, 
unknown late toxicities, and awaited data on overall survival. Identifying the right 
patients for adjuvant treatment (i.e., high risk patients who do not develop metastasis 
due to adjuvant treatment) would optimize outcome, lower toxicity, and reduce costs. 
However, as we have not analyzed T cell landscapes in stage III melanoma patients who 
did not develop distant metastasis, further research is needed to determine the value 
of T cell infiltration at this stage of disease.
Often, the immune system is not capable of efficiently controlling tumor growth 
despite proper infiltration of immune cells in the tumor. This inefficiency may be caused 
by several mechanisms, including decreased function of tumor antigen-specific T cells 
by immunosuppressive strategies caused by tumor cells. Therefore, we believe it will 
be important to reveal the phenotype and function of the CD3+ T cells. On the basis of 
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previous studies examining the tumor microenvironment,8,12,43 we presume that the 
majority of intratumoral cells are CD8+ T cells, as cytotoxic T cells are considered to 
be the most important effector cells in the tumor microenvironment. However, given 
that T cells in the margin appear detrimental, the peritumoral T cells could have a 
distinct, perhaps regulatory, phenotype. Further research should focus on unraveling 
the phenotype of the CD3+ T cells and the underlying mechanisms that give rise to the 
strong predictive value of the I/P ratio.
So far, most groups studying the correlation between TILs and patient survival 
classify the presence of TILs as absent, non-brisk and brisk.11,15,16 Some characterize 
TILs only as present or absent,44 while few use a more elaborate method that takes 
both the distribution and the density of TILs into account.12 Our method also takes 
distribution and density into account and does this in an automated and quantitative 
manner using the entire tumor slide. This way we are able to quantify all CD3+ T cells 
and assess their exact location. Computing the I/P ratio requires sufficient availability 
of both peritumoral and intratumoral tissue. In this study, we aimed for including 
peritumoral tissue within 500-700 µm around the tumor, which was possible in most 
cases. Thus, we believe that this method is practically applicable, provides highly 
accurate predictive information, and may lead to more reproducible results than 
manual qualitative assessment.
In summary, we have shown that T cell infiltration into the tumor is a highly accurate 
predictor of survival in metastatic melanoma patients receiving DC vaccination: on 
average, patients with a high I/P ratio appear to benefit from DC-based immunotherapy, 
whereas patients with a low I/P ratio do not. The predictive power of the I/P ratio does 
not wane when taking into account established late-stage prognostic markers, which 
is remarkable given that DC vaccination was only administered at metastatic stage, 
years after resection of the primary tumor. This finding underscores the importance 
of the tumor microenvironment throughout the entire course of disease. From a 
clinical perspective, assessing the T cell landscape at initial melanoma diagnosis is 
attractive for two reasons: primary tumors are more easily accessible than metastases, 
and the marker is available early on for diagnostic decision-making and, potentially, 
(adjuvant) treatment selection. As all immunotherapies are based on the same 
principle, this tool may be generally applicable for all types of immunotherapy. Further 
studies are warranted to confirm that strong intratumoral T cell infiltration is indeed 
a predictive biomarker and to investigate the prognostic and predictive potentials 
of the T cell landscape for other types of immunotherapy in melanoma. Finally, this 
approach may be useful for the investigation of other tumor types, especially for other 
immunogenic tumors.
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Abstract
To assess the safety and efficacy of dendritic cell vaccination in metastatic uveal 
melanoma we analyzed 14 patients with metastatic uveal melanoma treated with 
dendritic cell vaccination. Patients with metastatic uveal melanoma received at least 
3 vaccinations with autologous dendritic cells, professional antigen-presenting cells 
loaded with melanoma antigens gp100 and tyrosinase. The main outcome measures 
were safety, immunological response, and overall survival. Tumor-specific immune 
responses were induced with dendritic cell vaccination in 4 (29%) of 14 patients. 
Dendritic cell-vaccinated patients showed a median overall survival with metastatic 
disease of 19.2 months, relatively long compared with that reported in the literature. 
No severe treatment-related toxicities (common toxicity criteria grade 3 or 4) were 
observed. In conclusion, dendritic cell vaccination is feasible and safe in metastatic 
uveal melanoma. Dendritic cell-based immunotherapy is potent to enhance the host’s 
antitumor immunity against uveal melanoma in approximately one third of patients. 
Compared with other prospective studies with similar inclusion criteria, dendritic cell 
vaccination may be associated with longer than average overall survival in patients 
with metastatic uveal melanoma.
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Introduction
Uveal melanoma is the most common primary intraocular malignancy in adults with an 
annual incidence of 4 to 10 per 1 million in the white population, although representing 
only 3% of all melanoma cases.1, 2 Uveal melanoma arises from melanocytes residing 
in the uveal tract of the eye that have migrated out of the neural crest. Approximately 
90% of uveal melanoma arise in the choroid, 6% in the ciliary body, and 4% in the 
iris.3 In up to 50% of the patients with primary uveal melanoma,  metastatic disease 
ultimately develops, which occurs by hematogenous dissemination; the median 
time from initial diagnosis of uveal melanoma until detection of metastatic disease 
ranges from 2 to 5 years.4-7 Currently, there is no effective systemic treatment for 
metastasis to improve overall survival,8 resulting inevitably in tumor-related death 
when metastasis occurs, with the minor exceptions of a small proportion of patients 
who have successful curative surgery of metastasis or patients with spontaneous 
regression of metastatic disease. 
Prognostic factors to identify patients with primary uveal melanoma at risk for 
metastatic disease include clinical (tumor location, tumor size, age), histologic (cell 
type, vascular pattern, mitotic count, extraocular extension), and genetic (chromosomal 
aberrations, expression profiling, gene mutations) parameters, partially included in the 
American Joint Committee on Cancer classification of uveal melanoma.9-11 Over the past 
few decades, treatment of the primary tumor has changed drastically because several 
forms of radiotherapy have replaced enucleation as the preferred treatment of the 
primary tumor, depending on size and location of the tumor and patient preference. 
However, despite the improvements in diagnosis and the development of eye-
conserving treatments, none of these treatment methods prevents the development 
of metastases. The relative 5-year survival rates have not increased over the past 
decades, fluctuating at approximately 70 to 80%.4, 12-14
Only up to 2% of patients have detectable metastasis when their primary uveal 
melanoma is diagnosed15; most patients have a long disease-free interval before 
metastasis become clinically evident.4 In uveal melanoma, liver metastases are seen 
most frequently (90 to 95%), and it is often the sole site of metastatic disease. Other 
common sites of metastases, mostly in the presence of liver metastases, are lungs 
(25%), bone (15%), skin (10%), and lymph nodes (10%); in contrast to cutaneous 
melanoma, uveal melanoma infrequently metastasizes to the brain.16 After 
metastasis develops, overall survival mainly is independent of previously mentioned 
prognostic factors if one is identifying patients with primary uveal melanoma at risk 
for metastatic disease. Presence of symptomatic disease, metastatic extensiveness, 
and metastatic-free interval may correlate with survival time.17 Nevertheless, 
median survival is short, typically less than 9 months, with a poor 1-year survival 
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rate (10 to 40%).7, 17-19 The small group of patients in whom metastases are confined 
to extrahepatic locations have a significantly longer median survival, approximately 
19 to 28 months.20, 21 
Several locoregional treatment options can be considered in selected patients 
with metastasis confined to the liver, including surgery, isolated hepatic perfusion, 
or radiofrequency ablation. Although prolonged survival has been reported after 
surgical resection of liver metastasis,20 this may be the result in part of selection bias. 
To date, treatment options for metastatic uveal melanoma are limited, and compelling 
evidence that any systemic therapy, including chemotherapy, improves overall survival 
is lacking.6 Disease stabilization is described in several patients receiving ipilimumab, 
which recently has shown survival benefit in metastatic cutaneous melanoma 
patients.22 However, data are based on a limited number of patients.23, 24 Therefore, 
effective therapies resulting in meaningful clinical benefit are required urgently, and 
immunotherapy may be a promising treatment method.
Immune-based therapies aim to induce antitumor immunity. Despite uveal 
melanoma developing in the immune-privileged environment of the eye, immune 
cells have been found within uveal melanoma, including dendritic cells and T cells.25-27 
Dendritic cells are antigen-presenting cells with the unique capacity to activate naïve 
antigen-specific T cells, and hence are suitable for inducing immunologic anti-tumor 
responses (Figure 1). Dendritic cell-based immunotherapy has shown promising results 
in cutaneous melanoma patients.28 Although uveal and cutaneous melanoma are 
different biologically, cutaneous melanoma and uveal melanoma share many antigenic 
features, including tumor antigens, providing a rationale for the application of dendritic 
cell-based therapies in uveal melanoma. The tumor antigens used in our dendritic cell 
vaccination studies for metastatic melanoma patients, gp100 and tyrosinase, are both 
expressed in most human uveal melanoma tumor cells,29, 30 and thus constitute an 
appropriate target for immunotherapy in uveal melanoma. 
Our research group has performed several prospective dendritic cell vaccination 
studies in patients with melanoma, of which most consisted of patients with cutaneous 
melanoma. We here present data on the subset of metastatic uveal melanoma patients 
who were enrolled in these studies.
Patients and Methods
The studies were approved by the Dutch Centrale Commissie Mensgebonden Onderzoek 
(Central Committee on Research Involving Human Subjects,) and written informed 
consent to participate in research was obtained from all patients. The trials were 
registered at ClinicalTrials.gov (identifiers NCT00940004, NCT01690377, NCT01530698, 
and NCT00243529).
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Patient characteristics
We analyzed a cohort of 14 patients with metastatic uveal melanoma who were 
enrolled in our prospective dendritic cell vaccination studies between October 2002 
and May 2011. Patients were required to have at least 1 measurable target lesion. 
Additional inclusion criteria were melanoma expressing the melanoma-associated 
antigens gp100 (compulsory) and tyrosinase (noncompulsory), HLA-A*02:01 phenotype 
Figure 1. Diagram showing dendritic cell (DC) vaccination rational and treatment schedule. DC are 
antigen-presenting cells with the unique capacity to activate naïve antigen-specific T cells, and by this 
means are very suitable to induce immunologic antitumor responses. (Left) DC cultured from monocytes 
can be loaded with tumor antigen ex vivo and administered to cancer patients via different routes, after 
culture in the presence of maturation stimuli. (Middle) Within the lymph node, DC present antigens to T cells 
to initiate an immune response. (Right) The activated tumor antigen-specific T cells proliferate and migrate 
out of the lymph node toward the site of the antigen, the tumor site, to effectuate T cell killing of tumor 
cells. Patients were vaccinated with autologous DC loaded with tumor antigens (gp100 and tyrosinase), 
obtained by leukapheresis, according to a schedule of 3 biweekly vaccinations. One to 2 weeks after the 
last vaccination, a skin test was performed to analyze the induction of immunologic responses. Computed 
tomography (CT) scans were performed prior to vaccination and every 3 months thereafter. CD4 = CD4+ 
T-helper cell; CD8 = CD8+ cytotoxic T cell; DTH = delayed-type hypersensitivity skin test; i.d. = intradermal; 
i.n. = intranodal; i.v. = intravenous. 
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(protocols I, III, IV, V, and VI), known HLA-DRB*01:04 status (protocol IV), and World 
Health Organization performance status 0 or 1. Patients with serious concomitant 
disease or a history of second malignancy were excluded. 
Treatment schedule
All patients were vaccinated with autologous dendritic cells loaded with tumor-
associated antigens of gp100 and tyrosinase according to a schedule of 3 biweekly 
vaccinations. One to 2 weeks after the last vaccination, a skin test was performed; see 
the treatment schedule in Figure 1. In absence of disease progression, patients received 
a maximum of 2 maintenance cycles at 6-month intervals. Variations in protocols 
included the type of dendritic cells, route of administration, method of antigen loading, 
and pretreatment with anti-CD25 antibody, described in the Supplementary Table. 
Stable disease was defined according to Response Evaluation Criteria in Solid Tumors 
with a minimal duration of 4 months. Adverse events were graded according to the 
National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0.
Dendritic cell vaccine
Monocytes were enriched from leukapheresis products by counterflow centrifugation 
using Elutra-cell separator (Gambro BCT, Inc) and single-use, functionally sealed 
disposable Elutra sets, according to the manufacturer. Monocytes were cultured 
in the presence of interleukin (IL)-4 (500 U/mL) granulocyte-macrophage colony-
stimulating factor (800 U/mL; both Cellgenix) and control antigen keyhole limpet 
hemocyanin (10 μg/mL; Calbiochem). Dendritic cells were matured with autologous 
monocyte-conditioned medium (30%, v/v) supplemented with prostaglandin E2 
(10 μg/mL; Pharmacia & Upjohn) and 10 ng/mL tumor necrosis factor-α (Cellgenix) for 
48 hours as described previously.31 Plasmacytoid dendritic cells and myeloid dendritic 
cells were directly isolated from leukaphaeresis products using the fully closed 
immunomagnetic CliniMACS isolation system (Miltenyi Biotec). Good manufacturing 
practice-grade magnetic bead-coupled BDCA4 (plasmacytoid dendritic cells) or BDCA1 
(myeloid dendritic cells) antibodies were used, following the manufacturer’s guidelines. 
Plasmacytoid and myeloid dendritic cells were cultured overnight at a concentration 
of 106 cells/mL in X-VIVO-15 (Cambrex) containing 2% pooled human serum (Sanquin), 
supplemented with 10 ng/mL recombinant human IL-3 (plasmacytoid dendritic cells) 
or 800 U/mL granulocyte-macrophage colony-stimulating factor (both Cellgenix) and 
10 μg/mL control antigen (Calbiochem; myeloid dendritic cells). The plasmacytoid 
dendritic cells were activated subsequently for 6 hours by addition of FSME-IMMUN 
(1:10 v/v; Baxter AG).50
Dendritic cells were pulsed with the human leukocyte antigen (HLA) class I gp100-
derived peptides gp100:154-162, gp100:280-288, and the tyrosinase-derived peptide 
tyrosinase:369-377. In one protocol, dendritic cells from HLA-DRB*01:04–positive 
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patients also were pulsed with HLA-DRB*01:04–binding peptides of both gp100 
and tyrosinase (gp100:44-59 and tyro:448-462 analog).51 In protocols IV, V, and VIII, 
mature dendritic cells were electroporated with mRNA encoding gp100 or tyrosinase 
as described previously,52 and cells were resuspended in 0.1 mL for injection. 
All administered dendritic cell vaccines met the release criteria described 
previously:32 mature phenotype with low expression of CD14, high expression of major 
histocompatibility complex (MHC) class I, MHC class II, CD83, and CD86 and expression 
of gp100 and tyrosinase for mRNA-electroporated cells.
Flow cytometry
Flow cytometry was used to characterize the phenotype of the ex vivo-generated 
dendritic cells and immune cell subpopulations in the peripheral blood. Flow cytometry 
measures multiple cell surface proteins simultaneously after staining the cells with 
fluorescently labeled antibodies specific for a certain antigen. The following monoclonal 
antibodies or appropriate isotype controls were used: anti–HLA ABC (W6/32), anti–HLA 
DR/DP (Q5/13), anti–HLA DR, anti-CD80 (all BD Biosciences), anti-CD14, anti-CD83 (both 
Beckman Coulter), anti-CD86 (BD Pharmingen), and anti-CCR7 (kind gift of Martin Lipp, 
Max Planck Institute). For intracellular staining, NKI/beteb (immunoglobulin [Ig]G2b; 
purified antibody) against gp100 and T311 (IgG2a; Cell Marque Corp) against tyrosinase 
were used. Flow cytometry was carried out with FACSCalibur flow cytometer equipped 
with CellQuest software (BD Biosciences).
Supplementary Table. Dendritic cell vaccination protocols used in metastatic uveal melanoma patients.
Protocol No of patients Type of DC Method of antigen loading Route of administration Anti-CD25
I 1 moDC Class I mod i.v./i.d. No
III-B 2 moDC Class I wt i.d. Yes
IV-A 2 moDC Class I wt + II i.n. No
IV-B 1 moDC Class I wt i.n. No
IV-D 1 moDC mRNA i.n. No
V-A 1 moDC mRNA i.v./i.d. No
VI-B 1 myDC myDC Class I wt i.n. No
VI-DE 2 pDC pDC Class I wt i.n. No
VIII 3 moDC mRNA i.v./i.d. No
Abbreviations: Class I mod, HLA class I-restricted modified gp100-derived peptides 154-162 Q→A 
and 280-288 A→V and HLA class I-restricted tyrosinase-derived peptide 369-377; Class I wt, HLA class 
I-restricted wt gp100-derived peptides 154-162 and 280-288 and HLA class I-restricted tyrosinase-derived 
peptide 369-377; Class II, HLA class II-restricted gp100-derived peptide 44-59 and tyrosinase-derived 
peptide 448-462 analog; DC, dendritic cell; i.d., intradermal; i.n., intranodal; i.v., intravenous; mod, 
modified; moDC, monocyte-derived dendritic cell; mRNA, messenger RNA (encoding full length gp100 
and tyrosinase protein); myDC, myeloid dendritic cell; pDC, plasmacytoid dendritic cell; wt, wild type.
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Control antigen-specific proliferation
CD4+ T cell responses against the control antigen were measured using a 3H-thymidine 
incorporation proliferation assay with peripheral blood mononuclear cells of the patients 
before and after vaccination. Briefly, peripheral blood mononuclear cells were isolated 
from heparinized blood by Ficoll-Paque density centrifugation, stimulated with control 
antigen (4 µg/2 x 105 peripheral blood mononuclear cells) in X-VIVO with 2% human 
serum. After 3 days, cells were pulsed with 3H-thymidine for 8 hours, and incorporation 
was measured with a ß-counter. Experiments were carried out in triplicate; nonspecific 
proliferation upon stimulation with ovalbumin was used as control.
Control antigen-specific antibody production
Antibodies against control antigen were measured in the serum of vaccinated patients 
using enzyme-linked immunosorbent assay (available at: http://www.klhanalysis.com). 
Briefly, microtiter plates were coated with control antigen, and different concentrations 
of patient serum were allowed to bind. After washing, patient antibodies were detected 
with mouse anti-human IgG, IgA, or IgM antibodies labeled with horseradish peroxidase 
(Invitrogen); 3,30-5,5-tetramethyl benzidine was used as a substrate. An isotype-
specific calibration curve for the control antigen response was included in each plate; 
the detection limit was determined at more than 20 mg/L.
Analyses of skin test infiltrating lymphocytes for tumor recognition
To assess the immune response against tumor peptides generated in vaccinated patients, 
delayed-type hypersensitivity challenges were performed with mature dendritic cells 
loaded with gp100, tyrosinase, or both. We have shown that the presence of skin test-
infiltrated, tumor-specific T cells correlated with clinical outcome. 28,33 Skin tests were 
performed within 1 to 2 weeks after each vaccination cycle. Briefly, dendritic cells 
pulsed with gp100, tyrosinase, or both epitopes or electroporated with mRNA encoding 
either gp100, tyrosinase, or both were injected intradermally in the skin of the back of 
the patient at different sites. After 48 hours, the maximum diameter of induration was 
measured by palpation, and punch biopsy samples (6 mm) were obtained. Half of the 
biopsy was cryopreserved by snap freezing and the other part was cut manually and 
cultured for 2 to 4 weeks in RPMI-1640 containing 7% human serum and IL-2 (100 U/
mL). Every 7 days, half of the medium was replaced by fresh medium containing human 
serum and IL-2. After 2 to 4 weeks of culturing, skin test-infiltrating lymphocytes of HLA-
A*02:01-positive patients were stained with tetrameric-MHC complexes as described 
previously.33 Each tetramer was validated by staining against a cytotoxic lymphocyte 
cell line specific for HLA-A*02:01 in association with the peptide of interest. The ability 
of skin test-infiltrating lymphocytes to recognize vaccine-specific antigens and produce 
cytokines was determined by the production of cytokines and cytotoxic activity of skin 
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test-infiltrating lymphocytes in response to T2 pulsed with the indicated peptides or 
BLM (a melanoma cell line expressing HLA-A*02:01 but no endogenous expression of 
gp100 and tyrosinase), transfected with control antigen G250, with gp100 or tyrosinase, 
or with an allogeneic HLA-A*02:01-positive, gp100-positive, and tyrosinase-positive 
tumor cell line (MEL624).28 In 2 HLA-A*02:01-negative patients, antigen recognition 
was determined using autologous EBV-transformed B cells as described previously.53
Mixed lymphocyte-peptide cultures
Blood frequencies of anti-vaccine CD8+ T cells were estimated using mixed lymphocyte-
peptide cultures in protocol VI as described previously.50,54 Briefly, peripheral blood 
mononuclear cells isolated before and after 1 cycle of plasmacytoid dendritic cell 
vaccinations were thawed and divided in 3 groups incubated for 1 hour at room temperature 
in Iscove’s medium (Life Technologies, Carlsbad, California, USA) with 1% human serum 
and 2 µM of the peptides tyrosinase:369-377 (YMDGTMSQV), wild-type gp100:154-168 
(KTWGQYWQV), or wild-type gp100:280-288 (YLEPGPVVTA). These pulsed cells were then 
washed, pooled, and distributed at 2 x 105 cells/0.2 mL in round-bottom microwells in 
Iscove’s with 10% human serum, L-arginine (116 mg/L), L-asparagine (36 mg/L), L-glutamine 
(216 mg/L), 1-methyl-L-tryptophan (100 µM),  IL-2 (20 U/mL), and IL-7 (10 ng/mL). On day 7, 
50% of the medium was replaced by fresh medium containing IL-2 and peptides at 4 µM. 
Tetramer labeling was performed on day 14 as described previously.54 Anti-gp100:154-168 
T cell clones were derived that represented either the spontaneous anti-gp100 T cells 
present before vaccination or the plasmacytoid dendritic cell-induced anti-gp100 T cells 
present after vaccination. Tetramer-positive CD8+ T cells were sorted at 1 cell/well and 
restimulated weekly with irradiated HLA-A*02+ EBV-transformed B cells pulsed with the 
gp100:154-168 peptide at 2 µM, and irradiated allogeneic peripheral blood mononuclear 
cells as feeder cells, in medium supplemented with IL-2 and IL-7. 
Tetramer staining
To determine the presence of tumor-associated antigen-specific T cells, skin test-
infiltrating lymphocyte cultures and peripheral blood mononuclear cells were 
reanalyzed and stained with tetrameric-MHC complexes containing the MHC class I 
epitopes gp100:154–168, gp100:280–288, or tyrosinase:369–377 (Sanquin) or MHC 
class II epitopes gp100:44–59 and tyrosinase:448–462 (provided by W.W. Kwok, 
Benaroya Research Institute, Seattle, Washington, USA), as described previously.51 
In addition, in 2 patients, peripheral blood mononuclear cells were restimulated for 
8 days with DR4-binding gp100 or tyrosinase peptides and stained with tetrameric 
MHC complexes containing MHC-II epitopes gp100:44–59 and tyrosinase:448–462. 
Tetrameric MHC complexes recognizing the human immunodefiency virus were used 
as correction for background binding. Tetramer positivity was defined as at least 2-fold 
increase in the double-positive population.
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Fluorescent in situ hybridization analysis
Fresh tumor material from enucleated eyes containing uveal melanoma were cultured 
routinely for karyotyping and were used directly for fluorescent in situ hybridization (FISH) 
analysis of chromosome 3 as previously described.34 Dual-color FISH was performed with 
the following probes: Pα3.5 (centromere 3), RP11-64F6 (3q25), and RP11-1059N10 (5q12). 
Chromosome 5 is rarely involved in genetic changes in uveal melanoma and was used as a 
control for aneuploidy, truncation, and cutting artifacts. The concentration for centromeric 
probe was 5 ng per slide, whereas for the bacterial artificial chromosome probes, 50 to 
75 ng per slide was used. After hybridization and washing, the slides were counterstained 
with 4’, 6-diamidino-2-phenylindole and mounted in antifade solution (Dabco-Vectashield 
1:1; Vector Laboratories). Signals were counted in 300 interphase nuclei. Scoring for 
deletion (>20% of the nuclei with 1 signal) or amplification (>10% of the nuclei with 3 signals 
or more) was adapted from the available literature.35 Using FISH analysis, we subdivided 
the variation in chromosome 3 into the following categories: monosomy 3 (loss of 1 copy), 
disomy 3 (normal copy numbers [2 copies]), and hyperdiploidy (gain of 1 copy). 
Statistical analysis
Overall survival was calculated from the date of leukapheresis to death. Patients who 
did not die during the follow-up period were censored at the time of last follow-up. 
The Kaplan-Meier method was used to obtain estimates of median survival times and 
to generate survival curves. IBM SPSS Statistics (SPSS version 20.0) software (SPSS Inc) 
was used for statistical analysis.
Results
Patient characteristics
Fourteen uveal melanoma patients with metastatic disease were enrolled in dendritic 
cell vaccination studies. Patient characteristics are shown in Table 1. The mean age 
was 52 years; 9 patients were men and 5 were women. One patient had metastases 
confined to extrahepatic locations. All other patients had liver metastases, of which 
the liver was the sole site of metastasis in 5 patients. Six patients had received prior 
treatment for their metastatic disease, mostly consisting of surgery or dacarbazine 
(chemotherapy). Lactate dehydrogenase, (if elevated a negative prognostic factor in 
metastatic uveal melanoma), was elevated at baseline in 3 of 14 patients. Median time 
between diagnosis of the primary tumor and metastatic disease was 20.4 months. Four 
patients had synchronous metastasis at presentation (Table 2).
All tumors were confirmed histopathologically as uveal melanoma. Histopathologic 
examination results of the primary tumor were available in 9 patients who were treated 
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with enucleation. Based on cell type, 8 primary tumors were classified as epithelioid or mixed 
and 1 as spindle. The median largest tumor diameter of the primary tumor was 13 mm. One 
tumor was located in the ciliary body (VI-DE3) and 11 were located in the choroid (2 unknown 
primary location in the ciliary body or choroid). In 12 of 14 patients, metastatic disease was 
confirmed by histopathologic analysis. All uveal melanoma tumor cells tested, 6 primary 
tumors and 8 metastases, showed positive results for gp100 expression. Additionally, 11 of 
12 uveal melanoma tumor cells tested also expressed tyrosinase. 
Cytogenetic results
Uveal melanomas of 11 patients were analyzed for chromosomal changes by using 
cytogenetic and FISH analyses and were classified for gain and loss in chromosome 3 
(Table 1). Analyses were performed on primary tumors in 5 patients, on metastases 
in 4 patients, and on both in 2 patients. Not enough tumor material was available to 
analyze the remaining 3 patients. Clonal chromosomal abnormalities were present in 
8 of 11 tumors tested. Seven tumors showed monosomy 3, 3 patients showed disomy, 
and 1 patient had a tumor showing hyperdiploidy of chromosome 3. No discrepancies 
were seen in the patients where both the primary tumor and a metastasis were tested.
Immunological responses
To test the capacity of the patients in this study to generate an immune response with 
vaccination, dendritic cells were loaded with a control antigen. Peripheral blood mononuclear 
cells collected after each vaccination were analyzed for the presence of control antigen-
specific T cells. Almost all patients (12 of 14) showed a cellular response to control antigen 
in the first cycle. In 7 of 13 patients tested, control antigen-specific IgG antibodies were 
detected after vaccination (Table 3). These results indicate that the vaccine induced de 
novo immune responses. To determine the presence of tumor antigen-specific CD4+ and 
CD8+ T cells, tetramer analyses for 1 tyrosinase and 2 gp100 epitopes were performed 
after 3 vaccinations. In peripheral blood, tetramer-positive CD4+ T cells, indicative of tumor 
recognition by T-helper cells, could be seen in 1 of 2 HLA-DRB*01:04-positive patients tested, 
which were also detectable in the blood before dendritic cell vaccination. 
In 3 patients (protocol VI), blood mononuclear cells were restimulated in vitro 
over 2 weeks with the 3 antigenic peptides, before screening all microcultures for the 
presence of CD8+ tetramer-positive cells. This procedure allowed estimation of the 
frequencies of tumor antigen-specific CD8+ T cells in blood that proliferate in vitro in 
response to tumor antigen. Two patients showed a significant increase (≥5-fold) of the 
frequency of gp100-specific CD8+ T cells.
Antigen-specific CD8+ T cells were detected in delayed-type hypersensitivity skin 
tests in 2 of 11 HLA-A*02:01-positive patients (Figure 2; Table 3). In patient IV-B11, 
functionality of the antigen-specific CD8+ T cells was tested, and they proved to be fully 
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functional and to produce high levels of interleukin-2 and interferon-y upon antigen-
specific stimulation.
Clinical outcome
All patients received at least 3 vaccinations (1 cycle), and 1 patient did not have a skin 
test because of rapid progressive disease. Ten patients showed stable disease at the 
first evaluation point, 3 months after start of vaccination, but 7 patients progressed 
before a second cycle was started after 6 months according to protocol. One patient 
received a second cycle of vaccinations, and 2 patients received all 3 vaccination cycles 
and had stable disease up to 28 months. Seven (50%) patients survived more than 
2 years after start of dendritic cell vaccination for metastatic uveal melanoma. Thus far, 
12 patients have died of melanoma-related disease and 2 patients are still alive with 
metastases. Figure 3 shows the Kaplan-Meier curve for overall survival. Our patients 
were substaged according to the American Joint Committee on Cancer tumor-node-
metastasis staging system for melanoma of the eye based on the diameter of the largest 
Table 3. Immunologic responses to dendritic cell vaccination in metastatic uveal melanoma patients.
Tumor-antigen specific
Control antigen-specific CD8+ T cell response CD4+ T cell response
Patient
T cell response 
blood
Antibody response 
blood skin test blood blood
I-C14 + - - - n.t.
III-B7 + - - - n.t.
III-B8 + n.t. n.t. - n.t.
IV-A4 + + + - +a
IV-A10 + + - - -
IV-B11 + + + - n.a.b
IV-D3 + + - - n.a.b
V-A3 + - - - n.t.
VI-B6 - - - - n.t.
VI-DE3 + + - + n.t.
VI-DE4 - + - + n.t.
VIII-A1 + - n.a. n.a.c n.t.
VIII-A4 + + n.a. n.a.c n.t.
VIII-DE2 + - - - n.t.
Abbreviations: n.a., not applicable; n.t., not tested; +, response present; -, response absent.
a Tumor antigen-specific CD4+ T cell response also was detectable in the blood before dendritic cell 
vaccination.
b HLA-DRB*01:04-negative patients.
c HLA-A*02:01-negative patients.
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metastasis. Six patients had M1a substage (diameter of the largest metastasis of 3.0 cm 
or less), 6 patients had M1b substage (diameter of the largest metastasis between 3.1 
and 8.0 cm), and 2 patients had M1c substage (diameter of largest metastasis more 
than 8.1 cm). Our patients showed a median overall survival of 29 months for M1a, 
22.5 months for M1b, and 6 months for M1c.
Side effects
No severe toxicity (grade 3 or 4) occurred. The vaccine-related side effects observed in 
the vaccinated patients were grade 1 fatigue (5 patients), flu-like symptoms (8 patients), 
and erythema at the intradermal injection site (6 patients). 
Figure 2. Tumor-specific T cells in skin test after dendritic cell vaccination in a metastatic uveal melanoma 
patient. To assess the immune response against tumor peptides generated in vaccinated patients, delayed-
type hypersensitivity challenges were performed with mature dendritic cells loaded with gp100, tyrosinase, 
or both. The ability of skin test infiltrating lymphocytes to recognize vaccine-specific antigens was measured 
with tetrameric-major histocompatibility complex (TM) complexes by flow cytometry. (Top left) Skin 
test infiltrating lymphocytes double-positive for CD8 and a specific tetrameric- major histocompatibility 
complex, tumor antigen-recognizing cytotoxic T cells, are shown in the upper right quadrant. (Top right) 
Analyses of patient IV-A4 show skin test infiltrating lymphocytes recognizing 1 of the gp100 epitopes tested. 
(Bottom left and bottom right) No skin test infiltrating lymphocytes recognizing gp100:280 or tyrosinase 
are found in this patient.
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Figure 3. Kaplan-Meier estimate for overall survival 
after dendritic cell vaccination in metastatic uveal 
melanoma patients. Kaplan-Meier estimate for 
overall survival from leukapheresis to date of death 
or censored at date of last follow-up. Dendritic cell 
vaccinated patients showed long overall survival 
with metastatic uveal melanoma; the median overall 
survival was 19.2 months.
Discussion
The intrinsic resistance of uveal melanoma to conventional systemic therapies has 
made the treatment of metastatic uveal melanoma a tough challenge. The development 
of uveal melanoma at an immune-privileged site, the eye, made it questionable if 
immunotherapy would be a suitable treatment method. The lack of proper immune 
surveillance in the eye can lead to characteristics that make tumor cells more susceptible 
for recognition by the immune system when cells disseminate systemically, for example, 
high expression of tumor-specific antigens, as well as less susceptible, for example, 
resistance to interferon-γ-induced upregulation of major histocompatibility complex 
class II molecules.36-38 At present, accumulating evidence shows that uveal melanoma 
tumor cells can be lysed by CD8+ T cells in vitro39 and by T cells adoptively transferred in 
a mouse model,40 indicating the susceptibility of uveal melanoma for immunotherapy.
In our study, we vaccinated metastatic uveal melanoma patients with autologous, 
mature dendritic cells to induce or strengthen a tumor-specific immune response. First, 
we showed that dendritic cell vaccination in metastatic uveal melanoma is feasible 
and safe, as shown in more than 200 patients with cutaneous melanoma. Second, 
the control antigen-specific T cell proliferation indicated that the vaccine effectively 
induced de novo immune responses in all patients. Tumor-specific CD8+ T cells were 
detected in 29% of patients in peripheral blood or in antigen-challenged skin sites. 
Our previous findings in metastatic melanoma patients, of which most had cutaneous 
melanoma, showed a similar immunologic response rate (32%) and demonstrated that 
the presence of tumor-specific T cells after dendritic cell vaccination correlates with 
clinical outcome.28 The cohort is too small to confirm these data in metastatic uveal 
melanoma patients. 
Obviously, our study has several limitations. First, this study consists of a small 
cohort, mainly because of rarity of the tumor and selection on HLA-A*02:01 phenotype 
228
8DC vaccination in metastatic uveal melanoma patients
in most protocols (approximately 50% of the white population).41 The latter was 
necessary because the selected peptides only bind HLA-A*02:01. We do not expect that 
this has influenced our results, since HLA-A*02:01 phenotype has shown no correlation 
with survival.42 Other factors were more likely to be of influence on overall survival, for 
example, excluding patients with World Health Organization performance status of 2 
or more. However, patients were not excluded based on anatomic site of metastasis, 
number of metastases, or metastatic-free interval, all known to be prognostic factors 
in metastatic uveal melanoma.17 
The primary endpoint of the dendritic cell vaccination studies was safety and 
feasibility; however, the data on overall survival appeared interesting. The median 
overall survival of the vaccinated patients was 19.2 months, calculated from the day 
of leukapheresis instead of from diagnosis of metastasis, as is done in unselected case 
series. Overall survival from date of diagnosis of metastatic disease in our dendritic 
cell vaccinated patients was 30.3 months. According to the American Joint Committee 
on Cancer Staging Manual, median overall survival is 17 months for M1a, 9 months for 
M1b, and 4.5 months for M1c.43 Our patients showed a median overall survival of 29 
months for M1a, 22.5 months for M1b, and 6 months for M1c. No large difference in 
overall survival was seen in patients who received prior therapy for metastatic disease 
to treatment-naïve patients. Comparing our results on survival with other published 
series, the observed median overall survival of 19.2 months in dendritic cell-vaccinated 
patients not only exceeded the overall survival as reported in studies using systemic 
treatment (range, 5.2 to 15.3 months), but also the overall survival in almost all studies 
in more selected metastatic uveal melanoma patients treated with local therapies 
of the liver (range, 5.2 to 24 months), such as surgical resection of liver metastasis, 
hepatic artery chemoembolization, and hepatic artery infusion chemotherapy.17 These 
invasive therapies excluded patients with extrahepatic metastasis and high World 
Health Organization performance status, that is, have more strict inclusion criteria, 
and consequently included patients with more favorable prognostic factors. Further 
comparison with a cohort of patients with a similar proportion of pretreated patients 
(12 of 20 patients) and selection criteria, treated with treosulfan and gemcitabine, 
showed a similar median overall survival (19.2 vs 17 months).44 Although our results 
do not allow definite conclusions about clinical outcome, the immunologic responses, 
previous shown to correlate with clinical outcome,28 and the observed long overall 
survival in our cohort of metastatic uveal melanoma patients seem promising. 
Additionally, the minimal toxicity associated with dendritic cell vaccination compares 
favorably with other treatment methods. 
As to metastatic patients, the high tumor burden may hamper the induction of effective 
immune responses, creating a suppressive tumor microenvironment by the secretion of 
suppressive cytokines and attraction of regulatory T cells.45 Robust immunologic responses 
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on dendritic cell vaccination are induced more frequently in patients with no evidence of 
disease (72%) (manuscript in preparation) compared with patients with macroscopic tumor 
burden (32%).28 On the basis of the association of tumor-specific T cells and improved 
clinical outcome, this suggests that dendritic cell-based vaccination may have a more 
pronounced role in an adjuvant setting and should be initiated at an early stage after tumor 
resection. Patients with primary uveal melanoma usually have no detectable metastatic 
disease at time of diagnosis, and most patients have a lengthy disease-free interval 
before metastasis become evident. Therefore, after treatment of the primary tumor, in 
the presence of only minimal residual disease and with little immune suppression, there 
is sufficient time to develop an effective immune response with adjuvant dendritic cell 
vaccination. Furthermore, patients with a high risk for relapse could be selected based on 
monosomy 3 status. The presence of monosomy 3 in the primary tumor is accepted widely 
as the most simple and reliable prognostic parameter, identified in approximately 50% of 
patients with primary uveal melanoma.46 Long-term studies have shown a 3-year survival 
rate of 40% if monosomy 3 is present, whereas tumors with normal chromosome 3 status 
rarely give rise to metastatic disease and have a 90% 3-year survival rate.47
To date, no adjuvant therapy has shown survival benefit in uveal melanoma,48, 49 and 
because immunologic responses are seen more frequently in patients before clinically 
detectable metastasis develop, dendritic cell vaccination may be a good candidate. We 
currently are investigating this strategy in a randomized study. In conclusion, we show 
that dendritic cell vaccination is feasible and safe in metastatic uveal melanoma. Our 
data suggest the potential of dendritic cell-based immunotherapy to enhance the host’s 
antitumor immunity and that it may be associated with longer than average overall 
survival times in metastatic uveal melanoma. 
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9Part III. DC vaccination in subsets of melanoma patients
Abstract
In primary uveal melanoma, the presence of monosomy 3 in the tumor is widely accepted 
as a reliable prognostic parameter. This genetic event is identified in approximately 
50% of patients with primary uveal melanoma. Long-term studies have shown a 
3-year survival rate of approximately 60% if monosomy 3 is present, whereas tumors 
with normal chromosome 3 status rarely give rise to metastatic disease and have a 
95-100% 3-year survival rate. Currently, no effective adjuvant treatment is available 
for patients with primary uveal melanoma at high risk for relapse. We conducted an 
open label phase II study to examine the immunological responses to adjuvant dendritic 
cell vaccination, following primary treatment. Twenty-three HLA-A*02:01-positive 
high-risk uveal melanoma patients received vaccinations with autologous dendritic cells 
loaded with melanoma antigens gp100 and tyrosinase. Fourteen HLA-A*02:01-negative 
patients and 27 HLA-A*02:01-positive patients with high-risk uveal melanoma served as 
controls. All tested dendritic cell vaccinated patients (n=22) showed a cellular immune 
response against the control antigen. Tumor antigen-specific immune responses were 
induced in 17 (74%) of 23 patients. Patients with a tumor antigen-specific immune 
response had a median overall survival of 58.0 months. Patients without a detectable 
tumor antigen-specific immune response had a median overall survival of 45.0 months 
(p<0.05). No severe treatment-related toxicities (common toxicity criteria grade 3 or 
4) were observed. In conclusion, dendritic cell vaccination is feasible and seems safe in 
high-risk uveal melanoma patients. Dendritic cell-based immunotherapy enhances the 
host antitumor immunity against uveal melanoma and the presence of an antitumor 
immune response correlates with longer overall survival. 
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Introduction
Although uveal melanoma (UM) only comprises 3% of all melanoma cases, UM is the 
most common primary intraocular malignancy in adults with an annual incidence of 4 to 
10 per million in the Caucasian population.1, 2 UM arises from proliferating melanocytes 
residing in the uveal tract of the eye that have migrated out of the neural crest. About 
90% of UM arise in the choroid, 6% in the ciliary body and 4% in the iris.3 Over the 
past few decades, there has been a trend towards the use of eye-sparing radiotherapy 
techniques for patients with UM, depending on the size and location of the tumor. 
Enucleation, however, continues to be widely used for large or juxtapapillary UM. 
The overall survival (OS) is fluctuating around 70- 80% with no change over the 
last decades.2, 4-6 Thus far, no adjuvant therapy has shown survival benefit in UM.7 Up 
to 50% of the patients with primary UM ultimately develop metastases, of which less 
than 2-4% have clinical detectable metastatic disease at presentation. Metastases 
occur by hematogenous dissemination and most patients have a long disease-free 
interval (2 to 5 years) before metastases become clinically evident.4, 8, 9 Once patients 
develop metastatic disease, they have a dismal prognosis, with a 1-year survival rate 
of 10-40%.9-12 Currently, no effective systemic treatment for UM metastasis improving 
OS are available.13 Of the immune checkpoint inhibitors, anti-CTLA-4 antibodies seem 
to have a very limited effect in metastatic UM, in contrast to cutaneous melanoma, 
with a response rate below 5%. The role of anti-PD-(L)1 antibodies in UM is unclear as 
only very few patients have received it thus far.14
Our research group, as well as others,15-17 have performed several prospective 
dendritic cell (DC) vaccination studies in patients with cutaneous melanoma showing 
little toxicity and promising immunological and clinical results.18 DC are antigen-
presenting cells with the unique capacity to activate naïve antigen-specific T cells, 
hence suitable to induce anti-tumor immune responses. The tumor antigens gp100 
and tyrosinase used in our DC vaccination studies for metastatic cutaneous melanoma 
patients, are both expressed in the majority of human UM tumor cells,19, 20 and thus 
constitute an appropriate target for immunotherapy in UM. Recently, we showed that 
DC vaccination is feasible and safe in metastatic UM, has the potential to enhance 
the host’s antitumor immunity and may be associated with longer than average OS in 
metastatic UM.21
The high tumor burden in metastatic patients may hamper the induction of effective 
immune responses, by creating a suppressive tumor microenvironment with the 
secretion of suppressive cytokines and attraction of regulatory T cells and myeloid 
derived suppressor cells.22 Robust immunological responses upon DC in cutaneous 
melanoma patients are more frequently induced in patients with no evidence of disease 
(72%)23 compared to patients with macroscopic tumor burden (32%).18 This suggests 
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that DC-based vaccination may have a more pronounced effect in an adjuvant setting 
and should be initiated at an early stage after tumor resection. 
Preferably, patients with a high risk for development of metastatic disease are 
selected for adjuvant treatment. Of all known prognostic parameters of UM, monosomy 
3 correlates most strongly with decreased survival. The presence of monosomy 3 in the 
primary tumor is widely accepted as a reliable prognostic parameter, and is identified 
in approximately 50% of patients with primary UM.24 Long-term studies have shown a 
3-year survival rate of approximately 60% if monosomy 3 is present, whereas UM with 
normal chromosome 3 status rarely give rise to metastatic disease and have a 95-100% 
3-year survival rate.24-26 In this open label phase II study we therefore investigated the 
immunological responses after vaccination with monocyte-derived DC loaded with 
tyrosinase and gp100 mRNA in high-risk UM patients with monosomy 3. 
Patients and Methods
Patient characteristics and study design
UM patients with a loss of chromosome 3 (monosomy 3; further referred to as high-risk 
UM), with an interval since local treatment <12 months, were included in this trial. 
Additional inclusion criteria were UM expressing the melanoma-associated antigens 
gp100, age 18-75 years, and WHO performance status 0 or 1. Patients with distant 
metastases, serious concomitant disease or a history of a second malignancy were 
excluded. Human leukocyte antigen (HLA)-A*02:01-positive patients were vaccinated 
with DC transfected with mRNA encoding the tumor-antigens gp100 and tyrosinase, 
and HLA-A*02:01-negative patients served as a control group. Selection on HLA-
A*02:01 was chosen for the feasibility of immunomonitoring. In both groups follow-up 
consisted of physical examination, blood liver enzyme analysis and imaging of the 
liver every 6 months and additional analysis if clinically appropriate. An additional 
historical high-risk UM, HLA-A*02:01-positive control group was obtained from a 
database. Ethics Committee approval was obtained and written informed consent was 
obtained from all patients eligible for DC vaccination. Twenty-four patients underwent 
a leukapheresis, of which 23 received DC vaccination. In one patient a monoclonal B 
cell lymphocytosis was found in the apheresis product; she did not receive adjuvant 
DC vaccination as it was unclear whether it might have a negative effect on the course 
of the monoclonal B cell lymphocytosis (Supplementary Figure 1A). The primary 
study endpoint was the in vivo immunological response induced in high-risk UM 
patients vaccinated with mRNA-transfected DC. The secondary study endpoints were 
disease-free survival (DFS), OS, and toxicity. ClinicalTrials.gov registration number is 
NCT00929019.
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Treatment schedule
All patients were vaccinated with autologous DC loaded with tumor-associated 
antigens of gp100 and tyrosinase according to a schedule of 3 biweekly intradermal/
intravenous (i.d./i.v.) vaccinations. One to two weeks after the last vaccination a skin 
test was performed, from which biopsies were taken 2 days later for T cell analysis 
(Supplementary Figure 1B). In the absence of disease recurrence, patients received 
a maximum of two maintenance cycles at 6-month intervals. Adverse events were 
graded according to the National Cancer Institute Common Terminology Criteria for 
Adverse Events version 3.0.
Patient accrual
The Rotterdam Ocular Melanoma Study-group, based at the Rotterdam Eye Hospital and 
the Erasmus Medical Center, is a regional and national reference center for UM patients 
with on average 30 patients with medium to large sized melanoma being treated each 
year. Independent of HLA phenotype, approximately 50% of the population has loss 
of chromosome 3, making them high-risk UM patients. We expected to recruit 7-8 
patients per year for inclusion in each group, with in total 30 patients per arm in 4 years. 
Supplementary Figure 1. Flow chart + treatment schedule. (A) Consort flow chart. (B) Schematic treatment 
schedule. Patients were vaccinated with autologous dendritic cells according to a schedule of 3 biweekly 
intradermal/intravenous (i.d./i.v.) vaccinations. One to two weeks after the last vaccination a skin test was 
performed, from which biopsies were taken 2 days later for T cell analysis. In absence of disease recurrence, 
patients received a maximum of two maintenance cycles at 6-month intervals.
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Unfortunately, the accrual rate was much lower than anticipated, despite collaboration 
with the Moorfields Eye hospital, and the trial was discontinued after 23 evaluable 
patients were included in the DC vaccinated group over a period of over 6 years (3-4 
patients per year). The low accrual rate was considered mainly due to the upper age 
limit and the introduction of eye-conserving treatments which necessitate a separate 
biopsy for testing of inclusion criteria (monosomy 3 and expression of tumor associated 
antigen) that was often refused by patients.
DNA extraction and copy number analysis
DNA was extracted directly from fresh tumor tissue or frozen sections using the QIAmp 
DNA-mini kit (Qiagen) according to the manufacturers’ instructions. The tumors 
were processed for fluorescence in situ hybridization (FISH) and single nucleotide 
polymorphism (SNP) array analysis (Illumina HumanCytoSNP-12 v2.1 BeadChip and 
Illumina HC850 BeadChip, Illumina), as described previously.27, 28 
Dendritic cell vaccine
Monocytes were enriched from leukapheresis products by counterflow centrifugation 
using Elutra-cell separator (Gambro BCT Inc.) and single-use, functionally sealed 
disposable Elutra sets, according to the manufacturer, or by plastic adherence of 
peripheral blood mononuclear cells (PBMC) after density gradient centrifugation. 
Monocytes were cultured in the presence of interleukin (IL)-4 (500 U/mL), granulocyte-
macrophage colony-stimulating factor (800 U/mL) (both Cellgenix) and control antigen 
keyhole limpet hemocyanin (KLH; 10 μg/mL; Calbiochem). DC were matured with a 
cytokine cocktail consisting of tumor necrosis factor α (10 ng/mL), IL-1β (5 ng/mL), 
IL-6 (15 ng/mL) (all Cellgenix) and prostaglandin E2 (10 μg/mL; Pharmacia & Upjohn) 
for 48 hours as described previously.20 Mature DC were electroporated with mRNA 
encoding gp100 or tyrosinase as described previously 29 and cells were resuspended 
in 0.1 mL for injection.
Flow cytometry
Flow cytometry was used to characterize the phenotype of the ex vivo generated DC 
and immune-cell subpopulations in the peripheral blood. The following monoclonal 
antibodies or appropriate isotype controls were used: anti-HLA ABC-PE, anti-HLA DR-PE, 
anti-CD80-PE, anti-CD83-PE, anti-CD86-PE, anti-CD3-PE, anti-CD25-PE, anti-CD95-PE 
(all BD Biosciences), anti-CD14-PE (Sanquin), anti-HLA-DQ-PE, anti-CD20-PE (both 
Biolegend), and anti-CCR7-PE (Miltenyi Biotec). For intracellular staining, NKI/beteb 
(IgG2b; purified antibody) against gp100 and T311 (IgG2a; Cell Marque Corp.) against 
tyrosinase were used. Flow cytometry was done with FACSCalibur flow cytometer 
equipped with CellQuest software (BD Biosciences).
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KLH-specific proliferation
To measure T cell responses against the control antigen KLH before and after vaccination, 
PBMC were isolated from heparinized blood by Ficoll-Paque density centrifugation and 
stimulated with KLH (4 µg/2 x 105 PBMC) in X-VIVO with 2% human serum. After 3 days, 
cells were pulsed with 3H-thymidine for 8 hours; incorporation was measured with a 
ß-counter. Experiments were carried out in triplicate; nonspecific proliferation upon 
stimulation with ovalbumin was used as control.
Analyses of skin test-infiltrating lymphocytes for tumor recognition
To assess the immune response against tumor peptides generated in vaccinated patients, 
delayed-type hypersensitivity (DTH) challenges were performed with mature DC loaded 
with gp100 or tyrosinase.18, 30 Briefly, DC electroporated with mRNA encoding either gp100 
or tyrosinase were injected intradermally in the skin of the back of the patient at different 
sites. After 48 hours, the maximum diameter of induration was measured by palpation 
and punch biopsies (6 mm) were taken. Half of the biopsy was manually cut and cultured 
as described.30 After 2 to 4 weeks of culturing, skin test-infiltrating lymphocytes (SKIL) 
were stained with tetrameric-MHC complexes described previously.30 The ability of SKIL 
to recognize vaccine-specific antigens was determined by the production of cytokines 
of SKIL in response to T2 pulsed with the indicated peptides or BLM (a melanoma cell 
line expressing HLA-A*02:01 but no endogenous expression of gp100 and tyrosinase), 
transfected with control antigen G250, with gp100 or tyrosinase, or an allogeneic HLA-
A*02:01-positive, gp100-positive and tyrosinase-positive tumor cell line (MEL624).18
Tetramer staining
To determine the presence of tumor-associated antigen-specific T cells, SKIL cultures 
and PBMC were analyzed and stained with tetrameric-MHC complexes containing the 
MHC class I epitopes gp100:154–168, gp100:280–288, or tyrosinase:369–377 (Sanquin) 
as described previously.30 Tetrameric MHC complexes recognizing HIV were used as 
correction for background binding. Tetramer positivity was defined as at least 2-fold 
increase in the double-positive population.
Statistical analysis
Statistical significance of baseline characteristics was evaluated using chi-square tests. 
DFS and OS  were calculated from the date of start of treatment of the primary UM to 
the first documented distant metastasis or death. Patients in which the event did not 
occur during the follow-up period were censored at the time of last follow-up. The 
Kaplan-Meier method was used to obtain estimates of median survival times and to 
generate survival curves. IBM SPSS Statistics (SPSS version 20.0) software (SPSS Inc.) 
was used for statistical analysis. Statistical significance was defined as p<0.05.
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Results
Patient characteristics
Twenty-three HLA-A*02:01-positive high-risk UM patients received adjuvant DC 
vaccination after local treatment of the primary tumor. Baseline characteristics are 
shown in Table 1. Seventeen patients were treated with primary enucleation of the eye, 
one patient was treated with primary enucleation and additional orbital radiotherapy 
for extrascleral extension, one patient was treated with plaque brachytherapy, and 
4 patients were treated with radiotherapy as single treatment of which one patient 
received secondary thermotherapy and two patients had a secondary enucleation due 
to growth of the primary tumor. The median largest tumor diameter of the primary 
tumor was 14 mm (range 7-23 mm) and the median largest thickness was 7 mm (range 
2-12 mm). The median time from the treatment of the primary tumor to the start of 
DC vaccination (apheresis) was 5.6 months.
Fourteen HLA-A*02:01-negative and 27 HLA-A*02:01-positive patients with high-risk 
UM served as control groups.  In general, patient populations were comparable in terms 
of the major factors determining prognoses in UM such as age and tumor size, only 
less ciliary body involvement was present in the HLA-A*02:01-positive control group 
(Table 1). 
Cytogenetic results
All UM were analysed for chromosomal changes by SNP arrays and/or FISH analyses and 
classified as high-risk UM based on loss of chromosome 3. One control patient showed 
partial 3q loss but was considered as a high-risk UM patient and included in the trial 
as the BAP1 gene, a tumor-suppressor gene on chromosome 3, was deleted.28 Besides 
analyses of chromosome 3, patients were tested for the non-random chromosomal 
abnormalities frequently associated with UM in chromosome 1, chromosome 6 and 
chromosome 8. Clonal chromosomal abnormalities, beside monosomy 3, were present 
in all 18 patients tested (100%). In the DC vaccinated patients, loss of 1p was present 
in 5 of 15 tumors tested (33%) and gain of 6p was present in 4 of 15 tumors tested 
(27%). Of both chromosomal rearrangements the effect on clinical outcome is not 
clearly established.25, 31 Although the groups are too small for definite conclusion, in 
DC vaccinated patients loss of 1p and gain of 6p was associated with worse DFS and OS 
(Supplementary Figure 2A, B, D,E). Gain of chromosome 8q is known to be associated 
with poor clinical outcome when present in combination with loss of chromosome 3.25, 
31 In DC vaccinated patients, 16 of 18 tumors tested showed gain of 8q (89%); the 2 
patients without chromosome 8q abnormalities showed better survival (Supplementary 
Figure 2C, F).
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In the control group, also all 12 patients tested (100%) showed clonal chromosomal 
abnormalities besides monosomy 3. No statistical differences were seen in the presence 
of additional chromosomal rearrangements between de DC vaccinated patients and 
the control group.
Dendritic cell vaccination
DC vaccination consisted of a maximum of 3 cycles of 3 biweekly vaccinations. 
Twenty-three patients received at least one cycle and were considered evaluable; 19 
patients received a second cycle of vaccinations, 18 patients completed all 3 cycles 
of vaccinations. Four patients did not receive a second cycle and one patient did not 
receive a third cycle due to development of distant metastases before the next cycle 
(Supplementary Figure 1). After maturation, DC highly expressed MHC class I and II 
and co-stimulatory molecules (Figure 1A). Intracellular protein expression of tumor-
associated antigens gp100 and tyrosinase after electroporation was variable, but 
for each patient protein expression of either gp100 or tyrosinase was at least 20% 
(Figure 1B).
Supplementary Figure 2. Chromosomal abnormalities and their effect on survival. Kaplan-Meier curves 
of disease-free (upper figures) and overall survival (lower figures) for high-risk uveal melanoma patients 
treated with adjuvant dendritic cell vaccination in relation to chromosome 1p loss (A, D), chromosome 
6p gain (B, E), and chromosome 8q gain (C, F). Statistical significance was determined by a log rank test.
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Immunological responses
To test the capacity of the patients in this study to generate an immune response upon 
vaccination, DC were loaded with KLH, a control antigen. All patients tested showed a 
cellular response to KLH in the first cycle, indicating that the vaccine induced de novo 
immune responses. To study tumor antigen-specific T cell responses, DTH skin tests 
were performed. The medium maximum induration of the DTH sites was 10 mm (range, 
0-20 mm), with no significant differences between the different sites, challenged with 
either gp100 or tyrosinase. 
Previously, we showed that the presence of tumor antigen-specific T cells in cultures 
of SKIL positively correlated with clinical outcome in metastatic cutaneous melanoma 
patients.18, 30 To investigate if tumor antigen-specific immune responses were induced by 
DC vaccination in UM patients, tetramer staining to detect T cells recognizing tyrosinase 
or gp100 epitopes in peripheral blood or SKIL were performed after each vaccination 
cycle, and functional antigen-recognition by SKIL was determined by cytokine production 
upon co-culture with cells presenting gp100 or tyrosinase-derived peptides. After DC 
vaccination, tetramer-positive CD8+ T cells were detected in peripheral blood of 3 of 22 
patients tested (14%). Tumor antigen-specific T cells in the DTH skin tests, either detected 
by tetramer-staining or by cytokine production, were present in 17 patients (74%), of 
which 13 patients where positive after the first cycle of vaccinations (57%; Table 1).
Toxicity
DC vaccinations were well tolerated. The most common side effects that are associated 
with DC vaccination are transient flu-like symptoms, including fatigue and fever, and 
erythema at the site of injection. All but one patient (96%) receiving DC vaccinations 
Figure 1. Dendritic cell (DC) vaccine characteristics. (A) Expression of HLA-ABC, HLA-DR/DP, HLA-DQ, 
CD14, CD25, CD80, CD83, CD86, CD95 and CCR7 was measured by flow cytometry on DC of all patients. (B) 
Tumor antigen expression of gp100 and tyrosinase by DC after loading. Data are shown as percentage of 
positive DC of the first DC vaccine of each patient.
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experienced one or more mild adverse events; 61% of patients experienced grade 1 
and 30% grade 2 flu-like symptoms and 78% of patients experienced grade 1 and 9% 
grade 2 injection site reactions (Table 2). Vitiligo occurred in one patient. No treatment 
related grade 3 or 4 toxicity was observed. 
Disease-free survival
Up to April 2016, 9 patients (39%) are free of melanoma relapse and 14 patients (61%) 
developed metastatic disease after DC vaccination. The median DFS was 34.5 months 
(95%CI, 27.2-41.8 months), with a 3-year DFS rate of 47%. In patients with a tumor 
antigen-specific T cell response after DC vaccination (n=17) DFS was longer than in 
patients in whom we could not detect a tumor antigen-specific T cell response (n=6); 
the median DFS were 51.9 and 18.8 months, respectively (Figure 2A). No significant 
difference in DFS of the DC vaccinated patients compared to controls could be found 
(Figure 2C). 
Overall survival
Thus far, 12 patients (52%) have died of metastatic melanoma and 11 patients (48%) 
are still alive, of which 2 patients (9%) have metastatic disease. Treatment in patients 
with disease recurrence consisted of various local treatments, including radiofrequency 
ablation, radioembolisation, surgery and local chemotherapy, and systemic treatment, 
mainly consisting of anti-CTLA-4 antibodies (Table 2). In line with literature14, only one 
of the patients showed a response to anti-CTLA-4 blockade (1 year). The median OS 
Table 2. Toxicity and subsequent treatment.
DC vaccinated 
patients n=23 %
HLA-A2 negative 
controls n=14 %
Toxicity
Flu-like symptoms (gr. 1/2) 21 (14/7) 91% n.a. n.a.
Injection site reaction (gr. 1/2) 20 (18/2) 87% n.a. n.a.
Subsequent treatment in patients with 
advanced disease
n=14 n=6
Local treatment of liver metastasis* 9 64% 4 67%
Chemotherapy 4 29% 1 17%
Immunotherapy 4 29% 0 0%
Targeted therapy 1 7% 3 50%
No systemic treatment 5 36% 3 50%
Abbreviations: n.a., not applicable.
* Local treatment of liver metastasis includes all treatments confined to the liver: surgery, local 
chemotherapy, radiofrequency ablation, and radioembolization.
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after DC vaccination was 51.8 months (95%CI, 42.1-62.7 months), with a 3-year OS 
rate of 79%. The median OS was 45.0 months for patients without detectable tumor 
antigen-specific T cells and 58.0 months for patients in whom tumor antigen-specific 
T cells were found (Figure 2B). The 3-year OS rate was higher (87%) in patients with 
functional tumor antigen-specific T cells compared to DC vaccinated patients without 
functional tumor antigen-specific T cells (60%). 
The 3-year OS rate in the HLA-A*02:01-negative control group (Co1) was 100% and 
59% in the historical HLA-A*02:01-positive control group (Co2). The OS of the total 
DC vaccinated patients was comparable to the control groups. However, OS is longer 
in patients that showed tumor antigen-specific T cells after vaccination compared to 
controls, and shorter in patients without tumor antigen-specific immune response 
compared to controls (Figure 2D). 
Figure 2. Survival in correlation with tumor antigen-specific T cells after dendritic cell vaccination. (A, 
B) Kaplan-Meier curve of disease-free survival (A) and overall survival (B) for patients with high-risk uveal 
melanoma who received adjuvant dendritic cell (DC) vaccination after treatment of the primary tumor 
according to the presence (Tc+; solid black line) or absence (Tc-; dashed grey line) of functional tumor 
antigen-specific T cells in skin-test infiltrating lymphocytes. Kaplan-Meier curve of disease-free survival 
(C) and overall survival (D) of high-risk UM patients receiving DC vaccination, split based on the presence 
(Tc+; solid black line) or absence (Tc-; solid grey line) of functional tumor antigen-specific T cells, the HLA-
A*02:01-negative control patients (Co1; dashed black line), and the historical HLA-A*02:01-positive control 
patients (Co2; dashed grey line). Statistical significance was determined by a log rank test.
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Discussion
The treatment of metastatic cutaneous melanoma is rapidly evolving with the 
introduction of various targeted therapies and immune checkpoint inhibitors.32 Due to 
its rarity, limited interventional studies are performed in UM, resulting in little progress 
in the treatment of metastatic UM and slowly maturing data on the efficacy of the 
immune checkpoint inhibitors in UM. 
The limited effect of anti-CTLA-4 antibodies in metastatic UM compared to 
metastatic cutaneous melanoma14 and the development of UM at an immune-privileged 
site, the eye, makes it questionable if immunotherapy is a suitable treatment modality 
in UM. However, immune cells have been demonstrated within UM, including DC and T 
cells.33, 34 Furthermore, accumulating evidence shows that UM tumor cells can be lysed 
by CD8+ T cells in vitro 35 and in a mouse model,36 indicating the susceptibility of UM 
for immunotherapy, substantiating the rationale for this trial.
Previously, we have shown that DC vaccination is feasible and safe in metastatic 
UM21 and may have a more pronounced effect in the adjuvant setting. Therefore, we 
performed this study with DC vaccination in the adjuvant setting in patients with a 
primary UM with monosomy 3, thus patients at high risk for recurrent disease. The 
primary endpoint of this study was the immunological response upon DC vaccination. 
We showed that the DC vaccines were very potent in the induction of de novo immune 
responses, as all tested patients showed a response against the control antigen KLH 
after the first cycle of DC vaccinations, demonstrating the effectiveness of these type of 
vaccines. Tumor antigen-specific CD8+ T cells were detected in 74% of the DC vaccinated 
patients in antigen-challenged skin sites. Our previous findings in metastatic UM 
patients clearly showed a lower tumor antigen-specific immunologic response rate, as 
only 29% of metastatic UM patients showed tumor antigen-specific CD8+ T cells in blood 
or skin test after DC vaccination. This difference may partially be explained by the higher 
chance of finding tumor antigen-specific CD8+ T cells in multiple DTH skin tests, as most 
patients in this study received three cycles of vaccinations compared to a median of one 
cycle of vaccinations in the metastatic setting. However, the immunologic response rate 
of the first skin test only was 57% in high-risk UM patients; still approximately double the 
rate compared to metastatic UM patients. The rates observed in cutaneous melanoma 
patients were similar; 71% of patients with regional metastasis and 32% of patients 
with distant metastasis of cutaneous melanoma showed tumor antigen-specific CD8+ 
T cells after DC vaccination.18, 23 Therefore, the hypothesis that DC vaccination might be 
more potent in the adjuvant setting, is further supported by this study. Furthermore, in 
our study patients with tumor antigen-specific T cells after vaccination clearly showed 
better survival than patients in which no tumor antigen-specific immune response 
could be detected. 
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A survival benefit for all DC vaccinated patients in comparison to the HLA-A*02:01-
negative control patients could not be found. Unexpectedly, the HLA-A*02:01-negative 
controls included in this trial show extremely long survival compared to what is 
predicted based on monosomy 3 presence,24, 25 which cannot be explained by the 
eligibility criteria of this trial. In theory, HLA-type could be a confounding factor. As 
shown in Figure 2D, the HLA-A*02:01-negative controls survived significantly longer 
than the HLA-A*02:01-positive controls. However, HLA-A*02:01 phenotype has shown 
no correlation with survival in a large cohort of UM patients.37 The small groups, in 
particular in the HLA-A*02:01-negative control group, might have caused the lack of 
significant survival benefit and longer follow-up might be needed. The small control 
group is probably not explained based on the HLA-A*02:01-status of tested patients, 
as approximately 30% of the Caucasian population has a HLA-A*02:01 phenotype 
(http://www.allelefrequencies.net). However, in some referring centres, patients were 
first tested for HLA-A*02:01 phenotype, and if patients were HLA-A*02:01-negative, 
monosomy 3 was not tested, and patients were not referred for the control arm of the 
study. Therefore, a HLA-A*02:01-positive historical cohort was added to the analyses. 
Furthermore, due to low accrual rates, mainly caused by the rarity of the tumor, older 
age at diagnosis, and the increase of eye-conserving treatments interfering with the 
availability of tumor material for genetic testing, the trial was stopped prematurely 
and both groups did not contain the planned number of 30 patients. Finally, a lack of 
survival benefit compared to controls might suggest that DC vaccination does not have 
a positive effect on survival in high-risk UM patients. However, the clear correlation 
of survival with the immunologic response after DC vaccination, and the clear survival 
benefit of patients with a detectable tumor antigen-specific immune response against 
similar HLA-A*02:01-positive controls, tend to support a more positive effect of DC 
vaccination on survival. Moreover, and taking the restrictions of comparison results 
of small studies like this one with historical data into account, the 3-year OS rate of 
the DC vaccinated patients (79%) compared well to literature (approximately 60%).24, 
25 Of course, a randomized trial is needed to provide a definitive conclusion on the 
effect of DC vaccination in high-risk UM patients. Such a trial with a DC vaccine loaded 
with tumor mRNA recently opened elsewhere (NCT01983748). Compared to our DC 
vaccine loaded with mRNA of gp100 and tyrosinase, the advantage of loading DC with 
autologous tumor mRNA is that patient-specific mutated tumor antigens are included 
in the vaccine. Possible obstacles when using tumor mRNA are the availability of 
sufficient tumor material and potential presentation of self-antigens and induction of 
autoimmunity. Although results of this trial are not expected before 2020, it will be 
interesting to learn if the results confirm the findings of our current trial.
In conclusion, adjuvant treatment with DC vaccination in high-risk UM patients is 
safe and correlates with favorable OS in patients with a detectable tumor antigen-
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specific immune response after DC vaccination. Further evidence for the clinical efficacy 
of DC vaccination should be obtained from prospective randomized clinical trials.
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Abstract
Melanoma patients with regional metastatic disease are at high risk for recurrence and 
metastatic disease, despite radical lymph node dissection (RLND). We investigated the 
immunologic response and clinical outcome to adjuvant dendritic cell (DC) vaccination 
in melanoma patients with regional metastatic disease who underwent RLND with 
curative intent. In this retrospective study, 78 melanoma patients with regional lymph 
node metastasis who underwent RLND received autologous DC loaded with gp100 
and tyrosinase and were analyzed for functional tumor-specific T cell responses in 
skin-test infiltrating lymphocytes. The study shows that adjuvant DC vaccination in 
melanoma patients with regional lymph node metastasis is safe and induced functional 
tumor-specific T cell responses in 71% of the patients. The presence of functional 
tumor-specific T cells was correlated with a better 2-year overall survival (OS) rate. 
OS was significantly higher after adjuvant DC vaccination compared to 209 matched 
controls who underwent RLND without adjuvant DC vaccination, 63.6 months vs. 31.0 
months (p=0.018; hazard ratio 0.59; 95%CI 0.42-0.84). Five-year survival rate increased 
from 38% to 53% (p<0.01). In summary, in melanoma patients with regional metastatic 
disease, who are at high risk for recurrence and metastatic disease after RLND, 
adjuvant DC vaccination is well tolerated. It induced functional tumor-specific immune 
responses in the majority of patients and these were related to clinical outcome. OS 
was significantly higher compared to matched controls. A randomized clinical trial is 
needed to prospectively validate the efficacy of DC vaccination in the adjuvant setting.
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Introduction
The incidence of cutaneous melanoma continues to rise worldwide.1,2 Adequate 
surgical resection remains the standard of care for patients with non-systemic disease. 
However, approximately 15-20% of patients with cutaneous melanoma will develop 
regional (lymph node) metastasis.3 The likelihood of the primary cutaneous melanoma 
to metastasize mainly depends on thickness, presence of ulceration, and mitotic rate.4,5 
If patients have a positive sentinel node or develop palpable lymph node metastasis, 
RLND is potentially curative, although the survival is poor.6 The 5-year survival rate 
ranges between 27% and 69%, depending on the size and number of involved nodes 
and characteristics of the primary melanoma.7 In case of metastatic melanoma the 
prognosis is poor, despite recent therapeutic developments such as targeted therapies 
and immune checkpoint inhibitors and their positive impact on OS.8-11 This has initiated 
numerous trials over the last few decades in search of an effective adjuvant treatment 
in early stage high-risk melanoma (stage IIB, IIC, and III). Adjuvant radiotherapy after 
RLND can be considered for patients with extranodal extension, incomplete surgery 
or numerous positive lymph nodes to improve regional control, however, without any 
recurrence-free survival (RFS) or OS benefit.3,12
Since melanoma is considered one of the most immunogenic types of cancer, 
different immunomodulatory approaches have been tested in melanoma, however 
mostly without showing any therapeutic effect.13 IFN-α is the only approved adjuvant 
therapy based on significant improvement of RFS shown in phase III trials.14 Nonetheless, 
adjuvant IFN-α is not offered universally because of substantial toxicity and only minimal 
OS benefit, at best 3% shown in meta-analyses.15 Recently, anti-CTLA-4 antibodies in 
the adjuvant setting showed improvement on RFS compared to placebo, although with 
substantial toxicity.16 Data on OS are awaited.
Specific stimulation of the immune system with the use of vaccines aims to induce 
melanoma-specific responses and avoids the toxicity associated with the enhanced 
activity across multiple subsets of effector cells, as seen with cytokines and immune 
checkpoint inhibitors. Thus far trials with various vaccines illustrated the potential of 
vaccination strategies as they showed the ability of inducing tumor-specific immune 
responses, however, without consistent improvement in OS.17-19 
DC, the most effective antigen-presenting cells of the immune system, are exploited 
to induce melanoma-specific cytotoxic T cells in melanoma patients. Immature DC are 
very effective in antigen uptake and when stimulated by inflammatory mediators and 
‘danger signals’ they mature and migrate from peripheral tissues to lymphoid organs. 
Here the DC are able to activate the specific immune system.20-22 Since 1996, there have 
been several clinical studies investigating tumor antigen-loaded DC-based vaccines, 
mainly in metastatic melanoma patients.23,24 Over the years, many parameters in DC 
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vaccination have been optimized in clinical studies.25 Furthermore, DC vaccination has 
only minimal side effects and thus provides a well-tolerable treatment.
In this study, we retrospectively analyzed the safety and survival of melanoma 
patients with regional metastatic disease who underwent a RLND and received adjuvant 
DC vaccination.
Patients and Methods
Patient characteristics
We retrospectively analyzed a cohort of 78 melanoma patients with histologically 
proven regional metastasis without evidence of distant metastasis, who were enrolled 
in our DC vaccination studies between December 1999 and February 2009. Patients 
received adjuvant DC vaccination within 2 months from RLND. WHO performance status 
was 0 or 1. Additional inclusion criteria include HLA-A*02:01 phenotype and melanoma 
expressing the melanoma-associated antigens gp100 (compulsory) and tyrosinase (non-
compulsory). Patients with serious concomitant disease or a recent history of second 
malignancy were excluded. The studies were approved by the appropriate Medical 
Ethical Review Board and written informed consent was obtained from all patients. 
Treatment schedule
All patients were vaccinated with cytokine-matured monocyte-derived autologous DC 
loaded with tumor-associated antigens of gp100 and tyrosinase according to a schedule 
of three biweekly vaccinations. In absence of disease recurrence, patients received a 
maximum of two maintenance cycles at 6-month intervals. Differences in protocols 
included the route of administration, method of antigen loading and combined 
treatment with low-dose IL-2 (Table 1). Patients received a maximum of 10 x 106 DC 
intradermal, 15 x 106 intranodal or 20 x 106 intravenous per vaccination. For the exact 
details regarding the vaccination protocols we refer to these individual studies.26-29
Dendritic cell vaccine
Monocytes were enriched from leukapheresis products by plastic adherence of 
peripheral blood mononuclear cells or by counterflow centrifugation using Elutra-
cell separator (Gambro BCT) and single-use, functionally sealed disposable Elutra 
sets, as described before.30 Monocytes were cultured in the presence of IL-4 (500 U/
mL), GM-CSF (800 U/mL; both Cellgenix) and KLH (10 μg/mL; Calbiochem). DC were 
matured with autologous monocyte-conditioned medium (30%, v/v) supplemented 
with prostaglandin E2 (10 μg/mL; Pharmacia & Upjohn) and 10 ng/mL TNF-α (Cellgenix) 
for 48 h.31 This procedure gave rise to mature DC meeting the release criteria.24 DC 
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were pulsed with 2 gp100-derived peptides and a tyrosinase-derived peptide or 
electroporated with mRNA encoding full-length gp100 or tyrosinase protein.32-34 These 
melanoma-associated tumor-antigens were selected as they are widely expressed on 
primary melanoma and melanoma metastasis and have shown to induce functional 
cytotoxic T cells.32,35 Cells were resuspended in 0.1 mL for injection.36 
Skin-test infiltrating lymphocyte analyses
Skin tests were performed within two weeks after each vaccination cycle as described 
previously.37,38 Briefly, DC loaded with either gp100, tyrosinase or both epitopes were 
injected intradermally in the skin of the back of the patient. After 48 h, punch biopsies 
(6 mm) were taken. Half of the biopsy was manually cut and cultured in RPMI-1640 
containing 7% human serum and IL-2 (100 U/mL). After 2-4 weeks of culturing, skin-test 
infiltrating lymphocytes were stained with tetrameric-MHC complexes containing the 
gp100 or tyrosinase epitopes and functionality was tested. Functional tumor-specific 
Table 1. Dendritic cell vaccination protocols and toxicity.
Protocol 
No of 
patients 
Method of 
antigen loading 
Route of 
administration IL-2a 
Vaccination 
prior to 
RLND
Flu-like 
symptoms 
(gr 0/1/2)
Injection site 
reaction 
(gr 0/1/2)
1 1 Class I modb i.v./i.d. no no 0/1/0 1/0/0
2A 11 Class I wtc i.d. yes yes 0/8/3f 1/7/3f
2B 10 Class I wtc i.n. yes yes 2/5/3 7/2/1
2C 10 Class I wtc i.n. no yes 4/3/3 5/4/1
2D 11 Class I wtc i.d. no yes 4/7/0 1/9/1
2E 10 mRNAd i.n. no yes 2/4/4 3/7/0
4A 6 Class I wtc + IIe i.n. no no 2/1/3 4/0/2
4B 3 Class I wtc i.n. no no 1/2/0 0/3/0
4C+D 16 mRNAd i.n. no no 5/7/4 5/11/0
Total 78 
Abbreviations: wt, wild type; mod, modified, i.d., intradermal,; i.n., intranodal; i.v., intravenous; IL-2, 
Interleukin-2; RLND, radical lymph node dissection.
a Low-dose IL-2 (9 MIU) was administered subcutaneously once daily for 1 week starting 3 d after each 
vaccination.
b Class I mod; HLA class I-restricted modified gp100-derived peptides 154-162 Q→A and 280-288 A→V 
and HLA class I-restricted tyrosinase-derived peptide 369-377.
c Class I wt; HLA class I-restricted wild-type gp100-derived peptides 154-162 and 280-288 and HLA class 
I-restricted tyrosinase-derived peptide 369-377 
d mRNA; messenger RNA encoding full length gp100 and tyrosinase.
e Class II; HLA class II-restricted gp100-derived peptide 44-59 and tyrosinase-derived peptide 448-462 analog.
f Possibly IL-2 related.
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T cells were defined by binding of tetrameric-MHC complexes for at least one of the 
epitopes and either the production of cytokines or cytotoxic activity in response to 
tumor antigen stimulation. 
Matched controls
Matched controls were obtained from a database from the Erasmus MC Cancer 
Institute, an academic hospital comparable to Radboudumc were patients were not 
included in DC vaccination trials. This database consists of 563 melanoma patients who 
had undergone RLND between 1982 and 2010. Preoperative imaging and follow-up 
was performed according to the Dutch national guidelines. Controls were matched to 
study patients on the basis of N substage according to AJCC criteria and on timeframe 
(1992-2009). If more than 3 matches were found in the database for one study object, 
age and sex were used to select the closest matches.
Statistical analysis
OS was calculated from the date of RLND to death using the Kaplan-Meier method and 
compared using the log-rank test. Statistical significance of baseline characteristics 
was evaluated using chi-square tests. The univariate analysis was performed by the 
Cox proportional hazards model. Multivariate survival analysis was carried out using 
the Cox proportional hazards model with stepwise elimination of significant univariate 
parameters with forward and backward stepwise methods. Ulceration was assumed 
absent if not reported in the pathology report. P values less than 0.05 were considered 
significant. SPSS version 20.0 software (SPSS Inc.) was used for statistical analysis.
Results
Characteristics of the study population
Seventy-eight melanoma patients received adjuvant DC vaccination and were matched 
with 209 control patients who had undergone RLND without adjuvant DC vaccination 
in the same time period. Baseline characteristics are summarized in Table 2. In general, 
patient populations were comparable in terms of the major factors determining 
prognoses in regionally spread melanoma such as N substage, thickness and ulceration 
of the primary tumor, sex and age.4,39 However, matching did not prevent significant 
differences between the sites of RLND. After RLND, 8 patients (3.8%) in the control 
population received adjuvant radiotherapy and 15 patients (7.6%) received adjuvant 
IFN-α (in trials), while none of the patients treated with DC vaccination received 
additional adjuvant therapy. In patients who developed distant metastasis during 
follow-up, less control patients received systemic therapy (Table 3). Systemic therapy 
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Table 2. Baseline characteristics of dendritic cell vaccinated patients and controls.
DC group 
n=78              (%)
Control group
n=209            (%) p value
Sex 0.927
Male 46 (59.0) 122 (58.4)
Female 32 (41.0) 87 (41.6)
Age, years
Mean (range) 51.0 (22-79) 52.7 (18-80)
Age in 4 categories, years 0.402
≤40 20 (25.6) 49 (23.4)
41-50 18 (23.1) 41 (19.6)
51-60 25 (32.1) 58 (27.8)
≥61 15 (19.2) 61 (29.2)
Thickness of primary tumor, mm 0.603
</= 1.0 6 (7.7) 16 (7.7)
1.01 – 2.0 24 (30.8) 62 (29.7)
2.01 – 4.0 19 (24.4) 66 (31.6)
> 4.0 21 (26.9) 53 (25.4)
No primary/unknown 8 (10.3) 12 (5.7)
Ulceration of primary tumor 0.676
Absent 55 (70.5) 142 (67.9)
Present 23 (29.5) 67 (32.1)
N stage at inclusion 0.967
N1a 21 (26.9) 61 (29.2)
N1b 19 (24.4) 55 (26.3)
N2a 4 (5.1) 10 (4.8)
N2b 11 (14.1) 30 (14.4)
N3 23 (29.5) 53 (25.4)
Site radical lymph node dissection 0.009
Inguinal 34 (43.6) 98 (46.9)
Axilla 33 (42.3) 67 (32.1)
Head & neck 5 (6.4) 39 (18.7)
Unknown 6 (7.7) 5 (2.4)
mainly consisted of chemotherapy, whereas a small number of patients received other 
immunotherapy. The median follow-up in the entire study population was 39 months 
(range 1-165 months). In a few patients follow-up was extremely short, due to early 
death due to rapid progressive disease.
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Dendritic cell vaccination
DC vaccination consisted of a maximum of three cycles of three biweekly vaccinations. 
Two patients did not complete the first cycle of vaccinations due to rapid progressive 
disease. Another 13 patients did not receive a second cycle due to development of 
distant metastases within 6 months after RLND. The majority of patients, 54 out of 78, 
completed all three cycles of vaccinations. The two patients with rapid progressive 
disease both were screened for metastases before RLND. One patient had a chest X-ray 
but was later diagnosed with non-pulmonary metastases. The other patient had a CT of 
the chest and abdomen which showed one dubious lesion in the lungs, but developed 
multiple lung and liver metastases shortly after.
To determine the presence of functional tumor-specific T cells, tetramer staining 
for tyrosinase and gp100 epitopes were performed after each vaccination cycle on 
skin-test infiltrating lymphocytes and functionality was tested. Functional tumor-
specific T cells were detected in 55 out of 78 vaccinated patients (71%). The 2-year 
survival rate was significantly higher (82%) in patients with functional tumor-specific 
T cells compared to DC vaccinated patients without functional tumor-specific T cells 
(61%; p=0.04; Figure 1).
Table 3. Systemic therapy in patients with metastatic disease.
DC group 
n=47               (%)
Control group
n=143            (%) p value
Systemic therapy 0.016
None 23 (51.1) 87 (60.8)
Any 24 (48.9) 45 (31.5)
Unknown 0 (0) 11 (7.7)
Chemotherapy 0.007
Not received 24 (51.1) 96 (72.7)
Received 23 (48.9) 36 (27.3)
Immunotherapy 0.001
Not received 41 (87.2) 130 (98.5)
Received 6 (12.8) 2 (1.5)
     Of which ipilimumab 4 (8.5) 0 (0)
Targeted therapy 0.017
Not received 45 (95.7) 132 (100)
Received 2 (4.3) 0 (0)
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Toxicity
DC vaccinations were generally well tolerated. Forty-eight out of 57 patients (84%) 
receiving only DC vaccinations and 20 out of 21 patients (95%) receiving both DC 
vaccination and IL-2 suffered at least one mild adverse event (CTC grade 1 or 2; Table 1). 
The most common side effects that are associated with DC vaccination are transient 
flu-like symptoms, including fatigue and fever, and erythema at the site of injection. 
No treatment related grade 3 or 4 toxicity was observed. Treatment was discontinued 
in two patients at their own request due to vaccine-related grade 2 rash in the second 
cycle, both patients are still alive (94 and 115 months after RLND). 
Survival
Kaplan-Meier survival analysis demonstrates a significant difference in OS in favor 
of the DC vaccinated patients compared to matched controls (Figure 2). The median 
OS increased more than two-fold in patients who received adjuvant DC vaccination 
as compared with that of the matched controls, from 31.0 (95% CI 23.6-38.5) to 63.6 
Figure 1. Functional tumor-specific T cells correlate with clinical outcome in stage III melanoma patients. 
Kaplan-Meier curve of patients with regional metastasized melanoma who received adjuvant dendritic cell 
vaccination after radical lymph node dissection according to the presence or absence of functional tumor-
specific T cells in skin-test infiltrating lymphocytes. RLND, radical lymph node dissection.
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months (95% CI 24.5-102.7; p=0.018). The 1-, 2- and 5-years survival rates were 87%, 
76% and 53% for the DC vaccinated patients and 74%, 59% and 38% for the controls 
(p=0.018; p = 0.009; p=0.008, respectively). For the time to distant metastasis a trend 
was seen in favor of the DC vaccinated patients, with a median of 41.9 (95% CI 32.3-
51.4) vs. 24.3 months in the control group (95% CI 18.9-29.7; p=0.081; Figure 3).
Univariate and multivariate analyses on overall survival
Cox regression analysis was used to predict prognostic factors of OS in all patients. Four 
baseline characteristics were predictors of OS (p<0.05): age, ulceration, N substage 
and site of RLND. Furthermore, adjuvant DC vaccination was also a significant positive 
predictor of OS (Supplementary Table 1). To further investigate whether adjuvant 
DC vaccination is an independent prognostic factor for OS, the multivariate Cox 
proportional hazards model was applied to the significant variables of the univariate 
analysis. The multivariate analysis, in both forward and backward model, revealed that 
ulceration (HR 1.57; 95%CI 1.15-2.13; p=0.004; Wald 8.2), N substage (HR 1.23; 95%CI 
1.17-1.30; p<0.001; Wald 66.9), and adjuvant DC vaccination (HR 0.59; 95%CI 0.42-0.84; 
p=0.003; Wald 8.9) were independent predictors of OS.
Figure 2. Overall survival after radical lymph node dissection with or without adjuvant treatment with 
dendritic cell vaccination in melanoma patients with regional metastasis. Co, control group; DC, dendritic 
cell vaccinated patients; RLND, radical lymph node dissection. 
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Figure 3. Distant metastatic free survival after radical lymph node dissection with or without adjuvant 
treatment with dendritic cell vaccination in melanoma patients with regional metastasis. Co, control 
group; DC, dendritic cell vaccinated patients; RLND, radical lymph node dissection.
Discussion
Adjuvant treatment with DC vaccination in patients with regional metastasized 
melanoma, who are at high risk for recurrence of disease even after RLND, results in 
a significant benefit on OS compared to matched controls, with only minimal toxicity. 
This is the first study on a large cohort with sufficiently long follow-up to draw any 
conclusions on the clinical outcome in melanoma patients with regional metastasis 
treated with adjuvant DC vaccination. 
In distant metastatic melanoma patients we have shown that the presence of 
tumor-specific T cells is a positive predictive factor for OS and functionality correlates 
with survival.37,38 However, the presence of tumor-specific T cells after DC vaccination 
might also represent the patients with a more potent immune system and therefore 
longer survival regardless of treatment. In this study we demonstrate that in melanoma 
patients with regional metastasis the presence of functional tumor-specific T cells 
after adjuvant DC vaccination is also positively correlated with survival, which provides 
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Supplementary Table 1. Univariate analyses – Overall survival. (Continued)
n Median OS HR 95%CI p value
Sex
Male 168 33.6 1
Female 119 49.2 0.817 0.61 - 1.11 0.190
Age in 4 categories, years
≤40 69 54.6 1
41-50 59 32.1 1.508 0.96 - 2.37 0.074
51-60 83 48.3 1.138 0.74 - 1.74 0.551
≥61 76 28.8 1.656 1.09 - 2.52 0.018
Thickness of primary tumor, mm
</= 1.0 22 43.6 1
1.01 – 2.0 86 85.9 0.830 0.45 - 1.54 0.554
2.01 – 4.0 85 44.3 1.090 0.60 - 2.00 0.780
> 4.0 74 28.8 1.349 0.74 - 2.47 0.333
No primary/unknown 20 23.7 1.442 0.69 - 3.03 0.334
Ulceration of primary tumor
Absent 197 46.5 1
Present 90 28.4 1.425 1.05 - 1.93 0.023
N stage at inclusion
N1a 82 n.r. 1
N1b 74 39.2 2.697 1.69 - 4.31 <0.001
N2a 14 52.4 1.852 0.81 - 4.25 0.146
N2b 41 21.0 4.131 2.47 - 6.92 <0.001
N3 76 16.3 5.615 3.59 - 8.79 <0.001
Site of RLND
Axilla 100 40.3 1
Inguinal 132 49.2 0.922 0.66 - 1.29 0.636
Head & neck 44 23.7 1.579 1.04 - 2.41 0.034
Adjuvant radiotherapy
Not received 279 40.5 1
Received 8 12.3 1.708 0.76 - 3.86 0.198
Adjuvant DC vaccination
Not received 209 31.0 1
Received 78 63.6 0.662 0.47 - 0.93 0.018
Adjuvant IFN-α
Not received 260 43.4 1
Received 15 25.2 1.017 0.52 - 1.99 0.960
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Supplementary Table 1. Univariate analyses – Overall survival. (Continued)
n Median OS HR 95%CI p value
Systemic therapy
None received 110 18.2 1
Any received 69 26.0 0.752 0.55- 1.03 0.073
Chemotherapy
Not received 120 18.6 1
Received 59 26.2 0.767 0.56 - 1.06 0.107
Immunotherapy
Not received 160 20.8 1
Received 19 25.2 0.610 0.36 - 1.03 0.062
Abbreviations: n, number of patients; OS, overall survival; HR, hazard ratio; 95%CI, 95% confidence 
interval; mm, millimeter(s); RLND, radical lymph node dissection; n.r. not reached.
further evidence that activation of the immune system against melanoma cells by 
DC vaccination plays a pivotal role in its clinical efficacy. This is further substantiated 
by the finding that functional tumor-specific T cells are more frequently found in 
melanoma patients with regional metastasis (71%), in comparison to patients with 
distant metastasis (23%).37 This might partially be explained by that the patients with 
regional metastasis received more vaccinations and more DTH skin tests. Additionally, 
the greater efficacy of DC vaccination in the adjuvant setting, eradicating residual 
micrometastases if present, and higher frequencies of function tumor-specific T cells 
may also be caused by less tumor burden and therefore less tumor-mediated immune 
suppression compared to metastatic disease.40
Unfortunately, almost all clinical trials with DC vaccines are conducted in university 
hospitals that usually do not have the funds to run extensive randomized trials. As 
personalized cellular products are not commonly produced by pharmaceutical 
companies, randomized trials with DC vaccines are scarce. In the absence of a 
randomized study, this study used matched controls for survival analysis. To limit 
selection bias, we matched patients on N substage, which is the major prognostic 
factor in regionally spread melanoma.4,41 As DC vaccination was commenced within 2 
months after RLND and relapse within 2 months from surgery is rare, we believe this 
minimized the risk of selection bias. Furthermore, patients who did not complete their 
first cycle of vaccination were not excluded from the analyses. Comparison of baseline 
characteristics indicate that the controls used in this study were representative of 
the adjuvant treated patients. However, a small difference was present in the higher 
incidence of nodal metastasis in the cervical region in control patients. Since cervical 
metastasis may have longer disease-specific survival after RLND compared to patients 
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with axillae and groin metastasis,42 it is unlikely this would give a survival benefit for 
the DC vaccinated patients. Furthermore, in the multivariate analysis the site of RLND 
did not maintain a significant effect on OS. Adjuvant radiotherapy and IFN-α given to 
several patients in the control group did not show a statistically significant impact on 
OS in the univariate analysis. The absent or only minimal effect on OS is supported 
by literature.3,12,15
Potential time bias could occur due to the influence on OS of recent developments 
in the treatment of patients with distant metastases, mostly with the introduction of 
ipilimumab. A small difference was seen in treatment received in patients who developed 
metastatic disease during follow-up. This discrepancy may be caused by the duration 
of follow-up, which was longer in DC vaccinated patients, and the completeness of 
registration; numerous control patients returned to their local hospital after RLND 
for follow-up and data on further systemic treatment might not be accurately traced. 
Although referring hospitals were contacted to gather information, these data may be 
less robust. However, most patients who developed distant metastases did so before 
ipilimumab and BRAF inhibitors were widely used and only received dacarbazine or no 
systemic treatment at all. In addition, when the 4 ipilimumab-treated patients were 
excluded from the analyses, this had only little effect on the median OS (58.7 months) 
and remained statistically significant from matched controls (p=0.027). The larger 
difference in OS compared to distant metastatic free survival benefit of DC vaccination 
compared to controls, might also be partially explained by the less robust data from 
the controls as death is a more accurate to trace event than the development of distant 
metastases. Furthermore, in multiple studies with immunotherapy, both with DC 
vaccination as with immune checkpoint inhibitors, OS benefit is often more pronounced 
than the effect on progression-free survival. This widespread phenomenon might be 
explained by a treatment-induced slowing of tumor growth, without establishing an 
equilibrium in the tumor microenvironment, which is maintained after documented 
progression of disease. We believe that the findings of our study are important to 
both the research and clinical community, as with nowadays targeted therapies and 
checkpoint inhibitors, it will be difficult to analyze the effect of vaccination in itself 
without being obscured by perhaps many subsequent immune interventions.
Despite proper matching, the literature shows that historical controls generally have 
worse clinical outcome compared to randomized controls.43 For example, Canvaxin, a 
polyvalent vaccine, showed promising results in a phase II trial but failed to meet phase 
III trial endpoints. Still, our controls had a similar 5-year survival rate as a comparable 
group of melanoma patients after RLND reported in recent literature.44 
A randomized clinical trial with DC vaccination in the adjuvant setting is needed to 
prospectively validate the efficacy of DC-vaccines in the adjuvant treatment following 
RLND for melanoma. The introduction of adjuvant DC vaccination after RLND would 
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not interfere with the current standard of care, especially in Europe where IFN-α is 
not recommended. Recent data on the randomized trial with adjuvant ipilimumab are 
widely debated since the first results were shown.45 The effect on RFS is indisputable, 
but toxicity is high (42% grade 3/4 adverse events). Therefore, it is questionable if 
adjuvant ipilimumab will become the standard of care after RLND in patients with 
regional metastases. 
In conclusion, adjuvant treatment with DC vaccination after RLND in patients with 
regional metastases of melanoma is safe and results in a favorable OS compared to 
matched controls. Importantly, DC vaccination is well tolerated and clearly less toxic 
than adjuvant IFN-α or ipilimumab. These results suggest that DC vaccination has 
efficacy as adjuvant treatment of melanoma, and provide further support to test this 
in a prospective randomized clinical trial. 
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Abstract
Dendritic cell (DC) vaccination in cancer patients aims to induce or augment an effective 
antitumor immune response against tumor antigens and was first explored in a clinical 
trial in the 1990s. More than two decades later, numerous clinical trials have been 
performed or are ongoing with a wide variety of DC subsets, culture protocols, and 
treatment regimens. The safety of DC vaccination and its ability to induce antitumor 
responses have clearly been established; however, although scattered patients with 
long-term benefit were reported, DC vaccines have not yet fulfilled their promise, 
perhaps mainly due to the lack of large-scale well-conducted phase II/III trials. To 
allow meaningful multicenter phase III trials, the production of DC vaccines should be 
standardized between centers which is now becoming feasible. To improve the efficacy 
of DC-based immunotherapy, it could be combined with other treatments. 
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Introduction
DC are the most potent professional antigen-presenting cells of the immune system. In an 
immature state, they act as the sentinels of the immune system, continuously patrolling 
the environment in search of antigens. After antigen uptake, exogenous antigens are 
presented as antigenic peptides in MHC class II complexes on the cell surface and 
endogenous antigens are expressed in MHC class I. DC have the unique capability to 
present internalized antigens derived from exogenous sources, not only in MHC class II 
molecules, but also in MHC class I molecules, so-called cross-presentation. In this way, for 
example, tumor antigens can be presented to CD8+ T cells.1 In a mature state, DC migrate 
to the lymphoid organs, where they present the antigen to naive T cells. The activated T 
cells subsequently proliferate and leave the lymph nodes in search of and to kill cells in 
an antigen-dependent manner. 
DC comprise a heterogeneous population of cells. In human peripheral blood, two 
main populations of natural DC can be distinguished: myeloid DC (mDC) and plasmacytoid 
DC (pDC).2 Human mDC can be further subdivided into two populations, based on their 
differential surface expression of CD1c (BDCA-1) and CD141 (BDCA-3).3 The natural DC 
subtypes differ in function, localization, and phenotype.4,5 Both mDC and pDC express 
distinct Toll-like receptors (TLR) and respond differently to pathogenic stimuli, suggesting 
that each subset has a specialized function in directing immune responses.6 Because pDC 
produce high levels of type I IFNs in response to viral products, they play an important role in 
the detection and control of viral infections.7 Besides their antigen-presenting function, pDC 
also display tumoricidal activity, although to a lesser extent than natural killer (NK) cells.8 
mDC specialize in mediating immunity against fungi and bacteria.5,9 BDCA3+ mDC seem 
to specialize in detection and uptake of necrotic cells and subsequent cross-presentation 
of derived antigens to T cells.10 Recent observations suggest that both pDC and mDC are 
important for the induction of antitumor responses and may act synergistically.11 
DC vaccines
Malignant growth, in the beginning, is often a slow and silent process that either fails 
to elicit a “danger signal” necessary for the activation of the immune system, or tumor 
cells efficiently silence an initiated immune response to allow tumor growth. The goal 
of DC vaccines is to mend this inattention of the immune system by providing it with 
ex vivo “trained” DC, appropriately activated and loaded with tumor antigen, and thus 
capable of inducing strong antitumor T cell responses. 
With the recent introduction of immune checkpoint inhibitors to stimulate the 
immune response, the role of DC vaccination becomes more important because it induces 
tumor-specific T cells and directs the immune response toward antigens of interest. 
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As natural DC constitute only about 1% of peripheral blood mononuclear cells 
(PBMC), several ways to generate DC from precursors have been investigated for DC 
vaccination purposes. In 1994, the discovery that DC can be generated from monocytes 
or CD34+ progenitors, by culturing them in the presence of IL-4 and GM-CSF, allowed 
the procurement of DC in considerable numbers to facilitate clinical trials (Figure 1).12-15 
Although ex vivo-generated monocyte-derived DC share many phenotypic and 
functional characteristics with natural mDC, whether DC differentiated ex vivo from 
precursor cells are the optimal source of DC for DC-based immunotherapy remains 
unclear. The extensive culture period (7-9 days) of ex vivo-generated DC and compounds 
required to differentiate them into DC might negatively affect DC function, for example, 
by reducing proinflammatory cytokine production. Therefore, shorter culture protocols 
have been developed.16 Furthermore, natural DC do not require extensive culture, 
Figure 1. Ex vivo culture of DC. Natural DC or their precursor cells, either CD34+ progenitors or monocytes, 
can be obtained from the peripheral blood by apheresis. With different culture protocols immature DC can 
be obtained and matured. Subsequently, DC are loaded with tumor-associated antigens and administered 
to the patient. Refer to Box 1 for growth factors and maturation factors, and Box 2 for tumor antigens.
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and recently, it has been proven feasible to obtain more than 10 million pDC and 
even higher numbers of BDCA-1+ mDC after a single leukapheresis despite their low 
frequency in blood.17,18 Even BDCA-3+ mDC, constituting approximately 0.05% of the 
PBMC, can now be isolated from a leukapheresis, but this process has not been applied 
in clinical trials yet.
Recently, the first clinical trials with pDC and mDC have proven their safety and 
feasibility of this mode of treatment.17,18 Although these phase I studies in melanoma 
patients were primarily aimed at determining potential toxicity, the clinical results 
were promising, with a relatively larger number of patients surviving more than 2 
years after DC vaccination.17,19 In chapter 5 the results of the clinical trial with mDC 
in 14 metastatic melanoma patients are described. We were able to vaccinate with 
freshly isolate mDC with an average purity of 93%. Four out of 14 patients showed 
long-term progression-free survival (12-35 months), which directly correlated with 
the development of functional CD8+ T cell responses in 3 of these patients.19 A major 
advantage of these natural DC is their rapid isolation procedure with antibody-coated 
magnetic beads (CliniMACS Prodigy). This method is highly standardized and is being 
explored for application in multicenter trials. 
Safety
The safety of DC-based immunotherapy has been well documented in many phase I 
and II clinical trials. Side effects seen with the majority of DC vaccination protocols 
were minimal and self-limiting, mainly including flu-like symptoms, fever, and local 
reactions at the injection site. Grade 3 or 4 treatment-related toxicity is extremely 
uncommon when DC vaccination is given as monotherapy.20 These data are confirmed 
by the available data from phase III trials where DC vaccination is compared with 
placebo.21-25 Therefore, DC vaccination is considered safe and expected to preserve 
the quality of life in cancer patients. 
Maturation of DC
In the first clinical studies, immature or semimature monocyte-derived DC have 
been used.26 Later trials demonstrated superiority of mature DC over their immature 
counterparts in terms of the immunogenicity and clinical outcome.20,27-29 Besides their 
enhanced migratory capacity,30 mature DC also have a higher expression of MHC and 
costimulatory molecules. Together, these findings show the superiority of mature DC 
in antigen presentation and therefore in inducing T cell responses.28,31 Immature DC are 
potentially tolerogenic and might even promote antigen-specific tolerance when used 
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in DC vaccines.32 DC maturation is a complex process in which the outcome depends on 
the type of signals the DC receive. While these maturation signals primarily come from 
contact with pathogens or tissue injury in vivo,33 ex vivo maturation can be achieved 
by culturing DC with a variety of stimuli (Box 1). 
For example, in chapter 3 DC were electroporated with mRNA encoding 
CD40 ligand, CD70, and a constitutively active form of TLR4. The combination 
of CD40L and TLR4 mimics CD40 ligation and TLR4 signaling of the DC, whereas 
CD70 provides a co-stimulatory signal to naive T cells by inhibiting activated T cell 
apoptosis and by supporting T cell proliferation. Previous trials have shown that 
this maturation protocol leads to phenotypically mature and cytokine secreting DC 
and durable clinical responses in a subset of patients after intradermal/intravenous 
administration in metastatic melanoma patients.39,40 We administered these DC 
via the intranodal route, because of low CCR7 expression on these DC, but found 
only limited immunological responses against the tumor-associated antigens after 
vaccination. Especially, the ability to detect tumor-specific T cell responses in HLA-
A*02:01-negative patients was minimal.41 Another approach, maturation of DC 
with a cocktail of prophylactic vaccines (BCG, Typhim, and Act-HIB) is shown in 
chapter 4. Because of the limited availability of GMP-compliant TLR ligands, we 
used prophylactic vaccines, containing TLR ligands for DC maturation (VAC-DC) 
which were known to induce increased levels of costimulatory molecules and 
production of proinflammatory cytokines 36. In this study, the prophylactic vaccines 
Box 1. Maturation of DC
• DC vaccines have been developed using a wide variety of ex vivo DC culture 
conditions. The most widely used method to mature DC is a cytokine cocktail.
• The optimal DC vaccine should consist of DC capable of migrating to the 
lymph nodes, present antigen and costimulation to T cells, and survive long 
enough for optimal T cell activation. 
• Cytokine cocktails includes TNF-α, with any of the following cytokines in 
any combination: IL-1β, IL-6, prostaglandin E2, or monocyte-conditioned 
medium.14,15,34,35
• More recently, TLR ligands that trigger TLRs on DC, or costimulatory pathways 
(CD40-CD40L) form a more natural route to induce DC maturation.36
• TLR ligands can be combined with IFN to obtain type-1 polarized DC that 
produce high levels of IL-12.37
• Electroporation with mRNA-encoding proteins that modulate DC function 
has also been explored.38
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indeed induced optimal DC maturation and frequently induced tumor-specific T 
cell responses coinciding with clinical outcome, both after intravenous/intradermal 
and intranodal administration. However, VAC-DC induced more toxicity compared 
to cytokine-matured DC; Grade 2 and 3 local and systemic toxicity occurred, most 
likely caused by the BCG vaccine in the maturation cocktail.42 In chapter 5, BDCA1+ 
mDC were stimulated by overnight culture in the presence of GM-CSF. The mDC 
highly expressed MHC class I, MHC class II, CD83, and CD86, but CD80 and CCR7 were 
expressed at lower and highly variable levels, which may be suboptimal. We recently 
optimized natural DC maturation with clinical grade protamine-mRNA complexes 
that induce TLR7/8-mediated upregulation of maturation markers and production 
of proinflammatory cytokines in mDC as well as pDC,43 which will be used in our 
future studies and haven’t shown any toxicity comparable to our DC matured with 
prophylactic vaccines.
Tumor antigens and loading of DC
To induce an immune response in cancer patients, the MHC molecules of a mature DC 
must be loaded with relevant tumor antigens, proteins that are overexpressed in tumor 
cells or cancer-testis antigens. Several methods of loading of DC with relevant tumor 
epitopes have been examined (Box 2). 
Box 2. Methods of antigen loading of DC44
Advantages/disadvantages
• Short peptides: do not require antigen processing/ dependent on HLA-type, 
need for antigen identification
• Long peptides: contains both CD4+ and CD8+ T cell epitopes, prolonged 
antigen presentation/ need for antigen identification
• Tumor cell lysates: no antigen identification needed/ tumor cells required, 
presentation of self-antigens
• Dendritic/tumor fusion cells: very long antigen presentation/ tumor cells 
required
• RNA transfection: encodes specific antigens, can also encode maturation 
factors/ poor CD4+ T cell induction
• DNA transfer: high levels of antigen presentation/ integration into host 
genome, immune response against the viral vector
• Neoantigens: patient/tumor-specific antigens/ difficult45
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At present, the optimal method for antigen loading remains unknown but would 
ideally induce both CD4+ and CD8+ T cell responses, as this is of crucial importance 
for the induction of a strong and sustained antitumor T cell response.46,47 One of the 
antigen loading techniques that aims at inducing both CD4+ and CD8+ T cell responses 
is described in Chapter 2. Electroporation of DC with mRNA encoding tumor-associated 
antigens leads to presentation of both MHC class I and MHC class II epitopes. Our trial 
showed that this antigen loading technique can indeed lead to both CD8+ and CD4+ T cell 
responses.48 Another major advantage of this technique, compared to peptide-loading, 
is that it is not HLA-type dependent and that multiple epitopes are presented. Besides 
the induction of an immune response against an antigen loaded on the DC vaccine, 
antigen spreading, i.e., the induction of immune responses against antigens that were 
not in the vaccine, may occur, indicating that a secondary round of T cell priming has 
occurred with antigens taken directly from tumor cells.49,50
Currently, one of the most innovative developments is the use of RNA sequencing 
technologies to determine somatic mutations within the tumor, which may provide 
neoantigens and could enable patient- and tumor-specific antigens for vaccines.51,52 
Vaccination with neoantigen-loaded DC has recently been shown to be feasible and 
promoted neoantigen-specific T cell responses; it even expanded the diversity of the 
antitumor response.45 However, the frequency of neoantigens is strongly dependent on 
tumor type,53,54 which may serve to recommend the combined use of shared antigens 
(differentiation antigens, cancer-testis antigens) and neoantigens for DC loading. 
Immune responses upon DC vaccination and biomarkers
The primary goal of DC vaccination is to stimulate tumor antigen-specific T cells 
that can recognize and eliminate tumor cells, which are induced quite potently.51,55 
Different vaccination protocols are immunogenic in terms of T cell induction but 
lack clear identification of a superior route of administration, dose, and vaccination 
schedule. In cancer patients, imaging DC with scintigraphy and MRI has shown different 
migration efficacy of DC injected intradermally or intranodally.56 After intradermal 
injection, a consistent but low percentage of DC migrate to lymph nodes, while with 
intranodal vaccination higher percentages of DC reach subsequent lymph nodes when 
injected correctly. Despite these differences, immune responses were induced via both 
routes.57,58 Lymphocyte proliferation was detected after intranodal injection of DC with 
[18F]FLT PET scans. FLT uptake correlated with the presence of DC in lymph nodes and 
with antigen-specific immune responses ex vivo.59
An abundance of assays are used to measure tumor antigen-specific T cell responses 
and their (multi)functionality, including ELISpot assays, tetramer staining on peripheral 
blood.60-62 Among the immunomonitoring assays is the analysis of delayed-type 
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hypersensitivity (DTH) skin test biopsies.63 In chapter 6 we investigated the correlation 
between the presence of tumor-specific T cells in the DTH skin test biopsies from 91 
metastatic melanoma patients that were enrolled in our DC vaccination trials. The 
presence of tumor-associated antigen-specific CD8+ T cells in the DTH skin test showed 
a trend towards longer survival. When also functionality of the tumor-specific T cells 
was taken into account, the association with overall survival was strong.64 Similarly, in a 
phase III trial in prostate cancer, DC vaccination induced antibody and T cell responses 
in the majority of patients, and their presence correlated with survival.24,65 Although 
correlation of T cell responses with clinical outcome is shown more often,35,63,64,66 
measuring T cell responses remains notoriously difficult and laborious and assays are 
not validated in prospective clinical trials. Correlation with survival might become more 
accurate by broadening the immune cells analyzed, for example, with NK cell activation 
markers or tumor-specific antibodies.67-69 The ideal immunologic test might act as a 
surrogate endpoint in clinical trials, potentially providing insight on the immunogenicity 
of adjustments in the DC vaccine. 
Besides validated immunomonitoring assays, a biomarker that could predict the 
response to DC-based immunotherapy, or immunotherapy in general, would move 
the field forward. The presence or absence of specific immune cells within the tumor 
microenvironment prior to treatment, either in a metastatic lesion or the primary 
tumor, is a promising biomarker currently being explored in multiple tumor types.70,71 
In melanoma, we have shown in chapter 7 that CD3+ T cell infiltration in the primary 
tumor, especially the ratio of intratumoral versus peritumoral T cell densities, correlates 
strongly with longer survival after DC vaccination. Even after adjustment for late-stage 
prognostic markers such as M substage and LDH level, the infiltration remains predictive 
despite the several years that usually pass between primary tumor resection and start 
of DC vaccination for metastatic disease. Furthermore, T cell infiltration is a potential 
predictive biomarker for DC vaccination, as only patients with high infiltration seem 
to benefit from DC vaccination.72 As this approach may be useful for other types of 
immunotherapy and in other tumor types further research is warranted. 
Translation of immunological efficacy into clinical benefit 
Immune responses measured in patients that received DC vaccines support the concept 
of using DC-based immunotherapy to treat cancer. The first proof-of-principle studies 
exploring DC vaccination were performed in the 1990s, and the first clinical study of 
a DC vaccine was reported in Nature Medicine in 1996.73 Currently, over 200 clinical 
studies have been or are being carried out in cancer patients, mostly small exploratory 
studies with monocyte-derived DC aimed at optimizing vaccines and measuring 
immune responses. 
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Although immune responses are frequently reported using diverse immune 
monitoring methods and different culture protocols, objective clinical responses 
remain low, with classic objective tumor response rates rarely exceeding 15%. A recent 
meta-analysis including >100 phase I-III clinical trials showed objective response rates 
of 7.1% in prostate cancer, 8.5% in melanoma, 11.5% in renal cell carcinoma, and 15.6% 
in glioma.74 Interestingly, however, in cases where clinical responses were induced, 
these were often long lasting.
In theory, immunotherapy, including DC vaccination, should be applicable to all 
cancer types, although it might be more effective in more immunogenic tumors, as 
mutational load might correlate with benefit from immunotherapy.75 So far, only specific 
types of tumors have been studied, mainly due to practical limitations. These include 
the lack of appropriate tumor antigens or the absence of sufficient tumor material when 
tumor lysates are used for antigen loading of DC. We have conducted DC vaccination 
trials in patients with colorectal cancer, Lynch syndrome and prostate cancer, but 
have mainly focused on patients with melanoma. In our various trials with metastatic 
melanoma patients, most included patients had cutaneous melanoma, which is in line 
with the incidence of cutaneous melanoma compared to other melanoma subtypes 
such as uveal or mucosal melanoma. Despite only 3% of melanomas originate in the 
eye, we show in chapter 8 that DC vaccination is also feasible and safe in patients with 
uveal melanoma. Although susceptibility of uveal melanoma for immunotherapy is 
questioned, as limited responses to anti-CTLA-4 treatment are seen, DC vaccination 
induced tumor-specific T cell responses in one third of the patients. In addition, half of 
the DC vaccinated metastatic uveal melanoma patients survived more than 2 years.76 
To date, very few phase III trials have been performed with DC-based immunotherapy, 
perhaps because DC vaccines had not yet reached their full potential but mainly 
because financial support is hard to obtain as most pharmaceutical companies are 
not interested in producing laborious patient-specific vaccines. However, shortly after 
the first report on DC-based therapy was published, a prospective phase III trial was 
initiated in 2000 that compared standard dacarbazine chemotherapy with a DC vaccine 
as first-line treatment in patients with melanoma.21 This trial was prematurely stopped 
due to lack of any sign of efficacy in the treatment arm (objective response rate <6% 
in both arms). Possible negative contributing factors included a variable quality of 
the DC vaccine among participating centers and a suboptimal maturation status of 
the DC. In retrospect, this trial was carried out too early and was performed at a time 
when DC vaccination was still fully in development. Furthermore, DC vaccination might 
come too late for end-stage cancer patients and could be more effective in earlier 
stages of disease.
More recently, in 2010, a DC-based vaccine used in men with metastatic castration-
resistant prostate cancer has been brought to the market by a private company 
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(Sipuleucel-T; Dendreon). This cell-based vaccine consists of autologous PBMC obtained 
by leukapheresis, which include DC activated with a fusion protein of a prostate antigen 
and GM-CSF. Sipuleucel-T was approved on the basis of results from three placebo-
controlled phase III trials. No significant difference in time to biochemical failure,22 or 
improvement in progression-free survival could be shown; however, median overall 
survival was prolonged by approximately 4 months compared with the placebo 
group.23 25 Despite the discussion about the DC characteristics of this vaccine, as the 
vaccine consisted of less than 20% antigen-presenting cells of which the majority were 
CD14+,65 the impact of this first FDA-approved cancer vaccine has been significant and 
certainly boosted the field. More phase III trials testing DC vaccination with survival 
as the primary endpoint are currently ongoing (Table 1). 
After melanoma and prostate cancer, DC are mostly studied in glioma. A large phase 
III trial is ongoing after numerous smaller trials showing increased progression-free and 
overall survival in both recurrent and newly diagnosed glioma.74,77 The phase III trial 
uses tumor lysate-loaded DC. 
Sipuleucel-T clinical development has taught us some important lessons. A 
cellular product from cancer patients, cultured for at least 5 days at a production 
site distinct from the hospital, is a risk. The autologous cells, the starting material 
for Sipuleucel-T, are collected at the hospital but produced after shipping with the 
risk that this fresh product does not qualify once it arrives at the production site. 
Likewise, shipping the living Sipuleucel-T vaccine might result in a unacceptable 
product due to delayed arrival at the hospital. These risks resulted in high production 
costs for Sipuleucel-T (>$ 80,000).  Although marketing authorization was received 
from both the FDA and EMA, the product is not readily available due to various 
reasons, including financial problems.
Table 1. Phase III trials with dendritic cells
ClinicalTrials.gov identifier Tumor type Intervention
Recruiting
NCT00045968 Glioma DC only
NCT01582672 Renal cell carcinoma DC + sunitinib
NCT01875653 Melanoma DC + irradiated autologous tumor cells
NCT01983748 Uveal melanoma DC only (adjuvant)
NCT0211157 Prostate cancer DC + chemotherapy
Not yet recruiting
NCT02503150 Colorectal cancer DC + chemotherapy
NCT02546102 Glioma DC + radiochemotherapy
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For future success of DC vaccines, besides showing efficacy in phase III trials, a well-
established and reproducible product needs to be obtained. Currently, cost-benefit ratios 
for DC vaccines and other cellular therapies are poor, but recent developments may 
turn the tide. For example, natural DC vaccine products are isolated in a closed system 
according to a highly standardized protocol wereby they are cultured for only 48 hours 
and can be frozen.19 This could result in a lower production costs of future DC vaccines.
In vivo targeting of DC 
Another recent approach to exploit natural DC for cancer immunotherapy is to target 
DC subsets in vivo, by antibodies with activating agents and antigens.78 In a way, various 
vaccination strategies (e.g., with DNA, peptides) can also be characterized as in vivo 
DC loading; however, this will not be discussed here. Early studies have shown that 
when antigen is bound to antibodies directed against surface receptors of DC that are 
implicated in endocytosis, this leads to uptake of antigen. The DC are then efficiently 
channeled into endocytic compartments for loading of MHC class I and II molecules 
and subsequent induction of immune responses.79 However, if these antibody-antigen 
conjugates are not accompanied by adjuvant to stimulate the immune system, tolerance 
rather than immunity might occur.79 Therefore, in a phase I trial with an antibody 
against DEC205, a molecule expressed on DC, fused with the tumor antigen NY-ESO-1 
(Figure 2), this vaccine was combined with a topical or subcutaneously administered 
adjuvant consisting of different TLR agonists.80 This combination appeared safe, 
induced NY-ESO-1-specific immune responses, and led to two objective responses. 
Likewise, other investigators have developed (nano)particles loaded with both antigen 
and adjuvant and coated with antibodies to target natural DC subsets (Figure 2).81 The 
advantage of this approach is that adjuvants only activate those DC that are targeted 
by the antibodies, thereby preventing systemic activation and toxicity, and conversely, 
that DC loaded with antigens are also stimulated and matured with adjuvant, so that 
no immature DC are loaded with tumor antigens.82 However, the specificity of in vivo 
targeting techniques, the ideal antibody to target, and whether enough DC will be 
activated are under investigation. The main advantage of in vivo targeting strategies 
is the development of an off-the-shelf product. Several clinical trials are expected to 
start in the next few years. 
DC vaccination early in the course of disease
To translate DC-induced immunologic responses into clinical benefit, tumor-specific 
T cells should be able to exert their function within the tumor. As tumors have evolved 
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Figure 2. Interplay between DC, other immune cells, tumor cells, and therapies. Arrows indicate a 
stimulatory effect on cell function or a process, and blockers indicate an inhibitory effect on cell function 
or a process. The arrows/blockers shown in red indicate interactions that favor tumor growth. Arrows/
blockers shown in green indicate interactions that favor tumor killing, for example, sunitinib inhibits 
(blocker) MDSCs and by blocking MDSCs this favors tumor killing (green). To promote the clarity, not all 
known interactions are depicted in this figure. Abbreviations: αCD25, anti-CD25 antibody; αCTLA-4, anti-
CTLA-4 antibody; αPD-1, anti-PD-1 antibody; αPD-L1, anti-PD-L1 antibody; Arginase-i, arginase inhibitor; 
BRAFi, BRAF inihibitor; CD4, CD4+ T helper cell; CD8, cytotoxic CD8+ T cell; Chemo, chemotherapy; IDOi, 
indoleamine 2,3-dioxygenase inhibitor; MDSC, myeloid derived suppressor cell; NK, natural killer cell; 
Treg, regulatory T cell.
various mechanisms to evade immunologic surveillance or to counterattack the 
immune response to facilitate their own progression,83 it is essential to overcome this 
immunosuppressive barrier that may hamper the success of DC-based immunotherapy. 
Tumor-induced immunosuppression is dependent on the amount of tumor, making 
immunotherapy less effective in patients with a large tumor burden.84 In the clinical 
setting, we have shown that tumor-specific immunologic response rates obtained after 
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DC vaccination in the adjuvant setting are about two to three times as high as compared 
with the metastatic setting. This was both found in high-risk uveal melanoma patients, 
described in chapter 9,  as well as in stage III cutaneous melanoma patients after 
radical lymph node dissection described in chapter 10. In both groups, treated with DC 
vaccination in the adjuvant setting, we found tumor-specific T cells in approximately 
two-thirds of the patients. In more detail, we retrospectively analyzed 78 stage III 
melanoma patients and found that in 71% of these patients functional tumor-specific 
T cells were present in the DTH skin test. Their presence correlated with a better 
2-year overall survival rate. Furthermore, we matched our cohort with >200 matched 
control patients who underwent radical lymph node dissection without adjuvant DC 
vaccination. Overall survival of patients treated with DC vaccination was twice as long, 
64 versus 31 months, compared to matched controls.85 Our findings provides a rationale 
for the use of DC-based immunotherapy earlier in the course of disease, when tumor 
burden is still minimal, for example, in the adjuvant setting in patients at high risk of 
recurrence or in patients with minimal metastatic disease, but so far, most trials have 
been performed in end-stage cancer patients with high tumor loads. Of course, a 
randomized trial is needed to prospectively validate the efficacy of DC vaccination in 
the adjuvant setting, which we will start in the second half of 2016. 
Boosting DC vaccines with adjuvants or cytokines
Tumor cells produce a variety of cytokines and small molecules to promote tumor 
progression, mainly by increasing tumor invasiveness and angiogenesis, but 
also by impairing DC and T cell function, for example, via TGF-β, VEGF, IL-10, and 
prostaglandin E2.86-89 To counteract these immunosuppressive cytokines it is possible 
to use immunostimulatory cytokines or TLR ligands as DC vaccine adjuvants, either 
incorporated in the vaccine itself or applied concomitantly. 
IL-2 is the most extensively studied cytokine in combination with DC vaccination, 
as IL-2 is considered to protect effector CD8+ T cells from tumor-mediated dysfunction 
or death. Despite strong preclinical evidence,90 clinical trials combining DC vaccination 
with IL-2 have not shown superior immune or clinical responses.91,92 Also, the 
combination with IFN-α has not lived up to its expectations, with only limited immune 
responses induced.93 Other cytokines that are under investigation in combination 
with DC vaccination include GM-CSF, IFN-γ, and IL-12. Thus far, clinical successes of 
DC vaccination combined with cytokines or TLR ligands are limited, partly due to the 
restricted systemic administration because of toxic effects, but occasionally promising 
results without substantial toxicity are shown.94 
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Combinations to combat tolerance induced by 
immunosuppressive cells 
DC vaccination might be more efficient in combination with therapies that break the 
suppressive tumor microenvironment (Figure 2). Tumor escape mechanisms include the 
evasion of immune recognition by loss of tumor antigen expression or downregulation 
of MHC class I expression, the secretion of immunosuppressive cytokines, the expansion 
and recruitment of regulatory T cells (Treg), and myeloid-derived suppressor cells 
(MDSC),95,96 and the activation of negative regulatory pathways.97 Furthermore, the 
tumor vasculature itself can form an important barrier for T cells to reach the tumor.98 
Potential approaches to counteract the tumor escape mechanisms and to tilt the 
balance toward more effective DC-based immunotherapy are numerous, but thus far 
only a few are being investigated in clinical trials. 
Breaking peripheral tolerance by depletion of Tregs with anti-CD25 antibodies, thereby 
targeting the α-chain of the IL-2 receptor, has demonstrated an improved immune-
mediated tumor rejection in murine models.99 Unfortunately, in humans, anti-CD25 
antibodies did not enhance the efficacy of DC vaccination in multiple tumor types, despite 
efficient depletion of Tregs from the peripheral circulation and increased tumor-specific 
T cell frequencies.100,101 In contrast, Treg-depleting drugs appeared to have paradoxical 
immunologic effects that could impair the activity of DC vaccination (e.g., depletion of 
NK cells, induction of tolerogenic DC, and promotion of nonactivated Treg survival).102,103 
Along with Tregs, MDSCs, a variety of cells including macrophages and granulocytes, 
directly suppress CD8+ T cell responses at the tumor site, hampering the immune response 
and supporting tumor growth. As with Tregs, it is hypothesized that depletion or inhibition 
of MDSCs leads to recovery of CD8+ T cell antitumor activity. To target MDSCs, several 
interventions are under investigation, including COX-2 inhibitors and arginase inhibitors.104 
In addition, inhibitors of the indoleamine 2,3-dioxygenase (IDO) pathway form a novel 
class of immunomodulators that inactivate Tregs and MDSCs without known substantial 
immunologic effects that impair an effective antitumor response.105 The combination of 
an IDO inhibitor and DC vaccination is currently being tested in phase II trials in prostate 
and breast cancer (NCT01560923; NCT01042535-phase II part), and has been shown to 
be tolerated, but no objective responses were seen thus far (NCT01042535-phase I part). 
Combination with chemotherapy: an unexpected 
synergistic effect
The combination of DC with chemotherapy seems counterintuitive, as chemotherapy 
is known to have immunosuppressive effects, for example, chemotherapy-induced 
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depletion of leukocytes. However, besides lowering tumor burden, this strategy has 
several other immune-potentiating effects, for example, depletion of MDSC and 
Tregs and increasing tumor cell permeability to CD8+ T cell-derived cytolytic factors. 
Furthermore, by depleting immune cells, chemotherapy creates a cytokine milieu for 
optimal expansion of antitumor effector cells, and is for this reason often combined 
with adoptive T cell transfer.106,107 However, compared with adoptive T cell therapy, 
DC vaccination has the advantage that it is able to induce immunologic memory. The 
combination of DC vaccination and adoptive T cell transfer is being tested in multiple 
trials. These pilot trials have shown the feasibility of the approach, although without 
full conditioning for adoptive T cell transfer with lymphocyte-depleting chemotherapy 
and IL-2 infusion in most trials.108-110 Besides, a variety of chemotherapeutic agents 
seem to be able to induce immunogenic cell death, making these cells more susceptible 
for antitumor immunity elicited by DC vaccination.111,112 Thus far, no clinical trials 
have been reported that exclusively tested the combination of chemotherapy and 
DC vaccination, but numerous trials are ongoing in which the combination is being 
tested with or without additional therapies. Chemotherapy and DC vaccination were 
tested with the addition of a COX-2 inhibitor in melanoma in a phase III trial showing 
encouraging data, and with the addition of autologous T cells in lung cancer in two 
randomized trials showing longer overall survival compared with outcomes from 
chemotherapy alone.113-115
Combination with targeted therapy: more than tumor 
reduction
Monoclonal antibodies and small molecules targeting receptors on the cell surface 
or intracellular enzymatic proteins of specific pathways involved in tumor growth 
are numerous and still expanding. Preclinical evidence exists to confirm beneficial 
immunomodulatory effects for many targeted drugs. For example, vemurafenib, a BRAF 
inhibitor, inhibits Treg function, and trastuzumab, an anti-Her2 antibody, can restore MHC 
class I expression on cancer cells.116,117 Sunitinib, a tyrosinase kinase inhibitor targeting 
multiple receptors, decreased MDSCs in the tumor microenvironment, downregulated 
PD-1 expression on DC, and decreased the secretion of immunosuppressive cytokines 
in preclinical studies.118,119 A phase II clinical trial of sunitinib in combination with DC 
vaccination in advanced renal cell carcinoma patients showed expansion of CD8+ T 
cells and promising survival data.120 The combination is currently being evaluated in a 
phase III trial (NCT01582672).
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Combination with immune checkpoint inhibitors: 
the ideal combination?
The success of antibodies that counteract the activation of negative regulatory pathways 
by tumors, thereby recovering T cell function, has recently been a major breakthrough 
in cancer immunotherapy. CTLA-4- and PD-1-blocking antibodies have been approved 
by the FDA, and more immune checkpoint inhibitors are currently being tested in clinical 
trials, such as, anti-PD-L1 antibodies and IDO inhibitors.121-123 As treatment with immune 
checkpoint inhibitors is antigen nonspecific, although it can broaden the antitumor 
response, the combination with a vaccine could potentially direct the T cell response in 
a more specific manner. In theory, this might lead to a higher response rate to immune 
checkpoint inhibition. Furthermore, the unique capability of DC to cross-present antigens 
helps to induce an immune response to a wide variety of tumor antigens when applied 
in conjunction with immune checkpoint inhibitors.124 The timing of the combination may 
be of crucial importance for its efficacy. In theory, one should start with DC vaccination 
to enhance tumor-specific immune responses, and boosting this effect could result 
in higher numbers of circulating T cells by subsequent immune checkpoint inhibitors. 
The first anecdotal data that anti-CTLA-4 treatment after DC vaccination may indeed 
enhance DC vaccine-induced T cell responses was published in 2005,125 and there is some 
evidence that anti-CTLA-4 antibodies might be more effective after DC vaccination.126 
In addition, two small trials have shown that DC-based immunotherapy in combination 
with anti-CTLA-4 antibodies seems to be more effective than the use of these agents 
alone, showing a best overall response rate of 38% in melanoma patients,127,128 as is 
suggested in results from multiple small trials with other forms of antigen-specific 
immunotherapy.129,130 Currently, no clinical data on the combination of DC vaccination 
with anti-PD-1 antibodies are available, but anti-PD-1 antibodies are being investigated 
in combination with DC vaccination and the first results are expected in 2016 (Table 2). 
Table 2. Phase II trials testing anti-PD-1 antibodies in combination with dendritic cells
ClinicalTrials.gov identifier Tumor type Intervention
Inclusion completed
NCT01067287 Myeloma DC - tumor fusion vaccine
NCT01441765 Renal cell carcinoma DC - tumor fusion vaccine
Recruiting
NCT01420965 Prostate cancer +/- chemotherapy
NCT01096602 Acute myeloid leukemia DC - tumor fusion vaccine
Not yet recruiting
NCT02529072 Glioma Phase I trial
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Conclusion
In conclusion, DC vaccination has proven to be feasible and safe in multiple trials. 
The DC-based vaccine Sipuleucel-T was tested in phase III trials in which it showed 
proof of concept and induced a survival benefit. Significant advances over the past 
two decades in de field of DC-based immunotherapy have been made and DC vaccines 
are continuously being optimized. However, further progress in the field is needed to 
improve clinical outcomes and to exploit the full potential of DC-based immunotherapy. 
We believe that DC vaccination earlier in the course of disease is acceptable because 
of its low toxicity profile and is more beneficial as it more frequently induces tumor-
specific immune responses, most likely due to less tumor-induced immunosuppression. 
Therefore, DC-based immunotherapy might be most suitable in the adjuvant setting. 
Furthermore, two recent developments that might improve DC-based immunotherapy 
are (i) the use of neoantigens to load DC to induce stronger immune response and (ii) 
the rapid and highly standardized, automated production of DC vaccines consisting 
of natural DC subsets which can improve the quality of the DC vaccines and most 
importantly enable multicenter trials. 
Still, DC-based immunotherapy may have limitations as a monotherapy because of 
the immunosuppressive mechanism active in the tumor microenvironment. Combination 
therapy could play an important role in initiating by DC vaccination, boosting antigen-
specific antitumor immunity by subsequent treatment with immunomodulating agents. 
While the potential impact of such regimens is recognized, an optimal combination 
treatment is yet to be established. 
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Melanoom: een agressieve vorm van huidkanker
Melanoom is een vorm van huidkanker die ontstaat uit de pigmentcellen van het 
lichaam. Het is de meest agressieve vorm van huidkanker en is een relatief zeldzame 
vorm van kanker. In Nederland krijgen per jaar circa 4600 mensen een melanoom. Het 
aantal gevallen (de incidentie) is echter de laatste decennia aanzienlijk toegenomen. De 
gemiddelde leeftijd bij het optreden van de ziekte is 45 jaar. De overgrote meerderheid 
van de personen met een melanoom van de huid zal na chirurgische behandeling 
geen uitzaaiingen (metastasen) ontwikkelen. Bij een deel van de patiënten ontstaan 
via de lymfebanen uitzaaiingen in de lymfeklieren die direct van het oorspronkelijke 
huidmelanoom  afkomstig zijn, zogenoemde regionale lymfekliermetastasen (stadium 
III melanoom). Ook kunnen via de bloedbaan uitzaaiingen naar andere organen worden 
verspreid, afstandsmetastasen (stadium IV melanoom). In Nederland overlijden er circa 
800 patiënten per jaar aan de gevolgen van een gemetastaseerd melanoom. 
Nieuwe behandelingen leiden tot een verbeterde 
prognose
Tot enkele jaren geleden bestond, ondanks veel onderzoek, de standaard behandeling 
van het gemetastaseerde melanoom uit chemotherapie (dacarbazine) en was er 
geen standaard vervolgbehandeling beschikbaar na het falen van chemotherapie. 
Dacarbazine werd meestal goed verdragen, maar heeft slechts een responskans 
van 5-10%. Derhalve had het gemetastaseerde melanoom een slechte prognose. De 
helft van de patiënten komt binnen 4 tot 12 maanden na de diagnose te overlijden 
(mediane overleving), afhankelijk van het aantal metastasen en de betrokken organen. 
Met de recente introductie van nieuwe behandelmogelijkheden zijn er nu meer 
systemische behandelopties beschikbaar voor melanoom patiënten en neemt ook 
de mediane overleving toe. Met name met immunotherapie, behandelingen die een 
afweerreactie stimuleren tegen tumorcellen, bestaat er voor patiënten een (kleine) 
kans op langdurige overleving.
Het immuunsysteem en kanker
Dat het afweersysteem (het immuunsysteem) een rol speelt bij kanker werd 
duidelijk toen bleek dat kanker zich vaker ontwikkelt bij mensen met een verzwakt 
immuunsysteem. Echter, ook bij mensen met een goed functionerend immuunsysteem 
kan kanker aan de controle van dit systeem ontsnappen. Het immuunsysteem gaat 
pas in de aanval als het wordt geactiveerd. Dat gebeurt zodra het immuunsysteem 
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lichaamsvreemde eiwitten (antigenen) opmerkt op het oppervlak van cellen. Antigenen 
bevinden zich op het oppervlak van alle cellen, maar normaal zal het immuunsysteem 
niet in actie komen tegen lichaamseigen cellen. De verandering van een goedaardige cel 
in een kwaadaardige cel (maligne transformatie) kan gepaard gaan met bovenmatige 
aanwezigheid (overexpressie) van normale eiwitten of expressie van nieuwe eiwitten 
aan het celoppervlak. Van het melanoom zijn inmiddels meerdere tumorspecifieke 
eiwitten bekend, onder andere gp100 en tyrosinase. 
Sommige cellen van het immuunsysteem, in het specifiek de dendritische cellen, 
hebben als taak om lichaamseigen cellen en weefsels continue af te zoeken naar 
afwijkende antigenen. 
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Indien antigenen door onvolwassen (immature) dendritische cellen als 
lichaamsvreemd worden herkend, zullen ze door de dendritische cel worden 
opgenomen (gefagocyteerd) en worden afgebroken tot fragmenten (peptiden), zodat 
ze gepresenteerd kunnen worden aan andere afweercellen om deze te activeren. Na 
stimulatie met signaalstoffen (cytokinen) of via andere signaalmoleculen afkomstig van 
ziekteverwekkers (pathogenen) rijpen dendritische cellen uit. Ze veranderen dan van 
immature dendritische cellen, die antigenen herkennen en fagocyteren, naar mature 
dendritische cellen. Mature dendritische cellen migreren naar de dichtstbijzijnde 
lymfeklieren en presenteren aldaar het antigeen (antigeenpresentatie) aan andere 
cellen van het immuunsysteem, naïeve B en T cellen. Binnen de oncologie streeft 
men met name naar de activatie van bepaalde T cellen, de cytotoxische T cellen, die 
tumorspecifieke antigenen kunnen herkennen en tumorcellen kunnen doden. Voor 
activatie van T cellen door dendritische cellen in de lymfeklier zijn diverse stappen 
nodig.  De T cellen dienen het antigeen, gepresenteerd door de dendritische cel, te 
herkennen (signaal 1), gestimuleerd te worden via ondersteunende (co-stimulatoire) 
moleculen (signaal 2) en signaalstoffen te ontvangen die aanzetten tot activatie (pro-
inflammatoire cytokinen)(signaal 3). 
Helaas zijn dendritische cellen niet altijd in staat om tumorcellen te herkennen, 
omdat de tumorcellen vaak niet als lichaamsvreemd worden gezien, mede doordat 
zogenaamde “danger signals”, de cytokinen of signaalmoleculen die leiden tot 
maturatie van dendritische cellen, ontbreken. Het doel van immunotherapie 
binnen de oncologie is het eigen immuunsysteem te activeren tegen tumorcellen 
of de immuunreactie te versterken. Checkpoint inhibitors, een bepaalde vorm van 
immunotherapie met antilichamen, remmen de negatieve terugkoppeling naar 
cellen van het immuunsysteem. Als het ware wordt de rem op het immuunsysteem 
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weggenomen en zo de immuunrespons versterkt. Dendritische celvaccinaties, een 
andere vorm van immunotherapie wordt beschreven in dit proefschrift. Dendritische 
celvaccinaties activeren niet het immuunsysteem als geheel maar stimuleren een 
specifieke immuunrespons tegen bepaalde tumorantigenen. Het voordeel hiervan is 
dat het specifiek tumorcellen kan aanpakken, hierdoor minder bijwerkingen geeft en 
dat het een “geheugen” tegen tumorcellen kan ontwikkelen. 
Het werkingsmechanisme van dendritische celvaccinaties
Met dendritische celvaccinaties wordt gepoogd het immuunsysteem te activeren tegen 
tumorcellen en wordt een beroep gedaan op het in het lichaam aanwezige repertoire 
aan T cellen. Slechts een klein percentage van ons bloed bestaat uit dendritische cellen. 
Allereerst worden monocyten, voorlopercellen van dendritische cellen, geïsoleerd uit 
het bloed van kankerpatiënten middels een leukaferese, een bloedafname, waarbij 
specifieke cellen/cellagen kunnen worden afgenomen.  De monocyten kunnen 
vervolgens met verschillende cytokinencocktails in het laboratorium worden gekweekt 
tot dendritische cellen. 
De dendritische cellen moeten vervolgens worden gematureerd, hiervoor 
wordt veelal gebruik gemaakt van pro-inflammatoire cytokinen. De gekweekte 
mature dendritische cellen worden in het laboratorium in contact gebracht met 
tumorantigenen (gp100 en tyrosinase) zodat deze zullen worden gepresenteerd aan 
het oppervlakte van de dendritische cel. Er zijn meerdere methoden om relevante 
tumorantigenen op dendritische cellen tot expressie te brengen (zich presenteren), de 
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meest gebruikte methode is belading van HLA-moleculen met peptiden afkomstig van 
tumorantigenen. Na antigeenbelading van mature dendritische cellen worden deze als 
vaccin teruggegeven aan de patiënt. Van de injectieplaats moeten de dendritische cellen 
migreren naar de lymfeklieren, of het vaccin kan direct in de lymfeklier (intranodaal) 
worden toegediend. De lymfeklier is waar de dendritische cellen in contact komen 
met naïeve B en T cellen en een immuunrespons tegen de tumor kunnen induceren. 
Na activatie vermenigvuldigen de geactiveerde T cellen zich en verlaten vervolgens de 
lymfeklier op zoek naar cellen die het specifieke tumorantigeen tot expressie brengen 
om in deze cellen, tumorcellen, vervolgens celdood te induceren. 
Dendritische celvaccinaties bij het melanoom
De eerste klinische studies met dendritische celvaccinaties bij kankerpatiënten vonden 
plaats eind jaren 90 en toonden de uitvoerbaarheid en potentiële werkzaamheid aan. 
Dendritische celvaccinaties hebben bewezen veilig te zijn; ernstige toxiciteit wordt 
niet waargenomen. Bijwerkingen zijn meestal beperkt tot kortdurende klachten van 
griepachtige verschijnselen en lokale zwelling op de plek van de injectie. 
Dendritische celvaccinaties bij patiënten met gemetastaseerd melanoom laten 
nadien frequent T cellen die melanoomcellen herkennen, d.w.z. tumorspecifieke 
immuunresponsen, zien. Bij enkele patiënten kunnen tumorspecifieke T cellen in het 
bloed worden aangetoond, vaker kunnen tumorspecifieke T cellen worden gekweekt 
uit huidbiopten na een huidtest. Bij deze test worden kleine hoeveelheden met 
tumorantigeen-beladen dendritische cellen in de huid ingespoten, waarna na 48 uur 
huidbiopten worden genomen van de injectieplaatsen. In deze huidbiopten wordt 
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vervolgens de aanwezigheid van tumorspecifieke T cellen onderzocht. Bij stadium IV 
melanoom patiënten correleert de aanwezigheid van functionele tumorspecifieke 
T cellen in de biopten met een betere overleving (hoofdstuk 6).
De tot dusverre enige gerandomiseerde fase-III-studie met dendritische cellen liet 
geen verschil in overleving zien ten opzichte van chemotherapie. Deze studie werd 
echter in een heel vroege fase van de ontwikkeling van dendritische celvaccinatie 
opgestart. Hierdoor werden geen optimaal gematureerde dendritische cellen gebruikt, 
waarvan later door verschillende onderzoeksgroepen het belang werd aangetoond. 
Tot dusverre worden in de literatuur bij stadium IV melanoom patiënten objectieve 
responskansen beschreven van 5-20%. De huidige vaccins in fase-I/II-studies zijn 
echter steeds vaker in staat tumorspecifieke T cellen te induceren; de verwachting is 
dat deze verbeterde immunologische resultaten correleren met klinische resultaten, 
echter een nieuwe fase-III-studie met ‘het optimale dendritische celvaccin’ zal dit 
moeten uitwijzen. 
Bevindingen van dit proefschrift
In het eerste deel van dit proefschrift worden klinische studies beschreven waarbij 
melanoom patiënten worden behandeld met dendritische celvaccinaties. Het betreft 
verschillende studies waarbij telkens aanpassingen aan het dendritische celvaccin 
werden gemaakt met als doel het vaccin te optimaliseren. 
Hoofdstuk 2 beschrijft de resultaten van een klinische studie bij stadium III en IV 
melanoom patiënten waarbij de dendritische cellen werden beladen met mRNA dat 
codeert voor tumorantigenen. Na maturatie van de dendritische cellen in de cleanroom, 
met de standaard cocktail aan cytokinen, werd mRNA in de dendritische cel gebracht 
door middel van elektroporatie. Elektroporatie is een proces waarbij door toediening 
van een elektrische puls de celmembraan tijdelijk doorlaatbaar wordt gemaakt en 
het mRNA in de cel kan worden opgenomen. De voordelen van deze techniek zijn dat 
mRNA-beladen dendritische cellen de antigenen voor een langere tijd tot expressie 
brengen en er geen restrictie van HLA-type van de patiënt is, in tegenstelling tot 
bij peptidenbelading. Tevens zullen de dendritische cellen het mRNA zelf bewerken 
waardoor het antigeen zowel gepresenteerd kan worden in HLA klasse I als in HLA 
klasse II moleculen. Deze unieke eigenschap van dendritische cellen wordt cross-
presentatie genoemd en geeft de mogelijkheid zowel cytotoxische (CD8+) T cellen als 
(CD4+) T helper cellen te activeren. In het perifere bloed werden dan ook bij enkele 
patiënten naast tumorspecifieke CD8+ T cellen, CD4+ T cellen gedetecteerd. Opvallend 
was dat bij zowel stadium III als bij stadium IV melanoom patiënten frequent CD8+ T 
cellen aanwezig waren in de huidtest, echter bij de stadium III patiënten waren deze 
vaker functioneel en werden frequenter meerdere epitopen herkend. 
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In het onderzoek beschreven in hoofdstuk 3 vond niet alleen de antigeenbelading 
plaats middels mRNA elektroporatie, maar werd deze techniek ook gebruikt voor 
maturatie van de dendritische cellen door middel van mRNA coderend voor CD40 
ligand, CD70 en actief TLR4. Dit kweekprotocol leidde tot fraaie upregulatie van 
maturatiemarkers, echter gezien de lage expressie van de migratiemarker CCR7 werd 
gekozen voor intranodale toediening van de dendritische cellen. Deze toediening 
van dendritische cellen was goed uitvoerbaar en veilig. Echter, in tegenstelling tot 
resultaten van studies elders met vergelijkbare dendritische cellen welke intraveneus 
en intradermaal werden toegediend, werden in deze studie weinig immunologische 
responsen waargenomen. 
Een andere vorm van maturatie wordt beschreven in hoofdstuk 4. Preklinische data 
lieten zien dat dendritische cellen gematureerd kunnen worden met profylactische 
vaccins, vaccins tegen infectieziekten, welke Toll-like receptor liganden bevatten, 
de “danger signals” van pathogenen. In de klinische studie met deze dendritische 
cellen waren de dendritische cellen frequent in staat tumorspecifieke CD8+ T cellen 
te induceren, zowel na intraveneuze/intradermale als intranodale toediening. De 
aanwezigheid van tumorspecifieke CD8+ T cellen correleerde tevens sterk met 
de overleving. Echter, de vaccinatie ging gepaard met hevigere bijwerkingen dan 
normaliter bekend van dendritische celvaccinaties. Sommige patiënten ontwikkelden 
forse ontstekingsreacties, zowel lokaal, rond de injectieplaats, als systemisch, 
bijvoorbeeld een ontsteking van de longen (pneumonitis)  of de lever (hepatitis). De 
bijwerkingen waren zeer waarschijnlijk het gevolg van gebruik van een BCG vaccin in 
de maturatie cocktail. 
Alle bovengenoemde studies werden uitgevoerd met variaties van monocyt-
afgeleide dendritische cellen. Het kweekproces van deze cellen duurt circa anderhalve 
week. In het bloed komen ook van nature voorkomende dendritische cellen voor, echter 
slechts in zeer kleine aantallen. Met nieuwe isolatietechnieken lukt het inmiddels om 
van nature voorkomende dendritische cellen, plasmacytoide en myeloide dendritische 
cellen, te isoleren uit het bloed. 
In hoofdstuk 5 beschrijft een studie bij stadium IV melanoom patiënten met myeloide 
dendritische cellen. In twee dagen tijd kunnen de myeloide dendritische cellen worden 
gematureerd en beladen met tumorantigenen. De inductie van multifunctionele 
tumorspecifieke CD8+ T cellen correleerde met een langere progressievrije overleving. 
De waargenomen mediane overleving van de patiënten en een patiënt met een 
aanhoudende complete remissie zijn veelbelovend. De isolatie van de van nature 
voorkomende dendritische cellen is sterk gestandaardiseerd wat het mogelijk maakt 
deze dendritische cellen in de toekomst te gebruiken voor multicentrische studies. 
Het tweede deel van dit proefschrift beschrijft de invloed van de aanwezigheid 
van T cellen op de overleving van melanoom patiënten na dendritische celvaccinaties. 
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In hoofdstuk 6 wordt gekeken naar de uitkomst van de huidtest, welke wordt 
uitgevoerd na elke ronde van 3 dendritische celvaccinaties. De analyse laat zien dat 
aanwezigheid van tumorspecifieke T cellen correleert met een betere overleving na 
dendritische celvaccinatie bij stadium IV melanoom patiënten. Er werd aangetoond dat 
hoe groter de functionaliteit van de tumorspecifieke T cellen, hoe hoger de correlatie 
met overleving is. 
De huidtest is een weergave van de activatie van het immuunsysteem als gevolg 
van dendritische celvaccinaties. De test is derhalve niet geschikt om vóór de start 
van de behandeling patiënten te selecteren die baat zullen hebben bij dendritische 
celvaccinaties. Het is bekend dat in een deel van de patiënten het oorspronkelijke 
huidmelanoom en de metastasen zijn geïnfiltreerd met T cellen. Hoofdstuk 7 beschrijft 
het testen van de hypothese dat de aanwezigheid van T cellen in het oorspronkelijke 
huidmelanoom reeds kan voorspellen of een patiënt een betere overleving laat zien na 
dendritische celvaccinatie. Inderdaad bleek dat patiënten met een hoge intratumorale/
peritumorale T cel ratio, veel T cellen in de tumor ten opzichte van het aantal T cellen 
net buiten de tumor, langer overleven na dendritische celvaccinatie dan patiënten 
met een lage ratio. Aangezien het effect niet of in mindere mate aanwezig was bij 
patiënten die niet met immunotherapie zijn behandeld, betreft de intratumorale/
peritumorale T cel ratio een potentiële predictieve biomarker. Een prospectieve studie 
zal de daadwerkelijke waarde van de biomarker moeten uitwijzen. 
De klinische studies met dendritische celvaccinaties bij het oogmelanoom en in de 
adjuvante setting bij het oog- en huidmelanoom worden besproken in het derde deel 
van dit proefschrift. 
Allereerst wordt in hoofdstuk 8 de toepassing van dendritische celvaccinatie bij het 
gemetastaseerde oogmelanoom beschreven. Het oogmelanoom is een zeer zeldzame 
vorm van kanker en omvat slechts 3% van alle patiënten met een melanoom. Uit de 
analyse kan geconcludeerd worden dat, net als bij de patiënten met een huidmelanoom, 
de dendritische celvaccinaties ook veilig zijn bij patiënten met een oogmelanoom 
en in staat zijn om tumorspecifieke immuunresponsen te induceren. Verder liet de 
helft van de patiënten een overleving langer dan 2 jaar zien na start van dendritische 
celvaccinaties. 
Aangezien bij een hoge tumorload, d.w.z. veel tumorcellen in het lichaam, 
tumorcellen in staat zijn om immuunresponsen te onderdrukken, is onderzocht of de 
toepassing van dendritische celvaccinaties bij patiënten met volledige verwijderde 
ziekte maar met een hoog risico op terugkeer van de ziekte (een recidief) effectiever 
is dan bij patiënten met afstandsmetastasen. Hoofdstuk 9 beschrijft een studie van 
adjuvante dendritische celvaccinatie bij patiënten met een hoogrisico oogmelanoom 
(aanwezigheid van monosomie 3) na behandeling van de primaire tumor in het 
oog. In deze adjuvante setting werd in de ruime meerderheid van de patiënten een 
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tumorspecifieke immuunrespons teruggevonden in de huidtest, in tegenstelling tot een 
veel kleiner percentage bij patiënten met gemetastaseerde ziekte. Gezien het weinig 
voorkomen van het oogmelanoom, betreft het echter kleine patiëntenaantallen en is 
er geen duidelijke conclusie te trekken ten aanzien van de klinische uitkomst. 
Ook hoogrisico patiënten met een huidmelanoom, na chirurgische resectie 
van regionale lymfekliermetastasen, zijn adjuvant behandeld met dendritische 
celvaccinaties, zoals beschreven in hoofdstuk 10. Dit betreft een veel grotere groep 
vergeleken met het aantal patiënten met een hoogrisico oogmelanoom. Ook in 
deze populatie bleek in bijna 75% van de patiënten een functionele tumorspecifieke 
T cel respons in de huidtest. In vergelijking met een gematched cohort van controle 
patiënten, patiënten die na chirurgische resectie zijn geobserveerd (huidige standaard), 
had dendritische celvaccinatie een positief effect op de overleving. Deze veelbelovende 
resultaten zullen in de nabije toekomst worden onderzocht in een prospectieve, 
gerandomiseerde studie. 
Tot slot
Concluderend kan worden gesteld dat er op het gebied van dendritische celvaccinaties 
belangrijke stappen zijn gemaakt, deels beschreven in dit proefschrift. Diverse 
maturatie protocollen, dendritische cel subtypen en technieken voor antigeenbelading 
zijn onderzocht met als doel optimalisatie van het dendritische celvaccin. Vanwege de 
fraaie inductie van immuunresponsen en sterk vereenvoudigde en gestandaardiseerde 
isolatie methode lijken de van nature voorkomende dendritische cel subtypen zoals 
myeloide en plasmacytoide dendritische cellen mijns inziens de meest veelbelovende 
strategie. De zeer geringe toxiciteit van dendritische celvaccinaties en de twee- tot 
drievoudige inductie van immuunresponsen in de adjuvante setting in verhouding tot 
de gemetastaseerde setting, maakt dat dendritische celvaccinaties zeer geschikt lijken 
voor patiënten in de adjuvante setting met een hoge recidiefkans. Idealiter kunnen 
we reeds vooraf voorspellen welke patiënten baat zullen hebben bij vaccinatie, 
bijvoorbeeld door analyse van de T cel infiltratie in het huidmelanoom. In de tweede 
helft van 2016 zal een gerandomiseerde fase III studie starten bij stadium III melanoom 
patiënten om deze hypotheses te toetsen.
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Prof. de Vries, beste Jolanda, je vertrouwen in mij en steeds grotere 
verantwoordelijkheid die je me gaf tijdens mijn promotietraject, heeft het 
tot een uitdagende en mooie tijd gemaakt. Veel deadlines, maar altijd tijd 
om de stand van zaken te bespreken en de volgende stappen uit te stippelen. 
Was in 2010 het meerjarenplan nog ietwat beangstigend, inmiddels kijk ik uit 
naar de grote plannen voor de komende jaren! Prof. Gerritsen, beste Winald, 
je bent op een al rijdende trein gesprongen en een waardevolle toevoeging 
voor mijn onderzoek! Connecties en ideeën in overvloed, waarvan ik ook 
in de toekomst gebruik hoop te mogen maken. Al is het vinden van een 
gaatje in je agenda, voor een half uurtje overleg of voor mijn verdediging, 
een crime, toch straal je een alles overheersende rust uit. Die kunst kijk ik 
graag nog een tijdje af. 
Gerty, ondanks de stress rondom de nieuwe studies en de vele artikelen waar 
we samen aan schreven, liep de samenwerking met jou altijd vanzelfsprekend 
en soepel. Super; zoals jij zo’n immuno-groentje wegwijs hebt kunnen maken 
in de wereld van dendritische cellen en immunologische assays. Al sloeg 
je met kerst regelmatig groen uit, het waren mooie tijden met jou op het 
TIL en op de congressen! Mijn andere co-promotor is er een jaloezie van 
geworden... Erik, prettig gestoord wanneer het kan en serieus wanneer het 
moet, een goede combi. Weinig saaie momenten gehad met jou, ondanks 
de oneindige hoeveelheid CRFs die we zaten in te vullen. Bedankt voor je 
fantastische begeleiding en aanstekelijke enthousiasme, ik heb een hoop 
van je geleerd! 
Harm, je bekijkt de wereld regelmatig door een roze bril; you may say 
you’re a dreamer (John Lennon). Maar je onuitputtelijke nieuwsgierigheid en 
enthousiasme doen hun werk! Het is fantastisch om te zien hoe je in korte tijd 
je eigen ‘men-only’ niche hebt gecreëerd binnen het DC wereldje in Nijmegen. 
Een geduchte concurrent over enige tijd op de arbeidsmarkt maar nu vooral 
een erg fijne collega!
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Analisten, jullie houden er niet van om als groep te worden vermeld, maar 
toch ga ik daar mee van start. Zonder jullie harde werken had dit proefschrift 
er niet gelegen! Mijn kweekkunsten zouden de eerste pagina van de kritische 
vrijgifteprocedures al niet hebben doorstaan. De miljarden dendritische cellen 
die zijn toegediend aan honderden patiënten en waarvan de resultaten staan 
beschreven in dit proefschrift, zouden niet hebben bestaan zonder jullie! Ik 
had jullie graag allemaal meegenomen als paranimfen bij mijn verdediging. Het 
zou komische foto’s hebben opgeleverd. Mandy, aan jou de taak alle analisten 
te vertegenwoordigen als mijn paranimf. Maar met je lange staat van dienst, 
de eeuwige kalmte ondanks alle protocollenstress, ben ik blij dat je straks 
naast me staat! Nicole, miss TIL, gelukkig stond mijn computer niet in U’tje 8, 
dan zou mijn productiviteit flink minder zijn geweest, al had het me een hoop 
gezelligheid opgeleverd! Mooi om te zien hoe jij kletsen met hard werken weet 
te combineren. Annemiek, ietsje minder spraakzaam dan je U’tje-genoot en 
een tikje meer ongeordend. Toch worden alle huidbiopten wekenlang door jou 
gekoesterd en weet je altijd weer alle DTH-data bij elkaar te krijgen. Tom, een 
beetje mannelijke rust tussen al het vrouwengeweld in de cleanroom. Je moet 
er maar tegen kunnen. Niet te beroerd om een avond flink door te werken, maar 
ook niet te beroerd voor een biertje in de kroeg. Jeanette, voor jou geen tassen 
meer aan het fietsstuur, want zonder jouw harde werk komen we handen te 
kort. Bedankt voor je kritische blikken op de patiënten planningen; mijn originele 
plannen waren soms onmogelijk, maar je kwam altijd met een oplossing! Michel, 
mijn KLH-man! Al zat je altijd een beetje verstopt een paar U’tjes verderop, toch 
is je vertrek naar Utrecht me niet ontgaan. Je nuchterheid was heerlijk. Tjitske, 
een beetje de outsider van de groep, maar als FACS-queen van onschatbare 
waarde voor de vaccinaties! 
Met zoveel hard werkende analisten zijn er natuurlijk meer artsen nodig. 
Steve, de man met de kortste villatijd, maar met de meeste kamers. Pas in 
2014 aangesloten, maar alweer bijna klaar. Je hebt je ontpopt tot een echte 
stormtrooper, die elke statistische tegenstand weet te overwinnen! Martine, 
ook jij moet flink aan de bak. Qua inclusie nu een lange adempauze, maar 
top zoals jij nu een hoop andere taken oppakt. Straks proosten op elke 
geïncludeerde patiënt lijkt me voor onze gezondheid geen goed idee, maar 
toch zeker op de eerste!
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Hans, Gosse & Peter, aan jullie heb ik een fantastische wetenschappelijke 
stage als student te danken. Veel meegekregen: spierpijn in mijn onderarm 
(pipetteren!), een stagebezoek naar Pittsburgh, 2 scriptieprijzen en als 
belangrijkste, enthousiasme voor onderzoek en een promotietraject. Bedankt! 
Kees, mede dankzij jouw instemming kon ik aan dit promotietraject beginnen. 
En ondanks dat je kort nadien vertrok naar Amsterdam, kon ik altijd op je 
kritische beoordeling van een manuscript rekenen. Een beetje westerse 
directheid, heerlijk! Carl, als hoofd van het TIL had ik ook jouw goedkeuring 
voor dit promotietraject nodig. Destijds behoorlijk spannend. Inmiddels een 
zeer fijne samenwerking op diverse translationele projecten!
TILLERS, bij deze het bewijs dat ik niet alleen maar voor de taart naar het 
lab kwam! Al was de taart natuurlijk regelmatig een goede reden om mijn 
gezicht te laten zien. Bedankt voor de gezelligheid tijdens de lab-uitjes, de 
biertjes in de Aesculaaf, de roze woensdagen tijdens de Vierdaagse en vooral 
tijdens de fantastische kerstfeesten! Het blijft lastig uit te leggen aan mijn 
klinische collega’s hoe gaaf een feestje kan zijn op het kennisplein met als 
hoogtepunt de (niet altijd zuivere) TIL-band… Ik hoop nog vele jaren samen 
met jullie in diverse outfits “We want more!” te mogen roepen. En speciaal 
voor iedereen van de klinische club, bedankt voor jullie geduld met deze 
onwetende dokter!
Van de afdeling Medische Oncologie kan ik natuurlijk niet alleen Winald 
bedanken. Ik zou liegen als ik zou zeggen dat ik de dunne wandjes in de villa‘s nog 
ga missen, maar de villabewoners zeker wel! Gezellig lunchen met mijn mede 
PhD studenten, waaronder Annelieke, Chantal, Eline, Janneke, Myrella, Simône 
en Steve en nu ook de newbies. Of een avondje bowlen met alle villabewoners 
of elkaar beschieten! Ook dank aan alle stafleden van de afdeling. Jullie zijn 
nog niet van me af! Ik kom graag over een tijdje terug voor mijn fellowship. 
Winette, Carla, bedankt voor jullie ondersteuning. Rutger, wie zou het Radboud 
als melanoomcentrum draaiende houden als jij er niet was? Of zorgen voor 
een beetje opschudding in discussies, heerlijk. Het is verbazingwekkend dat 
niet iedereen op het secretariaat (patiënt & management), poli Rood en E30 
gillend gek van me is geworden: onmogelijke verzoeken, lastige planningen en 
ontelbare buizen bloed, niets was jullie te gek! Bedankt. Nog een klein bedankje 
naar een paar mensen in het bijzonder: Esther & Natascha, bedankt voor 
jullie ondersteuning en bijkletsmomentjes. Riet & Ine, super zoals ik altijd de 
patiënten in jullie vertrouwde handen kon achterlaten op E30! 
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De klinische studies konden uiteraard niet zonder de inzet van vele andere 
afdelingen. Allereerst, geen dendritische cellen zonder aferese via de afdeling 
Hematologie. Corry, Gaby, Sandra en al jullie oude en nieuwe collega’s, 
bedankt voor jullie flexibiliteit als ik weer eens aan kwam zetten met allerlei 
onmogelijke verzoeken! Met jullie patiëntvriendelijkheid en deskundigheid is het 
eenvoudig patiënten (of mezelf) een hele ochtend bij jullie te laten vertoeven. 
De verschuiving naar de adjuvante setting zou nooit mogelijk zijn geweest 
zonder de inzet van de afdeling Heelkunde, Han, Hans & Annelies. De grootste 
uitdagingen gaan we binnenkort samen aan! Na een periode van radiostilte 
zijn we weer op volle toeren intranodaal aan het vaccineren met de onmisbare 
hulp van de afdeling Radiologie & Nucleaire geneeskunde. Roel, de patiënten 
zijn dol op je, en terecht. Al jaren zorgt de afdeling Dermatologie, Michelle 
& Wilmy, voor het afnemen van de huidbiopten, cruciaal voor de bepaling van 
onze immunologische eindpunten. Geen gp100 kleuringen zonder de afdeling 
Pathologie. Willeke, we hebben mazzel met zo’n melanoomexpert in huis. Ook 
alle andere leden van de TWG melanoom, uit Nijmegen en wijde omgeving, 
bedankt voor jullie input en samenwerking! Tot slot, geen DC vaccinatie alvorens 
goedkeuring van de Apotheek; Marieke, Anna & Jeanine, bedankt voor al jullie 
hulp en inzet bij het opzetten van de nieuwe studies. 
Ook met mensen buiten het Radboudumc heb ik samengewerkt. Een aantal 
van hen is terug te vinden als auteur van een of meerdere hoofdstukken in dit 
proefschrift. Voor veel collega’s is dit echter niet het geval, maar er zou geen 
proefschrift zijn geweest zonder hun verwijzingen. Er is ook nog een –intern- 
leven buiten het onderzoek. Jacqueline, Jan & Ton, zonder mijn opleidingsplek 
Interne en jullie flexibiliteit was de fantastische combinatie van opleiding tot 
internist en onderzoek nooit gelukt. Bedankt!
Dit boekwerk doet wellicht anders vermoeden, maar het doel van het onderzoek 
beschreven in dit proefschrift is niet het afleveren van een mooi proefschrift, 
maar het vinden van een betere behandeling voor patiënten met kanker. Mijn 
speciale dank gaat dan ook uit naar alle patiënten en hun families die hebben 
deelgenomen aan dendritische celvaccinatie studies. Zij schonken vertrouwen 
en veel van hun kostbare tijd voor deelname aan wetenschappelijk onderzoek. 
Soms leidde deelname aan een van de studies tot direct zichtbaar succes, vaker 
is het gissen naar de winst op individuele basis, maar in elk geval komen de 
resultaten ten goede aan toekomstige patiënten.
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Oud-teamies, managers en trainers/coaches van Union Dames 1, de tijd dat 
ik niet op het veld stond, besteedde ik aan mijn coschappen, dit proefschrift 
en mijn opleiding tot internist. Soms moe van het werk, maar door jullie altijd 
weer energie voor het mooiste spelletje wat er is! Al kon ik niet elke donderdag 
en zondag mee op stap, ik heb genoten van alle jaren op en buiten het veld 
met jullie. 
Chris, van mijn lange hockeycarrière heb je precies één wedstrijd, mijn 
afscheidswedstrijd, gezien. De meeste Duitsers graven kuilen, maar jij hebt het 
grote gat waarin ik terecht zou komen prachtig weten te dichten. Bijna TIL-
collega’s af met je aanstaande verhuizing, maar hopelijk moeten we elkaar nog 
vaak op taart trakteren. Je bent de leukste!
Paps, mams & Jas, zoals jullie zien is dit boekje geen solowerk. En dat voor een 
Bolletje! Jullie bijdrage aan dit proefschrift is groter geweest dan de inzet van jullie 
talenknobbels. Een kleine selectie: Zonder de keuzevrijheid die jullie me gaven, 
was ik wellicht nooit Geneeskunde gaan studeren. Zonder de eigenwijsheid 
die ik thuis heb meegekregen, was ik wellicht nooit aan een promotietraject 
begonnen. Zonder de reislust die met de paplepel werd ingegoten, was ik 
wellicht nooit naar mijn buitenlandse stages vertrokken. Verder is het altijd 
gezellig thuiskomen in Pijnacker. Bedankt!
Al met al mag ik op 1 september om 14:30 dit proefschrift verdedigen mede dankzij 
jullie allemaal. Laten we er nadien met z’n allen op proosten! 
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Kalijn Fredrike Bol werd op 15 juli 1985 geboren te Groningen en groeide op in 
Aberdeen (GB) en Pijnacker. In 2003 behaalde zij haar VWO diploma aan het Haags 
Montessori Lyceum en begon aan haar studie Geneeskunde aan de Radboud Universiteit 
Nijmegen. Tijdens de studie deed ze haar wetenschappelijke stage op de afdeling Tumor 
Immunologie van het Radboud Institute for Molecular Life Sciences (RIMLS). Onder 
begeleiding van dr. Hans Jacobs, prof. dr. Gosse Adema en prof. dr. Peter Hoogerbrugge 
deed ze onderzoek naar de aanwezigheid van regulatoire T cellen in hersentumoren. 
Voor haar stage-werk heeft ze de Student KOC-award van het Loes Pellenfonds/
de Stichting Vrienden KOC Nijmegen en de Nijbakker-Morra Prijs van de Nijbakker-
Morra Stichting ontvangen. Dit stelde haar in staat een korte stage te lopen aan het 
Department of Immunology van de University van Pittsburg (US) dat onder leiding 
staat van dr. Pawel Kalinkski. In mei 2010 behaalde ze het artsexamen en koos er voor 
zich te specialiseren in Interne Geneeskunde en te starten met promotieonderzoek.
In 2010 begon zij als arts-onderzoeker bij de afdelingen Tumor Immunologie (RIMLS) 
en Medische Oncologie van het Radboudumc te Nijmegen. Onder begeleiding van prof. 
dr. Jolanda de Vries, prof. dr. Carl Figdor, prof. dr. Kees Punt en later prof. dr. Winald 
Gerritsen voerde zij het onderzoek uit dat wordt beschreven in dit proefschrift. 
Tijdens haar promotieonderzoek ontving zij een aantal prijzen, waaronder een 
reisbeurs van de René Vogels stichting en de Pieter de Mulder award van de Nederlandse 
Vereniging voor Medische Oncologie. Dit gaf haar de mogelijkheid een stage van drie 
maanden te lopen op de Early Phase Trials Unit van het Oxford Cancer Centre (GB) bij 
prof. dr. Mark Middleton en deel te nemen aan de FLIMS Clinical Research Workshop 
van de ECCO-AACR-EORTC-ESMO (CH). In de workshop schreef zij de eerste versie van 
het protocol van de gerandomiseerde trial met dendritische celvaccinatie die in 2016 
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